Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2206815,maximum plasma concentration,The tablets showed evidence of controlled-release properties: the maximum plasma concentration (10.8 +/- 2.5 mg/l) was obtained after 3.4 +/- 1.6 hours.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],10.8,113,DB00277,Theophylline
,2206815,trough level,The mean trough level was 6.6 +/- 1.5 mg/l and the difference between the peak and trough levels was 4.1 +/- 1.2 mg/l.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],6.6,114,DB00277,Theophylline
,2206815,steady-state plasma theophylline concentration,The mean steady-state plasma theophylline concentration was 8.5 +/- 2.2 mg/l.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],8.5,115,DB00277,Theophylline
,2206815,elimination half-life,The mean elimination half-life was 14 +/- 7 hours.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),h,14,116,DB00277,Theophylline
,2206815,volume of distribution,The mean volume of distribution was 0.8 +/- 0.4 l/kg.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[l] / [kg],0.8,117,DB00277,Theophylline
,2206815,total body clearance,The mean total body clearance was 0.05 +/- 1/h/kg.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),1/[h·kg],0.05,118,DB00277,Theophylline
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),[ml] / [kg·min],4.0,268,DB00277,Theophylline
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,4.2,269,DB00277,Theophylline
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,2.4,270,DB00277,Theophylline
,2748541,clearance,Theophylline clearance was reduced from 126 to 98 ml/hr/kg (22.2%) whereas the steady state volume of distribution of the drug increased from 461 to 550 ml/kg (19.3%).,Inhibition of theophylline elimination in rabbits by verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),[ml] / [h·kg],126 to 98,719,DB00277,Theophylline
,2748541,steady state volume of distribution,Theophylline clearance was reduced from 126 to 98 ml/hr/kg (22.2%) whereas the steady state volume of distribution of the drug increased from 461 to 550 ml/kg (19.3%).,Inhibition of theophylline elimination in rabbits by verapamil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),[ml] / [kg],461 to 550,720,DB00277,Theophylline
,2748541,terminal half-life,The terminal half-life of theophylline increased from 2.7 to 4.0 hr (49.8%).,Inhibition of theophylline elimination in rabbits by verapamil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),h,2.7,721,DB00277,Theophylline
,2748541,terminal half-life,The terminal half-life of theophylline increased from 2.7 to 4.0 hr (49.8%).,Inhibition of theophylline elimination in rabbits by verapamil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),h,4.0,722,DB00277,Theophylline
not exceed,6295106,maximum inhibition,LA 2851 and theophylline did not inhibit all the components of the inflammatory process since maximum inhibition did not exceed 60% up to 200 mg/kg and 100 mg/kg respectively.,Anti-inflammatory effect of LA 2851 and reference drugs on some models of inflammation. Investigation of the mechanism of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6295106/),%,60,942,DB00277,Theophylline
,865528,plasma half-life,"As compared to 19 normal subjects, these patients had a prolonged plasma half-life (mean, 25.6 vs. 6.7 hours) and a decreased plasma clearance (mean, 0.042 vs. 0.062 liter[kg-1]hr-1).",Theophylline disposition in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),h,25.6,3073,DB00277,Theophylline
,865528,plasma half-life,"As compared to 19 normal subjects, these patients had a prolonged plasma half-life (mean, 25.6 vs. 6.7 hours) and a decreased plasma clearance (mean, 0.042 vs. 0.062 liter[kg-1]hr-1).",Theophylline disposition in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),h,6.7,3074,DB00277,Theophylline
,865528,plasma clearance,"As compared to 19 normal subjects, these patients had a prolonged plasma half-life (mean, 25.6 vs. 6.7 hours) and a decreased plasma clearance (mean, 0.042 vs. 0.062 liter[kg-1]hr-1).",Theophylline disposition in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),1/[liter[kg],0.042,3075,DB00277,Theophylline
,865528,plasma clearance,"As compared to 19 normal subjects, these patients had a prolonged plasma half-life (mean, 25.6 vs. 6.7 hours) and a decreased plasma clearance (mean, 0.042 vs. 0.062 liter[kg-1]hr-1).",Theophylline disposition in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),1/[liter[kg],0.062,3076,DB00277,Theophylline
,865528,central-compartment volume,"Volumes of distribution of theophylline in the cirrhotic patients (central-compartment volume of 0.330, and steady-state volume of distribution of 0.785 liter per kilogram) did not substantially differ from normal (0.246 and 0.508 respectively).",Theophylline disposition in patients with hepatic cirrhosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),,0.330,3077,DB00277,Theophylline
,865528,steady-state volume of distribution,"Volumes of distribution of theophylline in the cirrhotic patients (central-compartment volume of 0.330, and steady-state volume of distribution of 0.785 liter per kilogram) did not substantially differ from normal (0.246 and 0.508 respectively).",Theophylline disposition in patients with hepatic cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),[l] / [kg],0.785,3078,DB00277,Theophylline
,865528,steady-state volume of distribution,"Volumes of distribution of theophylline in the cirrhotic patients (central-compartment volume of 0.330, and steady-state volume of distribution of 0.785 liter per kilogram) did not substantially differ from normal (0.246 and 0.508 respectively).",Theophylline disposition in patients with hepatic cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),[l] / [kg],0,3079,DB00277,Theophylline
,865528,steady-state volume of distribution,"Volumes of distribution of theophylline in the cirrhotic patients (central-compartment volume of 0.330, and steady-state volume of distribution of 0.785 liter per kilogram) did not substantially differ from normal (0.246 and 0.508 respectively).",Theophylline disposition in patients with hepatic cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),,0.,3080,DB00277,Theophylline
,865528,binding,Plasma theophylline binding in three patients with cirrhosis averaged 36.8 per cent as compared to 52.6 per cent in four normal subjects.,Theophylline disposition in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),%,36.8,3081,DB00277,Theophylline
,865528,binding,Plasma theophylline binding in three patients with cirrhosis averaged 36.8 per cent as compared to 52.6 per cent in four normal subjects.,Theophylline disposition in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/865528/),%,52.6,3082,DB00277,Theophylline
,6524719,elimination half-life,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),h,11.9,3370,DB00277,Theophylline
,6524719,distribution half-life,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),h,0.495,3371,DB00277,Theophylline
,6524719,apparent specific volume of distribution,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[l] / [kg],0.885,3372,DB00277,Theophylline
,6524719,apparent specific volume of central compartment,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[l] / [kg],0.080,3373,DB00277,Theophylline
,6524719,clearance,"The following mean pharmacokinetic values were determined; elimination half-life = 11.9 hours, distribution half-life = 0.495 hours, apparent specific volume of distribution = 0.885 +/- 0.075 L/kg, apparent specific volume of central compartment = 0.080 L/kg, and clearance = 51.7 +/- 11.2 ml/kg/hr.",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),[ml] / [h·kg],51.7,3374,DB00277,Theophylline
,6524719,PaCO2,"The horses at 0.5 hour after dosing had a significant decrease in PaCO2 (43.6 +/- 5.5 to 39.4 +/- 6.7 mm of Hg, P less than 0.001) and a significant increase in blood pH (7.38 +/- 0.017 to 7.41 +/- 0.023, P less than 0.001).",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),hg·mm,43.6,3375,DB00277,Theophylline
,6524719,PaCO2,"The horses at 0.5 hour after dosing had a significant decrease in PaCO2 (43.6 +/- 5.5 to 39.4 +/- 6.7 mm of Hg, P less than 0.001) and a significant increase in blood pH (7.38 +/- 0.017 to 7.41 +/- 0.023, P less than 0.001).",Pharmacokinetic disposition of theophylline in horses after intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524719/),hg·mm,39.4,3376,DB00277,Theophylline
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3863,DB00277,Theophylline
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3864,DB00277,Theophylline
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3865,DB00277,Theophylline
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3866,DB00277,Theophylline
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3867,DB00277,Theophylline
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3868,DB00277,Theophylline
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3869,DB00277,Theophylline
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3870,DB00277,Theophylline
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],3.83,3871,DB00277,Theophylline
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.14,3872,DB00277,Theophylline
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],5.09,3873,DB00277,Theophylline
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.41,3874,DB00277,Theophylline
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,5.9,4081,DB00277,Theophylline
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,7.3,4082,DB00277,Theophylline
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.065,4083,DB00277,Theophylline
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.049,4084,DB00277,Theophylline
,8500192,clearance,No significant differences of the elimination rates of TPH could be found between the times of TPH administration (clearance: 1.17 +/- 0.17 ml/kg/min at 07:00 h vs. 1.23 +/- 0.17 ml/kg/min at 19:00 hours).,Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],1.17,4085,DB00277,Theophylline
,8500192,clearance,No significant differences of the elimination rates of TPH could be found between the times of TPH administration (clearance: 1.17 +/- 0.17 ml/kg/min at 07:00 h vs. 1.23 +/- 0.17 ml/kg/min at 19:00 hours).,Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],1.23,4086,DB00277,Theophylline
,8500192,clearance,"The increase in clearance values was more expressed when TPH was injected at 07:00 h than at 19:00 h (2.48 +/- 0.67 vs. 2.06 +/- 0.41 ml/kg/min, p < 0.01).",Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],2.48,4087,DB00277,Theophylline
,8500192,clearance,"The increase in clearance values was more expressed when TPH was injected at 07:00 h than at 19:00 h (2.48 +/- 0.67 vs. 2.06 +/- 0.41 ml/kg/min, p < 0.01).",Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],2.06,4088,DB00277,Theophylline
,11069211,bioavailability,The bioavailability is approximately 50%.,Clinical pharmacokinetics of ropinirole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),%,50,4089,DB00277,Theophylline
,11069211,half-life,"Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses, and is eliminated with a half-life of approximately 6 hours.",Clinical pharmacokinetics of ropinirole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),h,6,4090,DB00277,Theophylline
,2714050,clearance,"2. The clearance of theophylline in the patients was faster than in 15 controls with a 'healthy lifestyle' [median 104 (range 18-320) ml h-1 kg-1 vs median 68 (range 50-97) ml h-1 kg-1, P less than 0.01].",Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714050/),[ml] / [h·kg],104,4644,DB00277,Theophylline
,2714050,clearance,"2. The clearance of theophylline in the patients was faster than in 15 controls with a 'healthy lifestyle' [median 104 (range 18-320) ml h-1 kg-1 vs median 68 (range 50-97) ml h-1 kg-1, P less than 0.01].",Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714050/),[ml] / [h·kg],68,4645,DB00277,Theophylline
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,42.8,5359,DB00277,Theophylline
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,81.9,5360,DB00277,Theophylline
,1926271,CL/F,Both these parameters were found to significantly correlate to weight alone in a directly proportional manner: CL/F = 40 +/- 2 ml/h/kg and V/F = 1.3 +/- 0.2 L/kg.,Population pharmacokinetics of rectal theophylline in neonates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),[ml] / [h·kg],40,5901,DB00277,Theophylline
,1926271,V/F,Both these parameters were found to significantly correlate to weight alone in a directly proportional manner: CL/F = 40 +/- 2 ml/h/kg and V/F = 1.3 +/- 0.2 L/kg.,Population pharmacokinetics of rectal theophylline in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),[l] / [kg],1.3,5902,DB00277,Theophylline
,1926271,half-life,"The absorption was best described by a first-order process, having a half-life of 1.6 +/- 0.7 h.",Population pharmacokinetics of rectal theophylline in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926271/),h,1.6,5903,DB00277,Theophylline
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.07,6247,DB00277,Theophylline
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.20,6248,DB00277,Theophylline
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],0.93,6249,DB00277,Theophylline
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.20,6250,DB00277,Theophylline
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],3.11,6251,DB00277,Theophylline
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],4.14,6252,DB00277,Theophylline
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.61,6253,DB00277,Theophylline
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.39,6254,DB00277,Theophylline
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,6.2,6255,DB00277,Theophylline
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,7.2,6256,DB00277,Theophylline
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,4.1,6257,DB00277,Theophylline
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,3.1,6258,DB00277,Theophylline
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.44,6259,DB00277,Theophylline
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.63-0.72,6260,DB00277,Theophylline
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.77,6261,DB00277,Theophylline
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.79,6262,DB00277,Theophylline
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.18,6263,DB00277,Theophylline
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.06,6264,DB00277,Theophylline
,3273483,minimum,"When Uniphyl was administered with food, bioavailability was increased by 10% (p less than 0.01), the time of maximum concentration occurred 3 hours later (p less than 0.01), and the minimum or ""trough"" theophylline concentration was 0.7 mg/L greater (p less than 0.01), as compared to administration while patients were fasting.",The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3273483/),[mg] / [l],0.7,7014,DB00277,Theophylline
,7431219,bioavailability,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,100.2,7068,DB00277,Theophylline
,7431219,bioavailability,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,98.5,7069,DB00277,Theophylline
,7431219,peak times,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,10.4,7070,DB00277,Theophylline
,7431219,peak times,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,4.36,7071,DB00277,Theophylline
,7431219,peak plasma concentrations,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],13.9,7072,DB00277,Theophylline
,7431219,peak plasma concentrations,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],22.6,7073,DB00277,Theophylline
,7431219,tpeak,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,1.52,7074,DB00277,Theophylline
,7431219,Cpeak,"Aminodur tablets (Cooper) and Slophyllin Gyrocap capsules (Dooner) had bioavailability (100.2% +/- 19.8% and 98.5% +/- 13.8%) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 10.4 +/- 2.8 and 4.36 +/- 1.35 hr) and lower peak plasma concentrations (13.9 +/- 4.5 and 22.6 +/- 3.5 micrograms/ml/g dose) than the standard (tpeak, 1.52 +/- 0.45 hr; Cpeak, 28.1 +/- 6.2 micrograms/ml/g dose).",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],28.1,7075,DB00277,Theophylline
,7431219,time of the plasma concentration peak,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),h,2.47,7076,DB00277,Theophylline
,7431219,peak concentration,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),[μg] / [g·ml],16.0,7077,DB00277,Theophylline
,7431219,availability,"The time of the plasma concentration peak (2.47 +/- 1.38 hr) after a dose of Tedral S.A. (Warner/Chilcott) was not statistically different from that after the standard, but both the peak concentration (16.0 +/- 3.9 micrograms/ml/g dose) and availability (76.0 +/- 18.4%) were.",Evaluation of the absorption from some commercial sustained-release theophylline products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431219/),%,76.0,7078,DB00277,Theophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),ng,0-15,7099,DB00277,Theophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),nM,0-46,7100,DB00277,Theophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μg,10-85,7101,DB00277,Theophylline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μM,50-429,7102,DB00277,Theophylline
,789845,half-life,"At the time, theophylline had a prolonged half-life ranging from 13 to 29 hours, a relatively large volume of distribution of 0.65 to 2.86 1/kg, and a small body clearance of 23 to 68 ml/hr/kg.",Theophylline pharmacokinetics in premature infants with apnea. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789845/),h,13 to 29,7177,DB00277,Theophylline
,789845,volume of distribution,"At the time, theophylline had a prolonged half-life ranging from 13 to 29 hours, a relatively large volume of distribution of 0.65 to 2.86 1/kg, and a small body clearance of 23 to 68 ml/hr/kg.",Theophylline pharmacokinetics in premature infants with apnea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789845/),[1] / [kg],0.65 to 2.86,7178,DB00277,Theophylline
,789845,body clearance,"At the time, theophylline had a prolonged half-life ranging from 13 to 29 hours, a relatively large volume of distribution of 0.65 to 2.86 1/kg, and a small body clearance of 23 to 68 ml/hr/kg.",Theophylline pharmacokinetics in premature infants with apnea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789845/),[ml] / [h·kg],23 to 68,7179,DB00277,Theophylline
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,5.5,7301,DB00277,Theophylline
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,12.7,7302,DB00277,Theophylline
,2627274,half-life,The half-life was 13.30 +/- 7.46 hours and Clss was 36.64 +/- 12.98 mL/h/kg.,"[Relation between dose, plasma concentration and therapeutic effect of theophylline in children with sleep apnea]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627274/),h,13.30,7429,DB00277,Theophylline
,2627274,Clss,The half-life was 13.30 +/- 7.46 hours and Clss was 36.64 +/- 12.98 mL/h/kg.,"[Relation between dose, plasma concentration and therapeutic effect of theophylline in children with sleep apnea]. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627274/),[ml] / [h·kg],36.64,7430,DB00277,Theophylline
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,5.7,8319,DB00277,Theophylline
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,9.2,8320,DB00277,Theophylline
,849997,bioavailability,"The bioavailability of dyphylline from sustained-release tablets, studied in seven normal subjects given a single dose of the drug, was 67.8 per cent of that from conventional tablets.",Bioavailability of a sustained-release dyphylline formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/849997/),%,67.8,8612,DB00277,Theophylline
,849997,peak serum dyphylline concentrations,"No adverse effects were noted, though in one subject peak serum dyphylline concentrations reached 30 microng/ml after multiple doses.",Bioavailability of a sustained-release dyphylline formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/849997/),[μng] / [ml],30,8613,DB00277,Theophylline
,4009445,tmax,The mean tmax ranged from 0.6 to 1.0 h for the six products.,Bioavailability of dyphylline and dyphylline-guaifenesin tablets in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009445/),h,0.6 to 1.0,8657,DB00277,Theophylline
,32919393,half-life,The median half-life was 39.5 h (range 27.2-50.4).,Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32919393/),h,39.5,9086,DB00277,Theophylline
,3243316,elimination half-life,"After single dose the elimination half-life was 7.22 +/- 2.36 h, the Vd area/F was 0.50 +/- 0.07 l/kg and the total clearance/F was 0.86 +/- 0.24 ml/Kg/min, which was similar to results reported in other studies.",Theophylline pharmacokinetics following single and repeated administration of slow-release capsules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243316/),h,7.22,9520,DB00277,Theophylline
,3243316,Vd area/F,"After single dose the elimination half-life was 7.22 +/- 2.36 h, the Vd area/F was 0.50 +/- 0.07 l/kg and the total clearance/F was 0.86 +/- 0.24 ml/Kg/min, which was similar to results reported in other studies.",Theophylline pharmacokinetics following single and repeated administration of slow-release capsules. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243316/),[l] / [kg],0.50,9521,DB00277,Theophylline
,3243316,total clearance/F,"After single dose the elimination half-life was 7.22 +/- 2.36 h, the Vd area/F was 0.50 +/- 0.07 l/kg and the total clearance/F was 0.86 +/- 0.24 ml/Kg/min, which was similar to results reported in other studies.",Theophylline pharmacokinetics following single and repeated administration of slow-release capsules. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243316/),[ml] / [kg·min],0.86,9522,DB00277,Theophylline
,1356725,Metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],6.8,9624,DB00277,Theophylline
,1356725,Metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],18.4,9625,DB00277,Theophylline
,1356725,metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],1.9,9626,DB00277,Theophylline
,1356725,metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],20.0,9627,DB00277,Theophylline
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,77,9628,DB00277,Theophylline
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,33,9629,DB00277,Theophylline
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,171,9630,DB00277,Theophylline
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,25,9631,DB00277,Theophylline
,7982257,maximum serum theophylline concentrations,"The mean serum theophylline concentration-time curves were similar for both formulations from 2 to 18 hours postdose, and the maximum serum theophylline concentrations were comparable (7.66 micrograms/mL for Uni-Dur compared with 7.78 micrograms/mL for Theo-Dur).",Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7982257/),[μg] / [ml],7.66,10391,DB00277,Theophylline
,7982257,maximum serum theophylline concentrations,"The mean serum theophylline concentration-time curves were similar for both formulations from 2 to 18 hours postdose, and the maximum serum theophylline concentrations were comparable (7.66 micrograms/mL for Uni-Dur compared with 7.78 micrograms/mL for Theo-Dur).",Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7982257/),[μg] / [ml],7.78,10392,DB00277,Theophylline
,9334881,steady state plasma levels,"Therapeutic steady state plasma levels around 12 micrograms/ml were rapidly achieved, and the pharmacokinetic parameters (CL = 1.1-1.5 ml/min/kg, Vd = 0.44-0.50 l/kg, t1/2 = 3.5-5.4 hr) differed slightly between the 3 methods applied.",Disposition of intravenous theophylline in asthmatic children: Bayesian approach vs direct pharmacokinetic calculations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9334881/),[μg] / [ml],12,10528,DB00277,Theophylline
,9334881,CL,"Therapeutic steady state plasma levels around 12 micrograms/ml were rapidly achieved, and the pharmacokinetic parameters (CL = 1.1-1.5 ml/min/kg, Vd = 0.44-0.50 l/kg, t1/2 = 3.5-5.4 hr) differed slightly between the 3 methods applied.",Disposition of intravenous theophylline in asthmatic children: Bayesian approach vs direct pharmacokinetic calculations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9334881/),[ml] / [kg·min],1.1-1.5,10529,DB00277,Theophylline
,9334881,Vd,"Therapeutic steady state plasma levels around 12 micrograms/ml were rapidly achieved, and the pharmacokinetic parameters (CL = 1.1-1.5 ml/min/kg, Vd = 0.44-0.50 l/kg, t1/2 = 3.5-5.4 hr) differed slightly between the 3 methods applied.",Disposition of intravenous theophylline in asthmatic children: Bayesian approach vs direct pharmacokinetic calculations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9334881/),[l] / [kg],0.44-0.50,10530,DB00277,Theophylline
,9334881,t1/2,"Therapeutic steady state plasma levels around 12 micrograms/ml were rapidly achieved, and the pharmacokinetic parameters (CL = 1.1-1.5 ml/min/kg, Vd = 0.44-0.50 l/kg, t1/2 = 3.5-5.4 hr) differed slightly between the 3 methods applied.",Disposition of intravenous theophylline in asthmatic children: Bayesian approach vs direct pharmacokinetic calculations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9334881/),h,3.5-5.4,10531,DB00277,Theophylline
,3677217,Cmin,"Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively.","Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677217/),[mg] / [l],6.8,11513,DB00277,Theophylline
,3677217,Cmax,"Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively.","Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677217/),[mg] / [l],14.5,11514,DB00277,Theophylline
,3677217,Cav,"Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively.","Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677217/),[mg] / [l],10.5,11515,DB00277,Theophylline
,3677217,plateau time,"Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively.","Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677217/),h,11.7,11516,DB00277,Theophylline
,3677217,peak-trough,"Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively.","Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677217/),%,72,11517,DB00277,Theophylline
,8478313,peak plasma concentration (Cmax),"In man, following an oral 500 mg dose of dirithromycin, a mean peak plasma concentration (Cmax) of 0.48 mg/L (range 0.1-1.97) was observed at 4 h.",Pharmacokinetics of dirithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[mg] / [l],0.48,11702,DB00277,Theophylline
,8478313,area under the plasma concentration versus time curve (AUC0-24h),The mean area under the plasma concentration versus time curve (AUC0-24h) measured 3.37 mg.h/L (range 0.39-17.16).,Pharmacokinetics of dirithromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[h·mg] / [l],3.37,11703,DB00277,Theophylline
,8478313,apparent volume of distribution,The extensive tissue penetration is reflected in a large mean apparent volume of distribution of 800 L (range 504-1041).,Pharmacokinetics of dirithromycin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),l,800,11704,DB00277,Theophylline
,8478313,Plasma protein binding,Plasma protein binding was determined to be 15-30% by ultracentrifugation.,Pharmacokinetics of dirithromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),%,15-30,11705,DB00277,Theophylline
,8478313,plasma elimination half-life,Dirithromycin is characterized by a plasma elimination half-life of 44 h (range 16-65 h) that permits once-daily administration.,Pharmacokinetics of dirithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),h,44,11706,DB00277,Theophylline
,8478313,Total body clearance,Total body clearance was 226-1040 mL/min in the 14C-radiolabelled study.,Pharmacokinetics of dirithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[ml] / [min],226-1040,11707,DB00277,Theophylline
,8478313,absolute bioavailability,The absolute bioavailability calculated from dose-corrected urinary excretion data was 10% (6-14%).,Pharmacokinetics of dirithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),%,10,11708,DB00277,Theophylline
,3407413,t1/2 alpha,After the intravenous administration the distribution is relatively fast (t1/2 alpha = 3.28h).,Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),h,3.28,11791,DB00277,Theophylline
,3407413,apparent volume of distribution,High values of the apparent volume of distribution--12.15 1/kg suggest tissue accumulation.,Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),[1] / [kg],12.15,11792,DB00277,Theophylline
,3407413,t1/2 beta,"Elimination is considerably slower (t1/2 beta = 19,00 h) than distribution.",Pharmacokinetics of vephylline--a new N-substituted theophylline derivative. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407413/),h,"19,00",11793,DB00277,Theophylline
,3982951,bioavailability,On postprandial administration of the 250 mg tablets the bioavailability was 89 +/- 16%.,"Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3982951/),%,89,11917,DB00277,Theophylline
,3982951,Cmax,"Good sustained release properties were obtained provided that the tablets were taken after a meal; Cmax was 7.9 +/- 2.0 mg X 1(-1), tmax was 5.3 +/- 1.6 h, the peak-trough difference was 2.3 +/- 0.6 mg X 1(-1) and the serum concentration fluctuation was accounted for 42.8 +/- 11.2%.","Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3982951/),mg,7.9,11918,DB00277,Theophylline
,3982951,tmax,"Good sustained release properties were obtained provided that the tablets were taken after a meal; Cmax was 7.9 +/- 2.0 mg X 1(-1), tmax was 5.3 +/- 1.6 h, the peak-trough difference was 2.3 +/- 0.6 mg X 1(-1) and the serum concentration fluctuation was accounted for 42.8 +/- 11.2%.","Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3982951/),h,5.3,11919,DB00277,Theophylline
,3982951,peak-trough difference,"Good sustained release properties were obtained provided that the tablets were taken after a meal; Cmax was 7.9 +/- 2.0 mg X 1(-1), tmax was 5.3 +/- 1.6 h, the peak-trough difference was 2.3 +/- 0.6 mg X 1(-1) and the serum concentration fluctuation was accounted for 42.8 +/- 11.2%.","Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3982951/),mg,2.3,11920,DB00277,Theophylline
,10423899,VdTD,(3) VdTD and theophylline clearance each showed 0.77-0.88 L/kg and 0.070-0.091 L/kg/hr.,[Analysis of the theophylline pharmacokinetics of sustained-release theophylline (Theodur) dry syrup in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423899/),[l] / [kg],0.77-0.88,12410,DB00277,Theophylline
,10423899,clearance,(3) VdTD and theophylline clearance each showed 0.77-0.88 L/kg and 0.070-0.091 L/kg/hr.,[Analysis of the theophylline pharmacokinetics of sustained-release theophylline (Theodur) dry syrup in children]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423899/),[l] / [h·kg],0.070-0.091,12411,DB00277,Theophylline
,10423899,Tmax,(4) Tmax was 2.9-3.5 hours and T1/2 was 7.1-8.8 hours.,[Analysis of the theophylline pharmacokinetics of sustained-release theophylline (Theodur) dry syrup in children]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423899/),h,2.9-3.5,12412,DB00277,Theophylline
,10423899,T1/2,(4) Tmax was 2.9-3.5 hours and T1/2 was 7.1-8.8 hours.,[Analysis of the theophylline pharmacokinetics of sustained-release theophylline (Theodur) dry syrup in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423899/),h,7.1-8.8,12413,DB00277,Theophylline
,688731,total clearance,Theophylline was cleared from the blood more rapidly in both marihuana and tobacco smokers with a mean increase in total clearance from 52 ml/kg/hr in nonsmokers to 74 ml/kg/hr in subjects who smoked either material alone.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],52,13215,DB00277,Theophylline
,688731,total clearance,Theophylline was cleared from the blood more rapidly in both marihuana and tobacco smokers with a mean increase in total clearance from 52 ml/kg/hr in nonsmokers to 74 ml/kg/hr in subjects who smoked either material alone.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],74,13216,DB00277,Theophylline
,688731,clearance,There was an additive increase in clearance to 93 ml/kg/hr in those who smoked both substances.,Enhanced biotransformation of theophylline in marihuana and tobacco smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688731/),[ml] / [h·kg],93,13217,DB00277,Theophylline
,3750368,V,An average V of 0.45 L/kg was utilized to calculate TBC with the Chiou and the iterative methods.,Evaluation of the effect of variability in the volume of distribution of theophylline on the predictability of the iterative and the Chiou methods using computer simulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750368/),[l] / [kg],0.45,13446,DB00277,Theophylline
,3750368,C1) serum concentrations,Separate simulations were conducted utilizing initial (C1) serum concentrations of 2 and 10 micrograms/ml.,Evaluation of the effect of variability in the volume of distribution of theophylline on the predictability of the iterative and the Chiou methods using computer simulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750368/),[μg] / [ml],2,13447,DB00277,Theophylline
,3750368,C1) serum concentrations,Separate simulations were conducted utilizing initial (C1) serum concentrations of 2 and 10 micrograms/ml.,Evaluation of the effect of variability in the volume of distribution of theophylline on the predictability of the iterative and the Chiou methods using computer simulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750368/),[μg] / [ml],10,13448,DB00277,Theophylline
,1474168,area,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13761,DB00277,Theophylline
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13762,DB00277,Theophylline
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],0.15,13763,DB00277,Theophylline
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],1438,13764,DB00277,Theophylline
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],2864,13765,DB00277,Theophylline
,3180633,unbound fraction,"The unbound fraction of theophylline was significantly raised in the elderly (mean 77.7% vs. 62.3%, p less than 0.001) and was correlated with the serum albumin level (r = -0.7, p less than 0.01).",Theophylline pharmacokinetics in normal elderly subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180633/),%,77.7,14618,DB00277,Theophylline
,3180633,unbound fraction,"The unbound fraction of theophylline was significantly raised in the elderly (mean 77.7% vs. 62.3%, p less than 0.001) and was correlated with the serum albumin level (r = -0.7, p less than 0.01).",Theophylline pharmacokinetics in normal elderly subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180633/),%,62.3,14619,DB00277,Theophylline
,3180633,total unbound clearance,"Theophylline nonrenal clearance was not changed, but the total unbound clearance was significantly reduced in the elderly subjects as compared with the young ones (mean 0.744 vs. 1.085 ml/min/kg, p less than 0.05).",Theophylline pharmacokinetics in normal elderly subjects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180633/),[ml] / [kg·min],0.744,14620,DB00277,Theophylline
,3180633,total unbound clearance,"Theophylline nonrenal clearance was not changed, but the total unbound clearance was significantly reduced in the elderly subjects as compared with the young ones (mean 0.744 vs. 1.085 ml/min/kg, p less than 0.05).",Theophylline pharmacokinetics in normal elderly subjects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180633/),[ml] / [kg·min],1.085,14621,DB00277,Theophylline
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.77,15035,DB00277,Theophylline
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.26,15036,DB00277,Theophylline
,1664467,renal clearance (CLR),"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.75,15037,DB00277,Theophylline
,1664467,CLR,"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.13,15038,DB00277,Theophylline
,9222075,steady-state plasma concentrations,"For 7 days, the subjects received morning and evening theophylline doses adjusted to achieve steady-state plasma concentrations of 8-15 mg/L, the lower end of the therapeutic range.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[mg] / [l],8-15,15751,DB00277,Theophylline
,9222075,Cmax,"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[mg] / [l],10.15,15752,DB00277,Theophylline
,9222075,AUC(0-12),"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[h·mg] / [l],107.32,15753,DB00277,Theophylline
,9222075,T(1/2),"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),h,9.0,15754,DB00277,Theophylline
,29936192,water solubility,"Due to its poor water solubility (16.82 μg/ml), the therapeutic effectiveness and oral bioavailability of Baicalein are highly limited.",A strategy to improve the oral availability of baicalein: The baicalein-theophylline cocrystal. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29936192/),[μg] / [ml],16.82,16035,DB00277,Theophylline
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00277,Theophylline
,10517354,flow-rate,Samples were separated in a pH 2.2 sodium sulfate-acetonitrile mobile phase at a flow-rate of 1.5 ml/min on a 15 cm octadecylsilyl column at room temperature.,Simple and rapid assay for acetaminophen and conjugated metabolites in low-volume serum samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517354/),[ml] / [min],1.5,16781,DB00277,Theophylline
,22824731,runtime,The plasma samples were extracted by liquid-liquid extraction with ethyl acetate and separated on Shim-pack XR-ODS II column by a gradient elution within a runtime of 8.0 min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),min,8.0,17333,DB00277,Theophylline
,22824731,flow rate,The mobile phase consisted of A (0.1% formic acid in acetonitrile) and B (0.1% formic acid in water) at a flow rate of 0.4 ml/min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ml] / [min],0.4,17334,DB00277,Theophylline
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],"10-10,000",17335,DB00277,Theophylline
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],2.0-2000,17336,DB00277,Theophylline
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],1.0-1000,17337,DB00277,Theophylline
,2407090,apparent volume of distribution,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),[l] / [kg],4,17631,DB00277,Theophylline
,2407090,plasma protein binding,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),%,95,17632,DB00277,Theophylline
,2407090,elimination half-life,"The elimination half-life of moricizine is 2 to 6 hours, but its duration of antiarrhythmic action is much longer suggesting active metabolites.",Clinical pharmacokinetics of moricizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),h,2 to 6,17633,DB00277,Theophylline
,3961896,Cls,No significant difference in mean serum clearance (Cls) values was found between small-for-gestational-age (SGA) patients (Cls = 17.9 +/- 5.3 ml/kg/h) and appropriate-for-gestational-age (AGA) patients (Cls = 18.8 +/- 5.8 ml/kg/h).,Factors influencing theophylline disposition in 179 newborns. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961896/),[ml] / [h·kg],17.9,18143,DB00277,Theophylline
,3961896,Cls,No significant difference in mean serum clearance (Cls) values was found between small-for-gestational-age (SGA) patients (Cls = 17.9 +/- 5.3 ml/kg/h) and appropriate-for-gestational-age (AGA) patients (Cls = 18.8 +/- 5.8 ml/kg/h).,Factors influencing theophylline disposition in 179 newborns. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961896/),[ml] / [h·kg],18.8,18144,DB00277,Theophylline
,3961896,clearance,"Conversely, asphyxiated patients had significantly lower mean clearance values than nonasphyxiated patients (16.4 +/- 5.3 ml/kg/h vs. 20.2 +/- 5.4 ml/kg/h, respectively, p less than 0.001).",Factors influencing theophylline disposition in 179 newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961896/),[ml] / [h·kg],16.4,18145,DB00277,Theophylline
,3961896,clearance,"Conversely, asphyxiated patients had significantly lower mean clearance values than nonasphyxiated patients (16.4 +/- 5.3 ml/kg/h vs. 20.2 +/- 5.4 ml/kg/h, respectively, p less than 0.001).",Factors influencing theophylline disposition in 179 newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961896/),[ml] / [h·kg],20.2,18146,DB00277,Theophylline
,3961896,Volume of distribution,Volume of distribution for theophylline (n = 147) was 0.77 +/- 0.17 L/kg; there was no significant difference in distribution volumes between asphyxiated and nonasphyxiated patients or between SGA and AGA patients.,Factors influencing theophylline disposition in 179 newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961896/),[l] / [kg],0.77,18147,DB00277,Theophylline
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB00277,Theophylline
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB00277,Theophylline
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB00277,Theophylline
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB00277,Theophylline
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB00277,Theophylline
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB00277,Theophylline
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB00277,Theophylline
,11736869,Cmax,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[μg] / [ml],9,19144,DB00277,Theophylline
,11736869,AUC,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[h·μg] / [ml],90,19145,DB00277,Theophylline
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],5,19146,DB00277,Theophylline
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],7,19147,DB00277,Theophylline
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],16,19148,DB00277,Theophylline
up to,7094987,Bioavailability,Bioavailability up to 7 h after administration was determined from the serum concentration-time course.,Influence of food intake on bioavailability of theophylline in premature infants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094987/),h,7,19399,DB00277,Theophylline
>,8229696,Recovery,Recovery of theophylline was > 50%.,High-pressure liquid chromatographic assay of theophylline in dog feces following oral administration of sustained-release products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229696/),%,50,19721,DB00277,Theophylline
,7229951,half-life,"After rapid intravenous doses of aminophylline, the theophylline half-life was 5-7 hr, which decreased slightly when the drug was administered concomitantly with caffeine during steady state of caffeine.",Effect of caffeine on circulating theophylline levels in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),h,5-7,20051,DB00277,Theophylline
,7229951,volume of distribution,The theophylline volume of distribution (0.75 liter/kg) was unaffected by caffeine.,Effect of caffeine on circulating theophylline levels in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),[l] / [kg],0.75,20052,DB00277,Theophylline
,6843559,milk/plasma-quotient,The milk/plasma-quotient varied within a range of 0.6 to 0.89 and was less when maxima of theophylline in plasma were reached.,"[Pharmacokinetics of drugs from the breast-feeding mother passing into the body of the infant, using theophylline as an example]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6843559/),,0.6 to 0.89,20193,DB00277,Theophylline
,9676350,Plateau times,Plateau times of 11.4 h and 20.2 h were achieved with both modes of administration.,[Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676350/),h,11.4,20229,DB00277,Theophylline
,9676350,Plateau times,Plateau times of 11.4 h and 20.2 h were achieved with both modes of administration.,[Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676350/),h,20.2,20230,DB00277,Theophylline
,884920,serum half-life (t1/2),"The serum concentration-time data were fitted to a two-compartment open model and yielded a mean serum half-life (t1/2) of 11.02 hr, a value longer than those previously reported.",Kinetics of intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884920/),h,11.02,21097,DB00277,Theophylline
,16358370,recovery rate,The average recovery rate was 102.3%.,Determination of theophylline concentration in serum by chemiluminescent immunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16358370/),%,102.3,21664,DB00277,Theophylline
,2589989,Distribution volume (Vd),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),[ml] / [kg],385,22487,DB00277,Theophylline
,2589989,Elimination rate constant (Ke),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),1/[h],0.155,22488,DB00277,Theophylline
,2589989,Clearance (CL),Distribution volume (Vd): 385 +/- 106 ml/kg (n = 115) Elimination rate constant (Ke): 0.155 +/- 0.0878/h (n = 176) Clearance (CL): 61.8 +/- 14.3 ml/kg.h (n = 85),[A clinical trial of microcomputer software for calculation of aminophylline dosages]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589989/),[ml] / [h·kg],61.8,22489,DB00277,Theophylline
,7600916,cardiac,"Rats with infarcts involving > 35% of the left ventricle (N = 9) had severe left ventricular failure, and, compared with control rats (N = 9), had reduced cardiac output (97.3 +/- 18.2 vs. 132 +/- 26 ml/min; p < 0.05), reduced mean arterial blood pressure (86 +/- 20 vs. 109 +/- 16 mm Hg; p < 0.05), markedly elevated left ventricular end-diastolic pressure (25.9 +/- 13.6 vs. 10.6 +/- 3.9 mm Hg; p < 0.01), and increased lung weight.",Effects of chronic left ventricular failure on hepatic oxygenation and theophylline elimination in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600916/),m,97.3,22648,DB00277,Theophylline
,7600916,central venous pressure,"There was also an increase in central venous pressure (6.44 +/- 2.60 vs. 3.67 +/- 2.60 mm Hg; p < 0.05), but no evidence of hepatic congestion, as judged by liver weights (14.7 +/- 1.5 vs. 15.3 +/- 1.3 g) and liver histology.",Effects of chronic left ventricular failure on hepatic oxygenation and theophylline elimination in the rat. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600916/),hg·mm,6.44,22649,DB00277,Theophylline
,7600916,central venous pressure,"There was also an increase in central venous pressure (6.44 +/- 2.60 vs. 3.67 +/- 2.60 mm Hg; p < 0.05), but no evidence of hepatic congestion, as judged by liver weights (14.7 +/- 1.5 vs. 15.3 +/- 1.3 g) and liver histology.",Effects of chronic left ventricular failure on hepatic oxygenation and theophylline elimination in the rat. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600916/),hg·mm,3.67,22650,DB00277,Theophylline
,7600916,total hepatic blood flow,"However, total hepatic blood flow, total hepatic oxygen delivery, and theophylline clearance were found to be similar in both groups (1.66 +/- 0.30 vs.",Effects of chronic left ventricular failure on hepatic oxygenation and theophylline elimination in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600916/),,1.66,22651,DB00277,Theophylline
,2076725,Vz,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),[l] / [kg],0.438,22732,DB00277,Theophylline
,2076725,Vz,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),[l] / [kg],0.440,22733,DB00277,Theophylline
,2076725,t1/2,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),h,9.19,22734,DB00277,Theophylline
,2076725,t1/2,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),h,9.69,22735,DB00277,Theophylline
,2076725,CL,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),[ml] / [h·kg],34.4,22736,DB00277,Theophylline
,2076725,CL,"However, pre- and post-exposure pharmacokinetic parameters for theophylline did not differ significantly: Vz = 0.438 vs 0.440 l.kg-1; t1/2 = 9.19 vs 9.69 h; CL = 34.4 vs 32.6 (ml.kg-1.h-1), respectively.",Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076725/),[ml] / [h·kg],32.6,22737,DB00277,Theophylline
,576829,elimination half-life,"After oral administration to the rat, elimination occurs within 2 h following application; in the dog, however, a relatively constant plasma level persists for up to 24 h, which is then reduced during an elimination half-life of 12.4 h.",[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),h,12.4,24132,DB00277,Theophylline
,576829,half-life,"Plasma levels following oral administration remain relatively constant during a time period of 8--30 h, after which they decrease with a half-life of 70 h.",[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),h,70,24133,DB00277,Theophylline
,576829,Ren,"Renal elimination in the dog and rabbit after i.v. application seems to be the main route of excretion (dog 57%, rabbit 66%), while in the rat there is 58% fecal elimination.",[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),%,57,24134,DB00277,Theophylline
,576829,Ren,"Renal elimination in the dog and rabbit after i.v. application seems to be the main route of excretion (dog 57%, rabbit 66%), while in the rat there is 58% fecal elimination.",[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),%,66,24135,DB00277,Theophylline
,576829,Absorption ratios,Absorption ratios following oral administration amount to 13% in the rabbit and 18% in the rat and dog.,[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),%,13,24136,DB00277,Theophylline
,576829,Absorption ratios,Absorption ratios following oral administration amount to 13% in the rabbit and 18% in the rat and dog.,[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),%,18,24137,DB00277,Theophylline
,576829,absorption ration,The absorption ration in the rat following intratracheal application reaches 90%.,[Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576829/),%,90,24138,DB00277,Theophylline
,32657910,CL/F,"The final model for hepatic function showed that CL/F in CH and LC patients was 0.043 and 0.027 L/h/kg, respectively, and it was lower than that in patients with normal hepatic function.",Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32657910/),[l] / [h·kg],0.043,24380,DB00277,Theophylline
,32657910,CL/F,"The final model for hepatic function showed that CL/F in CH and LC patients was 0.043 and 0.027 L/h/kg, respectively, and it was lower than that in patients with normal hepatic function.",Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32657910/),[l] / [h·kg],0.027,24381,DB00277,Theophylline
,3538957,peak expiratory flow rates,"There was a trend for peak expiratory flow rates to normalize more quickly in monitored patients, and their mean duration of hospital stay was shorter (6.3 versus 8.7 days, p = 0.029).",A randomized controlled clinical trial of pharmacokinetic theophylline dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538957/),,6,24451,DB00277,Theophylline
,3538957,peak expiratory flow rates,"There was a trend for peak expiratory flow rates to normalize more quickly in monitored patients, and their mean duration of hospital stay was shorter (6.3 versus 8.7 days, p = 0.029).",A randomized controlled clinical trial of pharmacokinetic theophylline dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538957/),,8.7,24452,DB00277,Theophylline
,3215203,bioavailability,The bioavailability of theophylline from TDS was 94% (range 54%-121%).,"Theophylline pharmacokinetics in children, comparing sustained release spheres (Theo-Dur sprinkle) with elixir. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3215203/),%,94,25738,DB00277,Theophylline
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],336,26251,DB00277,Theophylline
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],349,26252,DB00277,Theophylline
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],393,26253,DB00277,Theophylline
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],367,26254,DB00277,Theophylline
,3731682,steady-state serum,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26255,DB00277,Theophylline
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26256,DB00277,Theophylline
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[μg] / [ml],10.2,26257,DB00277,Theophylline
,11483122,Maximum serum concentrations,Maximum serum concentrations ranged from 55 to 123 mg/L.,Theophylline toxicokinetics in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[mg] / [l],55 to 123,26529,DB00277,Theophylline
,11483122,half-lives,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),h,24.7 to 36.5,26530,DB00277,Theophylline
,11483122,clearance,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[l] / [h·kg],0.02 to 0.05,26531,DB00277,Theophylline
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.1,26778,DB00277,Theophylline
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.8,26779,DB00277,Theophylline
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.11,26780,DB00277,Theophylline
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.16,26781,DB00277,Theophylline
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.8,26782,DB00277,Theophylline
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.0,26783,DB00277,Theophylline
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.39,26784,DB00277,Theophylline
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.41,26785,DB00277,Theophylline
,1517286,lowest detectable concentration,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),[ng] / [ml],25,26845,DB00277,Theophylline
,1517286,recovery,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),%,85,26846,DB00277,Theophylline
,11352444,times to Cmax(tmax),"At steady state, the plasma pharmacokinetics of theophylline for treatments B and C proved equivalent in terms of maximum concentration (Css(max)) and bodyweight- and dose-normalised Css(max) lestimated true ratio 96%, 90% confidence interval (CI) 87 to 105%] and also in terms of area under the concentration-time curve from 0 to 12 hours (AUCss(tau)) and normalised AUCss(tau) (ratio 95%, 90% CI 85 to 107%); the median times to Cmax(tmax) were also similar (5.0 and 6.0 hours for treatments B and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,5.0,27163,DB00277,Theophylline
,11352444,times to Cmax(tmax),"At steady state, the plasma pharmacokinetics of theophylline for treatments B and C proved equivalent in terms of maximum concentration (Css(max)) and bodyweight- and dose-normalised Css(max) lestimated true ratio 96%, 90% confidence interval (CI) 87 to 105%] and also in terms of area under the concentration-time curve from 0 to 12 hours (AUCss(tau)) and normalised AUCss(tau) (ratio 95%, 90% CI 85 to 107%); the median times to Cmax(tmax) were also similar (5.0 and 6.0 hours for treatments B and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,6.0,27164,DB00277,Theophylline
,11352444,tmax,"The plasma pharmacokinetics of moxifloxacin for treatments A and C were equivalent with respect to Css(max) (estimated true ratio 109%, 90% CI 97 to 123%) and AUCss(tau) (ratio 104%, 90% CI 100 to 108%); the median tmax values were also similar (0.5 and 1.0 hour for treatments A and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,0.5,27165,DB00277,Theophylline
,11352444,tmax,"The plasma pharmacokinetics of moxifloxacin for treatments A and C were equivalent with respect to Css(max) (estimated true ratio 109%, 90% CI 97 to 123%) and AUCss(tau) (ratio 104%, 90% CI 100 to 108%); the median tmax values were also similar (0.5 and 1.0 hour for treatments A and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,1.0,27166,DB00277,Theophylline
,6893618,peak concentrations,"Average peak concentrations of theophylline in plasma (range, 15 mumol/L) were not significantly different when Nuelin, Brondecon and Choledyl tablets were administered to healthy subjects.",Comparative bioavailability study of theophylline tablets marketed in Australasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6893618/),[μM] / [l],15,28353,DB00277,Theophylline
,6885204,plasma t 1/2,"The mean plasma t 1/2 after i.v. dosing was 6.5 h (3.5-9 h), and the mean plasma t 1/2 after oral doses was 5.9 h (3-8.3 h).",A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885204/),h,6.5,28559,DB00277,Theophylline
,6885204,plasma t 1/2,"The mean plasma t 1/2 after i.v. dosing was 6.5 h (3.5-9 h), and the mean plasma t 1/2 after oral doses was 5.9 h (3-8.3 h).",A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885204/),h,5.9,28560,DB00277,Theophylline
,6885204,total excretion,"The calculated mean total of 23% (11-70%) of the i.v. dose was excreted in the urine, and the mean total excretion after the oral dose was 15% (7-44%).",A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets). ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885204/),%,15,28561,DB00277,Theophylline
,6885204,absolute bioavailability,The absolute bioavailability of Afonilum was 108 +/- 11%.,A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885204/),%,108,28562,DB00277,Theophylline
,1277710,half-life,"The half-life of theophylline in smokers averaged 4.3 (SD = 1.4) hr, significantly shorter than the mean value in nonsmokers (7.0, SD =1.7 hr).",Effect of smoking on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),h,4.3,28827,DB00277,Theophylline
,1277710,half-life,"The half-life of theophylline in smokers averaged 4.3 (SD = 1.4) hr, significantly shorter than the mean value in nonsmokers (7.0, SD =1.7 hr).",Effect of smoking on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),h,7.0,28828,DB00277,Theophylline
,1277710,apparent volume of distribution,The apparent volume of distribution of theophylline was somewhat larger in smokers (0.50 +/-0.12 L/kg) than in nonsmokers (0.38 +/-0.04 L/kg).,Effect of smoking on theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),[l] / [kg],0.50,28829,DB00277,Theophylline
,1277710,apparent volume of distribution,The apparent volume of distribution of theophylline was somewhat larger in smokers (0.50 +/-0.12 L/kg) than in nonsmokers (0.38 +/-0.04 L/kg).,Effect of smoking on theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),[l] / [kg],0.38,28830,DB00277,Theophylline
,1277710,body clearance,The body clearance of theophylline was appreciably larger and relatively more variable in smokers (100 +/-44 ml/min/1.73 m2) than in nonsmokers (45 +/-13 ml/min/1.73 m2).,Effect of smoking on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),[ml] / [1.73·m2·min],100,28831,DB00277,Theophylline
,1277710,body clearance,The body clearance of theophylline was appreciably larger and relatively more variable in smokers (100 +/-44 ml/min/1.73 m2) than in nonsmokers (45 +/-13 ml/min/1.73 m2).,Effect of smoking on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277710/),[ml] / [1.73·m2·min],45,28832,DB00277,Theophylline
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],249,29195,DB00277,Theophylline
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],211,29196,DB00277,Theophylline
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,51.1,29197,DB00277,Theophylline
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,32.1,29198,DB00277,Theophylline
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30124,DB00277,Theophylline
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30125,DB00277,Theophylline
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30126,DB00277,Theophylline
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30127,DB00277,Theophylline
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,86.0,30128,DB00277,Theophylline
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,72.,30129,DB00277,Theophylline
,6470957,percentage of the dose released,The percentage of the dose released in 1 h in gastric fluid ranged from (mean +/- SD) 6.6 +/- 0.9 to 50.1 +/- 3.8%.,Dissolution studies of some sustained-release theophylline dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470957/),%,6.6,30237,DB00277,Theophylline
,6470957,percentage of the dose released,The percentage of the dose released in 1 h in gastric fluid ranged from (mean +/- SD) 6.6 +/- 0.9 to 50.1 +/- 3.8%.,Dissolution studies of some sustained-release theophylline dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470957/),%,50.1,30238,DB00277,Theophylline
,6470957,percentage of the dose released,"By 6 h, the percentage of the dose released ranged from 10.8 +/- 1.8 to 86.5 +/- 5.2%.",Dissolution studies of some sustained-release theophylline dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470957/),%,10.8,30239,DB00277,Theophylline
,6470957,percentage of the dose released,"By 6 h, the percentage of the dose released ranged from 10.8 +/- 1.8 to 86.5 +/- 5.2%.",Dissolution studies of some sustained-release theophylline dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470957/),%,86.5,30240,DB00277,Theophylline
,3709624,trough concentration,"With chronic oral dosing, however, the mean trough concentration was 12% higher at 9 a.m. than at 5 p.m., the end of the dose interval (3.94 +/- 0.55 vs. 3.50 +/- 0.45 micrograms X ml-1).",Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709624/),[μg] / [ml],3.94,30704,DB00277,Theophylline
,3709624,trough concentration,"With chronic oral dosing, however, the mean trough concentration was 12% higher at 9 a.m. than at 5 p.m., the end of the dose interval (3.94 +/- 0.55 vs. 3.50 +/- 0.45 micrograms X ml-1).",Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709624/),[μg] / [ml],3.50,30705,DB00277,Theophylline
,10499237,distribution half-lives (t1/2 alpha),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,1.37,31527,DB00277,Theophylline
,10499237,distribution half-lives (t1/2 alpha),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,2.66,31528,DB00277,Theophylline
,10499237,elimination half-lives (t1/2 beta),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,11.8,31529,DB00277,Theophylline
,10499237,elimination half-lives (t1/2 beta),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,10.4,31530,DB00277,Theophylline
,10499237,steady state volumes of distribution (Vss),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.88,31531,DB00277,Theophylline
,10499237,steady state volumes of distribution (Vss),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.76,31532,DB00277,Theophylline
,10499237,volumes of the central compartment (Vc),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.41,31533,DB00277,Theophylline
,10499237,volumes of the central compartment (Vc),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.51,31534,DB00277,Theophylline
,10499237,total body clearances (Clt),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],62.3,31535,DB00277,Theophylline
,10499237,total body clearances (Clt),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],50.2,31536,DB00277,Theophylline
,10499237,renal clearance (Vr),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],0.6,31537,DB00277,Theophylline
,10499237,protein binding,Theophylline protein binding at a concentration of 5 micrograms/mL was 32.2 +/- 3.3%.,The disposition of theophylline in camels after intravenous administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),%,32.2,31538,DB00277,Theophylline
,10499237,steady state serum concentration,This dosing regimen should achieve an average steady state serum concentration of 10 micrograms/mL with peak serum concentration not exceeding 15 micrograms/mL.,The disposition of theophylline in camels after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[μg] / [ml],10,31539,DB00277,Theophylline
not exceeding,10499237,peak serum concentration,This dosing regimen should achieve an average steady state serum concentration of 10 micrograms/mL with peak serum concentration not exceeding 15 micrograms/mL.,The disposition of theophylline in camels after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[μg] / [ml],15,31540,DB00277,Theophylline
,2654849,maximal Conc. (Cmax),"The theophylline dose administered was 7.9 +/- 0.4 (mean +/- SD) mg/kg, which produced a maximal Conc. (Cmax) of 14.6 +/- 2.7 microgram/ml.",Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2654849/),[μg] / [ml],14.6,31649,DB00277,Theophylline
,2654849,half-life (T1/2),"The half-life (T1/2), volume of distribution (Vd), and total body clearance (TBC) were 4.9 +/- 1.9 h, 537 +/- 124 mL/kg, and 80 +/- 16 ml/h/kg, respectively.",Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2654849/),h,4.9,31650,DB00277,Theophylline
,2654849,volume of distribution (Vd),"The half-life (T1/2), volume of distribution (Vd), and total body clearance (TBC) were 4.9 +/- 1.9 h, 537 +/- 124 mL/kg, and 80 +/- 16 ml/h/kg, respectively.",Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2654849/),[ml] / [kg],537,31651,DB00277,Theophylline
,2654849,total body clearance (TBC),"The half-life (T1/2), volume of distribution (Vd), and total body clearance (TBC) were 4.9 +/- 1.9 h, 537 +/- 124 mL/kg, and 80 +/- 16 ml/h/kg, respectively.",Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2654849/),[ml] / [h·kg],80,31652,DB00277,Theophylline
,25700100,clearance,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),[ml] / [kg·min],0.95,32052,DB00277,Theophylline
,25700100,elimination half-life,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),h,17.63,32053,DB00277,Theophylline
,10354968,tmax,"The mean tmax (+/- SD) value for theophylline, when coadministered with indinavir (0.9 +/- 0.5 h), was comparable to that observed for theophylline alone (1.0 +/- 0.5 h).",Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354968/),h,0.9,32080,DB00277,Theophylline
,10354968,tmax,"The mean tmax (+/- SD) value for theophylline, when coadministered with indinavir (0.9 +/- 0.5 h), was comparable to that observed for theophylline alone (1.0 +/- 0.5 h).",Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354968/),h,1.0,32081,DB00277,Theophylline
,2600801,Cardiac output,Cardiac output averaged 2.87 +/- 0.86 liters/min and was similar to the sum of compartmental blood flows estimated from the intercompartmental clearances of urea and inulin (2.74 +/- 0.96 liters/min) and to the sum of theophylline intercompartmental clearances (2.62 +/- 0.74 liters/min).,"Splanchnic tissues are a major part of the rapid distribution spaces of inulin, urea and theophylline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600801/),[l] / [min],2.87,32471,DB00277,Theophylline
,2600801,intercompartmental clearances,Cardiac output averaged 2.87 +/- 0.86 liters/min and was similar to the sum of compartmental blood flows estimated from the intercompartmental clearances of urea and inulin (2.74 +/- 0.96 liters/min) and to the sum of theophylline intercompartmental clearances (2.62 +/- 0.74 liters/min).,"Splanchnic tissues are a major part of the rapid distribution spaces of inulin, urea and theophylline. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600801/),[l] / [min],2.74,32472,DB00277,Theophylline
,2600801,intercompartmental clearances,Cardiac output averaged 2.87 +/- 0.86 liters/min and was similar to the sum of compartmental blood flows estimated from the intercompartmental clearances of urea and inulin (2.74 +/- 0.96 liters/min) and to the sum of theophylline intercompartmental clearances (2.62 +/- 0.74 liters/min).,"Splanchnic tissues are a major part of the rapid distribution spaces of inulin, urea and theophylline. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600801/),[l] / [min],2.62,32473,DB00277,Theophylline
,1812479,bioavailability,"Euphylong showed a bioavailability of 83%, the maximum of the serum level was attained at night.",[Euphylong in standard dosage: comparison with an international retard preparation for twice-daily administration in recommended dosage]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812479/),%,83,32600,DB00277,Theophylline
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,1.6,32654,DB00277,Theophylline
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,16.5,32655,DB00277,Theophylline
,7229976,extraction efficiency,The extraction efficiency of the hollow-fiber dialyzers averaged 44.6%.,Pharmacokinetics of dyphylline elimination by uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),%,44.6,33096,DB00277,Theophylline
,7229976,clearance,The mean dialysis clearance was 108.7 ml/min which compares favorably to the 57 ml/min metabolic clearance of the drug.,Pharmacokinetics of dyphylline elimination by uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),[ml] / [min],108.7,33097,DB00277,Theophylline
,7229976,metabolic clearance,The mean dialysis clearance was 108.7 ml/min which compares favorably to the 57 ml/min metabolic clearance of the drug.,Pharmacokinetics of dyphylline elimination by uremic patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),[ml] / [min],57,33098,DB00277,Theophylline
,7229976,Half-lives,Half-lives for dyphylline during dialysis ranged from 3.43 to 7.62 hr.,Pharmacokinetics of dyphylline elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),h,3.43 to 7.62,33099,DB00277,Theophylline
,7229976,half-lives,The off-dialysis half-lives for two of the four patients studied on a separate occasion were 10.6 and 13.2 hr.,Pharmacokinetics of dyphylline elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),h,10.6,33100,DB00277,Theophylline
,7229976,half-lives,The off-dialysis half-lives for two of the four patients studied on a separate occasion were 10.6 and 13.2 hr.,Pharmacokinetics of dyphylline elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229976/),h,13.2,33101,DB00277,Theophylline
,583044,peak concentration,With conventional tablets the mean peak concentration (8.10 +/- 0.751 microgram/ml) was reached at 3 hours and concentrations less than 5 microgram/ml were observed in 4 out of 7 subjects at 6 hours.,Comparative bioavailability of sustained-release and conventional tablets of hydroxyethyltheophylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/583044/),[μg] / [ml],8.10,33122,DB00277,Theophylline
,583044,peak concentration,"In contrast, with sustained-release tablets of theophylline and hydroxytheophylline complex the mean peak concentration (8.90 +/- 0.88 microgram/ml) was reached at 6 hours and levels above 5 microgram/ml were observed in 4 out of 7 cases at 12 hours.",Comparative bioavailability of sustained-release and conventional tablets of hydroxyethyltheophylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/583044/),[μg] / [ml],8.90,33123,DB00277,Theophylline
,583044,trough plasma concentrations,"Administration of 2 sustained-release tablets twice a day produced trough plasma concentrations varying between 6.9-13.8 microgram/ml, i.e. within the therapeutic range in all the 5 subjects.",Comparative bioavailability of sustained-release and conventional tablets of hydroxyethyltheophylline in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/583044/),[μg] / [ml],6.9-13.8,33124,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],56.2,33222,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],50.1,33223,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],58.7,33224,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],48.3,33225,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],65.7,33226,DB00277,Theophylline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],52.1,33227,DB00277,Theophylline
,15289794,initial,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33852,DB00277,Theophylline
,15289794,clearance,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33853,DB00277,Theophylline
,15289794,new steady state,kg(-1) body weight) to a new steady state of 1.53 mL. min(-1).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],1.53,33854,DB00277,Theophylline
,15289794,apparent half-life,The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),h,38.6,33855,DB00277,Theophylline
,6691624,T concentration,"The mean actual T concentration was 12.7 +/- 6.62 micrograms/mL, while the mean predicted T concentration was 11.4 +/- 5.37 micrograms/mL.",Prediction of serum theophylline levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691624/),[μg] / [ml],12.7,34847,DB00277,Theophylline
,6691624,T concentration,"The mean actual T concentration was 12.7 +/- 6.62 micrograms/mL, while the mean predicted T concentration was 11.4 +/- 5.37 micrograms/mL.",Prediction of serum theophylline levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691624/),[μg] / [ml],11.4,34848,DB00277,Theophylline
,8593491,inhibition constant (Ki),"Cimetidine showed competitive inhibition of theophylline elimination in vivo, with an inhibition constant (Ki) of 28.5 microM.","Drug interactions between theophylline and H2-antagonists, roxatidine acetate hydrochloride and cimetidine: pharmacokinetic analysis in rats in vivo. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593491/),μM,28.5,34910,DB00277,Theophylline
,11554438,Km,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [l],2.4,35741,DB00277,Theophylline
,11554438,Km,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [l],5.1,35742,DB00277,Theophylline
,11554438,Km,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [l],112.3,35743,DB00277,Theophylline
,11554438,Vmax,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [h],3.5,35744,DB00277,Theophylline
,11554438,Vmax,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [h],7.5,35745,DB00277,Theophylline
,11554438,Vmax,"The Km values for theophylline metabolism to 3-MX, 1-MU and DMU were 2.4+/-0.6, 5.1+/-1.8+/- and 112.3+/-36.8 mg/L respectively and the Vmax values were 3.5+/-0.7, 7.5+/-2.6 and 112.3+/-36.8 mg/hr respectively.",Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554438/),[mg] / [h],112.3,35746,DB00277,Theophylline
,12583008,C(min),"A lower dose in the morning could reach the effective level (C(min)4.97 +/- 1.60 microg/mL and C(max)10.68 +/- 1.80 micro g/mL over the a.m. dosing interval) and a higher dose in the evening did not result in toxic levels but led to a reasonable concentration range (C(max)9.72 +/- 1.56 microg/mL over p.m. dosing interval), which could maintain a higher plasma theophylline concentration without the risk of serious adverse events and control asthmatic symptoms probably occurring during the night or early in the morning.",Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583008/),[μg] / [ml],4.97,37491,DB00277,Theophylline
,12583008,C(max),"A lower dose in the morning could reach the effective level (C(min)4.97 +/- 1.60 microg/mL and C(max)10.68 +/- 1.80 micro g/mL over the a.m. dosing interval) and a higher dose in the evening did not result in toxic levels but led to a reasonable concentration range (C(max)9.72 +/- 1.56 microg/mL over p.m. dosing interval), which could maintain a higher plasma theophylline concentration without the risk of serious adverse events and control asthmatic symptoms probably occurring during the night or early in the morning.",Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583008/),[μg] / [ml],10.68,37492,DB00277,Theophylline
,12583008,C(max),"A lower dose in the morning could reach the effective level (C(min)4.97 +/- 1.60 microg/mL and C(max)10.68 +/- 1.80 micro g/mL over the a.m. dosing interval) and a higher dose in the evening did not result in toxic levels but led to a reasonable concentration range (C(max)9.72 +/- 1.56 microg/mL over p.m. dosing interval), which could maintain a higher plasma theophylline concentration without the risk of serious adverse events and control asthmatic symptoms probably occurring during the night or early in the morning.",Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583008/),[μg] / [ml],9.72,37493,DB00277,Theophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,7.2 to 15.4,37675,DB00277,Theophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,9.4,37676,DB00277,Theophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,5.4 to 27.2,37677,DB00277,Theophylline
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,14.4,37678,DB00277,Theophylline
,6540112,Peak concentrations,Peak concentrations of theophylline in the plasma (7.5 +/- 1.6 micrograms/ml) are below those which are thought to produce concentration-dependent side effects.,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),[μg] / [ml],7.5,37679,DB00277,Theophylline
,8335711,half-life of elimination,"The half-life of elimination for a 15 mg/kg intraperitoneal dose of theophylline was determined to be 3.1 +/- 0.4 h for MECC and 3.2 +/- 0.4 h for LC (n = 4, mean +/- standard error of the mean).",Pharmacokinetic studies using micellar electrokinetic capillary chromatography with in vivo capillary ultrafiltration probes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335711/),h,3.1,37733,DB00277,Theophylline
,8335711,half-life of elimination,"The half-life of elimination for a 15 mg/kg intraperitoneal dose of theophylline was determined to be 3.1 +/- 0.4 h for MECC and 3.2 +/- 0.4 h for LC (n = 4, mean +/- standard error of the mean).",Pharmacokinetic studies using micellar electrokinetic capillary chromatography with in vivo capillary ultrafiltration probes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335711/),h,3.2,37734,DB00277,Theophylline
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB00277,Theophylline
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB00277,Theophylline
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB00277,Theophylline
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB00277,Theophylline
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB00277,Theophylline
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB00277,Theophylline
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB00277,Theophylline
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB00277,Theophylline
,11978163,apparent bioavailability,"When oral theophylline was given to the patient in tablet form, the apparent bioavailability was only 20%, which agreed with our hypothesis.",Pharmacokinetic analysis of theophylline to assess noncompliance in therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978163/),%,20,39233,DB00277,Theophylline
,11978163,bioavailability,"However, the bioavailability of theophylline given in liquid form was almost 100%, and theophylline in tablet form was confirmed to be fully bioavailable when the test was performed under supervision by medical staff.",Pharmacokinetic analysis of theophylline to assess noncompliance in therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978163/),%,100,39234,DB00277,Theophylline
,1570234,clearance,Theophylline clearance was reduced from 65.7 +/- 9.8 ml/kg/hour at baseline to 50.2 +/- 4.1 ml/kg/hour (p less than 0.05) after 2 weeks and 50.1 +/- 6.2 ml/kg/hour (p less than 0.05) after 12 weeks of TAO therapy.,Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570234/),[ml] / [h·kg],65.7,39823,DB00277,Theophylline
,1570234,clearance,Theophylline clearance was reduced from 65.7 +/- 9.8 ml/kg/hour at baseline to 50.2 +/- 4.1 ml/kg/hour (p less than 0.05) after 2 weeks and 50.1 +/- 6.2 ml/kg/hour (p less than 0.05) after 12 weeks of TAO therapy.,Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570234/),[ml] / [h·kg],50.2,39824,DB00277,Theophylline
,1570234,clearance,Theophylline clearance was reduced from 65.7 +/- 9.8 ml/kg/hour at baseline to 50.2 +/- 4.1 ml/kg/hour (p less than 0.05) after 2 weeks and 50.1 +/- 6.2 ml/kg/hour (p less than 0.05) after 12 weeks of TAO therapy.,Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570234/),[ml] / [h·kg],50.1,39825,DB00277,Theophylline
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],140,40634,DB00277,Theophylline
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],100,40635,DB00277,Theophylline
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],136,40636,DB00277,Theophylline
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],128,40637,DB00277,Theophylline
,7937553,elimination half-life,From the terminal phase of the curves it is possible to calculate the elimination half-life: 2.69 apolisychrons for theophylline when it is administered alone and 3.86 apolisychrons when it is administered in combination with cimetidine.,Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937553/),,2.69,41037,DB00277,Theophylline
,7937553,elimination half-life,From the terminal phase of the curves it is possible to calculate the elimination half-life: 2.69 apolisychrons for theophylline when it is administered alone and 3.86 apolisychrons when it is administered in combination with cimetidine.,Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937553/),,3.86,41038,DB00277,Theophylline
,15948934,V dss,The predicted V dss of theophylline was 0.4-0.6 l kg(-1) and showed only a modest change with age.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[l] / [kg],0.4-0.6,41088,DB00277,Theophylline
,15948934,t(1/2),"Predicted t(1/2) was 18 h in the neonate, dropping rapidly to 4.6-7.2 h from 6 months onwards, and the MPE was 24%.",Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,18,41089,DB00277,Theophylline
,15948934,t(1/2),"Predicted t(1/2) was 18 h in the neonate, dropping rapidly to 4.6-7.2 h from 6 months onwards, and the MPE was 24%.",Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,4.6-7.2,41090,DB00277,Theophylline
,15948934,V dss,V dss ranged between 1.0 and 1.7 l kg(-1) and showed only modest change with age.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[l] / [kg],1.0 and 1.7,41091,DB00277,Theophylline
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],124,41092,DB00277,Theophylline
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],664,41093,DB00277,Theophylline
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],425,41094,DB00277,Theophylline
,15948934,t(1/2),Predicted t(1/2) was 6.9 h in the neonate and attained 'adult' values of 2.5-3.5 h from 1 year onwards.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,6.9,41095,DB00277,Theophylline
,15948934,t(1/2),Predicted t(1/2) was 6.9 h in the neonate and attained 'adult' values of 2.5-3.5 h from 1 year onwards.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,2.5-3.5,41096,DB00277,Theophylline
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB00277,Theophylline
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB00277,Theophylline
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB00277,Theophylline
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB00277,Theophylline
,10584979,K(i),"In vitro, omeprazole was mainly a competitive CYP1A2 inhibitor with K(i) values of around 150 microM.",Omeprazole weakly inhibits CYP1A2 activity in man. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584979/),μM,150,42427,DB00277,Theophylline
,10944826,PEF,"PEF in the morning was higher during the UP period (mean +/- SD: 335 +/- 110 L/min) than during the TD period (mean +/- SD: 308 +/- 95 L/min) (p < 0.05), and diurnal variabirity of PEF was lower during the UP period (17.1 +/- 8.0%) than TD period (22.9 +/- 13.4%) (p < 0.05).",[Efficacy of sustained-released theophylline on peak expiratory flow rate in asthmatic patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944826/),[l] / [min],335,42441,DB00277,Theophylline
,10944826,PEF,"PEF in the morning was higher during the UP period (mean +/- SD: 335 +/- 110 L/min) than during the TD period (mean +/- SD: 308 +/- 95 L/min) (p < 0.05), and diurnal variabirity of PEF was lower during the UP period (17.1 +/- 8.0%) than TD period (22.9 +/- 13.4%) (p < 0.05).",[Efficacy of sustained-released theophylline on peak expiratory flow rate in asthmatic patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944826/),[l] / [min],308,42442,DB00277,Theophylline
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,5.7,43650,DB00277,Theophylline
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,6.2,43651,DB00277,Theophylline
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,10.8,43652,DB00277,Theophylline
,15083216,volume of distribution (Vd),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [kg],0.77,43855,DB00277,Theophylline
,15083216,elimination rate constant (Ke),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),1/[h],0.027,43856,DB00277,Theophylline
,15083216,CL,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [h·kg],0.019,43857,DB00277,Theophylline
,15083216,t0.5,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),,30.7,43858,DB00277,Theophylline
,15083216,Css level,"In view of the results and practical considerations, initial dosage regimen to attain a TH Css level within the therapeutic range (6-12 ug/ml) was suggested: LD 6-7 mg/kg, MD 1.5 - 2.0 mg/kg/12 hours.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[ug] / [ml],6-12,43859,DB00277,Theophylline
,6832207,t1/2 beta,"In 8 children of normal weight, the t1/2 beta (4.93 h) plasma clearance (1.22 ml/min/kg and Vd area (504 ml/kg) were similar to those of Swedish children of normal weight.",Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832207/),h,4.93,44159,DB00277,Theophylline
,6832207,plasma clearance,"In 8 children of normal weight, the t1/2 beta (4.93 h) plasma clearance (1.22 ml/min/kg and Vd area (504 ml/kg) were similar to those of Swedish children of normal weight.",Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832207/),[ml] / [kg·min],1.22,44160,DB00277,Theophylline
,6832207,Vd area,"In 8 children of normal weight, the t1/2 beta (4.93 h) plasma clearance (1.22 ml/min/kg and Vd area (504 ml/kg) were similar to those of Swedish children of normal weight.",Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832207/),[ml] / [kg],504,44161,DB00277,Theophylline
,3429062,renal clearance,"However, renal clearance of erythromycin was enhanced by theophylline treatment (86.0 +/- 81.1 ml/min vs. 32.5 +/- 15.9 ml/min, with vs. without theophylline).",Influence of theophylline on the renal clearance of erythromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429062/),[ml] / [min],86.0,45002,DB00277,Theophylline
,3429062,renal clearance,"However, renal clearance of erythromycin was enhanced by theophylline treatment (86.0 +/- 81.1 ml/min vs. 32.5 +/- 15.9 ml/min, with vs. without theophylline).",Influence of theophylline on the renal clearance of erythromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429062/),[ml] / [min],32.5,45003,DB00277,Theophylline
,3429062,urinary flow rate,"Theophylline also altered urinary flow rate (4.7 +/- 1.6 ml/min vs. 1.9 +/- 1.2 ml/min, with vs. without theophylline) whereas fluid intake was identical (125 ml/h) as well as the pH of the urine (pH 6.5).",Influence of theophylline on the renal clearance of erythromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429062/),[ml] / [min],4.7,45004,DB00277,Theophylline
,3429062,urinary flow rate,"Theophylline also altered urinary flow rate (4.7 +/- 1.6 ml/min vs. 1.9 +/- 1.2 ml/min, with vs. without theophylline) whereas fluid intake was identical (125 ml/h) as well as the pH of the urine (pH 6.5).",Influence of theophylline on the renal clearance of erythromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429062/),[ml] / [min],1.9,45005,DB00277,Theophylline
,3429062,urinary flow rate,"In this trial, renal clearance of erythromycin was not influenced by enhanced urinary flow rate (7.2 +/- 1.9 ml/min) which was due to high fluid intake (500 ml/h) whereas the pH of the urine was kept at 6.5 as in the first part of the study.",Influence of theophylline on the renal clearance of erythromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429062/),[ml] / [min],7.2,45006,DB00277,Theophylline
,3439657,Peak theophylline,Peak theophylline plasma levels were 13.38 +/- 4.83 micrograms/ml and through plasma levels were 8.73 +/- 3.78 micrograms/ml.,[Monitoring of three delayed-release preparations of theophylline in the plasma of children: pharmacokinetic parameters and therapeutic significance]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439657/),[μg] / [ml],13.38,45119,DB00277,Theophylline
,3439657,plasma levels,Peak theophylline plasma levels were 13.38 +/- 4.83 micrograms/ml and through plasma levels were 8.73 +/- 3.78 micrograms/ml.,[Monitoring of three delayed-release preparations of theophylline in the plasma of children: pharmacokinetic parameters and therapeutic significance]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439657/),[μg] / [ml],13.38,45120,DB00277,Theophylline
,3439657,through plasma levels,Peak theophylline plasma levels were 13.38 +/- 4.83 micrograms/ml and through plasma levels were 8.73 +/- 3.78 micrograms/ml.,[Monitoring of three delayed-release preparations of theophylline in the plasma of children: pharmacokinetic parameters and therapeutic significance]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439657/),[μg] / [ml],8.73,45121,DB00277,Theophylline
,3439657,plasma half-life,Drug plasma half-life varied from 2.9 to 18.2 hr (means = 8.85 +/- 3.64 hr).,[Monitoring of three delayed-release preparations of theophylline in the plasma of children: pharmacokinetic parameters and therapeutic significance]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439657/),h,8.85,45122,DB00277,Theophylline
,3191816,Total body clearance (dose/Css),Total body clearance (dose/Css) of the drug ranged from 0.20 to 0.56 liter/h in 13 patients and 1.14 to 1.75 liter/h in 4 patients suggesting a binomial distribution in the disposition kinetics of the drug.,Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191816/),[l] / [h],0.20 to 0.56,45145,DB00277,Theophylline
,3191816,Total body clearance (dose/Css),Total body clearance (dose/Css) of the drug ranged from 0.20 to 0.56 liter/h in 13 patients and 1.14 to 1.75 liter/h in 4 patients suggesting a binomial distribution in the disposition kinetics of the drug.,Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191816/),[l] / [h],1.14 to 1.75,45146,DB00277,Theophylline
,3191816,volume of distribution,"The mean volume of distribution and half-life of doxapram were 7.33 +/- 4.55 liter/kg and 8.17 +/- 4.13 h, respectively.",Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191816/),[l] / [kg],7.33,45147,DB00277,Theophylline
,3191816,half-life,"The mean volume of distribution and half-life of doxapram were 7.33 +/- 4.55 liter/kg and 8.17 +/- 4.13 h, respectively.",Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191816/),h,8.17,45148,DB00277,Theophylline
,3191816,steady-state plasma concentration (Css),"Based on our calculations to accelerate the attainment of a steady-state plasma concentration (Css) of approximately 1.5 mg/l, a loading dose of 5.5 mg/kg and a maintenance dose of 1 mg/kg/h along with serum concentration monitoring are recommended.",Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191816/),[mg] / [l],1.5,45149,DB00277,Theophylline
,2795453,volume of distribution (Vd),The volume of distribution (Vd) for the population was estimated to be 0.62 L/kg.,Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795453/),[l] / [kg],0.62,45315,DB00277,Theophylline
,2371242,Vss,"In addition, the Vss decreased from 0.71 L/kg to 0.57 L/kg in the 2 and 20 month old rats, respectively, on a normal protein diet.",The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[l] / [kg],0.71,45391,DB00277,Theophylline
,2371242,Vss,"In addition, the Vss decreased from 0.71 L/kg to 0.57 L/kg in the 2 and 20 month old rats, respectively, on a normal protein diet.",The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[l] / [kg],0.57,45392,DB00277,Theophylline
,2371242,total body clearance,Dietary protein deficiency led to a significant reduction of total body clearance from approximately 73 to 45 ml/hr/kg in the 2 and 14 month old rats.,The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[ml] / [h·kg],73,45393,DB00277,Theophylline
,2371242,total body clearance,Dietary protein deficiency led to a significant reduction of total body clearance from approximately 73 to 45 ml/hr/kg in the 2 and 14 month old rats.,The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371242/),[ml] / [h·kg],45,45394,DB00277,Theophylline
,7784342,steady-state plasma concentrations,"The effects of norfloxacin (NOR), at steady-state plasma concentrations of 0-32 mg.l-1, on the plasma clearance of a 6 mg.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),[mg] / [l],0-32,45925,DB00277,Theophylline
,7784342,Ki,"The effects were characterised by a Ki value (Ki = 12 microM), which was comparable with Ki values obtained previously under identical conditions for ciprofloxacin, but higher than that obtained for enoxacin.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),μM,12,45926,DB00277,Theophylline
,17110179,linear dynamic,"A linear dynamic range of 100-10,000 ng/mL for both theophylline and etofylline was established.",A simple and rapid HPLC/UV method for the simultaneous quantification of theophylline and etofylline in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17110179/),[ng] / [ml],"100-10,000",46765,DB00277,Theophylline
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00277,Theophylline
,7341279,elimination half-live,"In this study, the elimination half-live increased from 7.8 +/- 1.7 h on the control day to 9.5 +/- 1.4 h following treatment with antibiotic (p less than 0.02).",The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),h,7.8,48541,DB00277,Theophylline
,7341279,elimination half-live,"In this study, the elimination half-live increased from 7.8 +/- 1.7 h on the control day to 9.5 +/- 1.4 h following treatment with antibiotic (p less than 0.02).",The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),h,9.5,48542,DB00277,Theophylline
,7341279,apparent volume of distribution for theophylline (V/F),The estimated apparent volume of distribution for theophylline (V/F) was also observed to increase from 0.42 +/- 0.09 l/kg before treatment with erythromycin to 0.53 +/- 0.15 l/kg after antibiotic treatment (0.05 less than p less than 0.10).,The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),[l] / [kg],0.42,48543,DB00277,Theophylline
,7341279,apparent volume of distribution for theophylline (V/F),The estimated apparent volume of distribution for theophylline (V/F) was also observed to increase from 0.42 +/- 0.09 l/kg before treatment with erythromycin to 0.53 +/- 0.15 l/kg after antibiotic treatment (0.05 less than p less than 0.10).,The effects of erythromycin on the absorption and disposition of kinetics of theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341279/),[l] / [kg],0.53,48544,DB00277,Theophylline
,8236689,maximum plasma concentration,A mean (+/- se) maximum plasma concentration of 12.2 +/- 0.65 micrograms/ml was obtained 5.17 +/- 0.70 hours after administration and it was calculated to have a mean residence time of 9.09 hours.,Pharmacokinetics and clinical effects in dogs of a sustained-release formulation of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236689/),[μg] / [ml],12.2,48706,DB00277,Theophylline
,8236689,mean residence time,A mean (+/- se) maximum plasma concentration of 12.2 +/- 0.65 micrograms/ml was obtained 5.17 +/- 0.70 hours after administration and it was calculated to have a mean residence time of 9.09 hours.,Pharmacokinetics and clinical effects in dogs of a sustained-release formulation of theophylline. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236689/),h,9.09,48707,DB00277,Theophylline
,4054200,half-life,The average half-life of theophylline in the former was 7.11 h and in the latter 4.72 h.,Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054200/),h,7.11,49230,DB00277,Theophylline
,4054200,half-life,The average half-life of theophylline in the former was 7.11 h and in the latter 4.72 h.,Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054200/),h,4.72,49231,DB00277,Theophylline
,4054200,clearances (CL),"The average clearances (CL) of theophylline were 2.83 and 4.58 l/h, respectively.",Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054200/),[l] / [h],2.83,49232,DB00277,Theophylline
,4054200,clearances (CL),"The average clearances (CL) of theophylline were 2.83 and 4.58 l/h, respectively.",Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054200/),[l] / [h],4.58,49233,DB00277,Theophylline
,8369754,clearance,"A final estimate of population mean clearance was 58.6 ml/kg/h, which was decreased by 36% in patients with hepatic dysfunction.",Population pharmacokinetics of theophylline. I: Intravenous infusion to children in the acute episode of asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369754/),[ml] / [h·kg],58.6,49293,DB00277,Theophylline
,7202475,peak time,The mean peak time after oral administration was 29 min.,Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),min,29,49570,DB00277,Theophylline
,7202475,fraction absorbed,"The mean fraction absorbed was 1.09 calculated from serum concentrations, and 1.05 calculated from urinary excretion of the drug.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),,1.09,49571,DB00277,Theophylline
,7202475,fraction absorbed,"The mean fraction absorbed was 1.09 calculated from serum concentrations, and 1.05 calculated from urinary excretion of the drug.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),,1.05,49572,DB00277,Theophylline
,7202475,apparent volume of distribution,"The apparent volume of distribution was 0.61 1/kg (0.53--0.72 1/kg), 26% higher in males than in females.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),[1] / [kg],0.61,49573,DB00277,Theophylline
,7202475,distribution half-life,"A two-compartment open model was found to describe the decline in the serum concentrations, giving a mean distribution half-life of 6 min.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),min,6,49574,DB00277,Theophylline
,7202475,biological half-life,"The intersubject ranges of biological half-life were 8.1--12.1 h and 8.3--12.6 h calculated from serum and urine data, respectively.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),h,8.,49575,DB00277,Theophylline
,7202475,biological half-life,"The intersubject ranges of biological half-life were 8.1--12.1 h and 8.3--12.6 h calculated from serum and urine data, respectively.",Pharmacokinetics of proxyphylline in adults after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202475/),h,8.3,49576,DB00277,Theophylline
,8423043,total body clearance,"The total body clearance of theophylline was also decreased (from 0.76 to 0.56 ml/kg/min; p < 0.05), and its elimination half-life was increased (from 8.4 to 11.7 hr; p < 0.05); however, the volume of distribution was not significantly affected.",Depression of drug-metabolizing activity in the human liver by interferon-beta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8423043/),[ml] / [kg·min],0.76 to 0.56,50929,DB00277,Theophylline
,8423043,elimination half-life,"The total body clearance of theophylline was also decreased (from 0.76 to 0.56 ml/kg/min; p < 0.05), and its elimination half-life was increased (from 8.4 to 11.7 hr; p < 0.05); however, the volume of distribution was not significantly affected.",Depression of drug-metabolizing activity in the human liver by interferon-beta. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8423043/),h,8,50930,DB00277,Theophylline
,6886029,Peritoneal clearance,"Peritoneal clearance averaged 9.5 ml/min, in contrast with the hemodialysis clearance of 84.8 ml/min, indicating a relative inefficiency of peritoneal dialysis with regard to theophylline removal.",Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886029/),[ml] / [min],9.5,51000,DB00277,Theophylline
,6886029,clearance,"Peritoneal clearance averaged 9.5 ml/min, in contrast with the hemodialysis clearance of 84.8 ml/min, indicating a relative inefficiency of peritoneal dialysis with regard to theophylline removal.",Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886029/),[ml] / [min],84.8,51001,DB00277,Theophylline
,6886029,half-life,"Theophylline half-life was reduced substantially during hemodialysis, 2.0 to 3.2 hours, in comparison with the normal half-life range of 4.7 to 6.8 hours during peritoneal dialysis.",Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886029/),h,2.0 to 3.2,51002,DB00277,Theophylline
,6886029,half-life,"Theophylline half-life was reduced substantially during hemodialysis, 2.0 to 3.2 hours, in comparison with the normal half-life range of 4.7 to 6.8 hours during peritoneal dialysis.",Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886029/),h,4.7 to 6.8,51003,DB00277,Theophylline
,7172970,clearance rate,"In a 6 1/2-month-old infant with hepatic failure secondary to hereditary tyrosinemia, the theophylline clearance rate of 0.016 liter/kg/h was reduced for age and the serum half-life was prolonged to 18.0 h.",The pharmacokinetics of theophylline in an infant with hepatic failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172970/),[l] / [h·kg],0.016,51258,DB00277,Theophylline
,7172970,serum half-life,"In a 6 1/2-month-old infant with hepatic failure secondary to hereditary tyrosinemia, the theophylline clearance rate of 0.016 liter/kg/h was reduced for age and the serum half-life was prolonged to 18.0 h.",The pharmacokinetics of theophylline in an infant with hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172970/),h,18.0,51259,DB00277,Theophylline
,7418718,Vd,Data from 10 severe acute asthmatic patients were used to test the model and the estimated parameters were: Vd = 0.26 +/- 0.029l/kg (mean +/- SEM) and Kel = 0.20 +/- 0.045 h(-1).,A hand-held calculator program for individualized dosage adjustment of intravenous theophylline in acute asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418718/),[l] / [kg],0.26,51415,DB00277,Theophylline
,7418718,Kel,Data from 10 severe acute asthmatic patients were used to test the model and the estimated parameters were: Vd = 0.26 +/- 0.029l/kg (mean +/- SEM) and Kel = 0.20 +/- 0.045 h(-1).,A hand-held calculator program for individualized dosage adjustment of intravenous theophylline in acute asthma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418718/),1/[h],0.20,51416,DB00277,Theophylline
,8835044,serum concentration (Cp),Subjects received extended-release oral theophylline at a constant dosage over 4 weeks to yield a serum concentration (Cp) between 5 and 10 micrograms/mL.,Effect of ranitidine on theophylline metabolism in healthy Koreans living in China. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835044/),[μg] / [ml],5 and 10,51752,DB00277,Theophylline
,9673785,pore size,The pore size was approximately 400 microns.,Preparation and evaluation of micro-porous ethylcellulose capsule as oral sustained-release preparation of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673785/),μns,400,52022,DB00277,Theophylline
,3719616,apparent volume of distribution,"Theophylline's apparent volume of distribution (mean +/- SD) was 1.02 +/- 0.13 L/kg, a value similar to those previously reported, but the half-life (16.9 +/- 6.2 hr) was considerably shorter.",Pharmacokinetics of theophylline in premature infants on the first day of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719616/),[l] / [kg],1.02,52223,DB00277,Theophylline
,3719616,half-life,"Theophylline's apparent volume of distribution (mean +/- SD) was 1.02 +/- 0.13 L/kg, a value similar to those previously reported, but the half-life (16.9 +/- 6.2 hr) was considerably shorter.",Pharmacokinetics of theophylline in premature infants on the first day of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719616/),h,16.9,52224,DB00277,Theophylline
,3719616,elimination rate constant,The elimination rate constant (0.046 +/- 0.020/hr) and the clearance rate (46 +/- 14 ml/kg/hr) were faster than in older infants.,Pharmacokinetics of theophylline in premature infants on the first day of life. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719616/),1/[h],0.046,52225,DB00277,Theophylline
,3719616,clearance rate,The elimination rate constant (0.046 +/- 0.020/hr) and the clearance rate (46 +/- 14 ml/kg/hr) were faster than in older infants.,Pharmacokinetics of theophylline in premature infants on the first day of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719616/),[ml] / [h·kg],46,52226,DB00277,Theophylline
,20662110,flow rate,"A mobile phase solvent consisting of 20 mm sodium dihydrogenphosphate (pH 3.0) and acetonitrile (85:15, v/v) was pumped at a flow rate of 1.0 mL/min.",A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662110/),[ml] / [min],1.0,52340,DB00277,Theophylline
,3952003,AUCratio,"A statistically significant difference between means and variances of the absolute bioavailability of oral theophylline, AUCoral male infinity/AUCIV male infinity, (AUCratio +/- SD) was demonstrated in the tetraplegic subjects who showed decreased bioavailability (AUCratio = 0.67 +/- 0.04, range 0.63-0.73) as compared to the paraplegic (AUCratio = 0.95 +/- 0.09, range 0.84-1.08) and control subjects (AUCratio = 0.90 +/- 0.12, range 0.78-1.02).",The absolute bioavailability of oral theophylline in patients with spinal cord injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952003/),,0.67,52351,DB00277,Theophylline
,3952003,AUCratio,"A statistically significant difference between means and variances of the absolute bioavailability of oral theophylline, AUCoral male infinity/AUCIV male infinity, (AUCratio +/- SD) was demonstrated in the tetraplegic subjects who showed decreased bioavailability (AUCratio = 0.67 +/- 0.04, range 0.63-0.73) as compared to the paraplegic (AUCratio = 0.95 +/- 0.09, range 0.84-1.08) and control subjects (AUCratio = 0.90 +/- 0.12, range 0.78-1.02).",The absolute bioavailability of oral theophylline in patients with spinal cord injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952003/),,0.95,52352,DB00277,Theophylline
,3952003,AUCratio,"A statistically significant difference between means and variances of the absolute bioavailability of oral theophylline, AUCoral male infinity/AUCIV male infinity, (AUCratio +/- SD) was demonstrated in the tetraplegic subjects who showed decreased bioavailability (AUCratio = 0.67 +/- 0.04, range 0.63-0.73) as compared to the paraplegic (AUCratio = 0.95 +/- 0.09, range 0.84-1.08) and control subjects (AUCratio = 0.90 +/- 0.12, range 0.78-1.02).",The absolute bioavailability of oral theophylline in patients with spinal cord injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952003/),,0.90,52353,DB00277,Theophylline
,22472450,t(max),Asmanyl(®) tablets showed faster absorption (t(max) 4.0 h) compared to the TPH formulation showing a t(max) value of 8.0 h.,Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472450/),h,4.0,52364,DB00277,Theophylline
,22472450,t(max),Asmanyl(®) tablets showed faster absorption (t(max) 4.0 h) compared to the TPH formulation showing a t(max) value of 8.0 h.,Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472450/),h,8.0,52365,DB00277,Theophylline
,22472450,relative bioavailability,"The C(max) and AUC values of TPH formulation were significantly (p < 0.05) higher than those for Asmanyl(®), revealing relative bioavailability of about 136.93 %.",Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472450/),%,136.93,52366,DB00277,Theophylline
,2274687,steady state concentrations,The plasma theophylline concentration after 8-10 h was then used to calculate the optimum maintenance dose of sustained release aminophylline required to achieve steady state concentrations between 55 and 110 mumols l-1.,A single oral dose method for predicting steady state theophylline concentrations in clinical practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2274687/),[mumols] / [l],55 and 110,52540,DB00277,Theophylline
,2712416,elimination half-life,The drug had a mean elimination half-life of 6.4 hours and a mean distribution half-life of 22 minutes.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),h,6.4,52798,DB00277,Theophylline
,2712416,distribution half-life,The drug had a mean elimination half-life of 6.4 hours and a mean distribution half-life of 22 minutes.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),min,22,52799,DB00277,Theophylline
,2712416,Total body clearance,Total body clearance averaged 91 ml/kg/h.,Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[ml] / [h·kg],91,52800,DB00277,Theophylline
,2712416,volume of the central compartment,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.502,52801,DB00277,Theophylline
,2712416,volume of distribution during the terminal phase,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.870,52802,DB00277,Theophylline
,2712416,volume of distribution at steady state,"The mean values for the pharmacokinetic volume of the central compartment, pharmacokinetic volume of distribution during the terminal phase, and volume of distribution at steady state were 0.502, 0.870, and 0.815 L/kg, respectively.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),[l] / [kg],0.815,52803,DB00277,Theophylline
,2712416,absorption half-life,"The plasma concentrations after oral dosing peaked in approximately 5 to 6 hours, with a mean absorption half-life of 3.7 hours.",Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712416/),h,3.7,52804,DB00277,Theophylline
,3186628,Half-times,Half-times of the two phases of accumulation were for theophylline 0.28 and 0.98 min.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.28,54322,DB00277,Theophylline
,3186628,Half-times,Half-times of the two phases of accumulation were for theophylline 0.28 and 0.98 min.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.98,54323,DB00277,Theophylline
,3186628,terminal disposition half-time,"The terminal disposition half-time for enprofylline was, however, 2.7 times higher than that of 0.91 min.",Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.91,54324,DB00277,Theophylline
,3186628,tissue-perfusion liquid ratios,Both xanthines accumulated against a concentration gradient showing myocardial tissue-perfusion liquid ratios of about 2.9 for theophylline and 3.7 for enprofylline.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),,2.9,54325,DB00277,Theophylline
,3186628,tissue-perfusion liquid ratios,Both xanthines accumulated against a concentration gradient showing myocardial tissue-perfusion liquid ratios of about 2.9 for theophylline and 3.7 for enprofylline.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),,3.7,54326,DB00277,Theophylline
,2653697,t1/2,"The t1/2 for enoxacin ranges from 4 to 6 hours, which allows effective twice-daily administration without significant accumulation.",Enoxacin absorption and elimination characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653697/),h,4 to 6,54494,DB00277,Theophylline
,21154966,lag time,Results showed that the tablets prepared according to the optimized values released no drug in the upper part of gastrointestinal tract; drug release was initiated at pH 6.4 (colon) after a lag time of 5 h.,Design and optimization of colon-targeted system of theophylline for chronotherapy of nocturnal asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154966/),h,5,54539,DB00277,Theophylline
,21154966,lag time,In vivo evaluation (pharmacokinetic studies and roentgenography) in rabbits revealed that the tablet remained intact until it reaches the colon and the drug release was initiated after a lag time of 5 h.,Design and optimization of colon-targeted system of theophylline for chronotherapy of nocturnal asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154966/),h,5,54540,DB00277,Theophylline
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],0.58,54661,DB00277,Theophylline
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],2.08,54662,DB00277,Theophylline
,3429692,clearance,"First, a 600-mg oral dose of aminophylline, a rapidly absorbed formulation, was studied to confirm that theophylline clearance was in the expected range (mean +/- SD, 0.710 +/- 0.096 mL/min/kg), t1/2 = 6.9 +/- 1.1 hr.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[ml] / [kg·min],0.710,55705,DB00277,Theophylline
,3429692,t1/2,"First, a 600-mg oral dose of aminophylline, a rapidly absorbed formulation, was studied to confirm that theophylline clearance was in the expected range (mean +/- SD, 0.710 +/- 0.096 mL/min/kg), t1/2 = 6.9 +/- 1.1 hr.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),h,6.9,55706,DB00277,Theophylline
,3429692,Cmax,"Theophylline Cmax levels averaged 16.5 micrograms/mL after 900 mg Theo-Dur, with 8% exceeding 20 micrograms/mL.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],16.5,55707,DB00277,Theophylline
,3429692,Cmax,"Theophylline Cmax levels averaged 16.5 micrograms/mL after 900 mg Theo-Dur, with 8% exceeding 20 micrograms/mL.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),,20,55708,DB00277,Theophylline
,3429692,trough levels,Uniphyl administration resulted in three-fourths of trough levels to be at 5 micrograms/mL or lower.,"Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],5,55709,DB00277,Theophylline
below,3429692,trough levels,"With Theo-24 only 17% of trough levels were below 5 micrograms/mL, as compared to 47% with Theo-Dur and 72% with Uniphyl.","Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429692/),[μg] / [ml],5,55710,DB00277,Theophylline
,6825748,peak serum theophylline concentration,The mean peak serum theophylline concentration of 58.9 +/- 4.5 mumol/1 on day 1 showed that the initial loading dose should be increased to about 7 mg theophylline per kg when the liquid is used in acute treatment.,Pharmacokinetics of a new theophylline liquid in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825748/),μM,58.9,56713,DB00277,Theophylline
,6825748,Peak serum levels,Peak serum levels were achieved in 96 +/- 7.5 min (day 1) and 71 +/- 5.5 min (day 5).,Pharmacokinetics of a new theophylline liquid in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825748/),min,96,56714,DB00277,Theophylline
,6825748,Peak serum levels,Peak serum levels were achieved in 96 +/- 7.5 min (day 1) and 71 +/- 5.5 min (day 5).,Pharmacokinetics of a new theophylline liquid in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825748/),min,71,56715,DB00277,Theophylline
,7349323,half-life (t1/2),Mean half-life (t1/2) of theophylline following single intravenous administration was 5.7 h and the apparent specific volume of distribution (V'd area) was 0.82 litre/kg.,Pharmacokinetic studies of theophylline in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),h,5.7,58052,DB00277,Theophylline
,7349323,apparent specific volume of distribution (V'd area),Mean half-life (t1/2) of theophylline following single intravenous administration was 5.7 h and the apparent specific volume of distribution (V'd area) was 0.82 litre/kg.,Pharmacokinetic studies of theophylline in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),[l] / [kg],0.82,58053,DB00277,Theophylline
,7349323,bioavailability,The bioavailability of theophylline was high (91%) following oral administration of aminophylline tablets and the absorption half-life (t1/2ab) was 0.4 h.,Pharmacokinetic studies of theophylline in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),%,91,58054,DB00277,Theophylline
,7349323,absorption half-life (t1/2ab),The bioavailability of theophylline was high (91%) following oral administration of aminophylline tablets and the absorption half-life (t1/2ab) was 0.4 h.,Pharmacokinetic studies of theophylline in dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349323/),h,0.4,58055,DB00277,Theophylline
,870547,half-life (t1/2),"After treatment with ephedrine, there was a mean decrease in plasma dexamethasone half-life (t1/2) of 132 minutes, or 36 per cent (P less than 0.025), and mean increase in metabolic clearance rate (MCR) of 148 liters/day, or 42 per cent (P less than 0.001).",The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870547/),min,132,58326,DB00277,Theophylline
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.157,58414,DB00277,Theophylline
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.232,58415,DB00277,Theophylline
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.266,58416,DB00277,Theophylline
,8452184,serum half-life,Its long serum half-life (8-12 hours) allows once-a-day dosing.,Overview of the pharmacokinetics of fleroxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452184/),h,8-12,58610,DB00277,Theophylline
,7507589,bioavailability,"Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically.",Pharmacokinetics of oral decongestants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),%,38,59010,DB00277,Theophylline
,7507589,apparent volume of distribution,All three drugs are extensively distributed into extravascular sites (apparent volume of distribution between 2.6 and 5.0 L/kg).,Pharmacokinetics of oral decongestants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),[l] / [kg],2.6 and 5.0,59011,DB00277,Theophylline
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,2.5,59012,DB00277,Theophylline
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,4,59013,DB00277,Theophylline
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,6,59014,DB00277,Theophylline
,21251889,total run time,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,9.0,59775,DB00277,Theophylline
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,4.8,59776,DB00277,Theophylline
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.5,59777,DB00277,Theophylline
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.0,59778,DB00277,Theophylline
,7251238,Bioavailability,Bioavailability amounted to 111 +/- 16% (X +/- SD) compared to i. v. administration.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),%,111,59932,DB00277,Theophylline
,7251238,time of peak theophylline concentration,Absorption from the sustained-release tablet appeared more erratic and less complete: the time of peak theophylline concentration varied between 2 and 14 h.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),h,2 and 14,59933,DB00277,Theophylline
,7251238,bioavailability,The mean plasma level curve showed a plateau between 2 and 14 h bioavailability was 72 +/- 13%.,Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),%,72,59934,DB00277,Theophylline
,7251238,peak theophylline concentrations,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],8.1,59935,DB00277,Theophylline
,7251238,trough levels,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],6.2,59936,DB00277,Theophylline
,7251238,trough levels,"On day 4 at steady state, peak theophylline concentrations were 8.1 +/- 0.63 mg/l, trough levels 6.2 +/- 1.4 mg/l in the morning and 5.6 +/- 0.67 mg/l in the evening.",Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7251238/),[mg] / [l],5.6,59937,DB00277,Theophylline
,6884413,bioavailability,"Whilst fasting the bioavailability was moderate at 64 +/- 22% (mean +/- SD), whereas in the non-fasting state the relatively high bioavailability of 90 +/- 13% was found.",Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884413/),%,64,60644,DB00277,Theophylline
,6884413,bioavailability,"Whilst fasting the bioavailability was moderate at 64 +/- 22% (mean +/- SD), whereas in the non-fasting state the relatively high bioavailability of 90 +/- 13% was found.",Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884413/),%,90,60645,DB00277,Theophylline
,6884413,peak non-fasting level,"Despite the slow absorption, the peak non-fasting level of 4.4 +/- 1.4 mg . 1(-1) was significantly higher than the 3.1 +/- 1.0 mg . 1(-1) observed in the fasting state.",Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884413/),mg,4.4,60646,DB00277,Theophylline
,6884413,peak non-fasting level,"Despite the slow absorption, the peak non-fasting level of 4.4 +/- 1.4 mg . 1(-1) was significantly higher than the 3.1 +/- 1.0 mg . 1(-1) observed in the fasting state.",Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884413/),mg,3.1,60647,DB00277,Theophylline
,6884413,bioavailability,"Based on the present results, Theograd-250 mg tablets have predictable absorption and a high (90%) bioavailability if taken after a meal.",Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884413/),%,90,60648,DB00277,Theophylline
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.702,60985,DB00277,Theophylline
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.641,60986,DB00277,Theophylline
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.542,60987,DB00277,Theophylline
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,7.58,60988,DB00277,Theophylline
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,8.59,60989,DB00277,Theophylline
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,10.08,60990,DB00277,Theophylline
,3814465,minimum,When corrected for body weight there were no significant differences in minimum and maximum plateau levels of furafylline between males (1.2-2.0 micrograms ml-1; mean body weight 67.2 kg) and females (1.6-2.6 micrograms ml-1; mean body weight 54.9 kg).,Accumulation of caffeine in healthy volunteers treated with furafylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),[μg] / [ml],1.2-2.0,61521,DB00277,Theophylline
,3814465,maximum plateau levels,When corrected for body weight there were no significant differences in minimum and maximum plateau levels of furafylline between males (1.2-2.0 micrograms ml-1; mean body weight 67.2 kg) and females (1.6-2.6 micrograms ml-1; mean body weight 54.9 kg).,Accumulation of caffeine in healthy volunteers treated with furafylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),[μg] / [ml],1.6-2.6,61522,DB00277,Theophylline
,3814465,elimination half-life,Subsequent studies showed that a single dose (90 mg) of furafylline results in a rapid accumulation of caffeine given orally (100 mg twice daily) and that this is accompanied by an elimination half-life of some 50 h and an abrupt decrease in metabolite levels.,Accumulation of caffeine in healthy volunteers treated with furafylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),h,50,61523,DB00277,Theophylline
,1559306,bioavailability,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),%,95 to 100,62035,DB00277,Theophylline
,1559306,peak serum concentrations,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),[mg] / [l],2 to 3,62036,DB00277,Theophylline
,1559306,half-life,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),h,5 to 8,62037,DB00277,Theophylline
,7286054,clearance,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),[ml] / [h·kg],78.6,62982,DB00277,Theophylline
,7286054,half-life,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),h,4.14,62983,DB00277,Theophylline
,7286054,apparent volume of distribution,"The overall results for mean plasma theophylline clearance (78.6 +/- 33.3 ml/kg/h), plasma theophylline half-life (4.14 +/- 1.36 h) and apparent volume of distribution (0.41 +/- 0.066 l/kg) are in accordance with previously published values.",A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286054/),[l] / [kg],0.41,62984,DB00277,Theophylline
,3410380,half-time (T1/2 beta),"The half-time (T1/2 beta) of theophylline was 5.63 +/- 0.83 hr, and the volume of distribution (Vd) was 0.73 +/- 0.04 l/kg.","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),h,5.63,63550,DB00277,Theophylline
,3410380,volume of distribution (Vd),"The half-time (T1/2 beta) of theophylline was 5.63 +/- 0.83 hr, and the volume of distribution (Vd) was 0.73 +/- 0.04 l/kg.","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),[l] / [kg],0.73,63551,DB00277,Theophylline
,3410380,elimination rate constant,The elimination rate constant was 0.37 +/- 0.05 hr-1.,"[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),1/[h],0.37,63552,DB00277,Theophylline
,3410380,bioavailability,"Absorption of theophylline (8.2 mg/kg, n = 5) administered intramuscularly was good as indicated by its high bioavailability (101.9 +/- 6.5%), but the value of bioavailability was low in oral administration (72.8 +/- 11.8%, n = 5).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,101.9,63553,DB00277,Theophylline
,3410380,bioavailability,"Absorption of theophylline (8.2 mg/kg, n = 5) administered intramuscularly was good as indicated by its high bioavailability (101.9 +/- 6.5%), but the value of bioavailability was low in oral administration (72.8 +/- 11.8%, n = 5).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,72.8,63554,DB00277,Theophylline
,3410380,percentage of protein binding,"The percentage of protein binding (about 44%, n = 3-7) did not change by increasing the serum concentration (8.2-24.6 micrograms/ml).","[Theophylline: pharmacokinetics, metabolism and urinary excretion in dogs]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410380/),%,44,63555,DB00277,Theophylline
,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,256.0,64109,DB00277,Theophylline
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,167.0,64110,DB00277,Theophylline
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,325.0,64111,DB00277,Theophylline
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,109.0,64112,DB00277,Theophylline
,17442639,limit of quantification (LOQ),"The limit of quantification (LOQ) was 0.4 ng/mL, the dynamic range being 0.4-200 ng/mL.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),[ng] / [ml],0.4,64113,DB00277,Theophylline
,580350,half-lives,Biological theophylline half-lives of 5.4--9.0 hours and plasma clearence values of 28--42 ml kg-1hr-1 were found.,Pharmacokinetics of theophylline in ten elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580350/),h,5.4,64253,DB00277,Theophylline
,580350,plasma clearence,Biological theophylline half-lives of 5.4--9.0 hours and plasma clearence values of 28--42 ml kg-1hr-1 were found.,Pharmacokinetics of theophylline in ten elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580350/),[ml] / [kg],28,64254,DB00277,Theophylline
,580350,plasma clearence,Biological theophylline half-lives of 5.4--9.0 hours and plasma clearence values of 28--42 ml kg-1hr-1 were found.,Pharmacokinetics of theophylline in ten elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580350/),[ml] / [kg],42,64255,DB00277,Theophylline
,580350,"apparent volumes of distribution during the beta-phase, Vdbeta","The apparent volumes of distribution during the beta-phase, Vdbeta, were 0.33--0.43 1 kg-1.",Pharmacokinetics of theophylline in ten elderly patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580350/),[1] / [kg],0.33,64256,DB00277,Theophylline
,7329425,plasma half-live,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),h,22.3,65016,DB00277,Theophylline
,7329425,clearance,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[ml] / [h·kg],28.3,65017,DB00277,Theophylline
,7329425,volume of distribution,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[l] / [kg],0.9,65018,DB00277,Theophylline
,7329425,plasma half-live,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),h,70.6,65019,DB00277,Theophylline
,7329425,clearance,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[ml] / [h·kg],8.6,65020,DB00277,Theophylline
,7329425,volume of distribution,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[l] / [kg],0.84,65021,DB00277,Theophylline
,7329425,rapidly effective plasma concentrations,A first oral dose of 7-9 mg/kg theophylline or caffeine should be administered to reach rapidly effective plasma concentrations of about 10 micrograms/ml.,[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[μg] / [ml],10,65022,DB00277,Theophylline
,7214790,apparent volume of distribution (Vd),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[1] / [kg],0.466,65173,DB00277,Theophylline
,7214790,apparent volume of distribution (Vd),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[1] / [kg],0.472,65174,DB00277,Theophylline
,7214790,apparent volume of distribution (Vd),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[1] / [kg],0.470,65175,DB00277,Theophylline
,7214790,elimination half-life (t1/2),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),h,7.4,65176,DB00277,Theophylline
,7214790,elimination half-life (t1/2),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),h,7.8,65177,DB00277,Theophylline
,7214790,elimination half-life (t1/2),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),h,8.5,65178,DB00277,Theophylline
,7214790,elimination half-life (t1/2),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),h,7.0,65179,DB00277,Theophylline
,7214790,total body clearance (ClB),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[ml] / [kg·min],0.747,65180,DB00277,Theophylline
,7214790,total body clearance (ClB),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[ml] / [kg·min],0.723,65181,DB00277,Theophylline
,7214790,total body clearance (ClB),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[ml] / [kg·min],0.683,65182,DB00277,Theophylline
,7214790,total body clearance (ClB),"Mean theophylline kinetic parameter values on each of the 4 study days were: apparent volume of distribution (Vd), 0.466, 0.466, 0.472, and 0.470 1/kg; elimination half-life (t1/2), 7.4, 7.8, 8.5, and 7.0 hr; and total body clearance (ClB), 0.747, 0.723, 0.683, and 0.821 ml/min/kg.",Effect of erythromycin base on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214790/),[ml] / [kg·min],0.821,65183,DB00277,Theophylline
,3668813,total body clearance,"By comparing the steady-state theophylline concentration in the control and treated animals, the total body clearance was found to increase from 94.4 +/- 7.5 to 210 +/- 27 mL/h/kg (mean +/- SE).",Kinetics of theophylline clearance in gastrointestinal dialysis with charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668813/),[ml] / [h·kg],94.4,65338,DB00277,Theophylline
,3668813,total body clearance,"By comparing the steady-state theophylline concentration in the control and treated animals, the total body clearance was found to increase from 94.4 +/- 7.5 to 210 +/- 27 mL/h/kg (mean +/- SE).",Kinetics of theophylline clearance in gastrointestinal dialysis with charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668813/),[ml] / [h·kg],210,65339,DB00277,Theophylline
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],58.02,65371,DB00277,Theophylline
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],56.57,65372,DB00277,Theophylline
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],54.07,65373,DB00277,Theophylline
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],58.02,65374,DB00277,Theophylline
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],56.57,65375,DB00277,Theophylline
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],54.07,65376,DB00277,Theophylline
,19924518,peak serum concentration (C(max)),"The THP peak serum concentration (C(max)) was 7.18 microg/ml for free THP and AUC(0-48) was 25.76 microg h/ml, while in the case of Xa-CS-THP, C(max) was of 5.72 microg/ml and AUC(0-48) = 45.72 microg h/ml.",Hydrogels based on chitosan-xanthan for controlled release of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19924518/),[μg] / [ml],7.18,66056,DB00277,Theophylline
,19924518,AUC(0-48),"The THP peak serum concentration (C(max)) was 7.18 microg/ml for free THP and AUC(0-48) was 25.76 microg h/ml, while in the case of Xa-CS-THP, C(max) was of 5.72 microg/ml and AUC(0-48) = 45.72 microg h/ml.",Hydrogels based on chitosan-xanthan for controlled release of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19924518/),[h·μg] / [ml],25.76,66057,DB00277,Theophylline
,19924518,C(max),"The THP peak serum concentration (C(max)) was 7.18 microg/ml for free THP and AUC(0-48) was 25.76 microg h/ml, while in the case of Xa-CS-THP, C(max) was of 5.72 microg/ml and AUC(0-48) = 45.72 microg h/ml.",Hydrogels based on chitosan-xanthan for controlled release of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19924518/),[μg] / [ml],5.72,66058,DB00277,Theophylline
,19924518,AUC(0-48),"The THP peak serum concentration (C(max)) was 7.18 microg/ml for free THP and AUC(0-48) was 25.76 microg h/ml, while in the case of Xa-CS-THP, C(max) was of 5.72 microg/ml and AUC(0-48) = 45.72 microg h/ml.",Hydrogels based on chitosan-xanthan for controlled release of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19924518/),[h·μg] / [ml],45.72,66059,DB00277,Theophylline
,6849776,trough levels,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[μg] / [ml],6.4,66558,DB00277,Theophylline
,6849776,trough levels,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[μg] / [ml],8.6,66559,DB00277,Theophylline
,6849776,half-life,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),h,6.5,66560,DB00277,Theophylline
,6849776,half-life,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),h,9.6,66561,DB00277,Theophylline
,6849776,total plasma clearance,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[l] / [h],3.88,66562,DB00277,Theophylline
,6849776,total plasma clearance,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[l] / [h],2.59,66563,DB00277,Theophylline
,1858831,clearances,"Predicted clearances were 0.04 L/kg/hour for normal subjects less than 70 years of age and 0.02 L/kg/hour for patients with congestive heart failure, chronic obstructive pulmonary disease, or liver disease.",A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1858831/),[l] / [h·kg],0.04,66949,DB00277,Theophylline
,1858831,clearances,"Predicted clearances were 0.04 L/kg/hour for normal subjects less than 70 years of age and 0.02 L/kg/hour for patients with congestive heart failure, chronic obstructive pulmonary disease, or liver disease.",A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1858831/),[l] / [h·kg],0.02,66950,DB00277,Theophylline
,1858831,elimination clearance,The predicted elimination clearance of theophylline of 0.02 L/kg/hour was too high in eight patients over 70 years old with cardiac or pulmonary disease.,A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1858831/),[l] / [h·kg],0.02,66951,DB00277,Theophylline
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB00277,Theophylline
,24277335,clearance,Concomitant morphine administration resulted in a 55 % reduction in theophylline clearance (0.14 ± 0.04 vs. 0.31 ± 0.061 · h(-1) kg(-1); p. < 0.0005).,Morphine inhibition of theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),1/[h·kg],0.14,68209,DB00277,Theophylline
,24277335,clearance,Concomitant morphine administration resulted in a 55 % reduction in theophylline clearance (0.14 ± 0.04 vs. 0.31 ± 0.061 · h(-1) kg(-1); p. < 0.0005).,Morphine inhibition of theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),1/[h·kg],0.31,68210,DB00277,Theophylline
,24277335,half-life,The reduction in theophylline clearance with morphine administration was accompanied by a significant prolongation in theophylline half-life (3.5 ± 1.5 vs. 1.4 ± 0.35 h; p < 0.02).,Morphine inhibition of theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),h,3.5,68211,DB00277,Theophylline
,24277335,half-life,The reduction in theophylline clearance with morphine administration was accompanied by a significant prolongation in theophylline half-life (3.5 ± 1.5 vs. 1.4 ± 0.35 h; p < 0.02).,Morphine inhibition of theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),h,1.4,68212,DB00277,Theophylline
,6105063,clearance,The theophylline clearance ranged from 479 +/- 30 ml/kg/hr in the A/J strain to 845 +/- 58 ml/kg/hr in the SJL strain.,Biodisposition of theophylline. I. Genetic variation in inbred mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105063/),[ml] / [h·kg],479,68458,DB00277,Theophylline
,6105063,clearance,The theophylline clearance ranged from 479 +/- 30 ml/kg/hr in the A/J strain to 845 +/- 58 ml/kg/hr in the SJL strain.,Biodisposition of theophylline. I. Genetic variation in inbred mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105063/),[ml] / [h·kg],845,68459,DB00277,Theophylline
,12698500,apparent clearance,"Considerable variability in apparent clearance (range 0.33-1.49 ml/min per kg of ideal body weight), Css(min)/D (range 0.28-1.86), Css(max)/D (range 0.65-2.33) and (Css(max)-Css(min))/Css(avg) (range 0.18-0.80) was observed.",Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698500/),[ml] / [kg·min],0.33-1.49,68939,DB00277,Theophylline
,12698500,Css(max)/D,"Considerable variability in apparent clearance (range 0.33-1.49 ml/min per kg of ideal body weight), Css(min)/D (range 0.28-1.86), Css(max)/D (range 0.65-2.33) and (Css(max)-Css(min))/Css(avg) (range 0.18-0.80) was observed.",Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698500/),,0.65-2.33,68940,DB00277,Theophylline
,12698500,Css(max)-Css(min)),"Considerable variability in apparent clearance (range 0.33-1.49 ml/min per kg of ideal body weight), Css(min)/D (range 0.28-1.86), Css(max)/D (range 0.65-2.33) and (Css(max)-Css(min))/Css(avg) (range 0.18-0.80) was observed.",Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698500/),,0.18-0.80,68941,DB00277,Theophylline
,3759279,relative bioavailability,The relative bioavailability of E with respect to U under steady-state conditions is 93 (83-105)%.,Once daily theophylline: multiple-dose comparison of an encapsulated micro-osmotic system (Euphylong) with a tablet (Uniphyllin). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759279/),%,93,69246,DB00277,Theophylline
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.03,69860,DB00277,Theophylline
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.05,69861,DB00277,Theophylline
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,9.68,69862,DB00277,Theophylline
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.08,69863,DB00277,Theophylline
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,6.84,69864,DB00277,Theophylline
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],259.0,70275,DB00277,Theophylline
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],326.7,70276,DB00277,Theophylline
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],34.5,70277,DB00277,Theophylline
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],74.3,70278,DB00277,Theophylline
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,8.7,70499,DB00277,Theophylline
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,17.4,70500,DB00277,Theophylline
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,6.1,70501,DB00277,Theophylline
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,12.3,70502,DB00277,Theophylline
,7178872,absolute bioavailability,"The mean absolute bioavailability in the steady state in 4 to 6 volunteers was 88% (range 52-127%) for Euphyllin retard 350 mg, 93% (78-106%) for Phyllotemp retard 225 mg and 131% (78-169%) for Theolair SR 175 mg.",[Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7178872/),%,88,70687,DB00277,Theophylline
,7178872,absolute bioavailability,"The mean absolute bioavailability in the steady state in 4 to 6 volunteers was 88% (range 52-127%) for Euphyllin retard 350 mg, 93% (78-106%) for Phyllotemp retard 225 mg and 131% (78-169%) for Theolair SR 175 mg.",[Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7178872/),%,93,70688,DB00277,Theophylline
,7178872,absolute bioavailability,"The mean absolute bioavailability in the steady state in 4 to 6 volunteers was 88% (range 52-127%) for Euphyllin retard 350 mg, 93% (78-106%) for Phyllotemp retard 225 mg and 131% (78-169%) for Theolair SR 175 mg.",[Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7178872/),%,131,70689,DB00277,Theophylline
,1812478,STCs,The morning STCs between 8 and 9 a.m. were intra-individually averaged over the longest interval with a constant dose; median and range were 11.6 (9.7-15.8) mg/l.,[Long-term stability of morning serum theophylline level in asthma patients under minimally 1-year therapy with Euphylong]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812478/),[mg] / [l],11.6,71239,DB00277,Theophylline
,1812478,peak-flow,The corresponding peak-flow values were 474 (239-622) l/min with a coefficient of variation of up to 10% in 16 patients and between 11 and 20% in 3 patients.,[Long-term stability of morning serum theophylline level in asthma patients under minimally 1-year therapy with Euphylong]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812478/),[l] / [min],474,71240,DB00277,Theophylline
,12207865,limit of detection,"The assay proved inexpensive, accurate and reproducible with a limit of detection of 100 ng/ml that makes it suitable for bioavailability studies.",A quantitative thin layer chromatography method for determination of theophylline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207865/),[ng] / [ml],100,71889,DB00277,Theophylline
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],61,72041,DB00277,Theophylline
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],53,72042,DB00277,Theophylline
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],40,72043,DB00277,Theophylline
,3718600,elimination half-lives,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),h,4 and 6,72044,DB00277,Theophylline
,10210731,peak concentration (Cmax),"The peak concentration (Cmax), 5.34+/-1.9 mg/l, was achieved 20 min following administration.",In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210731/),[mg] / [l],5.34,72555,DB00277,Theophylline
,10210731,mean residence time,"The mean residence time was 2.94 h, and the apparent clearance was 0.31 (l/h)/kg.",In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210731/),h,2.94,72556,DB00277,Theophylline
,10210731,apparent clearance,"The mean residence time was 2.94 h, and the apparent clearance was 0.31 (l/h)/kg.",In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210731/),[l] / [h)·kg],0.31,72557,DB00277,Theophylline
,10210731,Cmax,"After nanospheres administration the mean Cmax, 2.53+/-1.1 mg/l, was attained at 3 h.",In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210731/),[mg] / [l],2.53,72558,DB00277,Theophylline
,18005375,in,"For theophylline, the concentration/time profiles after intraperitoneal and after intravenous administration were almost identical, and the intraperitoneal bioavailability was calculated to 0.94.","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.94,73530,DB00277,Theophylline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.71,73531,DB00277,Theophylline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.65,73532,DB00277,Theophylline
,7324949,bioavailability,"The extent of bioavailability in adults is 0.91, and the peak serum concentration is reached after 8.7 h.",Evaluation of a new sustained-release theophylline tablet for children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324949/),,0.91,73737,DB00277,Theophylline
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.88,74098,DB00277,Theophylline
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],10.09,74099,DB00277,Theophylline
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.22,74100,DB00277,Theophylline
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],9.68,74101,DB00277,Theophylline
,23996078,CL,The mean CL among HCCs (n = 5) was considerably higher in the MA period [10.48 (5.62-15.33 l/h)] compared with the no MA period [6.30 (3.40-9.20 l/h)] (P < 0.05).,A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],10.48,74102,DB00277,Theophylline
,23996078,CL,The mean CL among HCCs (n = 5) was considerably higher in the MA period [10.48 (5.62-15.33 l/h)] compared with the no MA period [6.30 (3.40-9.20 l/h)] (P < 0.05).,A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.30,74103,DB00277,Theophylline
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,5.11,74274,DB00277,Theophylline
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.54,74275,DB00277,Theophylline
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),,4.78,74276,DB00277,Theophylline
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.94,74277,DB00277,Theophylline
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.051,74447,DB00277,Theophylline
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.035,74448,DB00277,Theophylline
,25794556,extraction ratio,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.57,74512,DB00277,Theophylline
,25794556,elimination half-life,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,2.3,74513,DB00277,Theophylline
,25794556,extraction ratio,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.46,74514,DB00277,Theophylline
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,5.3,74515,DB00277,Theophylline
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.61,74516,DB00277,Theophylline
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,10.6,74517,DB00277,Theophylline
,25794556,elimination half-life,"After cessation of SLED, elimination half-life was 26 h.",Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,26,74518,DB00277,Theophylline
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],177,75178,DB00277,Theophylline
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],121,75179,DB00277,Theophylline
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],52,75180,DB00277,Theophylline
,11719727,K(i),"The corresponding in vitro K(i) values based on unbound fluvoxamine concentrations were 35 nmol/L, 36 nmol/L, and 36 nmol/L.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],35,75181,DB00277,Theophylline
,11719727,K(i),"The corresponding in vitro K(i) values based on unbound fluvoxamine concentrations were 35 nmol/L, 36 nmol/L, and 36 nmol/L.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],36,75182,DB00277,Theophylline
,11719727,K(i)iv,"Mean values for K(i)iv based on total and unbound plasma concentrations at steady state were 25.3 nmol/L (range, 14-39 nmol/L) and 3.6 nmol/L (range, 2.4-5.9 nmol/L), respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],25.3,75183,DB00277,Theophylline
,11719727,K(i)iv,"Mean values for K(i)iv based on total and unbound plasma concentrations at steady state were 25.3 nmol/L (range, 14-39 nmol/L) and 3.6 nmol/L (range, 2.4-5.9 nmol/L), respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],3.6,75184,DB00277,Theophylline
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,1.36,76623,DB00277,Theophylline
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,2.38,76624,DB00277,Theophylline
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,4.62,76625,DB00277,Theophylline
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,13.1,76626,DB00277,Theophylline
<,9649122,t(1/2),"The fact that EO9 does not readily penetrate a multicell layer, in conjunction with its rapid elimination in vivo (t(1/2) < 10 min), suggests that EO9 is unlikely to penetrate more than a few microm from a blood vessel within its pharmacokinetic lifespan.",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),min,10,76627,DB00277,Theophylline
,868891,fraction of the dose absorbed,The fraction of the dose absorbed averaged 0.96 +/- 0.03 for the tablet while the value for the solution was 0.99 +/- 0.02.,Absolute bioavailability of oral theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),,0.96,77675,DB00277,Theophylline
,868891,fraction of the dose absorbed,The fraction of the dose absorbed averaged 0.96 +/- 0.03 for the tablet while the value for the solution was 0.99 +/- 0.02.,Absolute bioavailability of oral theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),,0.99,77676,DB00277,Theophylline
,868891,time of peak absorption,The time of peak absorption averaged 2 +/- 0.3 hours for the tablets and 1.4 +/- 0.3 hours for the solution.,Absolute bioavailability of oral theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),h,2,77677,DB00277,Theophylline
,868891,time of peak absorption,The time of peak absorption averaged 2 +/- 0.3 hours for the tablets and 1.4 +/- 0.3 hours for the solution.,Absolute bioavailability of oral theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),h,1.4,77678,DB00277,Theophylline
,868891,maximum serum concentration attained,"The maximum serum concentration attained was 15.3 +/- 0.7 microng/ml after a dose of 7.6 +/- 0.4 mg/kg of the tablet, and 14.6 +/- 0.6 microng/ml after a dose of 7.3 +/- 0.2 mg/kg of the solution.",Absolute bioavailability of oral theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),[μng] / [ml],15.3,77679,DB00277,Theophylline
,868891,maximum serum concentration attained,"The maximum serum concentration attained was 15.3 +/- 0.7 microng/ml after a dose of 7.6 +/- 0.4 mg/kg of the tablet, and 14.6 +/- 0.6 microng/ml after a dose of 7.3 +/- 0.2 mg/kg of the solution.",Absolute bioavailability of oral theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/868891/),[μng] / [ml],14.6,77680,DB00277,Theophylline
,16734985,CL(uptake),"A kinetic analysis indicated that a compound with a slower CL(uptake) and longer half-life (e.g., theophylline) is more prone to error and that the lower limit of the CL(uptake) of 0.17 mL min(-1) (g brain)(-1) may be set so as to have an error less than 20% of the estimation.",Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734985/),[ml] / [brain·g·min],0.17,78194,DB00277,Theophylline
greater,16734985,uptake clearance,These results suggest that the sample pooling method is applicable for use in the accelerated estimation of the uptake clearance of compounds in the brain for which the value is greater than 0.17 mL min(-1) (g brain)(-1).,Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734985/),[ml] / [brain·g·min],0.17,78195,DB00277,Theophylline
,6889140,bioavailability,"The bioavailability of the tablet calculated from saliva and serum was 93% and 102%, respectively.",Determination of theophylline bioavailability using saliva theophylline concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889140/),%,93,78250,DB00277,Theophylline
,6889140,bioavailability,"The bioavailability of the tablet calculated from saliva and serum was 93% and 102%, respectively.",Determination of theophylline bioavailability using saliva theophylline concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889140/),%,102,78251,DB00277,Theophylline
,6889140,bioavailability,The bioavailability of the capsule calculated from saliva and serum was 113% and 102% respectively.,Determination of theophylline bioavailability using saliva theophylline concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889140/),%,113,78252,DB00277,Theophylline
,6889140,bioavailability,The bioavailability of the capsule calculated from saliva and serum was 113% and 102% respectively.,Determination of theophylline bioavailability using saliva theophylline concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889140/),%,102,78253,DB00277,Theophylline
,11554434,Elimination half-life (t 1/2),"Elimination half-life (t 1/2), notably increased after hepatectomy (7.27+/-1.38 h), decreased with time (6.70+/-1.18 h, 6.47+/-0.69 and 5.17+/-0.87 h after 24 h, 3 days and 15 days post-hepatectomy, respectively) to reach a value close to that of the control group (4.30+/-1.37 h).",Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554434/),h,7.27,78545,DB00277,Theophylline
,11554434,Elimination half-life (t 1/2),"Elimination half-life (t 1/2), notably increased after hepatectomy (7.27+/-1.38 h), decreased with time (6.70+/-1.18 h, 6.47+/-0.69 and 5.17+/-0.87 h after 24 h, 3 days and 15 days post-hepatectomy, respectively) to reach a value close to that of the control group (4.30+/-1.37 h).",Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554434/),h,6.70,78546,DB00277,Theophylline
,11554434,Elimination half-life (t 1/2),"Elimination half-life (t 1/2), notably increased after hepatectomy (7.27+/-1.38 h), decreased with time (6.70+/-1.18 h, 6.47+/-0.69 and 5.17+/-0.87 h after 24 h, 3 days and 15 days post-hepatectomy, respectively) to reach a value close to that of the control group (4.30+/-1.37 h).",Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554434/),h,6.47,78547,DB00277,Theophylline
,11554434,Elimination half-life (t 1/2),"Elimination half-life (t 1/2), notably increased after hepatectomy (7.27+/-1.38 h), decreased with time (6.70+/-1.18 h, 6.47+/-0.69 and 5.17+/-0.87 h after 24 h, 3 days and 15 days post-hepatectomy, respectively) to reach a value close to that of the control group (4.30+/-1.37 h).",Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554434/),h,5.17,78548,DB00277,Theophylline
,11554434,Elimination half-life (t 1/2),"Elimination half-life (t 1/2), notably increased after hepatectomy (7.27+/-1.38 h), decreased with time (6.70+/-1.18 h, 6.47+/-0.69 and 5.17+/-0.87 h after 24 h, 3 days and 15 days post-hepatectomy, respectively) to reach a value close to that of the control group (4.30+/-1.37 h).",Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554434/),h,4.30,78549,DB00277,Theophylline
,6887346,half-life (t1/2),The mean plasma theophylline half-life (t1/2) following the single intravenous dose was 7.8 h and the mean apparent specific volume of distribution (V'd(area] was 0.46 1/kg.,Pharmacokinetic studies of theophylline in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),h,7.8,78818,DB00277,Theophylline
,6887346,apparent specific volume of distribution (V'd(area],The mean plasma theophylline half-life (t1/2) following the single intravenous dose was 7.8 h and the mean apparent specific volume of distribution (V'd(area] was 0.46 1/kg.,Pharmacokinetic studies of theophylline in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),[1] / [kg],0.46,78819,DB00277,Theophylline
,6887346,absorption half-life (t1/2ab),The absorption half-life (t1/2ab) was 0.5 h and the bioavailability was 96% following oral administration.,Pharmacokinetic studies of theophylline in cats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),h,0.5,78820,DB00277,Theophylline
,6887346,bioavailability,The absorption half-life (t1/2ab) was 0.5 h and the bioavailability was 96% following oral administration.,Pharmacokinetic studies of theophylline in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887346/),%,96,78821,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,116,78866,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,100,78867,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,134,78868,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,115,78869,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,99,78870,DB00277,Theophylline
,3299763,Bio-availability,"Bio-availability of theophylline from the halved tablets relative to the whole tablets was: 116% (100%, 134%) for the extent of absorption as judged by the area under the concentration time curve (AUC) and 115% (99%, 135%) for the rate of absorption as judged by maximum concentration (Cmax).",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),%,135,78871,DB00277,Theophylline
,3299763,plateau times T75% Cmax,"The plateau times T75% Cmax, which characterise the sustained-released properties, were 8.5 +/- 2.9 hours (halved) and 8.3 +/- 2.5 hours (whole) during the 12-hour dosing interval.",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),h,8.5,78872,DB00277,Theophylline
,3299763,plateau times T75% Cmax,"The plateau times T75% Cmax, which characterise the sustained-released properties, were 8.5 +/- 2.9 hours (halved) and 8.3 +/- 2.5 hours (whole) during the 12-hour dosing interval.",Comparative bio-availability of theophylline whole and halved sustained-release tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3299763/),h,8.3,78873,DB00277,Theophylline
,11848250,"overall elimination rate constant (lambda z,)","Following i.v. injection, the overall elimination rate constant (lambda z,) in goats was 0.006 +/- 0.00076/min and in camels was 0.0046 +/- 0.0008/min (P < 0.01).",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),1/[min],0.006,78961,DB00277,Theophylline
,11848250,"overall elimination rate constant (lambda z,)","Following i.v. injection, the overall elimination rate constant (lambda z,) in goats was 0.006 +/- 0.00076/min and in camels was 0.0046 +/- 0.0008/min (P < 0.01).",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),1/[min],0.0046,78962,DB00277,Theophylline
,11848250,elimination half-life (t 1/2 lambda z),The elimination half-life (t 1/2 lambda z) in goats (112 .7 min) was lower than in camels (154.7 min) (P < 0.01).,Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),min,112 .7,78963,DB00277,Theophylline
,11848250,elimination half-life (t 1/2 lambda z),The elimination half-life (t 1/2 lambda z) in goats (112 .7 min) was lower than in camels (154.7 min) (P < 0.01).,Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),min,154.7,78964,DB00277,Theophylline
,11848250,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) and the total body clearance (Cl) in goats were 1440.1 +/- 166.6 ml/kg and 8.9 +/- 1.4 ml/min/kg, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),[ml] / [kg],1440.1,78965,DB00277,Theophylline
,11848250,total body clearance (Cl),"The apparent volume of distribution (Vz) and the total body clearance (Cl) in goats were 1440.1 +/- 166.6 ml/kg and 8.9 +/- 1.4 ml/min/kg, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),[ml] / [kg·min],8.9,78966,DB00277,Theophylline
,11848250,peak plasma concentration (Cmax),"After i.m. administration, theophylline reached a peak plasma concentration (Cmax) of 1.8 +/- 0.1 and 1.7 +/- 0.2 microg/ml at a post-injection time (Tmax) of 67.5 +/- 8.6 and 122.3 +/- 6.7 min in goats and camels, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),[μg] / [ml],1.8,78967,DB00277,Theophylline
,11848250,peak plasma concentration (Cmax),"After i.m. administration, theophylline reached a peak plasma concentration (Cmax) of 1.8 +/- 0.1 and 1.7 +/- 0.2 microg/ml at a post-injection time (Tmax) of 67.5 +/- 8.6 and 122.3 +/- 6.7 min in goats and camels, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),[μg] / [ml],1.7,78968,DB00277,Theophylline
,11848250,post-injection time (Tmax),"After i.m. administration, theophylline reached a peak plasma concentration (Cmax) of 1.8 +/- 0.1 and 1.7 +/- 0.2 microg/ml at a post-injection time (Tmax) of 67.5 +/- 8.6 and 122.3 +/- 6.7 min in goats and camels, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),min,67.5,78969,DB00277,Theophylline
,11848250,post-injection time (Tmax),"After i.m. administration, theophylline reached a peak plasma concentration (Cmax) of 1.8 +/- 0.1 and 1.7 +/- 0.2 microg/ml at a post-injection time (Tmax) of 67.5 +/- 8.6 and 122.3 +/- 6.7 min in goats and camels, respectively.",Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),min,122.3,78970,DB00277,Theophylline
,11848250,bioavailability (T),The mean bioavailability (T) in both goats and camels was 0.9 +/- 0.2.,Comparative pharmacokinetics of theophylline in camels (Camelus dromedarius) and goats (Caprus hircus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848250/),,0.9,78971,DB00277,Theophylline
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00277,Theophylline
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00277,Theophylline
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00277,Theophylline
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00277,Theophylline
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00277,Theophylline
,8489790,steady-state (SS) 'peaks',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],10,81657,DB00277,Theophylline
,8489790,SS 'troughs',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],7.7,81658,DB00277,Theophylline
,7117353,Cl,"Geometric mean an 95%-confidence limits, derived from the log-normal distribution of these parameters, were: Cl = 0.044 (0.018-0.190) l/h/kg ideal body weight, Vd = 0.451 (0.258-0.789) l/kg ideal body weight, and t 1/2(el) = 7.1 (2.6-19.1) h.",Pharmacokinetics of theophylline in patients following short-term intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117353/),[l] / [h·ideal·kg],0.044,82180,DB00277,Theophylline
,7117353,Vd,"Geometric mean an 95%-confidence limits, derived from the log-normal distribution of these parameters, were: Cl = 0.044 (0.018-0.190) l/h/kg ideal body weight, Vd = 0.451 (0.258-0.789) l/kg ideal body weight, and t 1/2(el) = 7.1 (2.6-19.1) h.",Pharmacokinetics of theophylline in patients following short-term intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117353/),[l] / [ideal·kg],0.451,82181,DB00277,Theophylline
,7117353,t 1/2(el),"Geometric mean an 95%-confidence limits, derived from the log-normal distribution of these parameters, were: Cl = 0.044 (0.018-0.190) l/h/kg ideal body weight, Vd = 0.451 (0.258-0.789) l/kg ideal body weight, and t 1/2(el) = 7.1 (2.6-19.1) h.",Pharmacokinetics of theophylline in patients following short-term intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117353/),h,7.1,82182,DB00277,Theophylline
,2876080,beta elimination half-life,When the compound was given orally to humans at a dose of 1.3-1.9 mg kg-1 a mean beta elimination half-life of 48.1 +/- 10.8 h was obtained after an initial distribution phase.,"Some pharmacokinetic characteristics of furafylline, a new 1,3,8-trisubstituted xanthine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876080/),h,48.1,82817,DB00277,Theophylline
,16824636,AUC,"Although the two enteric-coated tablets showed a similar in vitro release pattern, saliva level profiles were quite different as reflected in AUC values of 16.4 and 4.68 microg h/ml for enteric-coated PIC- and enteric-coated HPC-tablet, respectively.",In vivo drug release from hydrophilic dextran tablets capable of forming polyion complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16824636/),[h·μg] / [ml],16.4,82825,DB00277,Theophylline
,16824636,AUC,"Although the two enteric-coated tablets showed a similar in vitro release pattern, saliva level profiles were quite different as reflected in AUC values of 16.4 and 4.68 microg h/ml for enteric-coated PIC- and enteric-coated HPC-tablet, respectively.",In vivo drug release from hydrophilic dextran tablets capable of forming polyion complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16824636/),[h·μg] / [ml],4.68,82826,DB00277,Theophylline
,3768245,peak plasma theophylline concentration,On day 1 the mean peak plasma theophylline concentration was 5.4 +/- 1.0 (+/- s.e. mean) micrograms ml-1 4 h after the morning dose and 11.2 +/- 1.6 micrograms ml-1 4 h after the evening dose which were significantly (P less than 0.01) different.,Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],5.4,82972,DB00277,Theophylline
,3768245,peak plasma theophylline concentration,On day 1 the mean peak plasma theophylline concentration was 5.4 +/- 1.0 (+/- s.e. mean) micrograms ml-1 4 h after the morning dose and 11.2 +/- 1.6 micrograms ml-1 4 h after the evening dose which were significantly (P less than 0.01) different.,Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],11.2,82973,DB00277,Theophylline
,3768245,peak plasma concentrations,"During day 4 mean peak plasma concentrations of theophylline after the morning and larger evening dose were 13.2 +/- 1.3 and 12.1 +/- 1.4 micrograms ml-1 respectively, which were not significantly different.",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],13.2,82974,DB00277,Theophylline
,3768245,peak plasma concentrations,"During day 4 mean peak plasma concentrations of theophylline after the morning and larger evening dose were 13.2 +/- 1.3 and 12.1 +/- 1.4 micrograms ml-1 respectively, which were not significantly different.",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],12.1,82975,DB00277,Theophylline
,3768245,time to peak,"However the post-dose time to peak was significantly delayed at night (6 h) compared to the morning (2 h, P less than 0.001).",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),h,6,82976,DB00277,Theophylline
,3768245,time to peak,"However the post-dose time to peak was significantly delayed at night (6 h) compared to the morning (2 h, P less than 0.001).",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),h,2,82977,DB00277,Theophylline
,8738770,Measurable,Measurable caffeine concentrations in serum ranged from 0.28 to 93.3 mg/L and in saliva from 0.35 to 91.5 mg/L.,Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738770/),,0.28 to 93.3,83243,DB00277,Theophylline
,4044074,maximum serum theophylline concentrations,"In fasting subjects, maximum serum theophylline concentrations of 3.8 +/- 1.2 mg X 1(-1) (mean +/- SD) were reached at 3.4 +/- 1.2 hours after dosing, whereas under non-fasting conditions maximum serum levels of 5.8 +/- 1.3 mg X 1(-1) were found at 7.4 +/- 1.4 hours after the tablet was given.",Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044074/),mg,3.8,83439,DB00277,Theophylline
,4044074,maximum serum levels,"In fasting subjects, maximum serum theophylline concentrations of 3.8 +/- 1.2 mg X 1(-1) (mean +/- SD) were reached at 3.4 +/- 1.2 hours after dosing, whereas under non-fasting conditions maximum serum levels of 5.8 +/- 1.3 mg X 1(-1) were found at 7.4 +/- 1.4 hours after the tablet was given.",Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044074/),mg,5.8,83440,DB00277,Theophylline
,4044074,bioavailability,"The bioavailability increased from 65 +/- 8%, observed on preprandial administration to 87 +/- 14%, when Theograd-350 mg tablets were taken after a meal.",Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044074/),%,65,83441,DB00277,Theophylline
,4044074,bioavailability,"The bioavailability increased from 65 +/- 8%, observed on preprandial administration to 87 +/- 14%, when Theograd-350 mg tablets were taken after a meal.",Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044074/),%,87,83442,DB00277,Theophylline
,4044074,bioavailability,"In conclusion, Theograd-350 mg tablets have a predictable absorption and give relatively high (87%) bioavailability, if the tablets are taken after a meal.",Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044074/),%,87,83443,DB00277,Theophylline
,3790413,peak level,"Following the first dose, the mean peak level was 12.5 mg/litre, mean time to peak was 8.1 hours and mean apparent elimination half-life was 6.6 hours.",The pharmacokinetics of uniphyllin in nocturnal asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790413/),[mg] / [l],12.5,84509,DB00277,Theophylline
,3790413,time to peak,"Following the first dose, the mean peak level was 12.5 mg/litre, mean time to peak was 8.1 hours and mean apparent elimination half-life was 6.6 hours.",The pharmacokinetics of uniphyllin in nocturnal asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790413/),h,8.1,84510,DB00277,Theophylline
,3790413,apparent elimination half-life,"Following the first dose, the mean peak level was 12.5 mg/litre, mean time to peak was 8.1 hours and mean apparent elimination half-life was 6.6 hours.",The pharmacokinetics of uniphyllin in nocturnal asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790413/),h,6.6,84511,DB00277,Theophylline
,697173,clearance,"Within 24 hours of admission, the mean clearance in our patients without congestive heart failure or pneumonia was 44.5 ml per hour per kg of body weight, 40 per cent less than the value on which the widely used 0.9 mg per kg per hour dosage is based.","Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697173/),[ml] / [h·kg],44.5,85504,DB00277,Theophylline
,1448840,time,Theophylline concentrations used in the Kurland equation were obtained 10.8 +/- 4.5 h after initiation of therapy and the time between the two concentrations used in the Chiou and Koup equations was 9.2 +/- 3.9 h.,Ability of three pharmacokinetic equations to predict steady-state serum theophylline concentrations in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448840/),h,9.2,85971,DB00277,Theophylline
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·kg],105.7,86190,DB00277,Theophylline
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·kg],83.1,86191,DB00277,Theophylline
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·mg],94.3,86192,DB00277,Theophylline
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·mg],65.4,86193,DB00277,Theophylline
,2744908,peak plasma theophylline concentrations,"The peak plasma theophylline concentrations at night with a symmetric dosage were lower than with an asymmetric dosage: 11.5 mg/l (+/- 3.8) and 13.6 mg/l (+/- 4.4), respectively.",Chronopharmacodynamics and kinetics after symmetric and asymmetric multiple theophylline doses in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744908/),[mg] / [l],11.5,86321,DB00277,Theophylline
,2744908,peak plasma theophylline concentrations,"The peak plasma theophylline concentrations at night with a symmetric dosage were lower than with an asymmetric dosage: 11.5 mg/l (+/- 3.8) and 13.6 mg/l (+/- 4.4), respectively.",Chronopharmacodynamics and kinetics after symmetric and asymmetric multiple theophylline doses in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744908/),[mg] / [l],13.6,86322,DB00277,Theophylline
exceeded,3440916,maximum levels,"A good prediction of the plasma concentration was observed only in one case and the maximum levels in the rest exceeded 20 micrograms/ml, a toxic concentration.",Time-dependent pharmacokinetics of theophylline: failure of application of the test-dose concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440916/),[μg] / [ml],20,86599,DB00277,Theophylline
,3812409,clearance,"When the patient groups were studied according to their initial clearance values, it became evident that only the patients with clearance values of 80 mL/kg/h showed significant changes of this value.",The use of theophylline clearance in pediatric status asthmaticus. I. Interpatient and intrapatient theophylline clearance variability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3812409/),[ml] / [h·kg],80,87446,DB00277,Theophylline
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],60.1,88065,DB00277,Theophylline
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],40.6,88066,DB00277,Theophylline
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,8.37,88067,DB00277,Theophylline
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,12.32,88068,DB00277,Theophylline
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],64.6,88069,DB00277,Theophylline
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],75.0,88070,DB00277,Theophylline
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],41.8,88071,DB00277,Theophylline
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],36.1,88072,DB00277,Theophylline
,18975172,absolute bioavailability,"The absolute bioavailability of theophylline in these experiments was between 63.8 and 72.8%(66.1% in BDL, 63.8% in Sham operated and Control, 72.8% in DMNA).",Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975172/),%,63.8 and 72.8,88155,DB00277,Theophylline
,18975172,absolute bioavailability,"The absolute bioavailability of theophylline in these experiments was between 63.8 and 72.8%(66.1% in BDL, 63.8% in Sham operated and Control, 72.8% in DMNA).",Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975172/),%,66.1,88156,DB00277,Theophylline
,18975172,absolute bioavailability,"The absolute bioavailability of theophylline in these experiments was between 63.8 and 72.8%(66.1% in BDL, 63.8% in Sham operated and Control, 72.8% in DMNA).",Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975172/),%,63.8,88157,DB00277,Theophylline
,18975172,absolute bioavailability,"The absolute bioavailability of theophylline in these experiments was between 63.8 and 72.8%(66.1% in BDL, 63.8% in Sham operated and Control, 72.8% in DMNA).",Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975172/),%,72.8,88158,DB00277,Theophylline
,7333345,absolute bioavailability,The absolute bioavailability of Theolair Retard 250 mg was 110.9 +/- 20.8% (mean +/-SD).,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),%,110.9,88192,DB00277,Theophylline
,7333345,rate constant,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.8,88193,DB00277,Theophylline
,7333345,rate constants,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.2,88194,DB00277,Theophylline
,7333345,rate constants,"Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine).",Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),1/[h],0.8,88195,DB00277,Theophylline
,7333345,peak levels,The peak levels accounted for 7.9 +/- 2.2 mg . 1-1.,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),mg,7.9,88196,DB00277,Theophylline
,7333345,steady state serum concentration,The optimal dosing interval to obtain an average steady state serum concentration of 12.5 mg .,Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333345/),mg,12.5,88197,DB00277,Theophylline
,10590713,ka(h-1),"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.223,88930,DB00277,Theophylline
,10590713,ke(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.047,88931,DB00277,Theophylline
,10590713,ke(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.076,88932,DB00277,Theophylline
,10590713,Vd(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),[1] / [kg],0.733,88933,DB00277,Theophylline
,10590713,Vd(,"The obtained parameters are ka(h-1) = 0.223, ke(h-1) = 0.047 (1-0.0025.age(y) (p.o.) and 0.076(1-0.0025.age(y)) (d.i.v.), Vd(1/kg) = 0.733 (p.o.) and 0.830 (d.i.v.).",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),[1] / [kg],0.830,88934,DB00277,Theophylline
,10590713,bioavailability,"The bioavailability is 0.732, and theophylline/aminophylline is 0.846.",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.732,88935,DB00277,Theophylline
,10590713,bioavailability,"The bioavailability is 0.732, and theophylline/aminophylline is 0.846.",[Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590713/),,0.846,88936,DB00277,Theophylline
,6872853,Cmax,"Cmax was higher in subjects when treated with the antacid (10.45 +/- 3.03 vs. 8.30 +/- 2.90 micrograms/ml, p less than 0.05) than when given theophylline alone.",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [ml],10.45,89099,DB00277,Theophylline
,6872853,Cmax,"Cmax was higher in subjects when treated with the antacid (10.45 +/- 3.03 vs. 8.30 +/- 2.90 micrograms/ml, p less than 0.05) than when given theophylline alone.",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [ml],8.30,89100,DB00277,Theophylline
,6872853,tmax,"The mean tmax for the two treatments did not differ (10.4 +/- 1.67 h-combination vs. 10.8 +/- 1.1 h-theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),h,10.4,89101,DB00277,Theophylline
,6872853,tmax,"The mean tmax for the two treatments did not differ (10.4 +/- 1.67 h-combination vs. 10.8 +/- 1.1 h-theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),h,10.8,89102,DB00277,Theophylline
,6872853,AUC,"Likewise, mean AUC was unchanged by the coadministration of antacid (140.65 +/- 41.6 micrograms/ml.h--combination vs. 155.13 +/- 46.6 micrograms/h--theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [h·ml],140.65,89103,DB00277,Theophylline
,6872853,AUC,"Likewise, mean AUC was unchanged by the coadministration of antacid (140.65 +/- 41.6 micrograms/ml.h--combination vs. 155.13 +/- 46.6 micrograms/h--theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [h],155.13,89104,DB00277,Theophylline
,2804252,area under the Cp vs time curve,Though plasma concentration (Cp) was higher with the tablets as was the area under the Cp vs time curve: 134 (74-252) vs 121 (75-197) mg h l-1; p = 0.028.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[h·mg] / [l],134,89305,DB00277,Theophylline
,2804252,area under the Cp vs time curve,Though plasma concentration (Cp) was higher with the tablets as was the area under the Cp vs time curve: 134 (74-252) vs 121 (75-197) mg h l-1; p = 0.028.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[h·mg] / [l],121,89306,DB00277,Theophylline
,2804252,Dose required,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[mg] / [d·kg],12.6,89307,DB00277,Theophylline
,2804252,Dose required,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[mg] / [d·kg],8.6,89308,DB00277,Theophylline
,2804252,Cp,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[mg] / [d·kg],12.6,89309,DB00277,Theophylline
,2804252,Cp,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[mg] / [d·kg],8.6,89310,DB00277,Theophylline
,2804252,apparent clearance,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[ml] / [h·kg],94,89311,DB00277,Theophylline
,2804252,apparent clearance,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),,68,89312,DB00277,Theophylline
,2804252,I,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),[ml] / [h·kg],94,89313,DB00277,Theophylline
,2804252,C,Dose required to reach target Cp was higher in the institutionalized group (12.6 vs 8.6 mg kg-1 day-1; p = 0.003) as was apparent clearance; I:94 (43-148) ml hr-1 kg-1 vs C:68 (34-163); p = 0.003.,Slow release theophylline disposition and effect in elderly patients with chronic obstructive lung disease: influence of dose formulation and institutionalization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804252/),,68,89314,DB00277,Theophylline
,7582553,Emax,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),b·m·p,198,89720,DB00277,Theophylline
,7582553,EC50,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),[ng] / [ml],2.1,89721,DB00277,Theophylline
,7582553,Hill factor,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),,2.3,89722,DB00277,Theophylline
,7582553,EC50,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),[ng] / [ml],3.7,89723,DB00277,Theophylline
,7582553,Hill factor,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),,3.1,89724,DB00277,Theophylline
,3336577,absorption,The extent of absorption of the slow-release product was 98.3 +/- 20.2% (mean +/- SD) relative to the liquid reference.,Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3336577/),%,98.3,90117,DB00277,Theophylline
,1517927,Clp,"Theophylline Clp was similar in 29 matched RSV-infected and -uninfected pairs (1.32 +/- 0.14 and 1.25 +/- 0.05 ml/kg per minute, respectively), as were other pharmacokinetic values.",Lack of effect of respiratory syncytial virus infection on theophylline disposition in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517927/),[ml] / [kg·min],1.32,90266,DB00277,Theophylline
,1517927,Clp,"Theophylline Clp was similar in 29 matched RSV-infected and -uninfected pairs (1.32 +/- 0.14 and 1.25 +/- 0.05 ml/kg per minute, respectively), as were other pharmacokinetic values.",Lack of effect of respiratory syncytial virus infection on theophylline disposition in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517927/),[ml] / [kg·min],1.25,90267,DB00277,Theophylline
,9248947,hair concentrations,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[ng] / [mg],52,90368,DB00277,Theophylline
,9248947,hair concentrations,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[ng] / [mg],4.9,90369,DB00277,Theophylline
,9248947,plasma AUCs,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[min·μg] / [ml],55.9,90370,DB00277,Theophylline
,9248947,plasma AUCs,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[min·μg] / [ml],22.3,90371,DB00277,Theophylline
,1797890,t 1/2 beta,The median t 1/2 beta was 18.8 h (range 5.8-25.5) compared to a normal value of 6 h.,Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,18.8,90686,DB00277,Theophylline
,1797890,t 1/2 beta,The median t 1/2 beta was 18.8 h (range 5.8-25.5) compared to a normal value of 6 h.,Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,6,90687,DB00277,Theophylline
,1797890,t 1/2 beta,"Due to this t 1/2 beta was 2.3 (2.0-2.7) h, which is 5 times the normal value of 0.55 h.",Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,2.3,90688,DB00277,Theophylline
,1797890,t 1/2 beta,"Due to this t 1/2 beta was 2.3 (2.0-2.7) h, which is 5 times the normal value of 0.55 h.",Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797890/),h,0.55,90689,DB00277,Theophylline
,2917584,serum trough,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[μg] / [ml],8.1 to 7.3,91160,DB00277,Theophylline
,2917584,peak expiratory flow rate,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[l] / [min],316,91161,DB00277,Theophylline
,2917584,peak expiratory flow rate,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[l] / [min],370,91162,DB00277,Theophylline
,2917584,t1/2,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),h,9,91163,DB00277,Theophylline
,2917584,t1/2,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),h,7,91164,DB00277,Theophylline
,2917584,systemic clearance,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[ml] / [h·kg],20.2,91165,DB00277,Theophylline
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB00277,Theophylline
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB00277,Theophylline
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB00277,Theophylline
,27662634,EPC,"EPC of theobromine was calculated with 3.80 µg/mL, and irrelevant concentrations of theobromine were determined at 8 ng/mL in plasma and at 142 ng/mL in urine.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.80,91484,DB00277,Theophylline
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.20,91485,DB00277,Theophylline
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],6,91486,DB00277,Theophylline
,27662634,IUC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],75,91487,DB00277,Theophylline
,12542900,total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )),"In rats with renal failure, the plasma concentrations of theophylline were considerably lower and the resultant total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )) of theophylline was significantly smaller (2,200 vs 1,550 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],"2,200",91693,DB00277,Theophylline
,12542900,total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )),"In rats with renal failure, the plasma concentrations of theophylline were considerably lower and the resultant total area under the plasma concentration-time curve from time zero to time infinity (AUC(0- infinity )) of theophylline was significantly smaller (2,200 vs 1,550 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],"1,550",91694,DB00277,Theophylline
,12542900,AUC(0-6 h),"In rats with renal failure, the plasma concentrations of 1,3-dimethyluric acid were considerably higher and the resultant AUC(0-6 h) of 1,3-dimethyluric acid was significantly greater (44.4 vs 456 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],44.4,91695,DB00277,Theophylline
,12542900,AUC(0-6 h),"In rats with renal failure, the plasma concentrations of 1,3-dimethyluric acid were considerably higher and the resultant AUC(0-6 h) of 1,3-dimethyluric acid was significantly greater (44.4 vs 456 microg min mL(-1)) compared with control rats.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[min·μg] / [ml],456,91696,DB00277,Theophylline
,12542900,intrinsic,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],734,91697,DB00277,Theophylline
,12542900,intrinsic,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],529,91698,DB00277,Theophylline
,12542900,formation clearance,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],734,91699,DB00277,Theophylline
,12542900,formation clearance,"The in-vitro intrinsic 1,3-dimethyluric acid formation clearance was significantly faster in rats with renal failure (734 vs 529 10(-6) mL min(-1)) compared with control rats using hepatic microsomal fraction.","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542900/),[ml] / [min],529,91700,DB00277,Theophylline
,2122422,area under the curve (AUC infinity 0),"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],126.0,91982,DB00277,Theophylline
,2122422,area under the curve (AUC infinity 0),"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],127.3,91983,DB00277,Theophylline
,2122422,maximum concentration,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[μg] / [ml],3.80,91984,DB00277,Theophylline
,2122422,maximum concentration,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[μg] / [ml],4.08,91985,DB00277,Theophylline
,2122422,time to peak plasma level,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),h,13,91986,DB00277,Theophylline
,2122422,time to peak plasma level,"No statistically significant differences in area under the curve (AUC infinity 0) (126.0 vs 127.3 micrograms hr/ml), maximum concentration (3.80 vs 4.08 micrograms/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2.",The influence of enteral feedings on sustained-release theophylline absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),h,11,91987,DB00277,Theophylline
,2122422,AUC infinity 0,Mean AUC infinity 0 for the intravenous phase (161.4 micrograms hr/ml) was significantly higher than the AUC for either oral study (p less than 0.05).,The influence of enteral feedings on sustained-release theophylline absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),[h·μg] / [ml],161.4,91988,DB00277,Theophylline
,2122422,bioavailability,The mean bioavailability was 81% for phase 1 and 80% for phase 2.,The influence of enteral feedings on sustained-release theophylline absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),%,81,91989,DB00277,Theophylline
,2122422,bioavailability,The mean bioavailability was 81% for phase 1 and 80% for phase 2.,The influence of enteral feedings on sustained-release theophylline absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2122422/),%,80,91990,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.042,92105,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.016,92106,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.038,92107,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.054,92108,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.030,92109,DB00277,Theophylline
,7140800,clearance,"Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p less than 0.001) mean clearance values were: 0.042 +/- 0.016 l/h/kg (mean +/- SD) in patients without CHF (n = 58) as opposed to 0.016 +/- 0.001 l/h/kg in patients with CHF (n = 7), 0.038 +/- 0.013 l/h/kg in non-smokers (n = 59) versus 0.054 +/- 0.015 l/h/kg in smoking subjects (n = 17), and 0.030 +/- 0.010 l/h/kg in elderly (greater than 60 years) non-smoking patients (n = 7) versus 0.057 +/- 0.017 l/h/kg in smoking patients (n = 5) aged 40 to 59 years.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[l] / [h·kg],0.057,92110,DB00277,Theophylline
,7140800,steady-state minimum concentration (Cmeas),"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],5.4 to 14.6,92111,DB00277,Theophylline
,7140800,steady-state minimum concentration (Cmeas),"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],9.0,92112,DB00277,Theophylline
,7140800,Cpred,"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],5.6 to 13.6,92113,DB00277,Theophylline
,7140800,Cpred,"The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 micrograms/ml (9.0 +/- 2.2 micrograms/ml: mean +/- SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0 +/- 1.6 micrograms/ml) in all patients (n = 60) who received the oral dose of aminophylline calculated from the test dose.",Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140800/),[μg] / [ml],9.0,92114,DB00277,Theophylline
,29019066,similarity factor (f 2 ),"Consequently, the similarity factor (f 2 ) between the novel and conventional theophylline osmotic pump tablet was 60.18, which indicated a similar drug-release behavior.",Release Mechanism Between Ion Osmotic Pressure and Drug Release in Ionic-Driven Osmotic Pump Tablets (I). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019066/),,60.18,93163,DB00277,Theophylline
,29019066,relative bioavailability,The relative bioavailability of the ionic-driven osmotic pump to the conventional osmotic pump calculated from the AUC (0-∞) was 93.6% and the coefficient (R = 0.9945) confirmed that the ionic-driven osmotic pump exhibited excellent IVIVC.,Release Mechanism Between Ion Osmotic Pressure and Drug Release in Ionic-Driven Osmotic Pump Tablets (I). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019066/),%,93.6,93164,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.29,93165,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.39,93166,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,12.9,93167,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,15.1,93168,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,2.00,93169,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,1.79,93170,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,7.98,93171,DB00277,Theophylline
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.91,93172,DB00277,Theophylline
,4028756,elimination half-time,"During hypothermia, the elimination half-time for gentamicin was significantly prolonged (135 +/- 19 min at 37 degrees C vs. 187 +/- 7 min at 29 degrees C), and there were significant decreases in the volume of the central compartment (Vc) of gentamicin, the gentamicin volume of distribution (Vd), and the gentamicin total body clearance (TBC).",Influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028756/),min,135,93688,DB00277,Theophylline
,4028756,elimination half-time,"During hypothermia, the elimination half-time for gentamicin was significantly prolonged (135 +/- 19 min at 37 degrees C vs. 187 +/- 7 min at 29 degrees C), and there were significant decreases in the volume of the central compartment (Vc) of gentamicin, the gentamicin volume of distribution (Vd), and the gentamicin total body clearance (TBC).",Influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028756/),min,187,93689,DB00277,Theophylline
,9676354,Plateau times,Plateau times which are independent of the asymmetric dosage regimen ranged from 16.4 h (T1) to 13.8 h (T2) and could therefore cover sufficient time of the dosage interval.,[Pharmacokinetics of a new fluid theophylline sustained-release drug form. Microcapsules in a sachet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676354/),h,16.4,94002,DB00277,Theophylline
,9676354,Plateau times,Plateau times which are independent of the asymmetric dosage regimen ranged from 16.4 h (T1) to 13.8 h (T2) and could therefore cover sufficient time of the dosage interval.,[Pharmacokinetics of a new fluid theophylline sustained-release drug form. Microcapsules in a sachet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676354/),h,13.8,94003,DB00277,Theophylline
,9676354,Maximum plasma levels,"Maximum plasma levels of 9.6 micrograms/ml and 10.0 micrograms/ml were attained 6.6 and 6.1 h after dosing of T1 and T2, coinciding perfectly with the time of the critical morning dip at 2-6 a.m.",[Pharmacokinetics of a new fluid theophylline sustained-release drug form. Microcapsules in a sachet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676354/),[μg] / [ml],9.6,94004,DB00277,Theophylline
,9676354,Maximum plasma levels,"Maximum plasma levels of 9.6 micrograms/ml and 10.0 micrograms/ml were attained 6.6 and 6.1 h after dosing of T1 and T2, coinciding perfectly with the time of the critical morning dip at 2-6 a.m.",[Pharmacokinetics of a new fluid theophylline sustained-release drug form. Microcapsules in a sachet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676354/),[μg] / [ml],10.0,94005,DB00277,Theophylline
,25594527,fractional absorbance,Theophylline may be administered trans-cutaneously by applying this drug to the back or abdomen of the infants and the mean fractional absorbance at 30 hours is 0.25.,"Clinical pharmacology of theophylline in preterm infants: effects, metabolism and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594527/),,0.25,94214,DB00277,Theophylline
,6700656,Peak serum levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],13.5,94488,DB00277,Theophylline
,6700656,peak levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],8.4,94489,DB00277,Theophylline
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,3.9,94490,DB00277,Theophylline
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,5.8,94491,DB00277,Theophylline
,3742937,distribution volume,Similar comparisons indicate that theophylline distribution volume and elimination t1/2 were increased from 30.7 +/- 4.4 L and 262 +/- 57 minutes to 36.8 +/- 4.2 L (P less than 0.05) and 389 +/- 73 minutes (P less than 0.01) in the third trimester of pregnancy.,Theophylline pharmacokinetics in pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),l,30.7,94571,DB00277,Theophylline
,3742937,distribution volume,Similar comparisons indicate that theophylline distribution volume and elimination t1/2 were increased from 30.7 +/- 4.4 L and 262 +/- 57 minutes to 36.8 +/- 4.2 L (P less than 0.05) and 389 +/- 73 minutes (P less than 0.01) in the third trimester of pregnancy.,Theophylline pharmacokinetics in pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),l,36.8,94572,DB00277,Theophylline
,3742937,elimination t1/2,Similar comparisons indicate that theophylline distribution volume and elimination t1/2 were increased from 30.7 +/- 4.4 L and 262 +/- 57 minutes to 36.8 +/- 4.2 L (P less than 0.05) and 389 +/- 73 minutes (P less than 0.01) in the third trimester of pregnancy.,Theophylline pharmacokinetics in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),min,262,94573,DB00277,Theophylline
,3742937,elimination t1/2,Similar comparisons indicate that theophylline distribution volume and elimination t1/2 were increased from 30.7 +/- 4.4 L and 262 +/- 57 minutes to 36.8 +/- 4.2 L (P less than 0.05) and 389 +/- 73 minutes (P less than 0.01) in the third trimester of pregnancy.,Theophylline pharmacokinetics in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),min,389,94574,DB00277,Theophylline
,3742937,intrinsic nonrenal clearance,"In the second and third trimesters, intrinsic nonrenal clearance was reduced to 0.82 +/- 0.25 ml/min X kg (P less than 0.05) and 0.67 +/- 0.18 ml/min X kg (P less than 0.01) compared with a remote postpartum value of 1.25 +/- 0.37 ml/min X kg.",Theophylline pharmacokinetics in pregnancy. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),[ml] / [kg·min],0.82,94575,DB00277,Theophylline
,3742937,intrinsic nonrenal clearance,"In the second and third trimesters, intrinsic nonrenal clearance was reduced to 0.82 +/- 0.25 ml/min X kg (P less than 0.05) and 0.67 +/- 0.18 ml/min X kg (P less than 0.01) compared with a remote postpartum value of 1.25 +/- 0.37 ml/min X kg.",Theophylline pharmacokinetics in pregnancy. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),[ml] / [kg·min],0.67,94576,DB00277,Theophylline
,3742937,intrinsic nonrenal clearance,"In the second and third trimesters, intrinsic nonrenal clearance was reduced to 0.82 +/- 0.25 ml/min X kg (P less than 0.05) and 0.67 +/- 0.18 ml/min X kg (P less than 0.01) compared with a remote postpartum value of 1.25 +/- 0.37 ml/min X kg.",Theophylline pharmacokinetics in pregnancy. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742937/),[ml] / [kg·min],1.25,94577,DB00277,Theophylline
,23436249,limit of,The method has a limit of quantification of 50 ng/mL for temozolomide in plasma and 125 ng/g in brain.,Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436249/),[ng] / [ml],50,95030,DB00277,Theophylline
,10698464,Frel,The Frel of Xanthium was 80.1% relative to Theo-Dur.,Comparative study of the pharmacokinetic characteristics of slow release theophylline oral preparations in Thai children with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698464/),%,80.1,95037,DB00277,Theophylline
,434905,half life,"In a pharmacokinetic study, the half life of theophylline was 30.3 +/- 7.2 hours and the clearance rate was 23.9 +/- 5.06 ml/kg per hour (means and SD).",Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434905/),h,30.3,96902,DB00277,Theophylline
,434905,clearance rate,"In a pharmacokinetic study, the half life of theophylline was 30.3 +/- 7.2 hours and the clearance rate was 23.9 +/- 5.06 ml/kg per hour (means and SD).",Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434905/),[ml] / [h·kg],23.9,96903,DB00277,Theophylline
,2692938,half-life,Terfenadine exhibits a bimodal elimination phase (slow component +/- 22 hours) and astemizole has an active metabolite with a half-life of 12 days.,Anti-allergy and anti-asthma drugs. Disposition in infancy and childhood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2692938/),d,12,96936,DB00277,Theophylline
,2692938,half-lives,"The half-lives of most other antihistamines lie in the 4- to 8-hour range (except chlorpheniramine, which has a longer half-life).",Anti-allergy and anti-asthma drugs. Disposition in infancy and childhood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2692938/),h,4- to 8-,96937,DB00277,Theophylline
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97098,DB00277,Theophylline
,3435693,total plasma,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97099,DB00277,Theophylline
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97100,DB00277,Theophylline
,3435693,clearance,"3. Saliva theophylline clearance was closely related (r = 0.967, n = 19, P less than 0.001) and numerically very similar to the free plasma theophylline clearance (mean 5.8 +/- 1.9l h-1) (mean difference = 0.06 +/- 0.12 s.e. mean).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97101,DB00277,Theophylline
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,79.6,97399,DB00277,Theophylline
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,10.8,97400,DB00277,Theophylline
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,3.7,97401,DB00277,Theophylline
over,1257607,peak plasma concentration,"Theophylline peak plasma concentration of over 170 ng/ml average was observed when 300 mg of caffeine, equivalent to 2-3 cups of coffee, was administered to humans.",The human metabolism of caffeine to theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257607/),[ng] / [ml],170,97595,DB00277,Theophylline
,6734703,bioavailability,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),%,93,98316,DB00277,Theophylline
,6734703,time to peak of the plasma concentration curve,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),h,7,98317,DB00277,Theophylline
,6734703,mean residence time,"The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h).",Food does not effect in bioavailability of theophylline from Theolin Retard. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734703/),h,14,98318,DB00277,Theophylline
,18608467,C(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),[μg] / [ml],15.16,100009,DB00277,Theophylline
,18608467,C(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),[μg] / [ml],11.41,100010,DB00277,Theophylline
,18608467,T(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),h,4.17,100011,DB00277,Theophylline
,18608467,T(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),%,97.69,100012,DB00277,Theophylline
,18608467,T(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),[μg] / [ml],11.41,100013,DB00277,Theophylline
,18608467,T(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),h,5,100014,DB00277,Theophylline
,18608467,T(max),"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),%,101.59,100015,DB00277,Theophylline
,18608467,relative bioavailability,"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),%,97.69,100016,DB00277,Theophylline
,18608467,relative bioavailability,"The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively.",Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608467/),%,101.59,100017,DB00277,Theophylline
,7717061,T1(2)beta,"Although T1(2)beta of theophylline was 6.08 h, the expected Cpss was attained in only 30 min (5 T1(2)alpha) after start of infusion and then well maintained.",Microprocessor-programmed infusion of theophylline rapidly attained expected steady-state level in rabbit plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7717061/),h,6.08,100254,DB00277,Theophylline
,9250566,Peak serum theophylline concentration,Peak serum theophylline concentration was 20 microg/ml (normal 10-20 microg/ml).,Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250566/),[μg] / [ml],20,100386,DB00277,Theophylline
,33313078,m/z,"TMZ was separated on a Waters UPLC® BEH C18 column with an isocratic mobile phase of ammonium acetate (10 mM)-0.1% formic acid/acetonitrile (30:70, v/v) in a positive-ion multi pie reaction monitoring mode (m/z 195.5 →137.6 for TMZ; m/z 181.5→124.2 for IS).",Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),,195.5,101036,DB00277,Theophylline
,33313078,m/z,"TMZ was separated on a Waters UPLC® BEH C18 column with an isocratic mobile phase of ammonium acetate (10 mM)-0.1% formic acid/acetonitrile (30:70, v/v) in a positive-ion multi pie reaction monitoring mode (m/z 195.5 →137.6 for TMZ; m/z 181.5→124.2 for IS).",Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),,137.6,101037,DB00277,Theophylline
,33313078,m/z,"TMZ was separated on a Waters UPLC® BEH C18 column with an isocratic mobile phase of ammonium acetate (10 mM)-0.1% formic acid/acetonitrile (30:70, v/v) in a positive-ion multi pie reaction monitoring mode (m/z 195.5 →137.6 for TMZ; m/z 181.5→124.2 for IS).",Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),,181.5,101038,DB00277,Theophylline
,33313078,m/z,"TMZ was separated on a Waters UPLC® BEH C18 column with an isocratic mobile phase of ammonium acetate (10 mM)-0.1% formic acid/acetonitrile (30:70, v/v) in a positive-ion multi pie reaction monitoring mode (m/z 195.5 →137.6 for TMZ; m/z 181.5→124.2 for IS).",Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),,124.2,101039,DB00277,Theophylline
,33313078,retention time,The retention time of TMZ and theophylline was 0.45 min with a total run time of 2.5 min.,Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),min,0.45,101040,DB00277,Theophylline
,33313078,total run time,The retention time of TMZ and theophylline was 0.45 min with a total run time of 2.5 min.,Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313078/),min,2.5,101041,DB00277,Theophylline
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],0.1,101755,DB00277,Theophylline
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],1,101756,DB00277,Theophylline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.2,104304,DB00277,Theophylline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.3,104305,DB00277,Theophylline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],11.6,104306,DB00277,Theophylline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],14.6,104307,DB00277,Theophylline
,3403868,Relative bioavailability,Relative bioavailability of theophylline suspension was 89% of that for the solution.,Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),%,89,104308,DB00277,Theophylline
,9352762,maximum rate of metabolism (Vmax),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),[mg] / [h],71,104350,DB00277,Theophylline
,9352762,Michaelis-Menten constant (Km),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),[mg] / [l],32.3,104351,DB00277,Theophylline
,9352762,volume of distribution (Vd),"Parameter estimates (SE) were: maximum rate of metabolism (Vmax) 71 (42) mg.h-1, Michaelis-Menten constant (Km) 32.3 (33.5) mg.l-1, volume of distribution (Vd) 46.9 (2.6)l.",Aspects of theophylline clearance in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352762/),l,46.9,104352,DB00277,Theophylline
,1448452,bioavailability,"Compared to TheoDur, the two Soviet drugs, Theobiolongas and Theopaek, had lower bioavailability (86% and 82%, respectively), and higher rate of absorption.",Bioavailability of two Soviet sustained-release theophylline formulations in comparison with TheoDur. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448452/),%,86,104648,DB00277,Theophylline
,1448452,bioavailability,"Compared to TheoDur, the two Soviet drugs, Theobiolongas and Theopaek, had lower bioavailability (86% and 82%, respectively), and higher rate of absorption.",Bioavailability of two Soviet sustained-release theophylline formulations in comparison with TheoDur. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448452/),%,82,104649,DB00277,Theophylline
,1778539,Km,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),[mg] / [l],0.42,106049,DB00277,Theophylline
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,7.54,106050,DB00277,Theophylline
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,2.01,106051,DB00277,Theophylline
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,1.08,106052,DB00277,Theophylline
,1778539,Residual,Residual variability in dosage rates was estimated as 0.90 mg/kg per day.,Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),mg,0.90,106053,DB00277,Theophylline
,4049460,elimination rate constant (lambda),"The computer-based and standard two-point methods provided similar estimates for mean (+/- SD) values of elimination rate constant (lambda) (0.172 +/- 0.103 h-1 and 0.179 +/- 0.010 h-1, respectively) and apparent volume of distribution (V) (22.7 +/- 9.9 L and 23.3 +/- 11.5 L, respectively).",Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),1/[h],0.172,106074,DB00277,Theophylline
,4049460,elimination rate constant (lambda),"The computer-based and standard two-point methods provided similar estimates for mean (+/- SD) values of elimination rate constant (lambda) (0.172 +/- 0.103 h-1 and 0.179 +/- 0.010 h-1, respectively) and apparent volume of distribution (V) (22.7 +/- 9.9 L and 23.3 +/- 11.5 L, respectively).",Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),1/[h],0.179,106075,DB00277,Theophylline
,4049460,apparent volume of distribution (V),"The computer-based and standard two-point methods provided similar estimates for mean (+/- SD) values of elimination rate constant (lambda) (0.172 +/- 0.103 h-1 and 0.179 +/- 0.010 h-1, respectively) and apparent volume of distribution (V) (22.7 +/- 9.9 L and 23.3 +/- 11.5 L, respectively).",Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),l,22.7,106076,DB00277,Theophylline
,4049460,apparent volume of distribution (V),"The computer-based and standard two-point methods provided similar estimates for mean (+/- SD) values of elimination rate constant (lambda) (0.172 +/- 0.103 h-1 and 0.179 +/- 0.010 h-1, respectively) and apparent volume of distribution (V) (22.7 +/- 9.9 L and 23.3 +/- 11.5 L, respectively).",Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),l,23.3,106077,DB00277,Theophylline
,4049460,troughs,The mean (+/- SD) of predicted AG troughs was 1.3 +/- 0.5 mg/L for the standard method and 1.3 +/- 0.6 mg/L for the computer-based method.,Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),[mg] / [l],1.3,106078,DB00277,Theophylline
,4049460,troughs,The mean (+/- SD) of predicted AG troughs was 1.3 +/- 0.5 mg/L for the standard method and 1.3 +/- 0.6 mg/L for the computer-based method.,Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),[mg] / [l],1.3,106079,DB00277,Theophylline
,4049460,trough,Neither was significantly different from the actual AG trough mean of 1.3 +/- 0.7 mg/L.,Experience with a computer-based technique for estimating pharmacokinetic constants from limited data. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049460/),[mg] / [l],1.3,106080,DB00277,Theophylline
,7248481,apparent bioavailability,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),%,1,106343,DB00277,Theophylline
,7248481,apparent bioavailability,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),%,2,106344,DB00277,Theophylline
,7248481,half-life,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),h,1.0,106345,DB00277,Theophylline
,7248481,half-life,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),h,2.4,106346,DB00277,Theophylline
,790952,Near-steady-state serum concentrations,Near-steady-state serum concentrations in the therapeutic range of 8-20 mg/liter were found in 72% of the patients.,System for clinical pharmacokinetic monitoring of theophylline therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/790952/),[mg] / [l],8-20,106409,DB00277,Theophylline
,10382900,AUC0-->infinity,"When the control phase (i.e. no dirithromycin) was compared with the treatment phase (i.e. with dirithromycin), theophylline exposures as measured by AUC0-->infinity were not significantly different: 141.7+/-25.9 and 136.4+/-33.1 mg x h/L respectively (P = 0.16).",Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382900/),[h·mg] / [l],141.7,107327,DB00277,Theophylline
,10382900,AUC0-->infinity,"When the control phase (i.e. no dirithromycin) was compared with the treatment phase (i.e. with dirithromycin), theophylline exposures as measured by AUC0-->infinity were not significantly different: 141.7+/-25.9 and 136.4+/-33.1 mg x h/L respectively (P = 0.16).",Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382900/),[h·mg] / [l],136.4,107328,DB00277,Theophylline
,1271155,clearance,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),[l] / [h·kg],0.100,107355,DB00277,Theophylline
,1271155,kel,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),1/[h],0.49,107356,DB00277,Theophylline
,1271155,betat1/2,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),h,3.38,107357,DB00277,Theophylline
,1271155,alphat1/2,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),h,0.13,107358,DB00277,Theophylline
,1271155,V1,"The man plasma theophylline clearance was 0.100 +/- 0.036 l/kg/hr, kel 0.49 +/- 0.30 hr-1, betat1/2 3.38 +/- 1.11 hr, alphat1/2 0.13 +/- 0.09 hr, and V1 0.25 +/- 0.13 1/kg.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),[1] / [kg],0.25,107359,DB00277,Theophylline
,1271155,steady-state plasma concentration,"Calculations based upon mean values of pharmacokinetic constants predict that a maintenance dose rate for aminophylline of 30 mg/kg/day, after a loading dose of 5.6 mg/kg, would rapidly achieve and maintain a mean steady-state plasma concentration of theophylline of 10 mg/1.",Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1271155/),mg,10,107360,DB00277,Theophylline
,7273607,elimination half-life,Serum theophylline elimination half-life rose from 4.79 +/- 0.43 hr before to 7.53 +/- 0.71 hr after erythromycin.,Depression of theophylline elimination by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273607/),h,4.79,108556,DB00277,Theophylline
,7273607,elimination half-life,Serum theophylline elimination half-life rose from 4.79 +/- 0.43 hr before to 7.53 +/- 0.71 hr after erythromycin.,Depression of theophylline elimination by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273607/),h,7.53,108557,DB00277,Theophylline
,7273607,clearance,Theophylline clearance decreased from a mean of 91.6 +/- 27.0 to 54.8 +/- 10.0 ml/kg/hr after erythromycin and the mean apparent volumes of distribution were much the same before and after the antibiotic.,Depression of theophylline elimination by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273607/),[ml] / [h·kg],91.6,108558,DB00277,Theophylline
,7273607,clearance,Theophylline clearance decreased from a mean of 91.6 +/- 27.0 to 54.8 +/- 10.0 ml/kg/hr after erythromycin and the mean apparent volumes of distribution were much the same before and after the antibiotic.,Depression of theophylline elimination by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273607/),[ml] / [h·kg],54.8,108559,DB00277,Theophylline
,934239,apparent volume of distribution,"Theophylline's apparent volume of distribution was 0.690 +/- 0.095 liters per kilogram (mean +/- S.E.), a value similar to that of children, but the half-life (30.2 +/- 6.5 hours) was nine times longer.",Pharmacokinetic aspects of theophylline in premature newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),[l] / [kg],0.690,108887,DB00277,Theophylline
,934239,half-life,"Theophylline's apparent volume of distribution was 0.690 +/- 0.095 liters per kilogram (mean +/- S.E.), a value similar to that of children, but the half-life (30.2 +/- 6.5 hours) was nine times longer.",Pharmacokinetic aspects of theophylline in premature newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),h,30.2,108888,DB00277,Theophylline
,934239,Blood clearance rate,Blood clearance rate (17.6 +/- 2.3 ml per kilogram per hour) was lower than plasma clearance rate (100 ml per kilogram per hour) of young children.,Pharmacokinetic aspects of theophylline in premature newborns. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),[ml] / [h·kg],17.6,108889,DB00277,Theophylline
,934239,plasma clearance rate,Blood clearance rate (17.6 +/- 2.3 ml per kilogram per hour) was lower than plasma clearance rate (100 ml per kilogram per hour) of young children.,Pharmacokinetic aspects of theophylline in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),[ml] / [h·kg],100,108890,DB00277,Theophylline
,934239,total plasma concentration,"At a total plasma concentration of 17 mg per liter, 56.4 +/- 3.8 and 36.4 +/- 3.8 per cent of the theophylline was bound to adult or full-term cord plasma proteins, respectively.",Pharmacokinetic aspects of theophylline in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),%,17,108891,DB00277,Theophylline
,934239,total plasma concentration,"At a total plasma concentration of 17 mg per liter, 56.4 +/- 3.8 and 36.4 +/- 3.8 per cent of the theophylline was bound to adult or full-term cord plasma proteins, respectively.",Pharmacokinetic aspects of theophylline in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),%,56.4,108892,DB00277,Theophylline
,934239,total plasma concentration,"At a total plasma concentration of 17 mg per liter, 56.4 +/- 3.8 and 36.4 +/- 3.8 per cent of the theophylline was bound to adult or full-term cord plasma proteins, respectively.",Pharmacokinetic aspects of theophylline in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),%,36.4,108893,DB00277,Theophylline
,934239,maintenance dose rate,Calculations suggest that a loading doses of 5.5 mg per kilogram and a maintenance dose rate of 1.1 mg per kilogram per eight hours would achieve and maintain a mean blood concentration of 8 mg per liter (about 10 mg per liter in plasma).,Pharmacokinetic aspects of theophylline in premature newborns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),,1,108894,DB00277,Theophylline
,934239,blood concentration,Calculations suggest that a loading doses of 5.5 mg per kilogram and a maintenance dose rate of 1.1 mg per kilogram per eight hours would achieve and maintain a mean blood concentration of 8 mg per liter (about 10 mg per liter in plasma).,Pharmacokinetic aspects of theophylline in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),[mg] / [l],8,108895,DB00277,Theophylline
,934239,blood concentration,Calculations suggest that a loading doses of 5.5 mg per kilogram and a maintenance dose rate of 1.1 mg per kilogram per eight hours would achieve and maintain a mean blood concentration of 8 mg per liter (about 10 mg per liter in plasma).,Pharmacokinetic aspects of theophylline in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/934239/),mg,10,108896,DB00277,Theophylline
,1181352,half-life,"The mean half-life of dyphylline is 2.11 +/- 0.36 hr; because of its short half-life and unproved efficacy, current dosage recommendations for dyphylline must be revised greatly.",The pharmacokinetics of dihydroxypropyltheophylline: a basis for rational therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1181352/),h,2.11,109248,DB00277,Theophylline
,3680816,Extent of absorption,"Extent of absorption was similar during single and multiple dosing but was significantly greater when dose was taken after breakfast; 68 +/- 7% (mean +/- SEM) and 61 +/- 4% of administered doses were absorbed during single and multiple dosing, respectively, when breakfast was withheld, whereas 83 +/- 4% and 86 +/- 4% of administered doses were absorbed when single and multiple doses, respectively, followed breakfast.",Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680816/),%,68,109630,DB00277,Theophylline
,3680816,Extent of absorption,"Extent of absorption was similar during single and multiple dosing but was significantly greater when dose was taken after breakfast; 68 +/- 7% (mean +/- SEM) and 61 +/- 4% of administered doses were absorbed during single and multiple dosing, respectively, when breakfast was withheld, whereas 83 +/- 4% and 86 +/- 4% of administered doses were absorbed when single and multiple doses, respectively, followed breakfast.",Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680816/),%,61,109631,DB00277,Theophylline
,3680816,Extent of absorption,"Extent of absorption was similar during single and multiple dosing but was significantly greater when dose was taken after breakfast; 68 +/- 7% (mean +/- SEM) and 61 +/- 4% of administered doses were absorbed during single and multiple dosing, respectively, when breakfast was withheld, whereas 83 +/- 4% and 86 +/- 4% of administered doses were absorbed when single and multiple doses, respectively, followed breakfast.",Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680816/),%,83,109632,DB00277,Theophylline
,3680816,Extent of absorption,"Extent of absorption was similar during single and multiple dosing but was significantly greater when dose was taken after breakfast; 68 +/- 7% (mean +/- SEM) and 61 +/- 4% of administered doses were absorbed during single and multiple dosing, respectively, when breakfast was withheld, whereas 83 +/- 4% and 86 +/- 4% of administered doses were absorbed when single and multiple doses, respectively, followed breakfast.",Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680816/),%,86,109633,DB00277,Theophylline
,2653832,oesoduodenal transit time,"Results showed that the presence of food in the stomach dramatically increased the oesoduodenal transit time of the tablet (74 +/- 27 min vs 352 +/- 77 min, P less than 0.001) but did not modify the biodisponibility of theophylline.",Gastrointestinal scintigraphy with 99mTc-DTPA labeled tablets in fed and fasting subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653832/),min,74,109645,DB00277,Theophylline
,2653832,oesoduodenal transit time,"Results showed that the presence of food in the stomach dramatically increased the oesoduodenal transit time of the tablet (74 +/- 27 min vs 352 +/- 77 min, P less than 0.001) but did not modify the biodisponibility of theophylline.",Gastrointestinal scintigraphy with 99mTc-DTPA labeled tablets in fed and fasting subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653832/),min,352,109646,DB00277,Theophylline
,31529628,Systemic bioavailability,Systemic bioavailability of the MCT was 96.2 ± 32.9%.,"Pharmacokinetics of a modified, compounded theophylline product in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),%,96.2,109878,DB00277,Theophylline
,31529628,times to maximum concentration,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,8.85,109879,DB00277,Theophylline
,31529628,mean absorption time,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,6.95,109880,DB00277,Theophylline
,31529628,terminal half-life,"MCT times to maximum concentration, mean absorption time and terminal half-life were 8.85 ± 3.63, 6.95 ± 3.42, and 8.67 ± 1.62 hr, respectively.","Pharmacokinetics of a modified, compounded theophylline product in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31529628/),h,8.67,109881,DB00277,Theophylline
,1264548,milk to serum concentration ratio,The average milk to serum concentration ratio of the drug was about 0.7 and milk concentrations paralleled the time-course of serum and saliva concentrations.,Theophylline secretion into breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1264548/),,0.7,110934,DB00277,Theophylline
,2713215,t,"5. The mean prediction errors of the revised estimates of the day and night-peak drug concentrations were -0.55 mg l-1 and -0.21 mg l-1 whilst those of the evening and morning troughs were 1.17 mg l-1 and 0.41 mg l-1, respectively.",Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713215/),[mg] / [l],1.17,111843,DB00277,Theophylline
,2713215,t,"5. The mean prediction errors of the revised estimates of the day and night-peak drug concentrations were -0.55 mg l-1 and -0.21 mg l-1 whilst those of the evening and morning troughs were 1.17 mg l-1 and 0.41 mg l-1, respectively.",Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713215/),[mg] / [l],0.41,111844,DB00277,Theophylline
,3244609,terminal plasma half-life,The terminal plasma half-life of theophylline following an i.v. dose was found to be approximately 24 hr.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),h,24,112664,DB00277,Theophylline
,3244609,volume of distribution,"The volume of distribution, Vdext, and clearance following the i.v. dose were approximately 0.7 liter/kg and 0.023 liter/hr/kg, respectively.",The effect of food on the absorption of controlled-release theophylline in mini-swine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),[l] / [kg],0.7,112665,DB00277,Theophylline
,3244609,clearance,"The volume of distribution, Vdext, and clearance following the i.v. dose were approximately 0.7 liter/kg and 0.023 liter/hr/kg, respectively.",The effect of food on the absorption of controlled-release theophylline in mini-swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),[l] / [h·kg],0.023,112666,DB00277,Theophylline
,3244609,terminal half-life,The terminal half-life of theophylline following the administration of theophylline capsules under fasting conditions was 21 hr.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),h,21,112667,DB00277,Theophylline
,3244609,bioavailability,The average bioavailability under fasting conditions was approximately 80% compared to the i.v. dose.,The effect of food on the absorption of controlled-release theophylline in mini-swine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244609/),%,80,112668,DB00277,Theophylline
,10387953,AUC0-2 h,"The AUC0-2 h of a metabolite of theophylline, 1,3-dimethyluric acid, 1,3-DMU (62.3 versus 106 microg/min per ml), and the percentages of intravenous dose of theophylline excreted in 24-h urine as 1,3-DMU (12.4% versus 20.8%, expressed in terms of theophylline) decreased significantly in 2-AP-pretreated rats when compared with those in control rats.","Effect of a new chemoprotective agent, 2-(allylthio)pyrazine, on the pharmacokinetics of intravenous theophylline in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10387953/),[μg] / [min·ml],62.3,112678,DB00277,Theophylline
,10387953,AUC0-2 h,"The AUC0-2 h of a metabolite of theophylline, 1,3-dimethyluric acid, 1,3-DMU (62.3 versus 106 microg/min per ml), and the percentages of intravenous dose of theophylline excreted in 24-h urine as 1,3-DMU (12.4% versus 20.8%, expressed in terms of theophylline) decreased significantly in 2-AP-pretreated rats when compared with those in control rats.","Effect of a new chemoprotective agent, 2-(allylthio)pyrazine, on the pharmacokinetics of intravenous theophylline in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10387953/),[μg] / [min·ml],106,112679,DB00277,Theophylline
,31386207,flow rate,The chromatography was performed in a gradient elution mode with a 1 mL/min flow rate.,"Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31386207/),[ml] / [min],1,113096,DB00277,Theophylline
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],1.55,113122,DB00277,Theophylline
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],7.01,113123,DB00277,Theophylline
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],14.34,113124,DB00277,Theophylline
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00277,Theophylline
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00277,Theophylline
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00277,Theophylline
,8361866,maximum serum concentration,"Mean (+/- SD) maximum serum concentration was 2.4 +/- 1.3 micrograms/ml, mean time to maximum serum concentration was 22 +/- 8.2 hours, and mean latency period was 8.0 +/- 4.9 hours.",Evaluation of transdermal theophylline pharmacokinetics in neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361866/),[μg] / [ml],2.4,113883,DB00277,Theophylline
,8361866,time to maximum serum concentration,"Mean (+/- SD) maximum serum concentration was 2.4 +/- 1.3 micrograms/ml, mean time to maximum serum concentration was 22 +/- 8.2 hours, and mean latency period was 8.0 +/- 4.9 hours.",Evaluation of transdermal theophylline pharmacokinetics in neonates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361866/),h,22,113884,DB00277,Theophylline
,8361866,latency period,"Mean (+/- SD) maximum serum concentration was 2.4 +/- 1.3 micrograms/ml, mean time to maximum serum concentration was 22 +/- 8.2 hours, and mean latency period was 8.0 +/- 4.9 hours.",Evaluation of transdermal theophylline pharmacokinetics in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361866/),h,8.0,113885,DB00277,Theophylline
,8361866,total amount,Mean total amount of theophylline delivered to the skin was 18.6 +/- 4.1 mg.,Evaluation of transdermal theophylline pharmacokinetics in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361866/),mg,18.6,113886,DB00277,Theophylline
,8361866,fractional absorption,Mean fractional absorption at 30 hours was 0.25 +/- 0.12.,Evaluation of transdermal theophylline pharmacokinetics in neonates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361866/),,0.25,113887,DB00277,Theophylline
greater,3813276,T0,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],15,114183,DB00277,Theophylline
,3813276,max,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),,44,114184,DB00277,Theophylline
,3813276,T12,In 11 patients T0 was greater than 15 mg/l (max = 44) and T12 was 10.5 +/- 6.4 mg/l.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10.5,114185,DB00277,Theophylline
less,3813276,initial clearances,Theophylline was withdrawn in 6 patients with initial clearances less than 5 ml/kg/h (zero in 5 cases).,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[ml] / [h·kg],5,114186,DB00277,Theophylline
,3813276,T48,T48 was within therapeutic values (10-20 mg/l) in 55 p. 100 of cases (21/38).,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10-20,114187,DB00277,Theophylline
less,3813276,T48,Twelve patients had T48 less than 10 mg/l due to an increase in theophylline clearance (+ 80 p. 100 on average) related to improved right ventricular function in 7 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],10,114188,DB00277,Theophylline
greater,3813276,T48,In 5 patients T48 was greater than 20 mg/l (max = 27.5) due to a fall in clearance (average -47 p. 100) which could have been caused by administration of erythromycin in 1 case and by dose-dependent kinetics in 2 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),[mg] / [l],20,114189,DB00277,Theophylline
,3813276,max,In 5 patients T48 was greater than 20 mg/l (max = 27.5) due to a fall in clearance (average -47 p. 100) which could have been caused by administration of erythromycin in 1 case and by dose-dependent kinetics in 2 cases.,[Intravenous theophylline: adaptation of dosage to blood theophylline levels at admission and to clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813276/),,27.5,114190,DB00277,Theophylline
,6879641,TBC,"At a daily dose of 10.6 mg/kg/day, the mean TBC was 0.76 ml/min/kg, whereas at a dose of 15.7 mg/kg/day the TBC averaged 0.68 ml/min/kg.",Evaluation of the effect of nonlinear kinetics on dosage adjustments of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879641/),[ml] / [kg·min],0.76,114259,DB00277,Theophylline
,6879641,TBC,"At a daily dose of 10.6 mg/kg/day, the mean TBC was 0.76 ml/min/kg, whereas at a dose of 15.7 mg/kg/day the TBC averaged 0.68 ml/min/kg.",Evaluation of the effect of nonlinear kinetics on dosage adjustments of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879641/),[ml] / [kg·min],0.68,114260,DB00277,Theophylline
,6879641,apparent maximum velocity (Vmax),"The apparent maximum velocity (Vmax) calculated in these subjects averaged 2,923 mg/day.",Evaluation of the effect of nonlinear kinetics on dosage adjustments of theophylline. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879641/),[mg] / [d],"2,923",114261,DB00277,Theophylline
,6879641,Michaelis-Menten constant (Km),The mean Michaelis-Menten constant (Km) was 23.70 micrograms/ml.,Evaluation of the effect of nonlinear kinetics on dosage adjustments of theophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879641/),[μg] / [ml],23.70,114262,DB00277,Theophylline
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],2.29,115359,DB00277,Theophylline
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],1.64,115360,DB00277,Theophylline
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],91.4,115361,DB00277,Theophylline
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],128.4,115362,DB00277,Theophylline
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],11. 9,115363,DB00277,Theophylline
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],15.5,115364,DB00277,Theophylline
,21486185,C(max),"The C(max) values were found to be 5.49 ± 0.46 and 5.12 ± 0.85 μg/mL for F3 and Avolen(®) SR, respectively, F3 showed higher mean plasma concentration than Avolen(®) SR from the beginning and continued till 7 h post administration indicating high potential as chronotherapeutic treatment of nocturnal asthma.",Theophylline colon specific tablets for chronotherapeutic treatment of nocturnal asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21486185/),[μg] / [ml],5.49,115421,DB00277,Theophylline
,21486185,C(max),"The C(max) values were found to be 5.49 ± 0.46 and 5.12 ± 0.85 μg/mL for F3 and Avolen(®) SR, respectively, F3 showed higher mean plasma concentration than Avolen(®) SR from the beginning and continued till 7 h post administration indicating high potential as chronotherapeutic treatment of nocturnal asthma.",Theophylline colon specific tablets for chronotherapeutic treatment of nocturnal asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21486185/),[μg] / [ml],5.12,115422,DB00277,Theophylline
,7223434,V1,"The shape of semilogarithmic plots of all measured plasma theophylline concentrations versus time was compatible with the use of an open 2-compartment pharmacokinetic model assuming first-order distribution and elimination processes, but in the comparison of the mean values of the pharmacokinetic parameters obtained after the administration of the low and the high theophylline dose, statistical analysis by Student's t-test showed beta and V1 to be significantly altered (low dose: beta = 0.00338 min.-1, V1 = 392 ml kg-a; high dose: beta = 0.00198 min.-1, V1 = 528 ml kg-1; P less than 0.05).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),kg-a·ml,392,115762,DB00277,Theophylline
,7223434,V1,"The shape of semilogarithmic plots of all measured plasma theophylline concentrations versus time was compatible with the use of an open 2-compartment pharmacokinetic model assuming first-order distribution and elimination processes, but in the comparison of the mean values of the pharmacokinetic parameters obtained after the administration of the low and the high theophylline dose, statistical analysis by Student's t-test showed beta and V1 to be significantly altered (low dose: beta = 0.00338 min.-1, V1 = 392 ml kg-a; high dose: beta = 0.00198 min.-1, V1 = 528 ml kg-1; P less than 0.05).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[ml] / [kg],528,115763,DB00277,Theophylline
,7223434,kel 3MX,"The administered 3-methylxanthine was eliminated unchanged with a first-order rate constant ten times larger than the total elimination rate constant of theophylline itself, the latter being observed after the administration of the equimolar dose of aminophylline (kel 3MX = 0.029 min.-1, kel theophylline = 0.00293 min.-1).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),-1·min,0.029,115764,DB00277,Theophylline
,7223434,kel,"The administered 3-methylxanthine was eliminated unchanged with a first-order rate constant ten times larger than the total elimination rate constant of theophylline itself, the latter being observed after the administration of the equimolar dose of aminophylline (kel 3MX = 0.029 min.-1, kel theophylline = 0.00293 min.-1).",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),-1·min,0.00293,115765,DB00277,Theophylline
,7223434,Clearance,Clearance was calculated to 14.4 ml kg-1 min.-1 for 3-methylxanthine and 1.50 ml kg-1 min.-1 for theophylline.,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[-1·min·ml] / [kg],14.4,115766,DB00277,Theophylline
,7223434,Clearance,Clearance was calculated to 14.4 ml kg-1 min.-1 for 3-methylxanthine and 1.50 ml kg-1 min.-1 for theophylline.,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. I. Single dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223434/),[-1·min·ml] / [kg],1.50,115767,DB00277,Theophylline
,7332728,serum concentration,4 Theophylline (300 mg) resulted on day 6 in a mean serum concentration of 4.4 +/- 0.8 microgram ml-1.,Pharmacokinetics of sustained release theophylline in low and high multidose regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332728/),[μg] / [ml],4.4,115931,DB00277,Theophylline
,7332728,T1/2,5 The T1/2 (300 mg) was 9.3 +/- 1.4 h and the T1/2 (900 mg) was 8.5 +/- 2.0 h.,Pharmacokinetics of sustained release theophylline in low and high multidose regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332728/),h,9.3,115932,DB00277,Theophylline
,7332728,T1/2,5 The T1/2 (300 mg) was 9.3 +/- 1.4 h and the T1/2 (900 mg) was 8.5 +/- 2.0 h.,Pharmacokinetics of sustained release theophylline in low and high multidose regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332728/),h,8.5,115933,DB00277,Theophylline
,2564283,tmax,"From single-dose data, tazifylline appeared to be rapidly absorbed (median tmax of 0.6 h) and eliminated (t1/2 = 1.0 +/- 0.2 h).",Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2564283/),h,0.6,117713,DB00277,Theophylline
,2564283,t1/2,"From single-dose data, tazifylline appeared to be rapidly absorbed (median tmax of 0.6 h) and eliminated (t1/2 = 1.0 +/- 0.2 h).",Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2564283/),h,1.0,117714,DB00277,Theophylline
,2564283,terminal half-life,A two-compartment model best described multiple-dose data with a terminal half-life of 15.6 +/- 7.6 h consistent with twice-daily dosing of tazifylline.,Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2564283/),h,15.6,117715,DB00277,Theophylline
,10424323,AUC,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[micog] / [h·ml],68.6,117799,DB00277,Theophylline
,10424323,AUC,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [h·ml],70.0,117800,DB00277,Theophylline
,10424323,Cmax,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [ml],11.07,117801,DB00277,Theophylline
,10424323,Cmax,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [ml],11.83,117802,DB00277,Theophylline
,10424323,AUC,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [h·ml],21.91,117803,DB00277,Theophylline
,10424323,AUC,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [h·ml],22.09,117804,DB00277,Theophylline
,10424323,Cmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [ml],5.65,117805,DB00277,Theophylline
,10424323,Cmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [ml],5.54,117806,DB00277,Theophylline
,10424323,tmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),h,2.0,117807,DB00277,Theophylline
,10424323,tmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),h,1.5,117808,DB00277,Theophylline
,8055680,terminal elimination half-life,The terminal elimination half-life is between 20 and 50 hours.,Clinical pharmacokinetics of ticlopidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8055680/),h,20 and 50,118182,DB00277,Theophylline
,16958785,total body clearance (Cl(B)),"Multiple doses of OFX significantly reduced the total body clearance (Cl(B)) of TP from 0.117 to 0.085 L/h/kg, although a single dose did not change it.",Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958785/),[l] / [h·kg],0.117,118591,DB00277,Theophylline
,16958785,total body clearance (Cl(B)),"Multiple doses of OFX significantly reduced the total body clearance (Cl(B)) of TP from 0.117 to 0.085 L/h/kg, although a single dose did not change it.",Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958785/),[l] / [h·kg],0,118592,DB00277,Theophylline
,3991030,bioavailability,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),,101.2,118902,DB00277,Theophylline
,3991030,peak times,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),h,3.6,118903,DB00277,Theophylline
,3991030,peak times,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),h,1.3,118904,DB00277,Theophylline
,3991030,peak plasma concentrations,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),[mg] / [1·g·l],16.8,118905,DB00277,Theophylline
,3991030,peak plasma concentrations,Aminomal-R tablets had bioavailability (101.2 +/- 19) statistically indistinguishable from that of the standard but showed significantly slower absorption (peak times of 3.6 +/- 1.1 h vs 1.3 +/- 0.8 h) and lower peak plasma concentrations (16.8 +/- 4.7 mg/l/1 g aminoph. dose vs 21.1 +/- 4.2 mg/l/1 g aminoph. dose).,[Bioavailability of a delayed-action aminophylline preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3991030/),[mg] / [1·l],21.1,118906,DB00277,Theophylline
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,9.2,119900,DB00277,Theophylline
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,10.6,119901,DB00277,Theophylline
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,8.3,119902,DB00277,Theophylline
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00277,Theophylline
,7746027,absolute bioavailability,The absolute bioavailability of theophylline and quinine from the two formulations Limptar and Limptar N was nearly complete (90% on the average).,Study on the absolute bioavailability of quinine and theophylline from tablets after single dose oral administration as compared to intravenous infusion in healthy male non-smoking volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7746027/),%,90,120106,DB00277,Theophylline
,23215698,K(i),AGS-IV was found to be a competitive inhibitor with a K(i) value of 6.29 μM in vitro.,Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23215698/),μM,6.29,120248,DB00277,Theophylline
,9314090,half-life,"Cefaclor is not metabolized to a significant degree, but it degrades chemically in the body with an approximate half-life of 2 hours.",Pharmacokinetic profile of cefaclor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314090/),h,2,120289,DB00277,Theophylline
,9314090,serum half-life,"Most of the drug is excreted unchanged in the urine, the serum half-life after oral administration is 0.5-0.7 hours.",Pharmacokinetic profile of cefaclor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314090/),h,0.5-0.7,120290,DB00277,Theophylline
,1379919,absolute oral bioavailability,"After oral administration in saline solution, a mean absolute oral bioavailability of 59.6% was calculated.",Bioavailability of oral isbufylline in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379919/),%,59.6,121113,DB00277,Theophylline
,1379919,elimination: t1/2,"The drug is rapidly absorbed and the comparison of the kinetic profiles after i.v. and per os administration, revealed a rapid elimination: t1/2 27.3 and 28.8 min respectively, and a total body clearance of 67.06 ml/min/kg.",Bioavailability of oral isbufylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379919/),min,27.3,121114,DB00277,Theophylline
,1379919,elimination: t1/2,"The drug is rapidly absorbed and the comparison of the kinetic profiles after i.v. and per os administration, revealed a rapid elimination: t1/2 27.3 and 28.8 min respectively, and a total body clearance of 67.06 ml/min/kg.",Bioavailability of oral isbufylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379919/),min,28.8,121115,DB00277,Theophylline
,1379919,total body clearance,"The drug is rapidly absorbed and the comparison of the kinetic profiles after i.v. and per os administration, revealed a rapid elimination: t1/2 27.3 and 28.8 min respectively, and a total body clearance of 67.06 ml/min/kg.",Bioavailability of oral isbufylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379919/),[ml] / [kg·min],67.06,121116,DB00277,Theophylline
,3449080,elimination half-life,It was shown that the elimination half-life of theophylline in Thai asthmatic children (average 7.21 hours) was longer than that observed for subjects in western countries.,Pharmacokinetics of oral theophylline in Thai asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),h,7.21,121350,DB00277,Theophylline
,3449080,elimination half-lives,Variations in elimination half-lives ranging from 4.44 to 14.34 hours were intersubject variations.,Pharmacokinetics of oral theophylline in Thai asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),h,4.44 to 14.34,121351,DB00277,Theophylline
,3449080,maximum,"Using data from this study, the predicted maximum and minimum serum theophylline concentrations at steady state were calculated to be 16.53 micrograms/ml and 9.96 micrograms/ml, respectively.",Pharmacokinetics of oral theophylline in Thai asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),[μg] / [ml],16.53,121352,DB00277,Theophylline
,3449080,minimum serum theophylline concentrations at steady state,"Using data from this study, the predicted maximum and minimum serum theophylline concentrations at steady state were calculated to be 16.53 micrograms/ml and 9.96 micrograms/ml, respectively.",Pharmacokinetics of oral theophylline in Thai asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449080/),[μg] / [ml],9.96,121353,DB00277,Theophylline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],0,121685,DB00277,Theophylline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],7.5,121686,DB00277,Theophylline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],15,121687,DB00277,Theophylline
,6586482,steady-state concentration,"At the highest steady-state concentration (15 micrograms/mL), 2 of the patients experienced nausea.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],15,121688,DB00277,Theophylline
,2576359,peak concentration,Additional theophylline administration significantly increased peak concentration of the intermediate active metabolite M2 by 23% from 7 to 8.6 ng/ml.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],7,123263,DB00277,Theophylline
,2576359,peak concentration,Additional theophylline administration significantly increased peak concentration of the intermediate active metabolite M2 by 23% from 7 to 8.6 ng/ml.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],8.6,123264,DB00277,Theophylline
,2576359,plasma protein binding,A supplementary in vitro study showed no change in plasma protein binding of picumast (100 ng/ml) in the presence of theophylline (20 micrograms/ml) and vice versa.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],100,123265,DB00277,Theophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,6.0,123270,DB00277,Theophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,9.3,123271,DB00277,Theophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,4.6,123272,DB00277,Theophylline
,2591473,half-life,"Theophylline half-life was significantly shorter in female non-smokers (FNS) versus male non-smokers (MNS), (FNS = 6.0 h; MNS = 9.3 h), and in female smokers (FS) versus male smokers (MS), (FS = 4.6 h; MS = 6.3 h).",Sex-related differences in theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),h,6.3,123273,DB00277,Theophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(-1)1.73·(m)^2·min],43.8,123274,DB00277,Theophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(m)^2·min],37.4,123275,DB00277,Theophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[1.73·ml] / [(m)^2·min],64.2,123276,DB00277,Theophylline
,2591473,Total body clearance,"Total body clearance was significantly different in FNS versus MNS, (FNS = 43.8 ml.min-1.-1(1.73) m-2; MNS = 37.4 ml.min-1.1.73 m-2), but did not reach statistical significance in FS vs. MS, (FS = 64.2 ml.min-1.1(-1).1.73 m-2; MS = 53.1 ml.min-1.1.73 m-2).",Sex-related differences in theophylline pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591473/),[ml] / [(m)^2·min],53.1,123277,DB00277,Theophylline
,3582477,trough plasma concentration at steady-state,"In 30 subjects, trough plasma concentration at steady-state were 12.0 +/- 4.9 micrograms X ml-1 (mean +/- SD) and differed by -2.7 +/- 39.3% from a mean target plasma concentration of 12.5 +/- 1.5 micrograms X ml-1.",Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582477/),[μg] / [ml],12.0,123513,DB00277,Theophylline
,3582477,target plasma concentration,"In 30 subjects, trough plasma concentration at steady-state were 12.0 +/- 4.9 micrograms X ml-1 (mean +/- SD) and differed by -2.7 +/- 39.3% from a mean target plasma concentration of 12.5 +/- 1.5 micrograms X ml-1.",Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582477/),[μg] / [ml],12.5,123514,DB00277,Theophylline
,20193253,capsule activation time,The mean capsule activation time for the small bowel and ascending colon was 2.07 hours and 6.08 hours post dose.,Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),h,2.07,123660,DB00277,Theophylline
,20193253,capsule activation time,The mean capsule activation time for the small bowel and ascending colon was 2.07 hours and 6.08 hours post dose.,Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),h,6.08,123661,DB00277,Theophylline
,20193253,area under the curve (AUC(t)) ratio,"Aminophylline had similar absorption profiles from the small bowel compared with the stomach, with an area under the curve (AUC(t)) ratio of 92% vs. the stomach, but a lower absorption profile from the ascending colon, with an AUC(t) ratio of 47.2% vs. the stomach.",Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),%,92,123662,DB00277,Theophylline
,20193253,AUC(t) ratio,"Aminophylline had similar absorption profiles from the small bowel compared with the stomach, with an area under the curve (AUC(t)) ratio of 92% vs. the stomach, but a lower absorption profile from the ascending colon, with an AUC(t) ratio of 47.2% vs. the stomach.",Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20193253/),%,47.2,123663,DB00277,Theophylline
,3733117,half-life,"However, there was a significant difference (P less than 0.05) between the mean plasma theophylline half-life in smokers (5.41 h, SEM 0.69 h) and non-smokers (10.40 h, SEM 1.90 h).",Theophylline pharmacokinetics in patients from a geriatric hospital: influence of cigarette smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733117/),h,5.41,123807,DB00277,Theophylline
,3733117,half-life,"However, there was a significant difference (P less than 0.05) between the mean plasma theophylline half-life in smokers (5.41 h, SEM 0.69 h) and non-smokers (10.40 h, SEM 1.90 h).",Theophylline pharmacokinetics in patients from a geriatric hospital: influence of cigarette smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733117/),h,10.40,123808,DB00277,Theophylline
,3768254,minimum concentration (Cmin),Plasma concentrations rose from a mean +/- s.d. minimum concentration (Cmin) of 7.9 +/- 2.3 mg l-1 to a mean maximum of 13.6 +/- 3.3 mg l-1 at a median time of 10 h after dosing.,"Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768254/),[mg] / [l],7.9,124191,DB00277,Theophylline
,3768254,maximum,Plasma concentrations rose from a mean +/- s.d. minimum concentration (Cmin) of 7.9 +/- 2.3 mg l-1 to a mean maximum of 13.6 +/- 3.3 mg l-1 at a median time of 10 h after dosing.,"Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768254/),[mg] / [l],13.6,124192,DB00277,Theophylline
,3768254,sa,Saliva theophylline concentrations were closely related to the plasma theophylline concentration both between and within subjects with a mean saliva to plasma concentration ratio between subjects (S/P ratio) of 0.62 (+/- 0.05) and a mean within subject coefficient of variation of 8.2% (+/- 4.5%).,"Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768254/),,0.62,124193,DB00277,Theophylline
,3768254,S/P ratio),Saliva theophylline concentrations were closely related to the plasma theophylline concentration both between and within subjects with a mean saliva to plasma concentration ratio between subjects (S/P ratio) of 0.62 (+/- 0.05) and a mean within subject coefficient of variation of 8.2% (+/- 4.5%).,"Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768254/),,0.62,124194,DB00277,Theophylline
,7450653,absolute bioavailability,"The absolute bioavailability was of th tablet 105 +/- 25%, of the retard table 81 +/- 23%, of the suppository 74 +/- 25%.",[Absolute bioavailability of theophylline (Euphylline)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450653/),%,105,125277,DB00277,Theophylline
,7450653,absolute bioavailability,"The absolute bioavailability was of th tablet 105 +/- 25%, of the retard table 81 +/- 23%, of the suppository 74 +/- 25%.",[Absolute bioavailability of theophylline (Euphylline)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450653/),%,81,125278,DB00277,Theophylline
,7450653,absolute bioavailability,"The absolute bioavailability was of th tablet 105 +/- 25%, of the retard table 81 +/- 23%, of the suppository 74 +/- 25%.",[Absolute bioavailability of theophylline (Euphylline)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450653/),%,74,125279,DB00277,Theophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,99,126273,DB00277,Theophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,102,126274,DB00277,Theophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,103,126275,DB00277,Theophylline
,7431220,bioavailability,"In a single-dose bioavailability study, Wales, Robinson, Columbia, and Choledyl (Warner/Chilcott) enteric-coated tablets all allowed a bioavailability of theophylline (99% +/- 25%, 102% +/- 23%, 103% +/- 18%, and 98% +/- 15%; mean +/- SD, n = 12) statistically indistinguishable from that of the standard uncoated tablet (Searle 200 mg aminophylline).",Evaluation of the absorption from some commercial enteric-release theophylline products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431220/),%,98,126276,DB00277,Theophylline
,23745275,plasma clearance,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),[ml] / [h·kg],17.88,126366,DB00277,Theophylline
,23745275,apparent volume of distribution,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),[l] / [kg],0.93,126367,DB00277,Theophylline
,23745275,half life time,"The results of aminophylline pharmacokinetics showed: the plasma clearance was (17.88 +/- 5.61) mL/(kg x h), the apparent volume of distribution was (0.93 +/- 0.18) L/kg, the half life time was (28.6 +/- 7.59) h.",[Investigation on pharmacokinetics of aminophylline in very low birth weight infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23745275/),h,28.6,126368,DB00277,Theophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],16 to 28,126871,DB00277,Theophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],7.4 to 14,126872,DB00277,Theophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],18 to 26,126873,DB00277,Theophylline
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],260 to 335,126874,DB00277,Theophylline
,12352930,trough theop,"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [ml],3.78,127256,DB00277,Theophylline
,12352930,blood levels,"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [ml],3.78,127257,DB00277,Theophylline
,12352930,blood levels,"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [ml],8.63,127258,DB00277,Theophylline
,12352930,C(max),"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [ml],6.53,127259,DB00277,Theophylline
,12352930,C(max),"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [ml],10.51,127260,DB00277,Theophylline
,12352930,AUC,"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [h·ml],50.04,127261,DB00277,Theophylline
,12352930,AUC,"All pharmacokinetic measurements were lower in group I as compared with group II: trough theophylline blood levels were 3.78 +/- 3.2 (0.5-10.77) microg/mL versus 8.63 +/- 4.6 (0-15.61) microg/mL ( P= 0.002); C(max) was 6.53 +/- 4.1 (1.3-13.33) microg/mL versus 10.51 +/- 3.30 (4.3-16.28) microg/mL (P = 0.0058), and AUC was 50.04 +/- 38.59 (11-112) microg/h/mL versus 80.37 +/- 28.8 (23-148) microg/h/ml (P = 0.024).",Therapeutic drug monitoring of theophylline in frail elderly patients: oral compared with nasogastric tube administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352930/),[μg] / [h·ml],80.37,127262,DB00277,Theophylline
,10839467,clearance,"Initial (day 2) caffeine clearance (n = 15, geometric mean) was 1.37 ml/min/kg body weight (coefficient of variation (CV) 48%).",Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839467/),[ml] / [body·kg·min·weight],1.37,127292,DB00277,Theophylline
,1662899,oral clearance,"Theophylline oral clearance increased from 2.67 +/- 1.01 L/hour to 2.69 +/- 0.93 L/hour, when given alone and with temafloxacin, respectively (p = 0.92).",Effect of temafloxacin on the pharmacokinetics of theophylline. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662899/),[l] / [h],2.67,127891,DB00277,Theophylline
,1662899,oral clearance,"Theophylline oral clearance increased from 2.67 +/- 1.01 L/hour to 2.69 +/- 0.93 L/hour, when given alone and with temafloxacin, respectively (p = 0.92).",Effect of temafloxacin on the pharmacokinetics of theophylline. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662899/),[l] / [h],2.69,127892,DB00277,Theophylline
,3376182,half-life,Large ranges were found in the half-life (2.3-21.3 h) and calculated apparent volume of distribution (Vd) (0.300-1.54 L/kg).,A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),h,2.3-21.3,128229,DB00277,Theophylline
,3376182,apparent volume of distribution (Vd),Large ranges were found in the half-life (2.3-21.3 h) and calculated apparent volume of distribution (Vd) (0.300-1.54 L/kg).,A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),[l] / [kg],0.300-1.54,128230,DB00277,Theophylline
,3376182,Vd,"Vd values than with the standard Vd of 0.5 L/kg (r = 0.31, NS), and predictions obtained with the individuals'",A pharmacokinetic dosing method for oral theophylline in pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3376182/),[l] / [kg],0.5,128231,DB00277,Theophylline
,30243056,extraction recovery,Calibration curves were linear over the range of 10-500 ng/mL with extraction recovery ranging from 77.3 to 97.3% while all validation parameters met the acceptance criteria and proved the methods' reliability.,Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243056/),%,77.3 to 97.3,128605,DB00277,Theophylline
,3059587,relative bioavailability,"Dose-normalized areas under the saliva concentration-time curves were significantly less than the reference for Theo-Dur Sprinkle (p = .02) but not for Slo-bid with the relative bioavailability determinations of 66 +/- 8% (mean +/- SEM) and 109 +/- 5% for Theo-Dur Sprinkle and Slo-bid, respectively.",Oral bioavailability of slow-release theophylline from unencapsulated beads in preschool children with chronic asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3059587/),%,66,128707,DB00277,Theophylline
,3059587,relative bioavailability,"Dose-normalized areas under the saliva concentration-time curves were significantly less than the reference for Theo-Dur Sprinkle (p = .02) but not for Slo-bid with the relative bioavailability determinations of 66 +/- 8% (mean +/- SEM) and 109 +/- 5% for Theo-Dur Sprinkle and Slo-bid, respectively.",Oral bioavailability of slow-release theophylline from unencapsulated beads in preschool children with chronic asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3059587/),%,109,128708,DB00277,Theophylline
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128746,DB00277,Theophylline
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128747,DB00277,Theophylline
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128748,DB00277,Theophylline
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128749,DB00277,Theophylline
,6760063,Plasma elimination half-life,"Plasma elimination half-life is significantly different (8,01 +/- 1,95 h in the morning, 6,23 +/- 1,75 h in the evening).",[Pharmacokinetics of theophylline and circadian rhythm]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760063/),h,"8,01",129296,DB00277,Theophylline
,6760063,Plasma elimination half-life,"Plasma elimination half-life is significantly different (8,01 +/- 1,95 h in the morning, 6,23 +/- 1,75 h in the evening).",[Pharmacokinetics of theophylline and circadian rhythm]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760063/),h,"6,23",129297,DB00277,Theophylline
,6828808,plasma half-life,Pharmacokinetic studies conducted during the hypothyroid state revealed a markedly prolonged theophylline plasma half-life of 29.5 h.,Life-threatening theophylline intoxication in a hypothyroid patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6828808/),h,29.5,130121,DB00277,Theophylline
,6828808,plasma half-life,"2 months later, after reestablishment of an euthyroid state, theophylline plasma half-life was shortened to normal, i.e. 5.7 h and the theophylline plasma level was 13.5 micrograms/ml, while the daily intake was 1 g.",Life-threatening theophylline intoxication in a hypothyroid patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6828808/),h,5.7,130122,DB00277,Theophylline
,18718822,flow rate,"A mobile phase of methanol-water containing 0.1% formic acid (50: 50, v/v) was used isocratically eluting at a flow rate of 1 mL/min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718822/),[ml] / [min],1,130617,DB00277,Theophylline
,18718822,plasma extraction recovery,The mean plasma extraction recovery of xanthinol was in the range of 90.9-100.2%.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718822/),%,90.9-100.2,130618,DB00277,Theophylline
,8996853,Plateau times,Plateau times which are independent of the asymmetric dosage regimen ranged from 16.4 hours (T1) to 13.8 hours (T2) and could therefore span sufficient time of the dosage interval.,Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: microcaps as sachet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996853/),h,16.4,131054,DB00277,Theophylline
,8996853,Plateau times,Plateau times which are independent of the asymmetric dosage regimen ranged from 16.4 hours (T1) to 13.8 hours (T2) and could therefore span sufficient time of the dosage interval.,Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: microcaps as sachet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996853/),h,13.8,131055,DB00277,Theophylline
,8996853,Maximum serum levels,"Maximum serum levels of 9.6 micrograms/ml and 10.0 micrograms/ml were attained 6.6 and 6.1 hours after dosing of T1 and T2, coinciding perfectly with the time of the critical morning dip at 2-4 a.m.",Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: microcaps as sachet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996853/),[μg] / [ml],9.6,131056,DB00277,Theophylline
,8996853,Maximum serum levels,"Maximum serum levels of 9.6 micrograms/ml and 10.0 micrograms/ml were attained 6.6 and 6.1 hours after dosing of T1 and T2, coinciding perfectly with the time of the critical morning dip at 2-4 a.m.",Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: microcaps as sachet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996853/),[μg] / [ml],10.0,131057,DB00277,Theophylline
,7446501,half-life,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),h,4.7,131473,DB00277,Theophylline
,7446501,total clearance,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),[ml] / [h·kg],91,131474,DB00277,Theophylline
,7446501,volume of distribution,"The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg.",Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446501/),[ml] / [kg],574,131475,DB00277,Theophylline
,2591470,Cmax,"Taken with a balanced meal, the mean parameters were similar; for Theo-Dur and Dilatrane A.P. they were respectively: Cmax: 11.32 mg.l-1 which plateaued from 8 to 10 h after dosing and 10.9 mg.l-1, which plateaued after 6 to 10 h; AUC 230 mg.h.l-1 and 220 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[mg] / [l],11.32,131561,DB00277,Theophylline
,2591470,Cmax,"Taken with a balanced meal, the mean parameters were similar; for Theo-Dur and Dilatrane A.P. they were respectively: Cmax: 11.32 mg.l-1 which plateaued from 8 to 10 h after dosing and 10.9 mg.l-1, which plateaued after 6 to 10 h; AUC 230 mg.h.l-1 and 220 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[mg] / [l],10.9,131562,DB00277,Theophylline
,2591470,AUC,"Taken with a balanced meal, the mean parameters were similar; for Theo-Dur and Dilatrane A.P. they were respectively: Cmax: 11.32 mg.l-1 which plateaued from 8 to 10 h after dosing and 10.9 mg.l-1, which plateaued after 6 to 10 h; AUC 230 mg.h.l-1 and 220 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[h·mg] / [l],230,131563,DB00277,Theophylline
,2591470,AUC,"Taken with a balanced meal, the mean parameters were similar; for Theo-Dur and Dilatrane A.P. they were respectively: Cmax: 11.32 mg.l-1 which plateaued from 8 to 10 h after dosing and 10.9 mg.l-1, which plateaued after 6 to 10 h; AUC 230 mg.h.l-1 and 220 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),,220,131564,DB00277,Theophylline
,2591470,MRT,h.l-1; and MRT 18.2 h and 17.7 h.,Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),h,18.2,131565,DB00277,Theophylline
,2591470,MRT,h.l-1; and MRT 18.2 h and 17.7 h.,Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),h,17.7,131566,DB00277,Theophylline
,2591470,Cmax,"After the hyperlipidic meal the values for Theo-Dur and Dilatrane A.P. respectively, were: Cmax 10.9 mg.l-1 at 12 h and 11.3 mg.l-1 at 10 h; AUC 237 mg.h.l-1 and 227 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[mg] / [l],10.9,131567,DB00277,Theophylline
,2591470,Cmax,"After the hyperlipidic meal the values for Theo-Dur and Dilatrane A.P. respectively, were: Cmax 10.9 mg.l-1 at 12 h and 11.3 mg.l-1 at 10 h; AUC 237 mg.h.l-1 and 227 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[mg] / [l],11.3,131568,DB00277,Theophylline
,2591470,AUC,"After the hyperlipidic meal the values for Theo-Dur and Dilatrane A.P. respectively, were: Cmax 10.9 mg.l-1 at 12 h and 11.3 mg.l-1 at 10 h; AUC 237 mg.h.l-1 and 227 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),[h·mg] / [l],237,131569,DB00277,Theophylline
,2591470,AUC,"After the hyperlipidic meal the values for Theo-Dur and Dilatrane A.P. respectively, were: Cmax 10.9 mg.l-1 at 12 h and 11.3 mg.l-1 at 10 h; AUC 237 mg.h.l-1 and 227 mg.",Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),mg,227,131570,DB00277,Theophylline
,2591470,MRT,h.l-1; and MRT 19.2 h and 18.9 h.,Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),h,19.2,131571,DB00277,Theophylline
,2591470,MRT,h.l-1; and MRT 19.2 h and 18.9 h.,Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591470/),h,18.9,131572,DB00277,Theophylline
,10434239,steady-state concentration,This was a concentration-controlled drug interaction study in which the subjects were administered a dose of SR theophylline every 12 hours to provide a mean steady-state concentration between 8 and 15 micrograms/ml.,The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434239/),[μg] / [ml],8 and 15,131955,DB00277,Theophylline
,11699723,clearance,"Steady-state bioavailability of sustained-release theophylline (SRT); Theo-Dur, Uni-Dur and Xanthium were compared in 10 healthy males with theophylline clearance ranged from 0.3 - 0.8 ml/min/kg.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[ml] / [kg·min],0.3 - 0.8,132313,DB00277,Theophylline
,11699723,oral bloavailability,"We found that the oral bloavailability relative to Franol (%F [90% CI]) of Theo-Dur, Uni-Dur and Xanthium were 97 (93-106), 85 (79-96) and 77 (72-87), respectively.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),%,97,132314,DB00277,Theophylline
,11699723,oral bloavailability,"We found that the oral bloavailability relative to Franol (%F [90% CI]) of Theo-Dur, Uni-Dur and Xanthium were 97 (93-106), 85 (79-96) and 77 (72-87), respectively.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),,85,132315,DB00277,Theophylline
,11699723,oral bloavailability,"We found that the oral bloavailability relative to Franol (%F [90% CI]) of Theo-Dur, Uni-Dur and Xanthium were 97 (93-106), 85 (79-96) and 77 (72-87), respectively.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),,77,132316,DB00277,Theophylline
,11699723,Css(min),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],5.07,132317,DB00277,Theophylline
,11699723,Css(min),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],4.29,132318,DB00277,Theophylline
,11699723,Css(min),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],4.18,132319,DB00277,Theophylline
,11699723,Css(max),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],11.02,132320,DB00277,Theophylline
,11699723,Css(av),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],11.02,132321,DB00277,Theophylline
,11699723,Css(av),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],7.87,132322,DB00277,Theophylline
,11699723,Css(av),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],8.51,132323,DB00277,Theophylline
,11699723,Css(av),"Average bioequivalence revealed that the Css(min) (microg/ml) of Uni-Dur (5.07) was higher than Theo-Dur (4.29), and Xanthiume (4.18), while the Css(max) and Css(av) (microg/ml) of Theo-Dur (11.02, 7.87) were statistically higher than Uni-Dur (8.51, 6.91) and Xanthium (7.65, 6.27).","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[μg] / [ml],7.65,132324,DB00277,Theophylline
,11699723,Tss(max),The median Tss(max) of Uni-Dur was 12 hours which was significantly longer than Xanthium (7 hours) and Theo-Dur (8 hours).,"Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),h,12,132325,DB00277,Theophylline
,11699723,Tss(max),The median Tss(max) of Uni-Dur was 12 hours which was significantly longer than Xanthium (7 hours) and Theo-Dur (8 hours).,"Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),h,7,132326,DB00277,Theophylline
,11699723,Tss(max),The median Tss(max) of Uni-Dur was 12 hours which was significantly longer than Xanthium (7 hours) and Theo-Dur (8 hours).,"Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),h,8,132327,DB00277,Theophylline
,11699723,clearance,"Moreover, 400 mg OD of Uni-Dur and Xanthium are suitable for subjects with a theophylline clearance of 0.3-0.55 ml/min/kg while 400 mg OD Theo-Dur can be used in subjects with slower clearance rates of 0.3-0.39 ml/min/kg.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[ml] / [kg·min],0.3-0.55,132328,DB00277,Theophylline
,11699723,clearance rates,"Moreover, 400 mg OD of Uni-Dur and Xanthium are suitable for subjects with a theophylline clearance of 0.3-0.55 ml/min/kg while 400 mg OD Theo-Dur can be used in subjects with slower clearance rates of 0.3-0.39 ml/min/kg.","Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[ml] / [kg·min],0.3-0.39,132329,DB00277,Theophylline
,11699723,clearance rates,Subjects with rapid theophylline clearance rates of 0.65-0.8 ml/min/kg required a higher dose of theophylline and twice-daily dosing was more appropriate.,"Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699723/),[ml] / [kg·min],0.65-0.8,132330,DB00277,Theophylline
,2920505,bioavailability,"The AUC during the dosing interval was significantly reduced in phases B and C compared with phase A, and bioavailability relative to the fasting state was reduced to 77% +/- 15% (range 61% to 104%) in phase B and 70% +/- 16% (range 40% to 103%) in phase C.",Effects of time of dose in relation to food on the bioavailability of Theo-Dur Sprinkle at steady state in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920505/),%,77,132407,DB00277,Theophylline
,2920505,bioavailability,"The AUC during the dosing interval was significantly reduced in phases B and C compared with phase A, and bioavailability relative to the fasting state was reduced to 77% +/- 15% (range 61% to 104%) in phase B and 70% +/- 16% (range 40% to 103%) in phase C.",Effects of time of dose in relation to food on the bioavailability of Theo-Dur Sprinkle at steady state in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920505/),%,70,132408,DB00277,Theophylline
,7350785,Elimination half-life,"Elimination half-life values of 14.5 and 15.2 hours, respectively, were shorter than reported in premature infants but longer than in infants aged 3 months or older.",Theophylline toxicity in term infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7350785/),h,14.5,132498,DB00277,Theophylline
,7350785,Elimination half-life,"Elimination half-life values of 14.5 and 15.2 hours, respectively, were shorter than reported in premature infants but longer than in infants aged 3 months or older.",Theophylline toxicity in term infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7350785/),h,15.2,132499,DB00277,Theophylline
,11888331,terminal elimination half-life,"The drug binds to plasma proteins (>99%), predominantly to albumin, and has a mean terminal elimination half-life of approximately 10 hours in both healthy volunteers and patients with asthma.",Pharmacokinetic profile of zafirlukast. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888331/),h,10,132702,DB00277,Theophylline
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.5,133072,DB00277,Theophylline
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.3,133073,DB00277,Theophylline
,1591403,clearance,Placental clearance was linear up to 2.0 mL/min for TH and 1.5 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],2.0,133367,DB00277,Theophylline
,1591403,clearance,Placental clearance was linear up to 2.0 mL/min for TH and 1.5 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.5,133368,DB00277,Theophylline
,1591403,um,The umbilical flow rate limit was 1.76 +/- 0.29 mL/min for TH and 1.72 +/- 0.49 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.76,133369,DB00277,Theophylline
,1591403,um,The umbilical flow rate limit was 1.76 +/- 0.29 mL/min for TH and 1.72 +/- 0.49 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.72,133370,DB00277,Theophylline
,1591403,clearance index,The clearance index was 0.71 +/- 0.04.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),,0.71,133371,DB00277,Theophylline
,1591403,resistances,Placental resistances did not change significantly at all flow rates with mean values between 6 and 9 mmHg/mL/min.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[mmhg] / [min·ml],6 and 9,133372,DB00277,Theophylline
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],48.0,134416,DB00277,Theophylline
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],38.9,134417,DB00277,Theophylline
,6740733,oral clearance,The mean oral clearance of theophylline was significantly increased from 54.9 +/- 21.2 to 68.9 +/- 26.5 ml/h/kg.,Effect of rifampin on theophylline disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740733/),[ml] / [h·kg],54.9,135319,DB00277,Theophylline
,6740733,oral clearance,The mean oral clearance of theophylline was significantly increased from 54.9 +/- 21.2 to 68.9 +/- 26.5 ml/h/kg.,Effect of rifampin on theophylline disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740733/),[ml] / [h·kg],68.9,135320,DB00277,Theophylline
,2689314,relative bioavailability,"The relative bioavailability of Pulmo-Timelets vis-a-vis the reference preparation referred to the area under the curve (AUC) in the 24-hour dosage interval, revealed a figure of 82%.",[Pharmacokinetics of theophylline. Repeated single evening administration of Pulmo-Timelets slow-release capsules in comparison with theophylline slow-release tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689314/),%,82,135452,DB00277,Theophylline
,2689314,maximum concentrations,"While the minima of the plasma concentrations were approximately comparable (mean values 24 hours after the last administration 9.3 and 8.2 mg/l for Pulmo-Timelets and reference preparation, respectively, the maximum concentrations after administration of the reference preparation (average 24.4 mg/l) were about 50% higher than after Pulmo-Timelets (16.3 mg/l).",[Pharmacokinetics of theophylline. Repeated single evening administration of Pulmo-Timelets slow-release capsules in comparison with theophylline slow-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689314/),[mg] / [l],24.4,135453,DB00277,Theophylline
,2689314,maximum concentrations,"While the minima of the plasma concentrations were approximately comparable (mean values 24 hours after the last administration 9.3 and 8.2 mg/l for Pulmo-Timelets and reference preparation, respectively, the maximum concentrations after administration of the reference preparation (average 24.4 mg/l) were about 50% higher than after Pulmo-Timelets (16.3 mg/l).",[Pharmacokinetics of theophylline. Repeated single evening administration of Pulmo-Timelets slow-release capsules in comparison with theophylline slow-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689314/),[mg] / [l],16.3,135454,DB00277,Theophylline
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],33.5,135472,DB00277,Theophylline
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],17.9,135473,DB00277,Theophylline
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],32.3,135474,DB00277,Theophylline
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],19.3,135475,DB00277,Theophylline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],12.6,135521,DB00277,Theophylline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],13.1,135522,DB00277,Theophylline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.0,135523,DB00277,Theophylline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],7.9,135524,DB00277,Theophylline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.6,135525,DB00277,Theophylline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],8.0,135526,DB00277,Theophylline
,6506136,Km for overall elimination,"The Km for overall elimination averaged 133 mumol/L (range 55-213 mumol/L) and the Vmax 611 mumol/h (2,640 mg/day; range 452-813 mumol/h).",Nonlinear metabolic disposition of theophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [l],133,135688,DB00277,Theophylline
,6506136,Vmax,"The Km for overall elimination averaged 133 mumol/L (range 55-213 mumol/L) and the Vmax 611 mumol/h (2,640 mg/day; range 452-813 mumol/h).",Nonlinear metabolic disposition of theophylline. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [h],611,135689,DB00277,Theophylline
,6506136,Km,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [l],88,135690,DB00277,Theophylline
,6506136,Vmax,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [h],110,135691,DB00277,Theophylline
,6506136,Km,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [l],90,135692,DB00277,Theophylline
,6506136,Vmax,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [h],78,135693,DB00277,Theophylline
,6506136,Km,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [l],179,135694,DB00277,Theophylline
,6506136,Vmax,"With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h.",Nonlinear metabolic disposition of theophylline. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506136/),[μM] / [h],357,135695,DB00277,Theophylline
,2714159,half-life,The caffeine half-life was 52.03 +/- 23.87 h (means +/- SD) and the theophylline half-life was 77.04 +/- 65.01 h (mean +/- SD).,Caffeine pharmacokinetics in preterm infants older than 2 weeks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714159/),h,52.03,135752,DB00277,Theophylline
,2714159,half-life,The caffeine half-life was 52.03 +/- 23.87 h (means +/- SD) and the theophylline half-life was 77.04 +/- 65.01 h (mean +/- SD).,Caffeine pharmacokinetics in preterm infants older than 2 weeks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714159/),h,77.04,135753,DB00277,Theophylline
,2721260,elimination half-life,"The elimination half-life of theophylline was 9.32 +/- 3.40 hours (mean +/- standard deviation), the apparent volume of distribution was 0.45 +/- 0.03 L/kg, and AAG concentrations were 63.8 +/- 15.76 mg/dL.",Clinical pharmacokinetics of theophylline and levels of alpha 1-acid glycoprotein in smokeless tobacco users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721260/),h,9.32,137646,DB00277,Theophylline
,2721260,apparent volume of distribution,"The elimination half-life of theophylline was 9.32 +/- 3.40 hours (mean +/- standard deviation), the apparent volume of distribution was 0.45 +/- 0.03 L/kg, and AAG concentrations were 63.8 +/- 15.76 mg/dL.",Clinical pharmacokinetics of theophylline and levels of alpha 1-acid glycoprotein in smokeless tobacco users. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721260/),[l] / [kg],0.45,137647,DB00277,Theophylline
,10567778,trough plasma concentration,"After a 4-8-day run-in phase to establish the dose of theophylline required to achieve a trough plasma concentration range of 8-15 mg/l, 15 healthy volunteers entered a randomized treatment phase.",Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567778/),[mg] / [l],8-15,138135,DB00277,Theophylline
,10567778,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) for theophylline ranged from 8.12 to 17.71 mg/l and from 8. 79 to 16.35 mg/l during concomitant administration with gemifloxacin and placebo, respectively.",Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567778/),[mg] / [l],8.12 to 17.71,138136,DB00277,Theophylline
,10567778,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) for theophylline ranged from 8.12 to 17.71 mg/l and from 8. 79 to 16.35 mg/l during concomitant administration with gemifloxacin and placebo, respectively.",Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567778/),[mg] / [l],8. 79 to 16.35,138137,DB00277,Theophylline
,10567778,area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration (AUC((0-12))),The corresponding ranges of the area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration (AUC((0-12))) were 84.6-177.5 mg.,Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567778/),mg,84.6-177.5,138138,DB00277,Theophylline
,3197743,clearance,"Theophylline clearance was significantly decreased in the patients with liver cirrhosis compared with both the patients with renal failure and the healthy subjects (the mean values in the three groups were 24, 47, and 46 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],24,138931,DB00277,Theophylline
,3197743,clearance,"Theophylline clearance was significantly decreased in the patients with liver cirrhosis compared with both the patients with renal failure and the healthy subjects (the mean values in the three groups were 24, 47, and 46 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],47,138932,DB00277,Theophylline
,3197743,clearance,"Theophylline clearance was significantly decreased in the patients with liver cirrhosis compared with both the patients with renal failure and the healthy subjects (the mean values in the three groups were 24, 47, and 46 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],46,138933,DB00277,Theophylline
,3197743,clearance,"Enprofylline clearance was significantly decreased in the patients with chronic renal failure, compared with both the patients with liver cirrhosis and the healthy subjects (the values in the three groups were 64, 250, and 289 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],64,138934,DB00277,Theophylline
,3197743,clearance,"Enprofylline clearance was significantly decreased in the patients with chronic renal failure, compared with both the patients with liver cirrhosis and the healthy subjects (the values in the three groups were 64, 250, and 289 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],250,138935,DB00277,Theophylline
,3197743,clearance,"Enprofylline clearance was significantly decreased in the patients with chronic renal failure, compared with both the patients with liver cirrhosis and the healthy subjects (the values in the three groups were 64, 250, and 289 ml.h-1.kg-1 respectively.",The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197743/),[ml] / [h·kg],289,138936,DB00277,Theophylline
,7582380,Cmax,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,0.90,139131,DB00277,Theophylline
,7582380,AUC,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,1.02,139132,DB00277,Theophylline
,7582380,Cmax/AUC,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,0.88,139133,DB00277,Theophylline
,7582380,T 1/2el,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,1.03,139134,DB00277,Theophylline
,7582380,Tmax,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),h,0.15,139135,DB00277,Theophylline
,1914365,(trough) levels,Mean predose (trough) levels rose from 8.1 +/- 0.1 microgram.,Mexiletine effects on theophylline disposition. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,8.1,140290,DB00277,Theophylline
,1914365,AUC(0-12),ml-1 and AUC(0-12) from 96.8 +/- 9.1 to 160.2 +/- 3.7 micrograms.,Mexiletine effects on theophylline disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,96.8,140291,DB00277,Theophylline
,1914365,AUC(0-12),ml-1 and AUC(0-12) from 96.8 +/- 9.1 to 160.2 +/- 3.7 micrograms.,Mexiletine effects on theophylline disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,160.2,140292,DB00277,Theophylline
,1914365,Plasma clearance,Plasma clearance was reduced by mexiletine from 44.7 +/- 5.1 to 25.4 +/- 1.2 ml.,Mexiletine effects on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),ml,44.7,140293,DB00277,Theophylline
,1914365,Plasma clearance,Plasma clearance was reduced by mexiletine from 44.7 +/- 5.1 to 25.4 +/- 1.2 ml.,Mexiletine effects on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),ml,25.4,140294,DB00277,Theophylline
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB00277,Theophylline
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB00277,Theophylline
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB00277,Theophylline
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB00277,Theophylline
,7309903,apparent volume of distribution (Vd),"The apparent volume of distribution (Vd) of dyphylline was found to be 0.505 +/- 0.162 l./kg, the elimination rate constant (Kel) was 0.228 +/- 0.055 hr-1, the biological half-life (t1/2) was 3.21 +/- 0.76 hr, and the total body clearance (CI) was 0.109 +/- 0.036 l./kg/hr.",Dyphylline elimination kinetics in lactating women: blood to milk transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309903/),[l] / [kg],0.505,141146,DB00277,Theophylline
,7309903,elimination rate constant (Kel),"The apparent volume of distribution (Vd) of dyphylline was found to be 0.505 +/- 0.162 l./kg, the elimination rate constant (Kel) was 0.228 +/- 0.055 hr-1, the biological half-life (t1/2) was 3.21 +/- 0.76 hr, and the total body clearance (CI) was 0.109 +/- 0.036 l./kg/hr.",Dyphylline elimination kinetics in lactating women: blood to milk transfer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309903/),1/[h],0.228,141147,DB00277,Theophylline
,7309903,biological half-life (t1/2),"The apparent volume of distribution (Vd) of dyphylline was found to be 0.505 +/- 0.162 l./kg, the elimination rate constant (Kel) was 0.228 +/- 0.055 hr-1, the biological half-life (t1/2) was 3.21 +/- 0.76 hr, and the total body clearance (CI) was 0.109 +/- 0.036 l./kg/hr.",Dyphylline elimination kinetics in lactating women: blood to milk transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309903/),h,3.21,141148,DB00277,Theophylline
,7309903,total body clearance (CI),"The apparent volume of distribution (Vd) of dyphylline was found to be 0.505 +/- 0.162 l./kg, the elimination rate constant (Kel) was 0.228 +/- 0.055 hr-1, the biological half-life (t1/2) was 3.21 +/- 0.76 hr, and the total body clearance (CI) was 0.109 +/- 0.036 l./kg/hr.",Dyphylline elimination kinetics in lactating women: blood to milk transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309903/),[l] / [h·kg],0.109,141149,DB00277,Theophylline
,4019794,Cmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[μg] / [ml],6.7,141426,DB00277,Theophylline
,4019794,Cmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[μg] / [ml],5.4,141427,DB00277,Theophylline
,4019794,tmax,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),h,2,141428,DB00277,Theophylline
,4019794,F8h,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),,0.79,141429,DB00277,Theophylline
,4019794,F8h,"The pharmacokinetic parameters obtained: Cmax 6.7 and 5.4 micrograms ml-1, tmax 2 h, and F8h 0.79 and 0.83 for theophylline and aminophylline, respectively, show that the two formulations are almost bioequivalent, with a slightly higher Cmax for theophylline.",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),,0.83,141430,DB00277,Theophylline
,4019794,release rate,"The in vitro release rate of theophylline from freshly prepared formulations was, however, higher (4.8 mg min-1) from aminophylline suppositories relative to those containing theophylline (2.9 mg min-1).",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],4.8,141431,DB00277,Theophylline
,4019794,release rate,"The in vitro release rate of theophylline from freshly prepared formulations was, however, higher (4.8 mg min-1) from aminophylline suppositories relative to those containing theophylline (2.9 mg min-1).",Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],2.9,141432,DB00277,Theophylline
,4019794,release rate,The release rate of aminophylline suppositories tested after 1-year storage at room temperature dropped from 4.8 to 0.5 mg min-1.,Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],4.8,141433,DB00277,Theophylline
,4019794,release rate,The release rate of aminophylline suppositories tested after 1-year storage at room temperature dropped from 4.8 to 0.5 mg min-1.,Theophylline versus aminophylline in rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019794/),[mg] / [min],0.5,141434,DB00277,Theophylline
,11243204,T1/2 (Ke),T1/2 (Ke) was 1.17 +/- 0.13 h after the 100 mg.,"[Preliminary study on the absorption, distribution and excretion of doxophylline in rats]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243204/),h,1.17,142036,DB00277,Theophylline
,11243204,Total excretion,"Total excretion of the drug in urine, bile and faeces was 5.2 per cent of the dose.","[Preliminary study on the absorption, distribution and excretion of doxophylline in rats]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243204/),%,5.2,142037,DB00277,Theophylline
,11243204,Plasma protein binding,Plasma protein binding was about 25 percent.,"[Preliminary study on the absorption, distribution and excretion of doxophylline in rats]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243204/),%,25,142038,DB00277,Theophylline
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB00277,Theophylline
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB00277,Theophylline
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB00277,Theophylline
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB00277,Theophylline
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB00277,Theophylline
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB00277,Theophylline
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.035,142979,DB00277,Theophylline
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.094,142980,DB00277,Theophylline
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.061,142981,DB00277,Theophylline
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.153,142982,DB00277,Theophylline
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,11.4,142983,DB00277,Theophylline
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,4.3,142984,DB00277,Theophylline
,2287562,hepatic blood flow,Estimated hepatic blood flow decreased from 790 +/- 190 to 665 +/- 100 ml/minute (p less than 0.05) after administration of aminophylline.,The effect of theophylline on estimated hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287562/),[ml] / [min],790,143450,DB00277,Theophylline
,2287562,hepatic blood flow,Estimated hepatic blood flow decreased from 790 +/- 190 to 665 +/- 100 ml/minute (p less than 0.05) after administration of aminophylline.,The effect of theophylline on estimated hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287562/),[ml] / [min],665,143451,DB00277,Theophylline
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],398,143694,DB00277,Theophylline
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],301,143695,DB00277,Theophylline
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],332,143696,DB00277,Theophylline
,1496815,elimination half-life (t1/2 beta),"The elimination half-life (t1/2 beta) was 16.91 +/- 0.93 h, the apparent volume of distribution (Vd) was 1.35 +/- 0.18 L/kg and the body clearance (ClB) was 0.061 +/- 0.009 L kg-1 h.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),h,16.91,143812,DB00277,Theophylline
,1496815,apparent volume of distribution (Vd),"The elimination half-life (t1/2 beta) was 16.91 +/- 0.93 h, the apparent volume of distribution (Vd) was 1.35 +/- 0.18 L/kg and the body clearance (ClB) was 0.061 +/- 0.009 L kg-1 h.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),[l] / [kg],1.35,143813,DB00277,Theophylline
,1496815,body clearance (ClB),"The elimination half-life (t1/2 beta) was 16.91 +/- 0.93 h, the apparent volume of distribution (Vd) was 1.35 +/- 0.18 L/kg and the body clearance (ClB) was 0.061 +/- 0.009 L kg-1 h.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),[h·l] / [kg],0.061,143814,DB00277,Theophylline
,1496815,half-life of absorption,"After oral administration the half-life of absorption was 1.24 +/- 0.30 h, and the calculated bioavailability was above 100%.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),h,1.24,143815,DB00277,Theophylline
above,1496815,bioavailability,"After oral administration the half-life of absorption was 1.24 +/- 0.30 h, and the calculated bioavailability was above 100%.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),%,100,143816,DB00277,Theophylline
,1496815,t1/2 beta,"The t1/2 beta after oral administration was 18.51 +/- 1.75 h, only a little longer than that after intravenous administration.",The pharmacokinetics of a slow-release theophylline preparation in horses after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496815/),h,18.51,143817,DB00277,Theophylline
,6832205,Total clearance,Total clearance was 65.5 +/- 11.3 ml/min.,Non-linear elimination processes of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),[ml] / [min],65.5,143846,DB00277,Theophylline
,6832205,Renal clearance,Renal clearance changed from 15.2 +/- 9.5 ml/min in the first two hours after administration to 4.9 +/- 5.5 ml/min between 16 and 24 h (p less than 0.001).,Non-linear elimination processes of theophylline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),[ml] / [min],15.2,143847,DB00277,Theophylline
,6832205,Renal clearance,Renal clearance changed from 15.2 +/- 9.5 ml/min in the first two hours after administration to 4.9 +/- 5.5 ml/min between 16 and 24 h (p less than 0.001).,Non-linear elimination processes of theophylline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),[ml] / [min],4.9,143848,DB00277,Theophylline
,6832205,renal clearance,The renal clearance of DMU was constant at 496.7 +/- 180 ml/min.,Non-linear elimination processes of theophylline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),[ml] / [min],496.7,143849,DB00277,Theophylline
,6832205,cumulative amounts excreted,"The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.",Non-linear elimination processes of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),%,16.6,143850,DB00277,Theophylline
,6832205,cumulative amounts excreted,"The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.",Non-linear elimination processes of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),%,44.3,143851,DB00277,Theophylline
,6832205,cumulative amounts excreted,"The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.",Non-linear elimination processes of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),%,24.3,143852,DB00277,Theophylline
,6832205,cumulative amounts excreted,"The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.",Non-linear elimination processes of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),%,12.9,143853,DB00277,Theophylline
,6832205,cumulative amounts excreted,"The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.",Non-linear elimination processes of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832205/),%,2.2,143854,DB00277,Theophylline
,434904,Apparent volume of distribution,Apparent volume of distribution of theophylline in 12 infants was 0.71 +/- 0.18 1/kg (mean +/- SD).,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[1] / [kg],0.71,143893,DB00277,Theophylline
,434904,Plasma clearance rate,Plasma clearance rate measured in 11 infants at steady state was 18.6 +/- 4.8 ml/kg per hour.,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[ml] / [h·kg],18.6,143894,DB00277,Theophylline
,10677921,area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN),"The means of unextrapolated area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN) and of the extrapolated AUC from time 0 to infinity (AUCEX) in the night phase were higher than those in the day phase (62.403 micrograms/ml/hr vs 53.081 micrograms/ml/hr, p = 0.9186; 107.21 micrograms/ml/hr vs 98.879 micrograms/ml/hr, p = 0.8807, respectively).",Influence of morning or evening administration on absorption of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [h·ml],62.403,143972,DB00277,Theophylline
,10677921,area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN),"The means of unextrapolated area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN) and of the extrapolated AUC from time 0 to infinity (AUCEX) in the night phase were higher than those in the day phase (62.403 micrograms/ml/hr vs 53.081 micrograms/ml/hr, p = 0.9186; 107.21 micrograms/ml/hr vs 98.879 micrograms/ml/hr, p = 0.8807, respectively).",Influence of morning or evening administration on absorption of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [h·ml],53.081,143973,DB00277,Theophylline
,10677921,area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN),"The means of unextrapolated area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN) and of the extrapolated AUC from time 0 to infinity (AUCEX) in the night phase were higher than those in the day phase (62.403 micrograms/ml/hr vs 53.081 micrograms/ml/hr, p = 0.9186; 107.21 micrograms/ml/hr vs 98.879 micrograms/ml/hr, p = 0.8807, respectively).",Influence of morning or evening administration on absorption of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [h·ml],107.21,143974,DB00277,Theophylline
,10677921,AUC from time 0 to infinity (AUCEX),"The means of unextrapolated area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN) and of the extrapolated AUC from time 0 to infinity (AUCEX) in the night phase were higher than those in the day phase (62.403 micrograms/ml/hr vs 53.081 micrograms/ml/hr, p = 0.9186; 107.21 micrograms/ml/hr vs 98.879 micrograms/ml/hr, p = 0.8807, respectively).",Influence of morning or evening administration on absorption of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [h·ml],107.21,143975,DB00277,Theophylline
,10677921,AUC from time 0 to infinity (AUCEX),"The means of unextrapolated area under the concentration vs time curve (AUC) from time 0 to 24 hours (AUCUN) and of the extrapolated AUC from time 0 to infinity (AUCEX) in the night phase were higher than those in the day phase (62.403 micrograms/ml/hr vs 53.081 micrograms/ml/hr, p = 0.9186; 107.21 micrograms/ml/hr vs 98.879 micrograms/ml/hr, p = 0.8807, respectively).",Influence of morning or evening administration on absorption of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [h·ml],98.879,143976,DB00277,Theophylline
,10677921,maximum concentration (Cmax),"The mean of maximum concentration (Cmax) was higher in the night phase than that in the day phase (4.166 micrograms/dl vs 3.451 micrograms/dl, p = 0.9234).",Influence of morning or evening administration on absorption of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [dl],4.166,143977,DB00277,Theophylline
,10677921,maximum concentration (Cmax),"The mean of maximum concentration (Cmax) was higher in the night phase than that in the day phase (4.166 micrograms/dl vs 3.451 micrograms/dl, p = 0.9234).",Influence of morning or evening administration on absorption of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[μg] / [dl],3.451,143978,DB00277,Theophylline
,10677921,time to maximum concentration (Tmax),"Daytime administration showed a delayed time to maximum concentration (Tmax) when compared to that of night-time administration (6.5 hr vs 5.75 hr, p = 0.6244).",Influence of morning or evening administration on absorption of theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),h,6.5,143979,DB00277,Theophylline
,10677921,time to maximum concentration (Tmax),"Daytime administration showed a delayed time to maximum concentration (Tmax) when compared to that of night-time administration (6.5 hr vs 5.75 hr, p = 0.6244).",Influence of morning or evening administration on absorption of theophylline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),h,5.75,143980,DB00277,Theophylline
,10677921,terminal elimination rate constant (Kel),"The terminal elimination rate constant (Kel) was lower in the day phase than in the night phase (0.053 l/hr vs 0.06 l/hr, p = 0.7601).",Influence of morning or evening administration on absorption of theophylline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[l] / [h],0.053,143981,DB00277,Theophylline
,10677921,terminal elimination rate constant (Kel),"The terminal elimination rate constant (Kel) was lower in the day phase than in the night phase (0.053 l/hr vs 0.06 l/hr, p = 0.7601).",Influence of morning or evening administration on absorption of theophylline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677921/),[l] / [h],0.06,143982,DB00277,Theophylline
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,54.8,144079,DB00277,Theophylline
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,50.2,144080,DB00277,Theophylline
,3493905,elimination rate constant,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),1/[h],3.92,144710,DB00277,Theophylline
,3493905,elimination rate constant,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),1/[h],3.74,144711,DB00277,Theophylline
,3493905,total body clearance,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),[min·ml] / [kg],1.71,144712,DB00277,Theophylline
,3493905,total body clearance,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),[min·ml] / [kg],1.8,144713,DB00277,Theophylline
,3493905,apparent volume of distribution,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),1/[kg],0.57,144714,DB00277,Theophylline
,3493905,apparent volume of distribution,"The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ.",Effect of miocamycin on theophylline kinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493905/),1/[kg],0.581,144715,DB00277,Theophylline
,31181483,flow rate,"After protein precipitation with methanol, the chromatographic separation was carried out on an ACQUITY UPLC HSS T3 column, with acetonitrile and 0.1% formic acid in water as mobile phase at a flow rate of 0.30 mL·min-1.",Development and validation of a UPLC-MS/MS method for quantification of doxofylline and its metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181483/),[ml] / [min],0.30,144877,DB00277,Theophylline
,2919803,peak concentration,The peak concentration (mean +/- SD) of serum theophylline (20.9 +/- 6.5 micrograms/mL) was observed eight hours after dosing while the through concentration (4.34 +/- 2.62 micrograms/mL) was measured 24 hours after dosing; the percent fluctuation (mean +/- SD) was 966.45 +/- 1105.55%.,Theophylline levels after single daily and divided dosing of a once-a-day theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919803/),[μg] / [ml],20.9,144968,DB00277,Theophylline
,2919803,through concentration,The peak concentration (mean +/- SD) of serum theophylline (20.9 +/- 6.5 micrograms/mL) was observed eight hours after dosing while the through concentration (4.34 +/- 2.62 micrograms/mL) was measured 24 hours after dosing; the percent fluctuation (mean +/- SD) was 966.45 +/- 1105.55%.,Theophylline levels after single daily and divided dosing of a once-a-day theophylline preparation in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919803/),[μg] / [ml],4.34,144969,DB00277,Theophylline
,2919803,peak serum level,"The peak serum level was 13.07 +/- 5.13 micrograms/mL at 2 PM, while the trough was 9.31 +/- 3.71 micrograms/mL at 10 AM, with a percent fluctuation of 155.21 +/- 147.95%.",Theophylline levels after single daily and divided dosing of a once-a-day theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919803/),[μg] / [ml],13.07,144970,DB00277,Theophylline
,2919803,trough,"The peak serum level was 13.07 +/- 5.13 micrograms/mL at 2 PM, while the trough was 9.31 +/- 3.71 micrograms/mL at 10 AM, with a percent fluctuation of 155.21 +/- 147.95%.",Theophylline levels after single daily and divided dosing of a once-a-day theophylline preparation in asthmatic children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919803/),[μg] / [ml],9.31,144971,DB00277,Theophylline
,2703972,Total body clearance,Total body clearance was significantly changed (P less than .01) from 0.156 +/- 0.020 l/kg/hr in control to 0.0556 +/- 0.0067 l/kg/hr in hypoxemic rats due to the reduction of both hepatic and renal clearances.,Blood oxygen tension-related change of theophylline clearance in experimental hypoxemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703972/),[l] / [h·kg],0.156,145100,DB00277,Theophylline
,2703972,Total body clearance,Total body clearance was significantly changed (P less than .01) from 0.156 +/- 0.020 l/kg/hr in control to 0.0556 +/- 0.0067 l/kg/hr in hypoxemic rats due to the reduction of both hepatic and renal clearances.,Blood oxygen tension-related change of theophylline clearance in experimental hypoxemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703972/),[l] / [h·kg],0.0556,145101,DB00277,Theophylline
,1792593,constant rate,The kinetics of TPh absorption from TW was marked by the zero order at a constant rate of 45 mg/h.,[The clinical efficacy and pharmacokinetic characteristics of theopek and theobiolong in bronchial asthma patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1792593/),[mg] / [h],45,145399,DB00277,Theophylline
,1792593,maximum concentration,"During continuous treatment with TP and TB, equiponderant concentrations of TPh were attained by the 4th day, the mean maximum concentration of TPh for TP was 10.6 +/- 1.8, that for TB 9.6 +/- 0.9 micrograms/ml.",[The clinical efficacy and pharmacokinetic characteristics of theopek and theobiolong in bronchial asthma patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1792593/),[μg] / [ml],10.6,145400,DB00277,Theophylline
,1792593,maximum concentration,"During continuous treatment with TP and TB, equiponderant concentrations of TPh were attained by the 4th day, the mean maximum concentration of TPh for TP was 10.6 +/- 1.8, that for TB 9.6 +/- 0.9 micrograms/ml.",[The clinical efficacy and pharmacokinetic characteristics of theopek and theobiolong in bronchial asthma patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1792593/),[μg] / [ml],9.6,145401,DB00277,Theophylline
,8735418,elimination half-life,For caffeine the mean elimination half-life was calculated to be 47 h.,Pharmacokinetics of caffeine in the oestrogen-implanted ovariectomized ewe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735418/),h,47,145402,DB00277,Theophylline
,16153010,"Peak theophylline plasma concentration, Cmax","Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),[μg] / [ml],21.5,146184,DB00277,Theophylline
,16153010,"Peak theophylline plasma concentration, Cmax","Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),[μg] / [ml],14,146185,DB00277,Theophylline
,16153010,AUC(0-t),"Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),,80.9,146186,DB00277,Theophylline
,16153010,AUC(0-t),"Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),,67,146187,DB00277,Theophylline
,16153010,"peak time, Tmax","The median peak time, Tmax, was 0.5 hr for theophylline rectal administration.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),h,0.5,146188,DB00277,Theophylline
,3428347,infusion rate,A reduction in the infusion rate from 69 to 33 mg.h-1 was made in Study 2 after 8 h in order to mimic the concentration/time profile of the oral formulation as closely as possible.,Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),[mg] / [h],69,146406,DB00277,Theophylline
,3428347,infusion rate,A reduction in the infusion rate from 69 to 33 mg.h-1 was made in Study 2 after 8 h in order to mimic the concentration/time profile of the oral formulation as closely as possible.,Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),[mg] / [h],33,146407,DB00277,Theophylline
,3428347,absolute bioavailability,"The absolute bioavailability was 100 (89, 115)% in Study 1 and 88 (73, 105)% in Study 2.",Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),%,100,146408,DB00277,Theophylline
,3428347,absolute bioavailability,"The absolute bioavailability was 100 (89, 115)% in Study 1 and 88 (73, 105)% in Study 2.",Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428347/),%,88,146409,DB00277,Theophylline
,7140801,Peak serum concentrations,Peak serum concentrations of theophylline measured by HPLC ranged from 8.48-21.6 micrograms/ml.,Pharmacokinetics of theophylline in infants with bronchiolitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[μg] / [ml],8.48-21.6,146538,DB00277,Theophylline
,7140801,Total,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],4.66 to 19.25,146539,DB00277,Theophylline
,7140801,renal,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],1.07 to 5.76,146540,DB00277,Theophylline
,7140801,nonrenal clearance,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],1.07 to 5.76,146541,DB00277,Theophylline
,7140801,nonrenal clearance,"Total, renal and nonrenal clearance of theophylline ranged from 4.66 to 19.25, 1.07 to 5.76 and 3.59 to 16.83 ml/min/m2, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[ml] / [m2·min],3.59 to 16.83,146542,DB00277,Theophylline
,7140801,apparent volume of distribution,"Mean apparent volume of distribution and elimination half-life were 8.75 l/m2 and 11.38 h, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),[l] / [m2],8.75,146543,DB00277,Theophylline
,7140801,elimination half-life,"Mean apparent volume of distribution and elimination half-life were 8.75 l/m2 and 11.38 h, respectively.",Pharmacokinetics of theophylline in infants with bronchiolitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140801/),h,11.38,146544,DB00277,Theophylline
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],0.88,147237,DB00277,Theophylline
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],1.21,147238,DB00277,Theophylline
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.104,147239,DB00277,Theophylline
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.148,147240,DB00277,Theophylline
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],104,147241,DB00277,Theophylline
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],76,147242,DB00277,Theophylline
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,7.0,147243,DB00277,Theophylline
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,4.8,147244,DB00277,Theophylline
,2760121,Apparent clearance,Apparent clearance of theophylline ranged from 0.28 to 0.51 ml/min/kg.,Theophylline pharmacokinetics in patients with bronchopulmonary dysplasia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760121/),[ml] / [kg·min],0.28 to 0.51,147980,DB00277,Theophylline
,2760121,steady-state trough serum concentration,The steady-state trough serum concentration of theophylline ranged from 3.5 to 11.2 micrograms/ml.,Theophylline pharmacokinetics in patients with bronchopulmonary dysplasia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760121/),[μg] / [ml],3.5 to 11.2,147981,DB00277,Theophylline
,2760121,steady-state serum concentration,"Based on our data, theophylline doses of 4-7 mg/kg/day may be required to achieve an average steady-state serum concentration of 10 micrograms/ml.",Theophylline pharmacokinetics in patients with bronchopulmonary dysplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760121/),[μg] / [ml],10,147982,DB00277,Theophylline
,2501512,half-life of elimination,"The mean half-life of elimination was shown to be 17.0 +/- 2.5 h, the mean half life of absorption was 1.6 +/- 1.8 h, the apparent volume of distribution was 852 +/- 99.0 ml/kg and total plasma clearance 0.61 +/- 0.08 ml/kg/min.",Pharmacokinetics and cardio-respiratory effects of oral theophylline in exercised horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501512/),h,17.0,148958,DB00277,Theophylline
,2501512,half life of absorption,"The mean half-life of elimination was shown to be 17.0 +/- 2.5 h, the mean half life of absorption was 1.6 +/- 1.8 h, the apparent volume of distribution was 852 +/- 99.0 ml/kg and total plasma clearance 0.61 +/- 0.08 ml/kg/min.",Pharmacokinetics and cardio-respiratory effects of oral theophylline in exercised horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501512/),h,1.6,148959,DB00277,Theophylline
,2501512,apparent volume of distribution,"The mean half-life of elimination was shown to be 17.0 +/- 2.5 h, the mean half life of absorption was 1.6 +/- 1.8 h, the apparent volume of distribution was 852 +/- 99.0 ml/kg and total plasma clearance 0.61 +/- 0.08 ml/kg/min.",Pharmacokinetics and cardio-respiratory effects of oral theophylline in exercised horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501512/),[ml] / [kg],852,148960,DB00277,Theophylline
,2501512,total plasma clearance,"The mean half-life of elimination was shown to be 17.0 +/- 2.5 h, the mean half life of absorption was 1.6 +/- 1.8 h, the apparent volume of distribution was 852 +/- 99.0 ml/kg and total plasma clearance 0.61 +/- 0.08 ml/kg/min.",Pharmacokinetics and cardio-respiratory effects of oral theophylline in exercised horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501512/),[ml] / [kg·min],0.61,148961,DB00277,Theophylline
,2501512,plasma protein binding,Theophylline showed very low plasma protein binding (12%).,Pharmacokinetics and cardio-respiratory effects of oral theophylline in exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501512/),%,12,148962,DB00277,Theophylline
,3472488,steady-state theophylline concentrations,Theophylline clearance was used to individualize subsequent doses to achieve average steady-state theophylline concentrations in plasma of 10 mg/liter.,Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472488/),[mg] / [l],10,149449,DB00277,Theophylline
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],42.5 to 30.1,149488,DB00277,Theophylline
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],41.7 to 29.9,149489,DB00277,Theophylline
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],57.7 to 44.7,149490,DB00277,Theophylline
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],50.2 to 49.4,149491,DB00277,Theophylline
,2611358,urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,11.3,149550,DB00277,Theophylline
,2611358,urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,13.9,149551,DB00277,Theophylline
,2611358,total urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,76.5,149552,DB00277,Theophylline
,2611358,total urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,85.3,149553,DB00277,Theophylline
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],6.1,149997,DB00277,Theophylline
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],3.3,149998,DB00277,Theophylline
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],1.0,149999,DB00277,Theophylline
,1772462,areas under the plasma concentration-time curves AUC,"The areas under the plasma concentration-time curves AUC amounted to 184.2 +/- 42.7 micrograms.h/ml (fasting) and 157.9 +/- 32.9 micrograms.h/ml (non-fasting, p = 0.031).",Influence of food on the bioavailability of theophylline from a sustained-released theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772462/),[h·μg] / [ml],184.2,150018,DB00277,Theophylline
,1772462,areas under the plasma concentration-time curves AUC,"The areas under the plasma concentration-time curves AUC amounted to 184.2 +/- 42.7 micrograms.h/ml (fasting) and 157.9 +/- 32.9 micrograms.h/ml (non-fasting, p = 0.031).",Influence of food on the bioavailability of theophylline from a sustained-released theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772462/),[h·μg] / [ml],157.9,150019,DB00277,Theophylline
,1772462,MRT,The MRT values of 13.4 and 13.9 h respectively showed furthermore that theophylline represents a twice-daily formulation.,Influence of food on the bioavailability of theophylline from a sustained-released theophylline preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772462/),h,13.4,150020,DB00277,Theophylline
,1772462,MRT,The MRT values of 13.4 and 13.9 h respectively showed furthermore that theophylline represents a twice-daily formulation.,Influence of food on the bioavailability of theophylline from a sustained-released theophylline preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772462/),h,13.9,150021,DB00277,Theophylline
,15317832,AUC(0- infinity ),"In addition, mean cilomilast exposure (AUC(0- infinity )) was found to be similar in both smokers and nonsmokers (8.47 +/- 2.20 microg*h/mL and 7.70 +/- 2.25 microg*h/mL, respectively).",Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317832/),[h·μg] / [ml],8.47,150633,DB00277,Theophylline
,15317832,AUC(0- infinity ),"In addition, mean cilomilast exposure (AUC(0- infinity )) was found to be similar in both smokers and nonsmokers (8.47 +/- 2.20 microg*h/mL and 7.70 +/- 2.25 microg*h/mL, respectively).",Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317832/),[h·μg] / [ml],7.70,150634,DB00277,Theophylline
,4091990,trough concentrations,"After repeated 12-hourly dosing to steady-state, and adjustment of dose to achieve trough concentrations of between 5 and 10 mg l-1 (28-55 mumol l-1), theophylline concentration fluctuated to a significantly greater extent within a dose interval when the subjects were taking Phyllocontin than when they were taking Theo-Dur.",The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091990/),[mg] / [l],5 and 10,151207,DB00277,Theophylline
,4091990,trough concentrations,"After repeated 12-hourly dosing to steady-state, and adjustment of dose to achieve trough concentrations of between 5 and 10 mg l-1 (28-55 mumol l-1), theophylline concentration fluctuated to a significantly greater extent within a dose interval when the subjects were taking Phyllocontin than when they were taking Theo-Dur.",The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091990/),[μM] / [l],28-55,151208,DB00277,Theophylline
,2715932,V (L),"Volume of distribution in this population was adequately described using only weight, with V (L) = 0.858 L/kg.",The population pharmacokinetics of theophylline in neonates and young infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715932/),[l] / [kg],0.858,151427,DB00277,Theophylline
,12534637,rate,Retrospective data were collected from 75 term neonates and children (age range 2 days to 17 years) receiving continuous infusions of aminophylline (mean rate 9.2 +/- 2.6 micro g kg-1 min-1) during ECMO.,Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534637/),μ,9.2,151483,DB00277,Theophylline
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.241,151535,DB00277,Theophylline
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.344,151536,DB00277,Theophylline
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,2.06,151537,DB00277,Theophylline
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,1.61,151538,DB00277,Theophylline
,669869,Serum half-life,"Serum half-life ranged between 86 and 351 minutes (mean, 259 minutes); mean peak serum concentration of theophylline after 3 weeks of treatment was 14.9 microgram/ml.","Exercise, induced bronchospasm in asthmatic children as a dose-response model for theophylline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/669869/),min,259,151749,DB00277,Theophylline
,669869,peak serum concentration,"Serum half-life ranged between 86 and 351 minutes (mean, 259 minutes); mean peak serum concentration of theophylline after 3 weeks of treatment was 14.9 microgram/ml.","Exercise, induced bronchospasm in asthmatic children as a dose-response model for theophylline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/669869/),[μg] / [ml],14.9,151750,DB00277,Theophylline
,2570830,maximum release,"The maximum release after 12 h was approximately 20 and 30% of total drug content of the tablet at pH 5.4 and 7.4, respectively.",Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570830/),%,20,151979,DB00277,Theophylline
,2570830,maximum release,"The maximum release after 12 h was approximately 20 and 30% of total drug content of the tablet at pH 5.4 and 7.4, respectively.",Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570830/),%,30,151980,DB00277,Theophylline
over,2570830,bioavailability,"However, in vivo bioavailability after oral administration of tablets to rabbits corresponded to over 95% of total drug, compared with the same dose administered intravenously.",Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570830/),%,95,151981,DB00277,Theophylline
,8950965,Cmax-Cmin,"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),μg,3.34,152879,DB00277,Theophylline
,8950965,Cmax-Cmin,"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),μg,4.22,152880,DB00277,Theophylline
,8950965,Cmax-Cmin,"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),μg,5.22,152881,DB00277,Theophylline
,8950965,zero half life time (T1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,18.9,152882,DB00277,Theophylline
,8950965,zero half life time (T1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,13.5,152883,DB00277,Theophylline
,8950965,zero half life time (T1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,10.1,152884,DB00277,Theophylline
,8950965,apparent distribution volume (V),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),1/[kg],0.811,152885,DB00277,Theophylline
,8950965,apparent distribution volume (V),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),1/[kg],0.78,152886,DB00277,Theophylline
,8950965,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,21.3,152887,DB00277,Theophylline
,8950965,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,16.7,152888,DB00277,Theophylline
,8950965,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,15.2,152889,DB00277,Theophylline
,8950965,moment half life time (Tm1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,13.7,152890,DB00277,Theophylline
,8950965,moment half life time (Tm1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,10.6,152891,DB00277,Theophylline
,8950965,moment half life time (Tm1/2),"There were no significant differences as to the zero absorption rate, clearance, the moment absorption rate, but there were significant differences to Cmax-Cmin of SB (3.34 micrograms) < TL (4.22) < TD (5.22) (P = 0.0150), the zero half life time (T1/2) of SB (18.9 hr) > TL (13.5) > TD (10.1) (P = 0.0061), the apparent distribution volume (V) of SB (0.811/ kg) > TL (0.78) > TD (0.55) (P = 0.0309), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (P = 0.0034), the moment half life time (Tm1/2) of SB (13.7 hr) > TL (10.6) > TD (9.55) (P = 0.009), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950965/),h,9.55,152892,DB00277,Theophylline
,8287631,peak (Cmax),Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose.,Clinical pharmacokinetics of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),[mg] / [l],0.7,152908,DB00277,Theophylline
,8287631,elimination half-life (t1/2),"This is followed by a monophasic slow decrease, with an elimination half-life (t1/2) of 15 to 20 hours.",Clinical pharmacokinetics of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),h,15 to 20,152909,DB00277,Theophylline
,8532073,AUCtissue/AUCplasma-ratio,The mean AUCtissue/AUCplasma-ratio was 0.56 (p.o.) and 0.55 (i.v.) for muscle and 0.55 (p.o.) and 0.72 (i.v.) for subcutaneous adipose tissue.,Theophylline kinetics in peripheral tissues in vivo in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8532073/),,0.56,153424,DB00277,Theophylline
,8532073,AUCtissue/AUCplasma-ratio,The mean AUCtissue/AUCplasma-ratio was 0.56 (p.o.) and 0.55 (i.v.) for muscle and 0.55 (p.o.) and 0.72 (i.v.) for subcutaneous adipose tissue.,Theophylline kinetics in peripheral tissues in vivo in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8532073/),,0.55,153425,DB00277,Theophylline
,8532073,AUCtissue/AUCplasma-ratio,The mean AUCtissue/AUCplasma-ratio was 0.56 (p.o.) and 0.55 (i.v.) for muscle and 0.55 (p.o.) and 0.72 (i.v.) for subcutaneous adipose tissue.,Theophylline kinetics in peripheral tissues in vivo in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8532073/),,0.72,153426,DB00277,Theophylline
,2882979,volume of distribution,"Chloramphenicol treatment, 75 mg/day intravenously for 3 days, significantly (p less than 0.05) decreased the plasma clearance of theophylline by 31% with no apparent effects on the volume of distribution (0.97 liter/kg).",Pharmacokinetic interaction between theophylline and chloramphenicol in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882979/),[l] / [kg],0.97,153453,DB00277,Theophylline
,2882979,elimination half-life,"The elimination half-life in chloramphenicol treated rats (N = 6) was 4.8 hr, significantly (p less than 0.05) longer than the corresponding half-life, 3.4 hr, in control rats (N = 6).",Pharmacokinetic interaction between theophylline and chloramphenicol in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882979/),h,4.8,153454,DB00277,Theophylline
,2882979,half-life,"The elimination half-life in chloramphenicol treated rats (N = 6) was 4.8 hr, significantly (p less than 0.05) longer than the corresponding half-life, 3.4 hr, in control rats (N = 6).",Pharmacokinetic interaction between theophylline and chloramphenicol in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882979/),h,3.4,153455,DB00277,Theophylline
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],26,153843,DB00277,Theophylline
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],19,153844,DB00277,Theophylline
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],21.2,153845,DB00277,Theophylline
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],14.9,153846,DB00277,Theophylline
,7165461,Cl,Pharmacokinetic characteristics (mean +/- SD) in 34 asthmatic children (age range 2-14 years) averaged 0.082 +/- 0.028 l/kg/h for Cl; 0.436 +/- 0.087 l/kg for Vd; 4.07 +/- 1.43 h for t 1/2.,[Adaptation of the oral dosage of theophylline to the asthmatic child. Value of a kinetic test by the intravenous route]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7165461/),[l] / [h·kg],0.082,154162,DB00277,Theophylline
,7165461,Vd,Pharmacokinetic characteristics (mean +/- SD) in 34 asthmatic children (age range 2-14 years) averaged 0.082 +/- 0.028 l/kg/h for Cl; 0.436 +/- 0.087 l/kg for Vd; 4.07 +/- 1.43 h for t 1/2.,[Adaptation of the oral dosage of theophylline to the asthmatic child. Value of a kinetic test by the intravenous route]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7165461/),[l] / [kg],0.436,154163,DB00277,Theophylline
,7165461,t 1/2,Pharmacokinetic characteristics (mean +/- SD) in 34 asthmatic children (age range 2-14 years) averaged 0.082 +/- 0.028 l/kg/h for Cl; 0.436 +/- 0.087 l/kg for Vd; 4.07 +/- 1.43 h for t 1/2.,[Adaptation of the oral dosage of theophylline to the asthmatic child. Value of a kinetic test by the intravenous route]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7165461/),h,4.07,154164,DB00277,Theophylline
,523786,half-lives,"The half-lives of theophylline and dyphylline were 5.5 +/- 1.3 and 0.74 +/- 0.10 hr, respectively.",Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),h,5.5,154319,DB00277,Theophylline
,523786,half-lives,"The half-lives of theophylline and dyphylline were 5.5 +/- 1.3 and 0.74 +/- 0.10 hr, respectively.",Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),h,0.74,154320,DB00277,Theophylline
,523786,Vdbeta,The apparent volume of distribution (Vdbeta) and total body clearance (TBC) of dyphylline (Vdbeta = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ML/HR/KG)a = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ml/hr/kg) were much higher than those of theophylline (Vdbeta = 545 +/- 160 ml/kg; TBC = 69 +/- 10 ml/hr/kg).,Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),[ml] / [kg],1008,154321,DB00277,Theophylline
,523786,a,The apparent volume of distribution (Vdbeta) and total body clearance (TBC) of dyphylline (Vdbeta = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ML/HR/KG)a = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ml/hr/kg) were much higher than those of theophylline (Vdbeta = 545 +/- 160 ml/kg; TBC = 69 +/- 10 ml/hr/kg).,Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),[ml] / [kg],1008,154322,DB00277,Theophylline
,523786,TBC,The apparent volume of distribution (Vdbeta) and total body clearance (TBC) of dyphylline (Vdbeta = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ML/HR/KG)a = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ml/hr/kg) were much higher than those of theophylline (Vdbeta = 545 +/- 160 ml/kg; TBC = 69 +/- 10 ml/hr/kg).,Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),[ml] / [h·kg],942,154323,DB00277,Theophylline
,523786,Vdbeta,The apparent volume of distribution (Vdbeta) and total body clearance (TBC) of dyphylline (Vdbeta = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ML/HR/KG)a = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ml/hr/kg) were much higher than those of theophylline (Vdbeta = 545 +/- 160 ml/kg; TBC = 69 +/- 10 ml/hr/kg).,Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),[ml] / [kg],545,154324,DB00277,Theophylline
,523786,TBC,The apparent volume of distribution (Vdbeta) and total body clearance (TBC) of dyphylline (Vdbeta = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ML/HR/KG)a = 1008 +/- 156 ml/kg; TBC = 942 +/- 118 ml/hr/kg) were much higher than those of theophylline (Vdbeta = 545 +/- 160 ml/kg; TBC = 69 +/- 10 ml/hr/kg).,Comparative pharmacokinetics of theophylline and dyphylline following intravenous injection in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523786/),[ml] / [h·kg],69,154325,DB00277,Theophylline
,6934089,mean absorption time,The mean absorption time for whole tablets was 5.7 h and for divided tablets 4.2 h.,Pharmacokinetics of whole and half Theo-Dur tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6934089/),h,5.7,154638,DB00277,Theophylline
,6934089,mean absorption time,The mean absorption time for whole tablets was 5.7 h and for divided tablets 4.2 h.,Pharmacokinetics of whole and half Theo-Dur tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6934089/),h,4.2,154639,DB00277,Theophylline
,8375128,total plasma clearance,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],3.6,154686,DB00277,Theophylline
,8375128,total plasma clearance,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],3.82,154687,DB00277,Theophylline
,8375128,elimination half-life,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),h,29.5,154688,DB00277,Theophylline
,8375128,elimination half-life,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),h,25.9,154689,DB00277,Theophylline
,8375128,steady-state volume of distribution,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [kg],153,154690,DB00277,Theophylline
,8375128,steady-state volume of distribution,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [kg],138,154691,DB00277,Theophylline
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],0.33,154692,DB00277,Theophylline
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],0.41,154693,DB00277,Theophylline
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],1.34,154694,DB00277,Theophylline
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],1.8,154695,DB00277,Theophylline
,2328304,peak plasma concentrations,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[ng] / [ml],38.3,154753,DB00277,Theophylline
,2328304,peak plasma concentrations,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[ng] / [ml],47.8,154754,DB00277,Theophylline
,2328304,time of peak concentration,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),h,2.6,154755,DB00277,Theophylline
,2328304,time of peak concentration,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),h,2.3,154756,DB00277,Theophylline
,2328304,total area under the plasma concentration-time curve (AUC),The mean total area under the plasma concentration-time curve (AUC) for sublingual administration was slightly but not significantly smaller than after oral dosage (221 vs 270 h ng ml-1).,"Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[h·ng] / [ml],221,154757,DB00277,Theophylline
,2328304,total area under the plasma concentration-time curve (AUC),The mean total area under the plasma concentration-time curve (AUC) for sublingual administration was slightly but not significantly smaller than after oral dosage (221 vs 270 h ng ml-1).,"Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[h·ng] / [ml],270,154758,DB00277,Theophylline
,2328304,Systemic availability,"Systemic availability of diphenhydramine after sublingual dimenhydrinate, measured by the ratio of oral AUC to intravenous AUC, was slightly less than after oral dimenhydrinate (0.58 vs 0.69, NS), and both were significantly less than 1.0.","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),,0.58,154759,DB00277,Theophylline
,2328304,Systemic availability,"Systemic availability of diphenhydramine after sublingual dimenhydrinate, measured by the ratio of oral AUC to intravenous AUC, was slightly less than after oral dimenhydrinate (0.58 vs 0.69, NS), and both were significantly less than 1.0.","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),,0.69,154760,DB00277,Theophylline
,3707813,volume of distribution (V),"Mean volume of distribution (V) rose from 0.33 +/- 0.07 to 0.39 +/- 0.06 1 kg-1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052).",The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707813/),[1] / [kg],0.33,154843,DB00277,Theophylline
,3707813,volume of distribution (V),"Mean volume of distribution (V) rose from 0.33 +/- 0.07 to 0.39 +/- 0.06 1 kg-1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052).",The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707813/),[1] / [kg],0.39,154844,DB00277,Theophylline
,1577056,oral clearance,The oral clearance of theophylline remained unchanged whether it was administered alone or with omeprazole (54.2 ml.min-1).,Theophylline steady state pharmacokinetics is not altered by omeprazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),[ml] / [min],54.2,155146,DB00277,Theophylline
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,9,155147,DB00277,Theophylline
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,32,155148,DB00277,Theophylline
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,12,155149,DB00277,Theophylline
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,22,155150,DB00277,Theophylline
,7712669,Plasma free fraction,Plasma free fraction of theophylline was higher in the subjects with diabetes than in the healthy subjects (0.61 +/- 0.04 versus 0.56 +/- 0.02; p < 0.001).,Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712669/),,0.61,155626,DB00277,Theophylline
,7712669,Plasma free fraction,Plasma free fraction of theophylline was higher in the subjects with diabetes than in the healthy subjects (0.61 +/- 0.04 versus 0.56 +/- 0.02; p < 0.001).,Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712669/),,0.56,155627,DB00277,Theophylline
,28108402,Cmax,"PBPK modelling of a 5 mg/kg iv loading dose (≤18yr) shows a mean Cmax of 8.99 mg/L (5th-95th centiles 5.5-13.7 mg/L), with 70.3% of subjects <10 mg/L, 29.4% achieving 10-20 mg/L, and 0.1% > 20 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],8.99,156698,DB00277,Theophylline
,28108402,steady state infusion concentration,"For an aminophylline infusion (0-12 y) of 1.0 mg/kg/h, the mean steady state infusion concentration was 16.4 mg/L, (5th-95th centiles 5.3-32 mg/L), with 26.8% having a serum concentration >20 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],16.4,156699,DB00277,Theophylline
,28108402,steady state infusion concentration,"For 12-18yr receiving 0.5 mg/kg/h infusion, the mean steady state infusion concentration was 9.37 mg/L (5th-95th centiles 3.4-18 mg/L), with 59.8% having a serum concentration <10 mg/L.",Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28108402/),[mg] / [l],9.37,156700,DB00277,Theophylline
,7285483,ClT,"ClT in smokers (0.053 +/- 0.006 1 . hr-1 . kg-1) was greater than in nonsmokers (0.032 +/- 0.002 l . hr-1 . kg-1, p less than 0.005).",Cigarette smoking and theophylline clearance and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285483/),[1] / [h·kg],0.053,156771,DB00277,Theophylline
,7285483,ClT,"ClT in smokers (0.053 +/- 0.006 1 . hr-1 . kg-1) was greater than in nonsmokers (0.032 +/- 0.002 l . hr-1 . kg-1, p less than 0.005).",Cigarette smoking and theophylline clearance and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285483/),[l] / [h·kg],0.032,156772,DB00277,Theophylline
,2766061,AUC,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),[h·ug] / [ml],275.1,157437,DB00277,Theophylline
,2766061,Kel,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),1/[h],0.068,157438,DB00277,Theophylline
,2766061,Ka,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),1/[h],0.33,157439,DB00277,Theophylline
,2766061,Tmax,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),h,6.3,157440,DB00277,Theophylline
,2766061,T 1/2,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),h,11.2,157441,DB00277,Theophylline
,2766061,Clearance/F,1) The average of a single dose (12 cases) is AUC (ug. hr/ml) 275.1 +/- 62. k; Kel (hr-1) 0.068 +/- 0.019; Ka (hr-1) 0.33 +/- 0.07); Tmax (hr) 6.3 +/- 1.4; T 1/2 (hr) 11.2 +/- 4.4; Clearance/F (ml/kg/hr) 37.9 +/- 9.0.2).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),[ml] / [h·kg],37.9,157442,DB00277,Theophylline
,2766061,Css,The average of steady state (12 cases) is Css (mg/L) 5. 7 +/- 2.6; Cmax-Cmin (mg/L) 10.09 +/- 1.46.3).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),[mg] / [l],5. 7,157443,DB00277,Theophylline
,2766061,Cmax-Cmin,The average of steady state (12 cases) is Css (mg/L) 5. 7 +/- 2.6; Cmax-Cmin (mg/L) 10.09 +/- 1.46.3).,Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),[mg] / [l],10.09,157444,DB00277,Theophylline
,2766061,relative bioavailability,"The average of relative bioavailability (3 cases) is 82%, 83%, 102%.",Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),%,82,157445,DB00277,Theophylline
,2766061,relative bioavailability,"The average of relative bioavailability (3 cases) is 82%, 83%, 102%.",Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),%,83,157446,DB00277,Theophylline
,2766061,relative bioavailability,"The average of relative bioavailability (3 cases) is 82%, 83%, 102%.",Sustained-release theophylline-uniphyllin in nocturnal asthmatics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766061/),%,102,157447,DB00277,Theophylline
,1432614,tubular secretion,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],21.25,158005,DB00277,Theophylline
,1432614,Michaelis-Menten constant,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],21.25,158006,DB00277,Theophylline
,1432614,maximum velocity,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [min],102.38,158007,DB00277,Theophylline
,1432614,competitive inhibition constant,The competitive inhibition constant of probenecid was 15.86 micrograms/mL.,Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],15.86,158008,DB00277,Theophylline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.44,158191,DB00277,Theophylline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.42,158192,DB00277,Theophylline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.82,158193,DB00277,Theophylline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.73,158194,DB00277,Theophylline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.27,158195,DB00277,Theophylline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.72,158196,DB00277,Theophylline
,1812482,peak-flow rates,"As a consequence of the improved theophylline medication morning and evening peak-flow rates increased in average from 272 +/- 99 l/min to 315 +/- 109 l/min and 278 +/- 101 l/min to 318 +/- 107 l/min, respectively.",[Multicenter study with a large number of patients for the validation of pharmacokinetic and clinical findings from controlled studies with small patient cohorts]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812482/),[l] / [min],272,158958,DB00277,Theophylline
,1812482,peak-flow rates,"As a consequence of the improved theophylline medication morning and evening peak-flow rates increased in average from 272 +/- 99 l/min to 315 +/- 109 l/min and 278 +/- 101 l/min to 318 +/- 107 l/min, respectively.",[Multicenter study with a large number of patients for the validation of pharmacokinetic and clinical findings from controlled studies with small patient cohorts]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812482/),[l] / [min],315,158959,DB00277,Theophylline
,1812482,peak-flow rates,"As a consequence of the improved theophylline medication morning and evening peak-flow rates increased in average from 272 +/- 99 l/min to 315 +/- 109 l/min and 278 +/- 101 l/min to 318 +/- 107 l/min, respectively.",[Multicenter study with a large number of patients for the validation of pharmacokinetic and clinical findings from controlled studies with small patient cohorts]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812482/),[l] / [min],278,158960,DB00277,Theophylline
,1812482,peak-flow rates,"As a consequence of the improved theophylline medication morning and evening peak-flow rates increased in average from 272 +/- 99 l/min to 315 +/- 109 l/min and 278 +/- 101 l/min to 318 +/- 107 l/min, respectively.",[Multicenter study with a large number of patients for the validation of pharmacokinetic and clinical findings from controlled studies with small patient cohorts]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1812482/),[l] / [min],318,158961,DB00277,Theophylline
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,4.5,159420,DB00277,Theophylline
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,134.5,159421,DB00277,Theophylline
,2305422,peak level,The mean extrapolated peak level was 8.5 +/- 0.9 mg/L.,Theophylline pharmacokinetics in black Zimbabwean males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[mg] / [l],8.5,159566,DB00277,Theophylline
,2305422,half-life,"The mean half-life and volume of distribution were 10.1 +/- 3.1 h and 0.55 +/- 0.7 L/kg, respectively.",Theophylline pharmacokinetics in black Zimbabwean males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),h,10.1,159567,DB00277,Theophylline
,2305422,volume of distribution,"The mean half-life and volume of distribution were 10.1 +/- 3.1 h and 0.55 +/- 0.7 L/kg, respectively.",Theophylline pharmacokinetics in black Zimbabwean males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[l] / [kg],0.55,159568,DB00277,Theophylline
,2305422,clearance,The mean clearance was 0.62 +/- 0.17 ml/kg/min.,Theophylline pharmacokinetics in black Zimbabwean males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305422/),[ml] / [kg·min],0.62,159569,DB00277,Theophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],9.8,160466,DB00277,Theophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],10.3,160467,DB00277,Theophylline
,7398417,steady-state average concentrations,"The steady-state average concentrations of theopylline in the plasma were 9.8 micrograms/ml, 10.3 micrograms/ml and 10.8 micrograms/ml for the tablet, capsulse, and elixir, respectively.",A multiple-dose study of sustained-release theophylline and aminophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398417/),[μg] / [ml],10.8,160468,DB00277,Theophylline
,276563,total,The mean total theophylline clearance rate was 1.32 +/- S.D. 0.66 ml/min/kg.,Pharmacokinetics of theophylline in acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/276563/),[ml] / [kg·min],1.32,160880,DB00277,Theophylline
,1524225,half-life of elimination,"There was no difference in the half-life of elimination of theophylline determined by microdialysis, 4.4 +/- 0.4 h, and whole blood sampling, 4.5 +/- 0.7 h.","Intravenous microdialysis sampling in awake, freely-moving rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524225/),h,4.4,160929,DB00277,Theophylline
,1524225,half-life of elimination,"There was no difference in the half-life of elimination of theophylline determined by microdialysis, 4.4 +/- 0.4 h, and whole blood sampling, 4.5 +/- 0.7 h.","Intravenous microdialysis sampling in awake, freely-moving rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524225/),h,4.5,160930,DB00277,Theophylline
,1524225,half-life of elimination,The half-life of elimination was 4.4 +/- 0.4 h when using simultaneous microdialysis and whole-blood sampling and only 3.0 +/- 0.4 h using microdialysis alone.,"Intravenous microdialysis sampling in awake, freely-moving rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524225/),h,4.4,160931,DB00277,Theophylline
,1524225,half-life of elimination,The half-life of elimination was 4.4 +/- 0.4 h when using simultaneous microdialysis and whole-blood sampling and only 3.0 +/- 0.4 h using microdialysis alone.,"Intravenous microdialysis sampling in awake, freely-moving rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524225/),h,3.0,160932,DB00277,Theophylline
,1524225,half-life of elimination,The half-life of elimination was 17.0 +/- 7.1 h in chloral hydrate anesthesized rats.,"Intravenous microdialysis sampling in awake, freely-moving rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524225/),h,17.0,160933,DB00277,Theophylline
,7252799,KA,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],2.1,161072,DB00277,Theophylline
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),[kg] / [ml],0.0023,161073,DB00277,Theophylline
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],0.27,161074,DB00277,Theophylline
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],0.20,161075,DB00277,Theophylline
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),[h·μg] / [ml],79.0,161076,DB00277,Theophylline
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.4,161347,DB00277,Theophylline
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.5,161348,DB00277,Theophylline
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161349,DB00277,Theophylline
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],4.9,161350,DB00277,Theophylline
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.13,161351,DB00277,Theophylline
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161352,DB00277,Theophylline
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.53,161353,DB00277,Theophylline
,2690330,volume of distribution,The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water.,Omeprazole: pharmacokinetics and metabolism in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),[l] / [kg],0.3,161885,DB00277,Theophylline
less,2690330,half-life,"The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours.",Omeprazole: pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),h,1,161886,DB00277,Theophylline
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,35,161887,DB00277,Theophylline
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,60,161888,DB00277,Theophylline
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00277,Theophylline
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00277,Theophylline
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00277,Theophylline
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00277,Theophylline
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00277,Theophylline
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00277,Theophylline
,758787,clearances,"Serum theophylline concentrations ranged from 5.1 microgram/ml to 20.1 microgram/ml, and clearances ranged from 0.03 liter/kg/hr to 0.09 liter/kg/hr.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[l] / [h·kg],0.03,162715,DB00277,Theophylline
,758787,clearances,"Serum theophylline concentrations ranged from 5.1 microgram/ml to 20.1 microgram/ml, and clearances ranged from 0.03 liter/kg/hr to 0.09 liter/kg/hr.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[l] / [h·kg],0.09,162716,DB00277,Theophylline
,758787,maximum concentration,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],10.4,162717,DB00277,Theophylline
,758787,maximum concentration,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],23.8,162718,DB00277,Theophylline
,758787,minimum,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],6.5,162719,DB00277,Theophylline
,758787,minimum,"During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml.",Reliability of theophylline clearance in determining chronic oral dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758787/),[μg] / [ml],15.2,162720,DB00277,Theophylline
,2570841,t1/2,"After intravenous administration to male rats with normal renal function, 8-PT was rapidly cleared from plasma with a t1/2 of about 14 min.",Pharmacokinetics of 8-phenyltheophylline in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),min,14,163141,DB00277,Theophylline
,2570841,apparent volume of distribution,Its apparent volume of distribution was some 76 mL/100 g and plasma clearance was 3.5 mL min-1/100 g.,Pharmacokinetics of 8-phenyltheophylline in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),[ml] / [100·g],76,163142,DB00277,Theophylline
,2570841,plasma clearance,Its apparent volume of distribution was some 76 mL/100 g and plasma clearance was 3.5 mL min-1/100 g.,Pharmacokinetics of 8-phenyltheophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),[ml] / [100·g·min],3.5,163143,DB00277,Theophylline
,1065903,plasma half-life,The mean plasma half-life for antipyrine was 17.5 hr on the high carbohydrate-low protein diet and 9.2 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,17.5,163495,DB00277,Theophylline
,1065903,plasma half-life,The mean plasma half-life for antipyrine was 17.5 hr on the high carbohydrate-low protein diet and 9.2 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,9.2,163496,DB00277,Theophylline
,1065903,plasma half-life,The mean plasma half-life for theophylline was 8.9 hr on the high carbohydrate-low protein diet and 5.9 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,8.9,163497,DB00277,Theophylline
,1065903,plasma half-life,The mean plasma half-life for theophylline was 8.9 hr on the high carbohydrate-low protein diet and 5.9 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,5.9,163498,DB00277,Theophylline
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],23.6,163548,DB00277,Theophylline
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],19.6,163549,DB00277,Theophylline
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.23,163550,DB00277,Theophylline
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.19,163551,DB00277,Theophylline
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.04,163552,DB00277,Theophylline
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.66,163553,DB00277,Theophylline
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.26,163554,DB00277,Theophylline
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.23,163555,DB00277,Theophylline
,12403641,Absolute bioavailability,Absolute bioavailability is about 10% under fasted conditions.,"Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),%,10,165022,DB00277,Theophylline
,12403641,volume of distribution at steady-state,"Tegaserod is approximately 98% bound to plasma proteins, primarily to alpha(1)-acid glycoprotein, and has a volume of distribution at steady-state of 368 +/- 223L.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),l,368,165023,DB00277,Theophylline
,12403641,plasma clearance,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),[l] / [h],77,165024,DB00277,Theophylline
,12403641,terminal half-life,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),h,11,165025,DB00277,Theophylline
,12570924,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[min·μg] / [ml],"1,040",165236,DB00277,Theophylline
,12570924,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[min·μg] / [ml],"1,750",165237,DB00277,Theophylline
,12570924,renal clearance (CL(R),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],1.39,165238,DB00277,Theophylline
,12570924,renal clearance (CL(R),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],0.571,165239,DB00277,Theophylline
,12570924,nonrenal clearance (CL(NR),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],3.36,165240,DB00277,Theophylline
,12570924,nonrenal clearance (CL(NR),"In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1,040 versus 1,750 microg min/ml) than that in control rats and this could be due to significantly faster renal clearance (CL(R), 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CL(NR), 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats.",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [kg·min],2.25,165241,DB00277,Theophylline
,12570924,intrinsic,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],267,165242,DB00277,Theophylline
,12570924,formation clearance,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],267,165243,DB00277,Theophylline
,12570924,formation clearance,"Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min).",Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12570924/),[ml] / [min],180 x 10(-6),165244,DB00277,Theophylline
,2451459,interferon levels,"In vitro lymphocyte interferon induction assay demonstrated mean interferon levels of 12,252 +/- 9,819 IU/ml for WVV and 888 +/- 1,180 IU/ml for SVV (p less than 0.05), demonstrating the immunocompetence of the subject's lymphocytes and confirming the greater immunogenic potential of WVV.",The effect of whole virus influenza vaccination on theophylline pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2451459/),[iu] / [ml],"12,252",165728,DB00277,Theophylline
,2451459,interferon levels,"In vitro lymphocyte interferon induction assay demonstrated mean interferon levels of 12,252 +/- 9,819 IU/ml for WVV and 888 +/- 1,180 IU/ml for SVV (p less than 0.05), demonstrating the immunocompetence of the subject's lymphocytes and confirming the greater immunogenic potential of WVV.",The effect of whole virus influenza vaccination on theophylline pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2451459/),[iu] / [ml],888,165729,DB00277,Theophylline
,11903871,peak blood level,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],5400,165824,DB00277,Theophylline
,11903871,half-life,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),h,15.3,165825,DB00277,Theophylline
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],300,165826,DB00277,Theophylline
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],150,165827,DB00277,Theophylline
,8160255,half-life,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),h,5.7,166254,DB00277,Theophylline
,8160255,half-life,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),h,7.5,166255,DB00277,Theophylline
,8160255,clearance,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),[ml] / [min],87.3,166256,DB00277,Theophylline
,8160255,clearance,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),[ml] / [min],68.3,166257,DB00277,Theophylline
,2328301,AUC0-infinity,"The single dose study data showed that there were no significant differences (n = 18, ANOVA, p greater than 0.05) between the three regimens with respect to AUC0-infinity values (mg h l-1), (mean +/- SD); Elixophyllin fasting = 97.1 +/- 33.7, Austyn with food = 90.9 +/- 31.3, Austyn fasting = 91.2 +/- 33.8.",Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328301/),[h·mg] / [l],97.1,167201,DB00277,Theophylline
,2328301,AUC0-infinity,"The single dose study data showed that there were no significant differences (n = 18, ANOVA, p greater than 0.05) between the three regimens with respect to AUC0-infinity values (mg h l-1), (mean +/- SD); Elixophyllin fasting = 97.1 +/- 33.7, Austyn with food = 90.9 +/- 31.3, Austyn fasting = 91.2 +/- 33.8.",Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328301/),[h·mg] / [l],90.9,167202,DB00277,Theophylline
,2328301,AUC0-infinity,"The single dose study data showed that there were no significant differences (n = 18, ANOVA, p greater than 0.05) between the three regimens with respect to AUC0-infinity values (mg h l-1), (mean +/- SD); Elixophyllin fasting = 97.1 +/- 33.7, Austyn with food = 90.9 +/- 31.3, Austyn fasting = 91.2 +/- 33.8.",Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328301/),[h·mg] / [l],91.2,167203,DB00277,Theophylline
,2328301,Austyn,"Austyn, compared with the sustained-release tablet, Theo-Dur (Austyn = 36.7 +/- 13.7 per cent, Theo-Dur = 53.1 +/- 14.1 per cent).",Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328301/),%,36.7,167204,DB00277,Theophylline
,2328301,Austyn,"Austyn, compared with the sustained-release tablet, Theo-Dur (Austyn = 36.7 +/- 13.7 per cent, Theo-Dur = 53.1 +/- 14.1 per cent).",Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328301/),%,53.1,167205,DB00277,Theophylline
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],4 to 8,167513,DB00277,Theophylline
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],3.6 to 11.5,167514,DB00277,Theophylline
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5,167515,DB00277,Theophylline
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5.2 to 8.9,167516,DB00277,Theophylline
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],79.9,167517,DB00277,Theophylline
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167518,DB00277,Theophylline
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],40.9,167519,DB00277,Theophylline
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167520,DB00277,Theophylline
,32040456,Cmax,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [l],42.4,167880,DB00277,Theophylline
,32040456,Cmax,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [l],19.0,167881,DB00277,Theophylline
,32040456,AUC0→∞,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [h·l],84.9,167882,DB00277,Theophylline
,32040456,AUC0→∞,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),[μM] / [h·l],41.4,167883,DB00277,Theophylline
,32040456,Ke,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),1/[h],0.12,167884,DB00277,Theophylline
,32040456,Ke,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),1/[h],0.24,167885,DB00277,Theophylline
,32040456,t1/2,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),h,5.87,167886,DB00277,Theophylline
,32040456,t1/2,"Pharmacokinetic parameters of the control group (amikacin only) vis-a-vis the test group were as follows: Cmax; 42.4 μmol/L vs 19.0 μmol/L, AUC0→∞; 84.9 μmol/L/h vs 41.4 μmol/L/h, Ke; 0.12 hours-1 vs 0.24 hours-1, and t1/2; 5.87 hours vs 2.88 hours, respectively.",Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32040456/),h,2.88,167887,DB00277,Theophylline
,3712142,first,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168092,DB00277,Theophylline
,3712142,second,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168093,DB00277,Theophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],58.1,168094,DB00277,Theophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],69.7,168095,DB00277,Theophylline
,3712142,clearances,"The mean (+/- SD) first, second, and third clearances measured at 24, 48, and 72 hours after the infusion increased from 58.1 +/- 13.8 to 69.7 +/- 28.0 to 84.1 +/- 36.3 ml/hr/kg, respectively (P less than 0.02 from the first and P less than 0.05 from the second).",Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712142/),[ml] / [h·kg],84.1,168096,DB00277,Theophylline
,2085333,absolute bioavailability,For the retard pellets a liberation/absorption of zero order for 12 h could be noted; the dose-corrected mean absolute bioavailability was 88%.,[Absorption profile and absolute bioavailability of a theophylline--retard preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085333/),%,88,168204,DB00277,Theophylline
,6839003,Cmax,"Theobid and Theo-Dur gave rise to plasma profiles that were characteristic of sustained-release formulations, with mean Cmax values of 5.5-5.7 micrograms ml-1 (Theobid) and 2.8-3.2 micrograms ml-1 (Theo-Dur) occurring at 5.8-9.1 h after dosing.",Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839003/),[μg] / [ml],5.5-5.7,168321,DB00277,Theophylline
,6839003,Cmax,"Theobid and Theo-Dur gave rise to plasma profiles that were characteristic of sustained-release formulations, with mean Cmax values of 5.5-5.7 micrograms ml-1 (Theobid) and 2.8-3.2 micrograms ml-1 (Theo-Dur) occurring at 5.8-9.1 h after dosing.",Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839003/),[μg] / [ml],2.8-3.2,168322,DB00277,Theophylline
,6839003,Cmax,Choledyl gave rise to a longer absorption lag time than the other formulations but was subsequently absorbed at a faster rate yielding mean Cmax values of 3.2-3.5 micrograms ml-1 at 2.8-4.1 h.,Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839003/),[μg] / [ml],3.2-3.5,168323,DB00277,Theophylline
,7378114,absorption rate,"After the administration of 350 mg a retard preparation of theophylline-ethylenediamine (Aminophyllin retard) p.o. to 10 healthy test persons the absorption rate of theophylline amounted to an average of 84%, after which the absorption had not been fully completed in all persons after 10 h.",[Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378114/),%,84,168385,DB00277,Theophylline
,3731681,t1/2,"With a low-protein diet, mean theophylline clearance fell 21% (P less than 0.04) and the t1/2 rose from 8.0 to 10.6 hours (P less than 0.02).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,8.0,168806,DB00277,Theophylline
,3731681,t1/2,"With a low-protein diet, mean theophylline clearance fell 21% (P less than 0.04) and the t1/2 rose from 8.0 to 10.6 hours (P less than 0.02).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,10.6,168807,DB00277,Theophylline
,3731681,t1/2,"With a high-protein diet, mean theophylline clearance rose 26% (P less than 0.004) and the t1/2 shortened to 7.4 hours (P less than 0.03).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,7.4,168808,DB00277,Theophylline
,11548856,compressibility,"The prepared granules showed good physical characteristics concerning the flow properties and compressibility, with the angles of repose in the range 29-31, and the compressibility indices ranged between 15% and 25%.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,15,169221,DB00277,Theophylline
,11548856,compressibility,"The prepared granules showed good physical characteristics concerning the flow properties and compressibility, with the angles of repose in the range 29-31, and the compressibility indices ranged between 15% and 25%.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,25,169222,DB00277,Theophylline
,11548856,friability,"The granules had low friability values (3.0%-4.2%), depending on SAL:CG ratios.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,3.0,169223,DB00277,Theophylline
,11548856,friability,"The granules had low friability values (3.0%-4.2%), depending on SAL:CG ratios.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,4.2,169224,DB00277,Theophylline
,11548856,bioavailability,The formulated tablets showed 104.65% bioavailability relative to that of the commercial tablets.,Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,104.65,169225,DB00277,Theophylline
,15065783,in vivo recoveries,"Average in vivo recoveries were 0.74 +/- 0.06 in blood and 0.27 +/- 0.07 in brain with theophylline at concentrations 1, 2 and 5 microg/ml.",Determination of unbound theophylline in rat blood and brain by microdialysis and liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15065783/),,0.74,169290,DB00277,Theophylline
,15065783,in vivo recoveries,"Average in vivo recoveries were 0.74 +/- 0.06 in blood and 0.27 +/- 0.07 in brain with theophylline at concentrations 1, 2 and 5 microg/ml.",Determination of unbound theophylline in rat blood and brain by microdialysis and liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15065783/),,0.27,169291,DB00277,Theophylline
,646186,half life,"The mean half life was 4.92 hours, with S.D. +/- 1.88 hours.",Theophylline half-life in infants and young children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/646186/),h,4.92,169546,DB00277,Theophylline
,3899457,Vmax,The mean Vmax was 1960 mg/day and the mean Km was 24.1 mg/L.,Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899457/),[mg] / [d],1960,169658,DB00277,Theophylline
,3899457,Km,The mean Vmax was 1960 mg/day and the mean Km was 24.1 mg/L.,Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899457/),[mg] / [l],24.1,169659,DB00277,Theophylline
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.1,169892,DB00277,Theophylline
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.7,169893,DB00277,Theophylline
,2350534,clearance,The mean clearance of theophylline was significantly lowered after INH (2.20 +/- 0.24 l h-1) (mean +/- s.e. mean) compared with the baseline value (2.80 +/- 0.24 l h-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [h],2.20,170839,DB00277,Theophylline
,2350534,clearance,The mean clearance of theophylline was significantly lowered after INH (2.20 +/- 0.24 l h-1) (mean +/- s.e. mean) compared with the baseline value (2.80 +/- 0.24 l h-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [h],2.80,170840,DB00277,Theophylline
,2350534,volume of distribution at steady state,The volume of distribution at steady state was also lowered significantly after INH (0.42 +/- 0.01 l kg-1 vs 0.47 +/- 0.02 l kg-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [kg],0.42,170841,DB00277,Theophylline
,2350534,volume of distribution at steady state,The volume of distribution at steady state was also lowered significantly after INH (0.42 +/- 0.01 l kg-1 vs 0.47 +/- 0.02 l kg-1).,Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),[l] / [kg],0.47,170842,DB00277,Theophylline
,2350534,half-life,"Consequently, there was no significant prolongation of theophylline half-life after INH (7.0 +/- 0.3 h vs 6.7 +/- 0.4 h control).",Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),h,7.0,170843,DB00277,Theophylline
,2350534,half-life,"Consequently, there was no significant prolongation of theophylline half-life after INH (7.0 +/- 0.3 h vs 6.7 +/- 0.4 h control).",Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350534/),h,6.7,170844,DB00277,Theophylline
,15074856,plasma terminal half-life,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),h,8.4,171278,DB00277,Theophylline
,15074856,volume of distribution,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),[l] / [kg],0.546,171279,DB00277,Theophylline
,15074856,systemic clearance,"Mean values for plasma terminal half-life, volume of distribution, and systemic clearance were 8.4 hours, 0.546 L x kg(-1), and 0.780 mL x kg(-1) x min(1), respectively, after i.v. administration of theophylline.",Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),[min(1·ml] / [kg],0.780,171280,DB00277,Theophylline
>,15074856,Systemic availability,Systemic availability was > 80% for both oral formulations.,Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15074856/),%,80,171281,DB00277,Theophylline
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00277,Theophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.57,172222,DB00277,Theophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.61,172223,DB00277,Theophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.63,172224,DB00277,Theophylline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.62,172225,DB00277,Theophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,7.9,172226,DB00277,Theophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,9.2,172227,DB00277,Theophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,10.3,172228,DB00277,Theophylline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,8.6,172229,DB00277,Theophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.90,172230,DB00277,Theophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.84,172231,DB00277,Theophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.78,172232,DB00277,Theophylline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.89,172233,DB00277,Theophylline
,2619780,tmax,The increase in serum concentration was slower with formulation E than for the reference formulation which led to a difference in tmax (10 vs.,[Comparison of the bioavailability and pharmacokinetic profile of a theophylline pellet formulation designed for once-daily dosage with a pellet preparation designed for twice-daily dosage]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619780/),,10,172234,DB00277,Theophylline
,2619780,percentage of residual concentration,"7 h), the percentage of residual concentration after 24 h (47 vs. 32%) and a plateau time that was 25% longer for formulation E.",[Comparison of the bioavailability and pharmacokinetic profile of a theophylline pellet formulation designed for once-daily dosage with a pellet preparation designed for twice-daily dosage]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619780/),,47,172235,DB00277,Theophylline
,2619780,percentage of residual concentration,"7 h), the percentage of residual concentration after 24 h (47 vs. 32%) and a plateau time that was 25% longer for formulation E.",[Comparison of the bioavailability and pharmacokinetic profile of a theophylline pellet formulation designed for once-daily dosage with a pellet preparation designed for twice-daily dosage]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619780/),,32,172236,DB00277,Theophylline
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.85,172631,DB00277,Theophylline
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.56,172632,DB00277,Theophylline
,8491248,apparent elimination,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,6.3,173369,DB00277,Theophylline
,8491248,apparent elimination,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,8.3,173370,DB00277,Theophylline
,8491248,half-life,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,6.3,173371,DB00277,Theophylline
,8491248,half-life,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,8.3,173372,DB00277,Theophylline
,8491248,total body clearance,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),[ml] / [h·kg],55.0,173373,DB00277,Theophylline
,8491248,total body clearance,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),[ml] / [h·kg],42.5,173374,DB00277,Theophylline
,7138734,clearance,3 Mean +/- s.d. theophylline clearance was decreased from 62 +/- 15.4 to 53 +/- 10.3 ml min-1 (P less than 0.05) and elimination half-life rose from 7.1 +/- 1.9 to 7.7 +/- 2 h (P less than 0.05) when erythromycin was co-administered.,Pharmacokinetic interaction between theophylline and erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[ml] / [min],62,173482,DB00277,Theophylline
,7138734,clearance,3 Mean +/- s.d. theophylline clearance was decreased from 62 +/- 15.4 to 53 +/- 10.3 ml min-1 (P less than 0.05) and elimination half-life rose from 7.1 +/- 1.9 to 7.7 +/- 2 h (P less than 0.05) when erythromycin was co-administered.,Pharmacokinetic interaction between theophylline and erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[ml] / [min],53,173483,DB00277,Theophylline
,7138734,elimination half-life,3 Mean +/- s.d. theophylline clearance was decreased from 62 +/- 15.4 to 53 +/- 10.3 ml min-1 (P less than 0.05) and elimination half-life rose from 7.1 +/- 1.9 to 7.7 +/- 2 h (P less than 0.05) when erythromycin was co-administered.,Pharmacokinetic interaction between theophylline and erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),h,7.1,173484,DB00277,Theophylline
,7138734,elimination half-life,3 Mean +/- s.d. theophylline clearance was decreased from 62 +/- 15.4 to 53 +/- 10.3 ml min-1 (P less than 0.05) and elimination half-life rose from 7.1 +/- 1.9 to 7.7 +/- 2 h (P less than 0.05) when erythromycin was co-administered.,Pharmacokinetic interaction between theophylline and erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),h,7.7,173485,DB00277,Theophylline
,7138734,area under the curves (0-8 h,4 Mean +/- s.d. erythromycin area under the curves (0-8 h) and (0-oc) were reduced from 6.09 +/- 3.2 to 3.8 +/- 2.5 micrograms ml-1 h and 7.2 +/- 3.6 to 5.0 +/- 2.9 micrograms ml-1 h (P less than 0.05) in the presence of theophylline.,Pharmacokinetic interaction between theophylline and erythromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[h·μg] / [ml],6.09,173486,DB00277,Theophylline
,7138734,area under the curves (0-8 h,4 Mean +/- s.d. erythromycin area under the curves (0-8 h) and (0-oc) were reduced from 6.09 +/- 3.2 to 3.8 +/- 2.5 micrograms ml-1 h and 7.2 +/- 3.6 to 5.0 +/- 2.9 micrograms ml-1 h (P less than 0.05) in the presence of theophylline.,Pharmacokinetic interaction between theophylline and erythromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[h·μg] / [ml],3.8,173487,DB00277,Theophylline
,7138734,area under the curves (0-8 h,4 Mean +/- s.d. erythromycin area under the curves (0-8 h) and (0-oc) were reduced from 6.09 +/- 3.2 to 3.8 +/- 2.5 micrograms ml-1 h and 7.2 +/- 3.6 to 5.0 +/- 2.9 micrograms ml-1 h (P less than 0.05) in the presence of theophylline.,Pharmacokinetic interaction between theophylline and erythromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[h·μg] / [ml],7.2,173488,DB00277,Theophylline
,7138734,area under the curves (0-8 h,4 Mean +/- s.d. erythromycin area under the curves (0-8 h) and (0-oc) were reduced from 6.09 +/- 3.2 to 3.8 +/- 2.5 micrograms ml-1 h and 7.2 +/- 3.6 to 5.0 +/- 2.9 micrograms ml-1 h (P less than 0.05) in the presence of theophylline.,Pharmacokinetic interaction between theophylline and erythromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[h·μg] / [ml],5.0,173489,DB00277,Theophylline
,7138734,steady state,Mean steady state and maximum steady state concentrations were also reduced from 0.75 +/- 0.4 to 0.47 +/- 0.3 microgram ml-1 (P less than 0.05) and 1.45 +/- 0.87 to 0.85 +/- 0.51 microgram ml-1 (P less than 0.05) respectively.,Pharmacokinetic interaction between theophylline and erythromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[μg] / [ml],0.75,173490,DB00277,Theophylline
,7138734,maximum steady state concentrations,Mean steady state and maximum steady state concentrations were also reduced from 0.75 +/- 0.4 to 0.47 +/- 0.3 microgram ml-1 (P less than 0.05) and 1.45 +/- 0.87 to 0.85 +/- 0.51 microgram ml-1 (P less than 0.05) respectively.,Pharmacokinetic interaction between theophylline and erythromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[μg] / [ml],1.45,173491,DB00277,Theophylline
,7138734,maximum steady state concentrations,Mean steady state and maximum steady state concentrations were also reduced from 0.75 +/- 0.4 to 0.47 +/- 0.3 microgram ml-1 (P less than 0.05) and 1.45 +/- 0.87 to 0.85 +/- 0.51 microgram ml-1 (P less than 0.05) respectively.,Pharmacokinetic interaction between theophylline and erythromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138734/),[μg] / [ml],0.85,173492,DB00277,Theophylline
,10951430,time of maximum serum concentration (T(max)),Mean time of maximum serum concentration (T(max)) ranged from 1.3 to 1.4 h.,Bioequivalence of immediate-release theophylline capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951430/),h,1.3 to 1.4,173907,DB00277,Theophylline
,2746720,mean residence time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,19.4,174292,DB00277,Theophylline
,2746720,mean residence time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,15.8,174293,DB00277,Theophylline
,2746720,mean absorption time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,8.0,174294,DB00277,Theophylline
,2746720,mean absorption time,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,4.8,174295,DB00277,Theophylline
,2746720,absolute bioavailability,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),%,82,174296,DB00277,Theophylline
,2746720,absolute bioavailability,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),%,76,174297,DB00277,Theophylline
,2746720,time to peak plasma concentrations,"Values were determined for mean residence time (SB = 19.4 +/- 3.2 h; TD = 15.8 +/- 4.8 h), mean absorption time (SB = 8.0 +/- 2.3 h; TD = 4.8 +/- 2.3 h), absolute bioavailability (SB = 82 +/- 27%; TD = 76 +/- 38%), and time to peak plasma concentrations (SB = 8 h; TD = 8 h).",Sustained-release theophylline pharmacokinetics in the cat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),h,8,174298,DB00277,Theophylline
,2746720,peak plasma concentrations,"After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 +/- 3.4 micrograms/ml; TD = 14.3 +/- 6.7 micrograms/ml).",Sustained-release theophylline pharmacokinetics in the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),[μg] / [ml],10.5,174299,DB00277,Theophylline
,2746720,peak plasma concentrations,"After normalization to a dose of 25 mg/kg, the average peak plasma concentrations were also predicted (SB = 10.5 +/- 3.4 micrograms/ml; TD = 14.3 +/- 6.7 micrograms/ml).",Sustained-release theophylline pharmacokinetics in the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746720/),[μg] / [ml],14.3,174300,DB00277,Theophylline
,1340905,maximum concentration at 12 hours,"A plasmatic curve was obtained with a maximum concentration at 12 hours of 10.18 mcg/ml, a minimum concentration of 3.27 mcg/ml and an area under the concentration/time curve of 198.4 mcg.h/ml.",[The pharmacokinetic study of a daily dose of theophylline]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340905/),[mcg] / [ml],10.18,174552,DB00277,Theophylline
,1340905,minimum concentration,"A plasmatic curve was obtained with a maximum concentration at 12 hours of 10.18 mcg/ml, a minimum concentration of 3.27 mcg/ml and an area under the concentration/time curve of 198.4 mcg.h/ml.",[The pharmacokinetic study of a daily dose of theophylline]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340905/),[mcg] / [ml],3.27,174553,DB00277,Theophylline
,1340905,area under the concentration/time curve,"A plasmatic curve was obtained with a maximum concentration at 12 hours of 10.18 mcg/ml, a minimum concentration of 3.27 mcg/ml and an area under the concentration/time curve of 198.4 mcg.h/ml.",[The pharmacokinetic study of a daily dose of theophylline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340905/),[h·mcg] / [ml],198.4,174554,DB00277,Theophylline
,2743384,serum theophylline concentration (STC),After the first dose in the morning the serum theophylline concentration (STC) did not differ in children and adults (10.4 and 10.5 mg/l).,[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),[mg] / [l],10.4,174758,DB00277,Theophylline
,2743384,serum theophylline concentration (STC),After the first dose in the morning the serum theophylline concentration (STC) did not differ in children and adults (10.4 and 10.5 mg/l).,[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),[mg] / [l],10.5,174759,DB00277,Theophylline
,2743384,half-time of absorption,"In adults the half-time of absorption was twice as high as in children (0.63 and 0.3 h), as well as the time when the peak theophylline concentration was reached (2.7 and 1.39 h).",[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),h,0.63,174760,DB00277,Theophylline
,2743384,half-time of absorption,"In adults the half-time of absorption was twice as high as in children (0.63 and 0.3 h), as well as the time when the peak theophylline concentration was reached (2.7 and 1.39 h).",[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),h,0.3,174761,DB00277,Theophylline
,2743384,half-time of absorption,"In adults the half-time of absorption was twice as high as in children (0.63 and 0.3 h), as well as the time when the peak theophylline concentration was reached (2.7 and 1.39 h).",[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),h,2.7,174762,DB00277,Theophylline
,2743384,time when the peak,"In adults the half-time of absorption was twice as high as in children (0.63 and 0.3 h), as well as the time when the peak theophylline concentration was reached (2.7 and 1.39 h).",[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),h,2.7,174763,DB00277,Theophylline
,2743384,time when the peak,"In adults the half-time of absorption was twice as high as in children (0.63 and 0.3 h), as well as the time when the peak theophylline concentration was reached (2.7 and 1.39 h).",[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),h,1.39,174764,DB00277,Theophylline
,2743384,STC,In children a double dose of the drug at night ensured a STC of 11.2 mg/l and a maximum theophyllinaemia (C max = 13.5 mg/l between 8 p.m. and 6 a.m. (measured by the EMIT method).,[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),[mg] / [l],11.2,174765,DB00277,Theophylline
,2743384,maximum theophyllinaemia (C max,In children a double dose of the drug at night ensured a STC of 11.2 mg/l and a maximum theophyllinaemia (C max = 13.5 mg/l between 8 p.m. and 6 a.m. (measured by the EMIT method).,[Pharmacokinetics and chronotherapy of delayed action theophylline (Euphyllin CR)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743384/),[mg] / [l],13.5,174766,DB00277,Theophylline
,711929,clearance rate,"The mean clearance rate was 1.07 +/- 0.55 ml/min-kg, which is comparable with values obtained by others in older children.",Pharmacokinetics of theophylline in infancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711929/),[ml] / [min-kg],1.07,174792,DB00277,Theophylline
,711929,half-life,The mean half-life was 4.4 +/- 2.2 hours.,Pharmacokinetics of theophylline in infancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711929/),h,4.4,174793,DB00277,Theophylline
,7086267,t1/2,"The t1/2 of theophylline in the newborn rabbit was 43.5 +/- 12.0 hr, approximately 15 times longer than in the nonpregnant rabbit.",Theophylline elimination in the pregnant and fetal rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086267/),h,43.5,175177,DB00277,Theophylline
,7438964,t 1/2,"In a patient severely poisoned with theophylline, saturation kinetics were demonstrated at serum concentrations > 35 micrograms/ml with subsequent conversion to first order kinetics (t 1/2 = 5.4 h).",Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438964/),h,5.4,175236,DB00277,Theophylline
,7438964,clearance,The mean theophylline clearance was greater for dialysate (5.11 ml/min) than for urine (1.98 ml/min) or gastric fluid (0.32 ml/min).,Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438964/),[ml] / [min],5.11,175237,DB00277,Theophylline
,7438964,clearance,The mean theophylline clearance was greater for dialysate (5.11 ml/min) than for urine (1.98 ml/min) or gastric fluid (0.32 ml/min).,Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438964/),[ml] / [min],1.98,175238,DB00277,Theophylline
,7438964,clearance,The mean theophylline clearance was greater for dialysate (5.11 ml/min) than for urine (1.98 ml/min) or gastric fluid (0.32 ml/min).,Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438964/),[ml] / [min],0.32,175239,DB00277,Theophylline
,7438964,t 1/2,Urinary elimination occurred as a constant first order process (t 1/2 = 4.3 h).,Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438964/),h,4.3,175240,DB00277,Theophylline
,7378252,maximum,"3 During the fifth 12 h dosing period the mean maximum and minimum plasma theophylline concentrations were 7.25 and 4.30 microgram/ml after 190 mg SR theophylline 12 hourly (n = 6) and 12.96 and 7.36 microgram/ml after 380 mg 12 hourly (n = 5), although there was marked between-subject variation in plasma theophylline concentrations.",Pharmacokinetics of a sustained-release theophylline formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378252/),[μg] / [ml],7.25,175462,DB00277,Theophylline
,7378252,maximum,"3 During the fifth 12 h dosing period the mean maximum and minimum plasma theophylline concentrations were 7.25 and 4.30 microgram/ml after 190 mg SR theophylline 12 hourly (n = 6) and 12.96 and 7.36 microgram/ml after 380 mg 12 hourly (n = 5), although there was marked between-subject variation in plasma theophylline concentrations.",Pharmacokinetics of a sustained-release theophylline formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378252/),[μg] / [ml],12.96,175463,DB00277,Theophylline
,7378252,minimum plasma theophylline concentrations,"3 During the fifth 12 h dosing period the mean maximum and minimum plasma theophylline concentrations were 7.25 and 4.30 microgram/ml after 190 mg SR theophylline 12 hourly (n = 6) and 12.96 and 7.36 microgram/ml after 380 mg 12 hourly (n = 5), although there was marked between-subject variation in plasma theophylline concentrations.",Pharmacokinetics of a sustained-release theophylline formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378252/),[μg] / [ml],4.30,175464,DB00277,Theophylline
,7378252,minimum plasma theophylline concentrations,"3 During the fifth 12 h dosing period the mean maximum and minimum plasma theophylline concentrations were 7.25 and 4.30 microgram/ml after 190 mg SR theophylline 12 hourly (n = 6) and 12.96 and 7.36 microgram/ml after 380 mg 12 hourly (n = 5), although there was marked between-subject variation in plasma theophylline concentrations.",Pharmacokinetics of a sustained-release theophylline formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378252/),[μg] / [ml],7.36,175465,DB00277,Theophylline
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.3,175652,DB00277,Theophylline
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,2.0,175653,DB00277,Theophylline
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.1,175654,DB00277,Theophylline
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.8,175655,DB00277,Theophylline
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.5,175656,DB00277,Theophylline
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.9,175657,DB00277,Theophylline
,7349339,half-life,"The mean half-life of theophylline following intravascular administration was 11.0 h, and the apparent specific volume of distribution was 0.61 liter/kg.",Pharmacokinetics of theophylline in swine: a potential model for human drug bioavailability studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349339/),h,11.0,175818,DB00277,Theophylline
,7349339,apparent specific volume of distribution,"The mean half-life of theophylline following intravascular administration was 11.0 h, and the apparent specific volume of distribution was 0.61 liter/kg.",Pharmacokinetics of theophylline in swine: a potential model for human drug bioavailability studies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349339/),[l] / [kg],0.61,175819,DB00277,Theophylline
,7349339,bioavailability,"Following oral administration, theophylline in solution was absorbed quite rapidly with a bioavailability of 79%.",Pharmacokinetics of theophylline in swine: a potential model for human drug bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349339/),%,79,175820,DB00277,Theophylline
,6829982,T1/2,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),h,4.45,175878,DB00277,Theophylline
,6829982,Vd,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),[ml] / [kg],505.8,175879,DB00277,Theophylline
,6829982,Cl,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),[ml] / [h·kg],87.9,175880,DB00277,Theophylline
,6829982,F,"Mean values (+/- S.D.) were T1/2 = 4.45 +/- 1.58 hrs, Vd = 505.8 +/- 40.7 ml/kg, Cl = 87.9 +/- 31.6 ml/kg/hr, F = 0.86 +/- 0.26.",Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6829982/),,0.86,175881,DB00277,Theophylline
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB00277,Theophylline
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB00277,Theophylline
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB00277,Theophylline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],19.8,176121,DB00277,Theophylline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],54.6,176122,DB00277,Theophylline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],113.3,176123,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,1.9,176124,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,3.3,176125,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,4.0,176126,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,23,176127,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,32,176128,DB00277,Theophylline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,24,176129,DB00277,Theophylline
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,2.7,177469,DB00277,Theophylline
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[ng] / [ml],2763.9,177470,DB00277,Theophylline
,21369441,AUC,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],9465.6,177471,DB00277,Theophylline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6,177472,DB00277,Theophylline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],2817.4,177473,DB00277,Theophylline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6.4,177474,DB00277,Theophylline
,18321743,AUC 0-infinity,"No significant difference was found in the AUC 0-infinity (77.7 vs. 83.8h ng/ml; p=0.280) and Cmax (6.70 vs. 7.77 ng/ml; p=0.125) of theophylline between the MK-0873+theophylline and theophylline only treatment, and bioequivalence was demonstrated for AUC0-infinity (geometric mean ratio with 90% confidence interval: 0.930 (0.826, 1.047)).","MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321743/),[h·ng] / [ml],77.7,178151,DB00277,Theophylline
,18321743,AUC 0-infinity,"No significant difference was found in the AUC 0-infinity (77.7 vs. 83.8h ng/ml; p=0.280) and Cmax (6.70 vs. 7.77 ng/ml; p=0.125) of theophylline between the MK-0873+theophylline and theophylline only treatment, and bioequivalence was demonstrated for AUC0-infinity (geometric mean ratio with 90% confidence interval: 0.930 (0.826, 1.047)).","MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321743/),[h·ng] / [ml],83.8,178152,DB00277,Theophylline
,18321743,Cmax,"No significant difference was found in the AUC 0-infinity (77.7 vs. 83.8h ng/ml; p=0.280) and Cmax (6.70 vs. 7.77 ng/ml; p=0.125) of theophylline between the MK-0873+theophylline and theophylline only treatment, and bioequivalence was demonstrated for AUC0-infinity (geometric mean ratio with 90% confidence interval: 0.930 (0.826, 1.047)).","MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321743/),[ng] / [ml],6.70,178153,DB00277,Theophylline
,18321743,Cmax,"No significant difference was found in the AUC 0-infinity (77.7 vs. 83.8h ng/ml; p=0.280) and Cmax (6.70 vs. 7.77 ng/ml; p=0.125) of theophylline between the MK-0873+theophylline and theophylline only treatment, and bioequivalence was demonstrated for AUC0-infinity (geometric mean ratio with 90% confidence interval: 0.930 (0.826, 1.047)).","MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321743/),[ng] / [ml],7.77,178154,DB00277,Theophylline
,3987803,tmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),h,1.34,178385,DB00277,Theophylline
,3987803,tmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),h,4.40,178386,DB00277,Theophylline
,3987803,cmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),[mg] / [l],7.82,178387,DB00277,Theophylline
,3987803,cmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),[mg] / [l],5.47,178388,DB00277,Theophylline
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00277,Theophylline
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00277,Theophylline
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00277,Theophylline
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00277,Theophylline
,991535,plasma half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,16.2,179839,DB00277,Theophylline
,991535,plasma half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,9.5,179840,DB00277,Theophylline
,991535,half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,8.1,179841,DB00277,Theophylline
,991535,half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,5.2,179842,DB00277,Theophylline
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,9.5,179843,DB00277,Theophylline
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,15.6,179844,DB00277,Theophylline
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,5.2,179845,DB00277,Theophylline
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,7.6,179846,DB00277,Theophylline
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00277,Theophylline
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.39,180088,DB00277,Theophylline
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.23,180089,DB00277,Theophylline
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.171,180090,DB00277,Theophylline
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.155,180091,DB00277,Theophylline
,3595701,clearance,"The clearance relative to total theophylline concentrations was only slightly affected during the first two trimesters (2.61 +/- 0.63 l/h and 2.85 +/- 1.05 l/h), while a statistically significant reduction was evident late in pregnancy (2.05 +/- 0.49 l/h).",Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),[l] / [h],2.61,180243,DB00277,Theophylline
,3595701,clearance,"The clearance relative to total theophylline concentrations was only slightly affected during the first two trimesters (2.61 +/- 0.63 l/h and 2.85 +/- 1.05 l/h), while a statistically significant reduction was evident late in pregnancy (2.05 +/- 0.49 l/h).",Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),[l] / [h],2.85,180244,DB00277,Theophylline
,3595701,clearance,"The clearance relative to total theophylline concentrations was only slightly affected during the first two trimesters (2.61 +/- 0.63 l/h and 2.85 +/- 1.05 l/h), while a statistically significant reduction was evident late in pregnancy (2.05 +/- 0.49 l/h).",Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),[l] / [h],2.05,180245,DB00277,Theophylline
,3595701,clearance,Post-partum clearance values (2.16 +/- 2.81 l/h) suggest an ongoing suppression relative to pre-pregnancy levels.,Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),[l] / [h],2.16,180246,DB00277,Theophylline
,3595701,fraction bound,"In addition, theophylline binding to plasma proteins decreased, albeit insignificantly, during the second (fraction bound = 29%) and third (32%) trimesters compared to post-partum values (41%).",Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),%,29,180247,DB00277,Theophylline
,3595701,half-life,Increases in half-life during the third trimester (13.00 +/- 2.31 h vs 9.53 +/- 3.53 h post-partum) were highly significant.,Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),h,13.00,180248,DB00277,Theophylline
,3595701,half-life,Increases in half-life during the third trimester (13.00 +/- 2.31 h vs 9.53 +/- 3.53 h post-partum) were highly significant.,Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595701/),h,9.53,180249,DB00277,Theophylline
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],77.8,180503,DB00277,Theophylline
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],31.8,180504,DB00277,Theophylline
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,9.7,180505,DB00277,Theophylline
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,4.5,180506,DB00277,Theophylline
,36261,initial drug clearance,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),[l] / [h·kg],0.77,181177,DB00277,Theophylline
,36261,half-life,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),h,9.1,181178,DB00277,Theophylline
,36261,apparent volume of drug distribution,"Mean initial drug clearance was 0.77 L/kg/hr, half-life 9.1 hr, and apparent volume of drug distribution .887 L/kg.",Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36261/),[l] / [kg],.887,181179,DB00277,Theophylline
,16336292,Vd,"The final pharmacokinetic parameters were CL (mL/h) = [6.98 . body weight (BW) (kg)(2.17) + 0.244 . post-conceptional age (weeks)] . 1.24(oxygen support), Vd (L) = 0.492 . BW (kg) and F = 0.660, respectively.",Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336292/),,0.492,181278,DB00277,Theophylline
,16336292,F,"The final pharmacokinetic parameters were CL (mL/h) = [6.98 . body weight (BW) (kg)(2.17) + 0.244 . post-conceptional age (weeks)] . 1.24(oxygen support), Vd (L) = 0.492 . BW (kg) and F = 0.660, respectively.",Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336292/),,0.660,181279,DB00277,Theophylline
,7995005,concentrations,Mean plasma theophylline concentrations rose to 16.1 mg.L-1 at 1 hour and 16.8 mg.L-1 at 2 hours.,Relationships between pharmacokinetics and nonpulmonary pharmacodynamic effects of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995005/),[mg] / [l],16.1,181372,DB00277,Theophylline
,7995005,concentrations,Mean plasma theophylline concentrations rose to 16.1 mg.L-1 at 1 hour and 16.8 mg.L-1 at 2 hours.,Relationships between pharmacokinetics and nonpulmonary pharmacodynamic effects of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995005/),[mg] / [l],16.8,181373,DB00277,Theophylline
,20853468,extraction recovery,The extraction recovery for paraxanthine and caffeine was approximately 70% in both saliva and plasma.,Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),%,70,181494,DB00277,Theophylline
,20853468,Detection limits,"Detection limits were 0.015 µg/mL for paraxanthine and caffeine in saliva, while it was 0.005 µg/mL for paraxanthine and caffeine in plasma.",Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),[μg] / [ml],0.015,181495,DB00277,Theophylline
,20853468,Detection limits,"Detection limits were 0.015 µg/mL for paraxanthine and caffeine in saliva, while it was 0.005 µg/mL for paraxanthine and caffeine in plasma.",Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),[μg] / [ml],0.005,181496,DB00277,Theophylline
,6740419,peak,"Assuming linear pharmacokinetics and projecting to therapeutic doses, Euphyllin Retard results in much wider fluctuations between peak and trough concentrations (18,9 and 9,8 micrograms/ml) than does Theo-dur (13,8 and 10,2 micrograms/ml), and this product might be more acceptable in smokers if given in an 8-hourly schedule.",Absorption properties of two theophylline sustained-release products in smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740419/),[μg] / [ml],"18,9",181520,DB00277,Theophylline
,6740419,trough concentrations,"Assuming linear pharmacokinetics and projecting to therapeutic doses, Euphyllin Retard results in much wider fluctuations between peak and trough concentrations (18,9 and 9,8 micrograms/ml) than does Theo-dur (13,8 and 10,2 micrograms/ml), and this product might be more acceptable in smokers if given in an 8-hourly schedule.",Absorption properties of two theophylline sustained-release products in smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740419/),[μg] / [ml],"18,9",181521,DB00277,Theophylline
,6740419,trough concentrations,"Assuming linear pharmacokinetics and projecting to therapeutic doses, Euphyllin Retard results in much wider fluctuations between peak and trough concentrations (18,9 and 9,8 micrograms/ml) than does Theo-dur (13,8 and 10,2 micrograms/ml), and this product might be more acceptable in smokers if given in an 8-hourly schedule.",Absorption properties of two theophylline sustained-release products in smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740419/),[μg] / [ml],"9,8",181522,DB00277,Theophylline
,6740419,trough concentrations,"Assuming linear pharmacokinetics and projecting to therapeutic doses, Euphyllin Retard results in much wider fluctuations between peak and trough concentrations (18,9 and 9,8 micrograms/ml) than does Theo-dur (13,8 and 10,2 micrograms/ml), and this product might be more acceptable in smokers if given in an 8-hourly schedule.",Absorption properties of two theophylline sustained-release products in smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740419/),[μg] / [ml],"13,8",181523,DB00277,Theophylline
,6740419,trough concentrations,"Assuming linear pharmacokinetics and projecting to therapeutic doses, Euphyllin Retard results in much wider fluctuations between peak and trough concentrations (18,9 and 9,8 micrograms/ml) than does Theo-dur (13,8 and 10,2 micrograms/ml), and this product might be more acceptable in smokers if given in an 8-hourly schedule.",Absorption properties of two theophylline sustained-release products in smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740419/),[μg] / [ml],"10,2",181524,DB00277,Theophylline
,9238759,excretion rates,"Highest excretion rates were observed for 1,3-U (70 +/- 29 mumol/h), 1-U (40 +/- 26 mumol/h) and 3-X (20 +/- 15 mumol/h) 6-9 h after TP ingestion suggesting the high excretion of 1,3-U, 1-U and 3-X by the kidneys.",Elimination of theophylline metabolites in healthy adults. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9238759/),[μM] / [h],70,181727,DB00277,Theophylline
,9238759,excretion rates,"Highest excretion rates were observed for 1,3-U (70 +/- 29 mumol/h), 1-U (40 +/- 26 mumol/h) and 3-X (20 +/- 15 mumol/h) 6-9 h after TP ingestion suggesting the high excretion of 1,3-U, 1-U and 3-X by the kidneys.",Elimination of theophylline metabolites in healthy adults. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9238759/),[μM] / [h],40,181728,DB00277,Theophylline
,9238759,excretion rates,"Highest excretion rates were observed for 1,3-U (70 +/- 29 mumol/h), 1-U (40 +/- 26 mumol/h) and 3-X (20 +/- 15 mumol/h) 6-9 h after TP ingestion suggesting the high excretion of 1,3-U, 1-U and 3-X by the kidneys.",Elimination of theophylline metabolites in healthy adults. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9238759/),[μM] / [h],20,181729,DB00277,Theophylline
,9238759,excretion rate,"The highest excretion rate of TP (50 +/- 8 mumol/h) occurring at 0-6 h after the load and rapidly declining thereafter, indicated the lower excretion of TP compared with its metabolites.",Elimination of theophylline metabolites in healthy adults. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9238759/),[μM] / [h],50,181730,DB00277,Theophylline
,9154697,half life time (T1/2),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),,18.9,182142,DB00277,Theophylline
,9154697,half life time (T1/2),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),,13.5,182143,DB00277,Theophylline
,9154697,half life time (T1/2),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),,10.1,182144,DB00277,Theophylline
,9154697,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),h,21.3,182145,DB00277,Theophylline
,9154697,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),,16.7,182146,DB00277,Theophylline
,9154697,mean residence time (MRT),"There were no significant differences as to the zero absorption rate, the moment absorption rate, clearance, but there were significant differences to the half life time (T1/2) of SB (18.9) > TL (13.5) > TD (10.1) (p = 0.0061), mean residence time (MRT) of SB (21.3 hr) > TL (16.7) > TD (15.2) (p = 0.0034), by measurements analysis of variance.","[Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9154697/),h,15.2,182147,DB00277,Theophylline
,12851661,AUC(0-24h),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[h·ng] / [ml],155.2,182433,DB00277,Theophylline
,12851661,AUC(0-infinity),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[h·ng] / [ml],195.3,182434,DB00277,Theophylline
,12851661,resident time,Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,16,182435,DB00277,Theophylline
,12851661,t(1/2),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,10,182436,DB00277,Theophylline
,12851661,C(max),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[ng] / [ml],14.5,182437,DB00277,Theophylline
,12851661,t(max),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,2.6,182438,DB00277,Theophylline
,12851661,plasma clearance,Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[ml] / [kg·min],9.0,182439,DB00277,Theophylline
less,2878729,pro,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.0,182563,DB00277,Theophylline
greater,2878729,PTR,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.5,182564,DB00277,Theophylline
,11794808,fluxes,"The in vitro fluxes of theophylline and salbutamol sulfate from the formulation were 1.22 +/- 0.4 mg/h/cm2 and 13.36 +/- 1.02 microg/h/cm2, respectively.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),[mg] / [cm2·h],1.22,182807,DB00277,Theophylline
,11794808,fluxes,"The in vitro fluxes of theophylline and salbutamol sulfate from the formulation were 1.22 +/- 0.4 mg/h/cm2 and 13.36 +/- 1.02 microg/h/cm2, respectively.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),[μg] / [cm2·h],13.36,182808,DB00277,Theophylline
,11794808,Tmax,"The Tmax of the drugs was 3 h, and appreciable concentrations of the drugs above their MEC could be analyzed even after 12 h.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),h,3,182809,DB00277,Theophylline
,27540211,clearance,The mean clearance was higher in children (0.85 to 2 ml/min/kg) than in neonates (0.24 to 0.6 ml/min/kg).,INTER-INDIVIDUAL VARIATION IN THEOPHYLLINE CLEARANCE IN CHILDREN. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540211/),[ml] / [kg·min],0.85 to 2,183634,DB00277,Theophylline
,27540211,clearance,The mean clearance was higher in children (0.85 to 2 ml/min/kg) than in neonates (0.24 to 0.6 ml/min/kg).,INTER-INDIVIDUAL VARIATION IN THEOPHYLLINE CLEARANCE IN CHILDREN. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540211/),[ml] / [kg·min],0.24 to 0.6,183635,DB00277,Theophylline
,3287354,serum half-life,The serum half-life ranges between 2.9 and 9 hours in a dose-dependent manner.,"Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3287354/),h,2.9 and 9,184730,DB00277,Theophylline
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB00277,Theophylline
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB00277,Theophylline
,2305414,elimination half-life,Theophylline elimination half-life rose from 8.4 to 17.1 h.,Impairment of theophylline clearance by a hypocaloric low-protein diet in chronic obstructive pulmonary disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305414/),h,8.4 to 17.1,185885,DB00277,Theophylline
,6680648,volume distribution,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),[ml] / [kg],573,186099,DB00277,Theophylline
,6680648,clearance rate,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),[ml] / [kg·min],.88,186100,DB00277,Theophylline
,6680648,half-life,"Compared to values reported in the literature for nonpregnant adult nonsmokers, the volume distribution (mean 573 +/- 53 ml/kg) and clearance rate (mean .88 +/- .24 ml/kg/min) of theophylline is increased in pregnant women, but the half-life (mean 7.95 +/- 2 hrs) remains unaltered.",Pharmacokinetics of intravenous theophylline in pregnant patients at term. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6680648/),h,7.95,186101,DB00277,Theophylline
,28215648,apparent PAMPA P,"Assuming that the fractional distribution parameter of 80% of the perfusion rate is a reasonable threshold for perfusion-limited distribution in PBPK, our theoretical prediction indicates that the pharmacokinetics of drugs having an apparent PAMPA P of 1×10-6cm/s or more will follow the traditional perfusion-limited distribution in PBPK for major tissues in the body.",Estimation of the minimum permeability coefficient in rats for perfusion-limited tissue distribution in whole-body physiologically-based pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28215648/),[cm] / [s],1×10-6,186114,DB00277,Theophylline
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],10.9,186571,DB00277,Theophylline
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],7.1,186572,DB00277,Theophylline
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.38,186573,DB00277,Theophylline
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.41,186574,DB00277,Theophylline
,9120768,elimination half-life,"As a consequence, the elimination half-life of theophylline was significantly (P < 0.05) shortened in the tamoxifen-treated rats (3.56 +/- 0.39 h vs 5.25 +/- 0.48 h) as well as its mean residence time (5.04 +/- 0.60 h vs 7.50 +/- 0.75 h).",Effect of tamoxifen on the pharmacokinetics of theophylline in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120768/),h,3.56,186600,DB00277,Theophylline
,9120768,elimination half-life,"As a consequence, the elimination half-life of theophylline was significantly (P < 0.05) shortened in the tamoxifen-treated rats (3.56 +/- 0.39 h vs 5.25 +/- 0.48 h) as well as its mean residence time (5.04 +/- 0.60 h vs 7.50 +/- 0.75 h).",Effect of tamoxifen on the pharmacokinetics of theophylline in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120768/),h,5.25,186601,DB00277,Theophylline
,9120768,mean residence time,"As a consequence, the elimination half-life of theophylline was significantly (P < 0.05) shortened in the tamoxifen-treated rats (3.56 +/- 0.39 h vs 5.25 +/- 0.48 h) as well as its mean residence time (5.04 +/- 0.60 h vs 7.50 +/- 0.75 h).",Effect of tamoxifen on the pharmacokinetics of theophylline in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120768/),h,5.04,186602,DB00277,Theophylline
,9120768,mean residence time,"As a consequence, the elimination half-life of theophylline was significantly (P < 0.05) shortened in the tamoxifen-treated rats (3.56 +/- 0.39 h vs 5.25 +/- 0.48 h) as well as its mean residence time (5.04 +/- 0.60 h vs 7.50 +/- 0.75 h).",Effect of tamoxifen on the pharmacokinetics of theophylline in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120768/),h,7.50,186603,DB00277,Theophylline
,9089427,Cmax,"There was no significant difference between the geometric mean values for Cmax of theophylline, 6.42 micrograms/mL and 6.00 micrograms mL on days 1 and 8, respectively.","Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089427/),[μg] / [ml],6.42,186684,DB00277,Theophylline
,9089427,Cmax,"There was no significant difference between the geometric mean values for Cmax of theophylline, 6.42 micrograms/mL and 6.00 micrograms mL on days 1 and 8, respectively.","Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089427/),ml·μg,6.00,186685,DB00277,Theophylline
,23501441,recoveries,The mean recoveries of doxofylline from DBS and urine were 93.46 and 89.86% respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),%,93.46,186824,DB00277,Theophylline
,23501441,recoveries,The mean recoveries of doxofylline from DBS and urine were 93.46 and 89.86% respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),%,89.86,186825,DB00277,Theophylline
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.24,186826,DB00277,Theophylline
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.84,186827,DB00277,Theophylline
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.28,186828,DB00277,Theophylline
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],1.00,186829,DB00277,Theophylline
,8032575,maximum concentrations,"The intentional differences in pharmacokinetic profiles between the once-daily and twice-daily administration were reflected in the maximum concentrations (15.0 vs 12.1 mg/l), the plateau time T75% Cmax (11.5 vs 17.1 hours), the percent peak-trough fluctuation (94 vs 47%) and the nocturnal excess (37 vs 4%).",Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032575/),[mg] / [l],15.0,187007,DB00277,Theophylline
,8032575,maximum concentrations,"The intentional differences in pharmacokinetic profiles between the once-daily and twice-daily administration were reflected in the maximum concentrations (15.0 vs 12.1 mg/l), the plateau time T75% Cmax (11.5 vs 17.1 hours), the percent peak-trough fluctuation (94 vs 47%) and the nocturnal excess (37 vs 4%).",Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032575/),[mg] / [l],12.1,187008,DB00277,Theophylline
,8032575,plateau time T75% Cmax,"The intentional differences in pharmacokinetic profiles between the once-daily and twice-daily administration were reflected in the maximum concentrations (15.0 vs 12.1 mg/l), the plateau time T75% Cmax (11.5 vs 17.1 hours), the percent peak-trough fluctuation (94 vs 47%) and the nocturnal excess (37 vs 4%).",Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032575/),h,11.5,187009,DB00277,Theophylline
,8032575,plateau time T75% Cmax,"The intentional differences in pharmacokinetic profiles between the once-daily and twice-daily administration were reflected in the maximum concentrations (15.0 vs 12.1 mg/l), the plateau time T75% Cmax (11.5 vs 17.1 hours), the percent peak-trough fluctuation (94 vs 47%) and the nocturnal excess (37 vs 4%).",Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032575/),h,17.1,187010,DB00277,Theophylline
,3429067,time to peak (tmax,"The food caused a slight but not significant (p greater than 0.05, Student's paired t-test) increase in the time to peak (tmax, 9.4 +/- 1.3 h vs. 8.4 +/- 1.7 h, mean +/- SD) and in the area under the curve (AUC0-48, 114.3 +/- 41.7 mg.l-1.h vs. 105.3 +/- 36.5 mg.l-1.h), the relative bioavailability being 108.9 +/- 12.4%, as compared with ingestion of the capsule in fasted state.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),h,9.4,187120,DB00277,Theophylline
,3429067,time to peak (tmax,"The food caused a slight but not significant (p greater than 0.05, Student's paired t-test) increase in the time to peak (tmax, 9.4 +/- 1.3 h vs. 8.4 +/- 1.7 h, mean +/- SD) and in the area under the curve (AUC0-48, 114.3 +/- 41.7 mg.l-1.h vs. 105.3 +/- 36.5 mg.l-1.h), the relative bioavailability being 108.9 +/- 12.4%, as compared with ingestion of the capsule in fasted state.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),h,8.4,187121,DB00277,Theophylline
,3429067,area under the curve (AUC0-48,"The food caused a slight but not significant (p greater than 0.05, Student's paired t-test) increase in the time to peak (tmax, 9.4 +/- 1.3 h vs. 8.4 +/- 1.7 h, mean +/- SD) and in the area under the curve (AUC0-48, 114.3 +/- 41.7 mg.l-1.h vs. 105.3 +/- 36.5 mg.l-1.h), the relative bioavailability being 108.9 +/- 12.4%, as compared with ingestion of the capsule in fasted state.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),[h·mg] / [l],114.3,187122,DB00277,Theophylline
,3429067,area under the curve (AUC0-48,"The food caused a slight but not significant (p greater than 0.05, Student's paired t-test) increase in the time to peak (tmax, 9.4 +/- 1.3 h vs. 8.4 +/- 1.7 h, mean +/- SD) and in the area under the curve (AUC0-48, 114.3 +/- 41.7 mg.l-1.h vs. 105.3 +/- 36.5 mg.l-1.h), the relative bioavailability being 108.9 +/- 12.4%, as compared with ingestion of the capsule in fasted state.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),[h·mg] / [l],105.3,187123,DB00277,Theophylline
,3429067,relative bioavailability,"The food caused a slight but not significant (p greater than 0.05, Student's paired t-test) increase in the time to peak (tmax, 9.4 +/- 1.3 h vs. 8.4 +/- 1.7 h, mean +/- SD) and in the area under the curve (AUC0-48, 114.3 +/- 41.7 mg.l-1.h vs. 105.3 +/- 36.5 mg.l-1.h), the relative bioavailability being 108.9 +/- 12.4%, as compared with ingestion of the capsule in fasted state.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),%,108.9,187124,DB00277,Theophylline
,3429067,cmax,"Maximum theophylline concentrations in plasma were slightly but significantly higher (cmax, 6.50 +/- 1.82 mg.l-1 vs. 5.26 +/- 1.36 mg.l-1, p less than 0.001) after intake with food but this will probably not be of any clinical relevance.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),[mg] / [l],6.50,187125,DB00277,Theophylline
,3429067,cmax,"Maximum theophylline concentrations in plasma were slightly but significantly higher (cmax, 6.50 +/- 1.82 mg.l-1 vs. 5.26 +/- 1.36 mg.l-1, p less than 0.001) after intake with food but this will probably not be of any clinical relevance.",Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane A. P. 400 mg) with and without breakfast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429067/),[mg] / [l],5.26,187126,DB00277,Theophylline
,2892545,apparent Cmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[μg] / [ml],11.1,187483,DB00277,Theophylline
,2892545,apparent Cmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[μg] / [ml],10.0,187484,DB00277,Theophylline
,2892545,Tmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,1.7,187485,DB00277,Theophylline
,2892545,Tmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,1.4,187486,DB00277,Theophylline
,2892545,oral clearance,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[l] / [h·kg],0.0200,187487,DB00277,Theophylline
,2892545,oral clearance,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[l] / [h·kg],0.0564,187488,DB00277,Theophylline
,2892545,elimination half-life,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,16.8,187489,DB00277,Theophylline
,2892545,elimination half-life,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,6.0,187490,DB00277,Theophylline
exceeds,1664830,bioavailability,"Studies in healthy volunteers indicate that the average bioavailability of temafloxacin exceeds 90%, with little intersubject variability.",A review of the pharmacokinetic profile of temafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664830/),%,90,187528,DB00277,Theophylline
,1664830,Steady-state peak serum levels,"Steady-state peak serum levels are approximately 1 mg/L per 100 mg oral dose administered; thus, the steady-state peak serum level after 600 mg bd oral dosing is approximately 6 mg/L.",A review of the pharmacokinetic profile of temafloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664830/),[mg] / [l],1,187529,DB00277,Theophylline
,1664830,steady-state peak serum level,"Steady-state peak serum levels are approximately 1 mg/L per 100 mg oral dose administered; thus, the steady-state peak serum level after 600 mg bd oral dosing is approximately 6 mg/L.",A review of the pharmacokinetic profile of temafloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664830/),[mg] / [l],6,187530,DB00277,Theophylline
,1664830,serum elimination half-life,The long serum elimination half-life (approximately 8 h in patients with normal renal function) allows for single or twice-daily dosing.,A review of the pharmacokinetic profile of temafloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664830/),h,8,187531,DB00277,Theophylline
,1664830,Non-renal clearance,"Non-renal clearance is approximately 60-80 mL per minute and consists of metabolism (5% of dose), biliary secretion of unchanged drug, and presumptive transintestinal elimination.",A review of the pharmacokinetic profile of temafloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664830/),[ml] / [min],60-80,187532,DB00277,Theophylline
,3957498,minimum plasma concentration,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),mg,5.0,188206,DB00277,Theophylline
,3957498,minimum plasma concentration,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),mg,6.0,188207,DB00277,Theophylline
,3957498,maximum plasma concentration,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),mg,9.7,188208,DB00277,Theophylline
,3957498,maximum plasma concentration,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),mg,9.0,188209,DB00277,Theophylline
,3957498,time to peak,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h,3.2,188210,DB00277,Theophylline
,3957498,time to peak,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h,3.9,188211,DB00277,Theophylline
,3957498,AUC,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h·mg,132.54,188212,DB00277,Theophylline
,3957498,AUC,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h·mg,126.90,188213,DB00277,Theophylline
,3957498,half-life of elimination,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h,6.6,188214,DB00277,Theophylline
,3957498,half-life of elimination,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),h,7.1,188215,DB00277,Theophylline
,3957498,clearance,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),[1] / [h·kg],0.059,188216,DB00277,Theophylline
,3957498,clearance,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),[1] / [h·kg],0.063,188217,DB00277,Theophylline
,3957498,volume of distribution,The pharmacokinetic parameters obtained on Day 9 during the two periods of drug treatment accounted for the following figures respectively: minimum plasma concentration 5.0 +/- 1.7 mg X 1(-1) (mean +/- SD) and 6.0 +/- 2.0 mg X 1(-1); maximum plasma concentration 9.7 +/- 2.6 mg X 1(-1) and 9.0 +/- 2.6 mg X 1(-1); time to peak 3.2 +/- 0.4 h and 3.9 +/- 0.8 h; AUC 132.54 +/- 41.73 mg X 1(-1) X h and 126.90 +/- 40.45 mg X 1(-1) X h; half-life of elimination 6.6 +/- 1.6 h and 7.1 +/- 1.2 h; clearance 0.059 +/- 0.011 1 X h-1 X kg-1 and 0.063 +/- 0.014 1 X h-1 X kg-1; volume of distribution 0.54 +/- 0.09 1 X kg-1 and 0.64 +/- 0.17 1 X kg-1.,Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957498/),,0.54,188218,DB00277,Theophylline
,2791445,steady-state theophylline concentration,Mean steady-state theophylline concentration in plasma during the dosing interval increased from 3.17 to 8.23 micrograms/ml.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),[μg] / [ml],3.17,189127,DB00277,Theophylline
,2791445,steady-state theophylline concentration,Mean steady-state theophylline concentration in plasma during the dosing interval increased from 3.17 to 8.23 micrograms/ml.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),[μg] / [ml],8.23,189128,DB00277,Theophylline
,2791445,12-hour,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,76.3,189129,DB00277,Theophylline
,2791445,12-hour,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,38.6,189130,DB00277,Theophylline
,2791445,recovery,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,76.3,189131,DB00277,Theophylline
,2791445,recovery,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,38.6,189132,DB00277,Theophylline
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,76,189383,DB00277,Theophylline
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,71,189384,DB00277,Theophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],15.3,189466,DB00277,Theophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],4.9,189467,DB00277,Theophylline
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],2.5,189468,DB00277,Theophylline
,6512916,half-life,A rapid distributive phase with a half-life of approximately 15-30 min was followed by a slower elimination half-life averaging 15-17 h.,Pharmacokinetics and bioavailability of theophylline in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),min,15-30,189496,DB00277,Theophylline
,6512916,elimination half-life,A rapid distributive phase with a half-life of approximately 15-30 min was followed by a slower elimination half-life averaging 15-17 h.,Pharmacokinetics and bioavailability of theophylline in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),h,15-17,189497,DB00277,Theophylline
,6512916,apparent volume of distribution,The apparent volume of distribution averaged 850-900 ml/kg.,Pharmacokinetics and bioavailability of theophylline in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512916/),[ml] / [kg],850-900,189498,DB00277,Theophylline
,3176107,steady-state serum theophylline concentrations,"These doses produced mean (+/- SE) steady-state serum theophylline concentrations of 6.3 (+/- 0.4), 12.1 (+/- 0.3) and 18.3 (+/- 0.5) mg/L, respectively.",The accuracy and stability of Bayesian theophylline predictions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176107/),[mg] / [l],6.3,189607,DB00277,Theophylline
,3176107,steady-state serum theophylline concentrations,"These doses produced mean (+/- SE) steady-state serum theophylline concentrations of 6.3 (+/- 0.4), 12.1 (+/- 0.3) and 18.3 (+/- 0.5) mg/L, respectively.",The accuracy and stability of Bayesian theophylline predictions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176107/),[mg] / [l],12.1,189608,DB00277,Theophylline
,3176107,steady-state serum theophylline concentrations,"These doses produced mean (+/- SE) steady-state serum theophylline concentrations of 6.3 (+/- 0.4), 12.1 (+/- 0.3) and 18.3 (+/- 0.5) mg/L, respectively.",The accuracy and stability of Bayesian theophylline predictions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176107/),[mg] / [l],18.3,189609,DB00277,Theophylline
,3176107,ME,"The ME (+/- SE) of the revised estimates for the low, medium, and high dosage periods was 0.34 (+/- 0.30), -0.02 (+/- 0.22) and -0.48 (+/- 0.31) mg/L, respectively.",The accuracy and stability of Bayesian theophylline predictions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176107/),[mg] / [l],0.34,189610,DB00277,Theophylline
,3176107,ME,"The ME (+/- SE) of the revised estimates for the low, medium, and high dosage periods was 0.34 (+/- 0.30), -0.02 (+/- 0.22) and -0.48 (+/- 0.31) mg/L, respectively.",The accuracy and stability of Bayesian theophylline predictions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176107/),[mg] / [l],0.02,189611,DB00277,Theophylline
,6739311,terminal half-life,"Limited pharmacokinetic data suggest a long distribution phase, a terminal half-life of 3-8 hours, and 10-20% oral bioavailability.","Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739311/),h,3-8,189827,DB00277,Theophylline
,6739311,oral bioavailability,"Limited pharmacokinetic data suggest a long distribution phase, a terminal half-life of 3-8 hours, and 10-20% oral bioavailability.","Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739311/),%,10-20,189828,DB00277,Theophylline
,2622858,total plasma theophylline clearance,The total plasma theophylline clearance in dogs following an i.v. dose was 0.128 liter/hr/kg and the volume of distribution was 0.8 liter/kg using a one-compartment model.,The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),[l] / [h·kg],0.128,190453,DB00277,Theophylline
,2622858,volume of distribution,The total plasma theophylline clearance in dogs following an i.v. dose was 0.128 liter/hr/kg and the volume of distribution was 0.8 liter/kg using a one-compartment model.,The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),[l] / [kg],0.8,190454,DB00277,Theophylline
,2622858,absolute bioavailabilities,"The absolute bioavailabilities of these two products under fasting conditions were 31 and 48%, respectively.",The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),%,31,190455,DB00277,Theophylline
,2622858,absolute bioavailabilities,"The absolute bioavailabilities of these two products under fasting conditions were 31 and 48%, respectively.",The beagle dog as an animal model for a bioavailability study of controlled-release theophylline under the influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2622858/),%,48,190456,DB00277,Theophylline
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,27,190508,DB00277,Theophylline
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,15,190509,DB00277,Theophylline
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],1.73,190591,DB00277,Theophylline
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],0.94,190592,DB00277,Theophylline
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],76.19,190593,DB00277,Theophylline
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],52.66,190594,DB00277,Theophylline
,7649598,Tmax,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,5.60,190595,DB00277,Theophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,16.80,190596,DB00277,Theophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,44.88,190597,DB00277,Theophylline
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,125.07,190598,DB00277,Theophylline
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],2.19,190599,DB00277,Theophylline
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],3.85,190600,DB00277,Theophylline
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],34.07,190601,DB00277,Theophylline
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],25.26,190602,DB00277,Theophylline
,27995649,Total,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.50,190647,DB00277,Theophylline
,27995649,renal,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.16,190648,DB00277,Theophylline
,27995649,nonrenal clearances,"Total, renal and nonrenal clearances of theophylline were 0.50 ± 0.29 ml kg-1 min-1 , 0.16 ± 0.06 ml kg-1 min-1 and 0.34 ± 0.28 ml kg-1 min-1 , respectively.",Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995649/),[ml] / [kg·min],0.34,190649,DB00277,Theophylline
,499310,serum half life (t 1/2 beta),"Its disposition could be described by a two-compartment open model, the mean serum half life (t 1/2 beta) was 3.75 h, i.e., shorter than in adults, but there was a considerable interindividual variation (1.8-7.0 h, in one patient 13.3 h).",Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),h,3.75,190733,DB00277,Theophylline
,499310,serum half life (t 1/2 beta),"Its disposition could be described by a two-compartment open model, the mean serum half life (t 1/2 beta) was 3.75 h, i.e., shorter than in adults, but there was a considerable interindividual variation (1.8-7.0 h, in one patient 13.3 h).",Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),h,13.3,190734,DB00277,Theophylline
,499310,half-time,"Absorption was slow (mean half-time 43 min), incomplete and variable (biological availability 8-100%, mean 80%).",Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),min,43,190735,DB00277,Theophylline
,499310,biological availability,"Absorption was slow (mean half-time 43 min), incomplete and variable (biological availability 8-100%, mean 80%).",Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),%,8-100,190736,DB00277,Theophylline
,499310,biological availability,"Absorption was slow (mean half-time 43 min), incomplete and variable (biological availability 8-100%, mean 80%).",Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),%,80,190737,DB00277,Theophylline
,499310,half-time,Absorbtion was rapid (mean half-time 5.5 min) and biological availability averaged 100%.,Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),min,5.5,190738,DB00277,Theophylline
,499310,biological availability,Absorbtion was rapid (mean half-time 5.5 min) and biological availability averaged 100%.,Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499310/),%,100,190739,DB00277,Theophylline
,77421,half-life,In this group the plasma-theophylline half-life (mean = 419.8 min) was significantly longer during the acute stage of their illness than 1 month later (mean 249.9 min).,Altered theophylline pharmacokinetics during acute respiratory viral illness. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/77421/),min,419.8,190768,DB00277,Theophylline
,77421,half-life,In this group the plasma-theophylline half-life (mean = 419.8 min) was significantly longer during the acute stage of their illness than 1 month later (mean 249.9 min).,Altered theophylline pharmacokinetics during acute respiratory viral illness. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/77421/),min,249.9,190769,DB00277,Theophylline
,30779257,systemic availabilities,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),%,7.8,190950,DB00277,Theophylline
,30779257,systemic availabilities,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),%,22.0,190951,DB00277,Theophylline
,30779257,maximum concentrations,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),[ng] / [ml],36,190952,DB00277,Theophylline
,30779257,maximum concentrations,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),[ng] / [ml],124,190953,DB00277,Theophylline
,30779257,terminal elimination half-lives,"The terminal elimination half-lives of diphenhydramine and dimenhydrinate were 5.0 (± 7.1) and 11.6 (± 17.7) h, respectively.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),h,5.0,190954,DB00277,Theophylline
,30779257,terminal elimination half-lives,"The terminal elimination half-lives of diphenhydramine and dimenhydrinate were 5.0 (± 7.1) and 11.6 (± 17.7) h, respectively.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),h,11.6,190955,DB00277,Theophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,6.3,190993,DB00277,Theophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,5.3,190994,DB00277,Theophylline
,6480875,t 1/2,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,4.9,190995,DB00277,Theophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],88.9,190996,DB00277,Theophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],75.4,190997,DB00277,Theophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),h,4.9,190998,DB00277,Theophylline
,6480875,AUC,"Theophylline t 1/2 and AUC with each regimen were respectively 6.3 +/- 0.5 (S.E.) hours and 88.9 +/- 8.4 mg/liter X hr with 5 Gm standard activated charcoal, 5.3 +/- 0.3 hours and 75.4 +/- 4.9 mg/liter X hr with 5 Gm PX-21, and 4.9 +/- 0.2 hours and 67.7 +/- 3.6 mg/liter X hr with 20 Gm standard activated charcoal.",Effect of the surface area of activated charcoal on theophylline clearance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480875/),[mg] / [h·l],67.7,190999,DB00277,Theophylline
,7137520,half-life,The half-life for intravenous theophylline in these asthmatics was 7.4 +/- 0.64.,Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7137520/),,7.4,191110,DB00277,Theophylline
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191767,DB00277,Theophylline
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191768,DB00277,Theophylline
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191769,DB00277,Theophylline
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191770,DB00277,Theophylline
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,402,191771,DB00277,Theophylline
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,409,191772,DB00277,Theophylline
,3908122,Clearance,Clearance values were 0.73 ml/min/kg below age 38 years and 0.75 ml/min/kg at and above age 38 years.,The relationship between clearance of theophylline and age within the adult age range. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3908122/),[ml] / [kg·min],0.73,191835,DB00277,Theophylline
,3908122,Clearance,Clearance values were 0.73 ml/min/kg below age 38 years and 0.75 ml/min/kg at and above age 38 years.,The relationship between clearance of theophylline and age within the adult age range. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3908122/),[ml] / [kg·min],0.75,191836,DB00277,Theophylline
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,94.5,191903,DB00277,Theophylline
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93,191904,DB00277,Theophylline
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93.7,191905,DB00277,Theophylline
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,95.1,191906,DB00277,Theophylline
,8085281,steady-state,"Mean +/- SD projected steady-state theophylline serum concentrations, Css, were 17.7 +/- 7.6 micrograms/ml with the PNA equation (n = 40) and 5.6 +/- 2.9 micrograms/ml with the FDA guidelines (n = 52).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],17.7,191923,DB00277,Theophylline
,8085281,steady-state,"Mean +/- SD projected steady-state theophylline serum concentrations, Css, were 17.7 +/- 7.6 micrograms/ml with the PNA equation (n = 40) and 5.6 +/- 2.9 micrograms/ml with the FDA guidelines (n = 52).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],5.6,191924,DB00277,Theophylline
,8085281,"serum concentrations, Css","Mean +/- SD projected steady-state theophylline serum concentrations, Css, were 17.7 +/- 7.6 micrograms/ml with the PNA equation (n = 40) and 5.6 +/- 2.9 micrograms/ml with the FDA guidelines (n = 52).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],17.7,191925,DB00277,Theophylline
,8085281,"serum concentrations, Css","Mean +/- SD projected steady-state theophylline serum concentrations, Css, were 17.7 +/- 7.6 micrograms/ml with the PNA equation (n = 40) and 5.6 +/- 2.9 micrograms/ml with the FDA guidelines (n = 52).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],5.6,191926,DB00277,Theophylline
>,8085281,Css,Over one-third of Css with the PNA equation were > 20 micrograms/ml.,Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],20,191927,DB00277,Theophylline
<,8085281,Css,"Using the FDA guidelines, 40% of Css were < 5 micrograms/ml.",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],5,191928,DB00277,Theophylline
>,8085281,Css,"The majority of infants < 40 weeks PCA attained projected Css > 20 micrograms/ml (21.7 +/- 5.1 micrograms/ml) with the PNA equation, but < 5 micrograms/ml (4.3 +/- 1.4 micrograms/ml) with FDA guidelines.",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],20,191929,DB00277,Theophylline
,8085281,Css,"The majority of infants < 40 weeks PCA attained projected Css > 20 micrograms/ml (21.7 +/- 5.1 micrograms/ml) with the PNA equation, but < 5 micrograms/ml (4.3 +/- 1.4 micrograms/ml) with FDA guidelines.",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],21.7,191930,DB00277,Theophylline
<,8085281,Css,"The majority of infants < 40 weeks PCA attained projected Css > 20 micrograms/ml (21.7 +/- 5.1 micrograms/ml) with the PNA equation, but < 5 micrograms/ml (4.3 +/- 1.4 micrograms/ml) with FDA guidelines.",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],5,191931,DB00277,Theophylline
,8085281,Css,"The majority of infants < 40 weeks PCA attained projected Css > 20 micrograms/ml (21.7 +/- 5.1 micrograms/ml) with the PNA equation, but < 5 micrograms/ml (4.3 +/- 1.4 micrograms/ml) with FDA guidelines.",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],4.3,191932,DB00277,Theophylline
,8085281,Css,"For the PNA equation, projected Css were significantly higher in infants < 40 weeks versus > or = 40 weeks PCA (21.7 +/- 5.1 versus 15.8 +/- 7.9 micrograms/ml, p < 0.01).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],21.7,191933,DB00277,Theophylline
,8085281,Css,"For the PNA equation, projected Css were significantly higher in infants < 40 weeks versus > or = 40 weeks PCA (21.7 +/- 5.1 versus 15.8 +/- 7.9 micrograms/ml, p < 0.01).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],15.8,191934,DB00277,Theophylline
,8085281,Css,"For FDA guidelines, projected Css were significantly lower in infants < 40 weeks PCA versus older infants (4.3 +/- 1.4 versus 8.5 +/- 4.3 micrograms/ml, p < 0.001).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],4.3,191935,DB00277,Theophylline
,8085281,Css,"For FDA guidelines, projected Css were significantly lower in infants < 40 weeks PCA versus older infants (4.3 +/- 1.4 versus 8.5 +/- 4.3 micrograms/ml, p < 0.001).",Pharmacokinetic evaluation of two theophylline dosing methods for infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085281/),[μg] / [ml],8.5,191936,DB00277,Theophylline
,8535404,mean residence times (MRTs),"The mean residence times (MRTs) of theophylline powder, Tab S and Tab L were 11.1 +/- 1.5, 25.4 +/- 6.3 and 17.1 +/- 1.5 h (N = 4-5, mean +/- S.D.), respectively.",Application of curdlan to controlled drug delivery. In vitro and in vivo drug release studies of theophylline-containing curdlan tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535404/),h,11.1,191976,DB00277,Theophylline
,8535404,mean residence times (MRTs),"The mean residence times (MRTs) of theophylline powder, Tab S and Tab L were 11.1 +/- 1.5, 25.4 +/- 6.3 and 17.1 +/- 1.5 h (N = 4-5, mean +/- S.D.), respectively.",Application of curdlan to controlled drug delivery. In vitro and in vivo drug release studies of theophylline-containing curdlan tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535404/),h,25.4,191977,DB00277,Theophylline
,8535404,mean residence times (MRTs),"The mean residence times (MRTs) of theophylline powder, Tab S and Tab L were 11.1 +/- 1.5, 25.4 +/- 6.3 and 17.1 +/- 1.5 h (N = 4-5, mean +/- S.D.), respectively.",Application of curdlan to controlled drug delivery. In vitro and in vivo drug release studies of theophylline-containing curdlan tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535404/),h,17.1,191978,DB00277,Theophylline
,21476905,clearance,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [h·kg],0.08,192013,DB00277,Theophylline
,21476905,volume of distribution,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [kg],0.91,192014,DB00277,Theophylline
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.24,192015,DB00277,Theophylline
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.37,192016,DB00277,Theophylline
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.39,192017,DB00277,Theophylline
,22541837,Cmax,"For Regimens A and B, mean theophylline Cmax values were 4.4 and 4.1 μg/ml, respectively, and mean theophylline AUC0-tlqc was 122.3 and 115.2 μg x h/ml, respectively.",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),[μg] / [ml],4.4,192143,DB00277,Theophylline
,22541837,Cmax,"For Regimens A and B, mean theophylline Cmax values were 4.4 and 4.1 μg/ml, respectively, and mean theophylline AUC0-tlqc was 122.3 and 115.2 μg x h/ml, respectively.",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),[μg] / [ml],4.1,192144,DB00277,Theophylline
,22541837,AUC0-tlqc,"For Regimens A and B, mean theophylline Cmax values were 4.4 and 4.1 μg/ml, respectively, and mean theophylline AUC0-tlqc was 122.3 and 115.2 μg x h/ml, respectively.",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),[h·μg] / [ml],122.3,192145,DB00277,Theophylline
,22541837,AUC0-tlqc,"For Regimens A and B, mean theophylline Cmax values were 4.4 and 4.1 μg/ml, respectively, and mean theophylline AUC0-tlqc was 122.3 and 115.2 μg x h/ml, respectively.",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),[h·μg] / [ml],115.2,192146,DB00277,Theophylline
,22541837,excreted amounts,"Mean excreted amounts in urine for 1-methylxanthine levels were higher in Regimen A vs. B (40.1 vs. 0.1 mg), while 1-methyluric acid levels were lower (3.1 vs. 56.2 mg).",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),mg,40.1,192147,DB00277,Theophylline
,22541837,excreted amounts,"Mean excreted amounts in urine for 1-methylxanthine levels were higher in Regimen A vs. B (40.1 vs. 0.1 mg), while 1-methyluric acid levels were lower (3.1 vs. 56.2 mg).",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),mg,0.1,192148,DB00277,Theophylline
,22541837,excreted amounts,"Mean excreted amounts in urine for 1-methylxanthine levels were higher in Regimen A vs. B (40.1 vs. 0.1 mg), while 1-methyluric acid levels were lower (3.1 vs. 56.2 mg).",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),mg,3.1,192149,DB00277,Theophylline
,22541837,excreted amounts,"Mean excreted amounts in urine for 1-methylxanthine levels were higher in Regimen A vs. B (40.1 vs. 0.1 mg), while 1-methyluric acid levels were lower (3.1 vs. 56.2 mg).",The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541837/),mg,56.2,192150,DB00277,Theophylline
,10065352,clearances,"In vitro drug release data were used to simulate plasma concentration-time (C,t) profiles based on a wide range of previously reported patient pharmacokinetic parameters (clearances of 2-5 L/hr and apparent volumes of distribution of 20-50 L).",Controlled-release hydrophilic tablets for individualized theophylline therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10065352/),[l] / [h],2-5,192271,DB00277,Theophylline
,10065352,apparent volumes of distribution,"In vitro drug release data were used to simulate plasma concentration-time (C,t) profiles based on a wide range of previously reported patient pharmacokinetic parameters (clearances of 2-5 L/hr and apparent volumes of distribution of 20-50 L).",Controlled-release hydrophilic tablets for individualized theophylline therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10065352/),l,20-50,192272,DB00277,Theophylline
,10065352,steady-state concentrations,Average steady-state concentrations were well within the therapeutic range of 10-20 micrograms/ml.,Controlled-release hydrophilic tablets for individualized theophylline therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10065352/),[μg] / [ml],10-20,192273,DB00277,Theophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],12.0,192614,DB00277,Theophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],22.5,192615,DB00277,Theophylline
,7060318,Renal clearance,"Renal clearance values of 3-MX, 1-MU, and 13-MU were 12.0 +/- 1.3 l/hr, 22.5 +/-1.5 l/hr, and 22.6 +/- 1.6 l/hr.",Nonlinear theophylline elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[l] / [h],22.6,192616,DB00277,Theophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],5,192617,DB00277,Theophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],13,192618,DB00277,Theophylline
,7060318,maximal rate of formation of metabolite (Vmax),"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [h],34,192619,DB00277,Theophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],2.7,192620,DB00277,Theophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],9.3,192621,DB00277,Theophylline
,7060318,apparent concentration,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],14.2,192622,DB00277,Theophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],2.7,192623,DB00277,Theophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],9.3,192624,DB00277,Theophylline
,7060318,Vmax,"1-MU, and 13-MU, the approximate mean maximal rate of formation of metabolite (Vmax) values were 5 mg/hr, 13 mg/hr, and 34 mg/hr and the apparent concentration of theophylline at which metabolite formation rate is half of Vmax values were 2.7 mg/l, 9.3 mg/l, and 14.2 mg/l.",Nonlinear theophylline elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060318/),[mg] / [l],14.2,192625,DB00277,Theophylline
,32725383,Vss ratio,"Changes in exposure (area under the curve) up to 5.1-fold were observed; however, ratios of Vss changes have a range of 0.70-1.26, with one outlier displaying a Vss ratio of 0.57.",Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725383/),,0.57,192758,DB00277,Theophylline
,19067397,relative bioavailability,Rats in vivo pharmacokinetics demonstrated that the relative bioavailability of theophylline after intragastric administration of CS capsules was 76.72% with delayed T(max) of 8 h comparing to that of theophylline solution with T(max) of 1.5 h.,In vitro and in vivo evaluation of a novel capsule for colon-specific drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19067397/),%,76.72,193009,DB00277,Theophylline
,19067397,T(max),Rats in vivo pharmacokinetics demonstrated that the relative bioavailability of theophylline after intragastric administration of CS capsules was 76.72% with delayed T(max) of 8 h comparing to that of theophylline solution with T(max) of 1.5 h.,In vitro and in vivo evaluation of a novel capsule for colon-specific drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19067397/),h,8,193010,DB00277,Theophylline
,19067397,T(max),Rats in vivo pharmacokinetics demonstrated that the relative bioavailability of theophylline after intragastric administration of CS capsules was 76.72% with delayed T(max) of 8 h comparing to that of theophylline solution with T(max) of 1.5 h.,In vitro and in vivo evaluation of a novel capsule for colon-specific drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19067397/),h,1.5,193011,DB00277,Theophylline
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,2,193226,DB00277,Theophylline
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,4,193227,DB00277,Theophylline
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,6,193228,DB00277,Theophylline
,6641096,Plasma t 1/2,Plasma t 1/2 varied among individuals from 1.2 to 1.9 hr.,Enprofylline kinetics in healthy subjects after single doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),h,1.2 to 1.9,193762,DB00277,Theophylline
,6641096,Volume of distribution (V beta,Volume of distribution (V beta or area) and volume of distribution at steady state (V ss) averaged 0.57 and 0.511 X kg-1.,Enprofylline kinetics in healthy subjects after single doses. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),1/[kg],0.57,193763,DB00277,Theophylline
,6641096,area),Volume of distribution (V beta or area) and volume of distribution at steady state (V ss) averaged 0.57 and 0.511 X kg-1.,Enprofylline kinetics in healthy subjects after single doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),1/[kg],0.57,193764,DB00277,Theophylline
,6641096,volume of distribution at steady state (V ss),Volume of distribution (V beta or area) and volume of distribution at steady state (V ss) averaged 0.57 and 0.511 X kg-1.,Enprofylline kinetics in healthy subjects after single doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),1/[kg],0.511,193765,DB00277,Theophylline
,6641096,Total clearance,Total clearance averaged 0.25 l X hr-1 X kg-1.,Enprofylline kinetics in healthy subjects after single doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),[l] / [h·kg],0.25,193766,DB00277,Theophylline
,6641096,Renal clearance,"Renal clearance ranged from 200 to 400 ml X min-1, indicating a large contribution by active tubular secretion.",Enprofylline kinetics in healthy subjects after single doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),[ml] / [min],200 to 400,193767,DB00277,Theophylline
,6641096,recovery of unchanged drug,The mean recovery of unchanged drug in the urine was 89%.,Enprofylline kinetics in healthy subjects after single doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641096/),%,89,193768,DB00277,Theophylline
,7882634,elimination half-life,Its elimination half-life ranges from 6.2 to 12.4 hours.,Pefloxacin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7882634/),h,6.2 to 12.4,193898,DB00277,Theophylline
,7023306,apparent volume of distribution,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194021,DB00277,Theophylline
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194022,DB00277,Theophylline
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.053,194023,DB00277,Theophylline
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],48,194338,DB00277,Theophylline
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],59,194339,DB00277,Theophylline
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,28,194340,DB00277,Theophylline
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,22,194341,DB00277,Theophylline
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1722,194342,DB00277,Theophylline
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1405,194343,DB00277,Theophylline
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,52,194344,DB00277,Theophylline
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,40,194345,DB00277,Theophylline
,2751433,maximum concentration (Cmax),"In the single dose study, the mean maximum concentration (Cmax) and the time taken to reach maximum concentration (Tmax) in serum were 5.5 micrograms/ml and 7.3 hours, and the same parameters in saliva were 3.8 micrograms/ml and 7.3 hours.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],5.5,194501,DB00277,Theophylline
,2751433,maximum concentration (Cmax),"In the single dose study, the mean maximum concentration (Cmax) and the time taken to reach maximum concentration (Tmax) in serum were 5.5 micrograms/ml and 7.3 hours, and the same parameters in saliva were 3.8 micrograms/ml and 7.3 hours.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],3.8,194502,DB00277,Theophylline
,2751433,time taken to reach maximum concentration (Tmax),"In the single dose study, the mean maximum concentration (Cmax) and the time taken to reach maximum concentration (Tmax) in serum were 5.5 micrograms/ml and 7.3 hours, and the same parameters in saliva were 3.8 micrograms/ml and 7.3 hours.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),h,7.3,194503,DB00277,Theophylline
,2751433,Cmax,"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],13.2,194504,DB00277,Theophylline
,2751433,minimum concentration (Cmin),"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],9.9,194505,DB00277,Theophylline
,2751433,minimum concentration (Cmin),"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],3.4,194506,DB00277,Theophylline
,2751433,peak-trough fluctuation (delta P-T),"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],9.9,194507,DB00277,Theophylline
,2751433,peak-trough fluctuation (delta P-T),"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],3.3,194508,DB00277,Theophylline
,2751433,peak-trough fluctuation (delta P-T),"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),[μg] / [ml],3.4,194509,DB00277,Theophylline
,2751433,Tmax,"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),h,5.4,194510,DB00277,Theophylline
,2751433,Tmax,"In the multiple dose study which lasted five days, Cmax, the mean minimum concentration (Cmin), the peak-trough fluctuation (delta P-T) and Tmax in plasma were 13.2 micrograms/ml, 9.9 micrograms/ml, 3.3 micrograms/ml and 5.4 hours, and those in saliva were 10.4 micrograms/ml, 7.0 micrograms/ml, 3.4 micrograms/ml and 5.0 hours, respectively.","[Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751433/),h,5.0,194511,DB00277,Theophylline
,8809648,steady-state concentrations,"This information was used to estimate an a priori dosing regimen that would permit steady-state concentrations of 5-15 mg/litre, now recommended for the treatment of chronic asthma, and to evaluate the need to establish monitoring strategies when theophylline is given at these lower doses and when it can be expected that almost no adverse effects are likely.",Application of population pharmacokinetics to the optimization of theophylline therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809648/),[mg] / [l],5-15,194810,DB00277,Theophylline
,3781672,half-life,"In the intravenous administration of theophylline (5 mg/kg) to dogs, the theophylline half-life was 4.0 +/- 0.2 h.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),h,4.0,195050,DB00277,Theophylline
,3781672,apparent volume of distribution (Vd),"The apparent volume of distribution (Vd) and plasma theophylline clearance (CL) were 0.734 +/- 0.019 l/kg and 126.7 +/- 3.4 ml/kg/h, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[l] / [kg],0.734,195051,DB00277,Theophylline
,3781672,clearance (CL),"The apparent volume of distribution (Vd) and plasma theophylline clearance (CL) were 0.734 +/- 0.019 l/kg and 126.7 +/- 3.4 ml/kg/h, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[ml] / [h·kg],126.7,195052,DB00277,Theophylline
,3781672,Vd,"In the multiple oral doses of the drug in amounts ranging from 7.52 to 9.09 mg/kg, the Vd and CL were 0.765 +/- 0.021 l/kg and 111.0 +/- 2.4 ml/kg/h, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[l] / [kg],0.765,195053,DB00277,Theophylline
,3781672,CL,"In the multiple oral doses of the drug in amounts ranging from 7.52 to 9.09 mg/kg, the Vd and CL were 0.765 +/- 0.021 l/kg and 111.0 +/- 2.4 ml/kg/h, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[ml] / [h·kg],111.0,195054,DB00277,Theophylline
,3781672,oral absorption rate constant (ka),The mean oral absorption rate constant (ka) was calculated to be 0.355 +/- 0.035 h-1 and the mean elimination rate constant (kel) was 0.146 +/- 0.007 h-1.,Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),1/[h],0.355,195055,DB00277,Theophylline
,3781672,elimination rate constant (kel),The mean oral absorption rate constant (ka) was calculated to be 0.355 +/- 0.035 h-1 and the mean elimination rate constant (kel) was 0.146 +/- 0.007 h-1.,Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),1/[h],0.146,195056,DB00277,Theophylline
,3781672,absolute bioavailability,The absolute bioavailability of the drug calculated by a computer fitting method was 1.08 +/- 0.07.,Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),,1.08,195057,DB00277,Theophylline
,3781672,Vd,"On the other hand, the pharmacokinetic parameters in the asthmatic patients were 0.337 +/- 0.055 l/kg for the Vd, 32.55 +/- 3.48 ml/kg/h for the CL, 0.222 +/- 0.058 h-1 for the ka and 0.105 +/- 0.016 h-1 for the kel, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[l] / [kg],0.337,195058,DB00277,Theophylline
,3781672,CL,"On the other hand, the pharmacokinetic parameters in the asthmatic patients were 0.337 +/- 0.055 l/kg for the Vd, 32.55 +/- 3.48 ml/kg/h for the CL, 0.222 +/- 0.058 h-1 for the ka and 0.105 +/- 0.016 h-1 for the kel, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),[ml] / [h·kg],32.55,195059,DB00277,Theophylline
,3781672,ka,"On the other hand, the pharmacokinetic parameters in the asthmatic patients were 0.337 +/- 0.055 l/kg for the Vd, 32.55 +/- 3.48 ml/kg/h for the CL, 0.222 +/- 0.058 h-1 for the ka and 0.105 +/- 0.016 h-1 for the kel, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),1/[h],0.222,195060,DB00277,Theophylline
,3781672,kel,"On the other hand, the pharmacokinetic parameters in the asthmatic patients were 0.337 +/- 0.055 l/kg for the Vd, 32.55 +/- 3.48 ml/kg/h for the CL, 0.222 +/- 0.058 h-1 for the ka and 0.105 +/- 0.016 h-1 for the kel, respectively.",Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3781672/),1/[h],0.105,195061,DB00277,Theophylline
,2013216,half-life,"The half-life is relatively long for this class of drugs, being approximately 2-3 hr.",The pharmacokinetics of ceftibuten in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013216/),h,2-3,195115,DB00277,Theophylline
,2013216,Apparent plasma clearance (CL/F),"Apparent plasma clearance (CL/F), is approximately 40-75 ml/min, and the renal clearance is approximately 30-50 ml/min, corresponding to the fraction excreted unchanged in the urine of approximately 60%-70% of the dose.",The pharmacokinetics of ceftibuten in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013216/),[ml] / [min],40-75,195116,DB00277,Theophylline
,2013216,renal clearance,"Apparent plasma clearance (CL/F), is approximately 40-75 ml/min, and the renal clearance is approximately 30-50 ml/min, corresponding to the fraction excreted unchanged in the urine of approximately 60%-70% of the dose.",The pharmacokinetics of ceftibuten in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013216/),[ml] / [min],30-50,195117,DB00277,Theophylline
,2013216,apparent volume of distribution after oral dosing (Vd/F),The apparent volume of distribution after oral dosing (Vd/F) was approximately 0.2 L/kg.,The pharmacokinetics of ceftibuten in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013216/),[l] / [kg],0.2,195118,DB00277,Theophylline
,7859239,relative extents of absorption,"The mean relative extents of absorption for the four Uni-Dur treatments were not significantly different from Slo-Phyllin treatment or from each other (84.30 +/- 23.6%, 600 mg, fasting; 88.73 +/- 18.63%, 600 mg, fed; 93.65 +/- 19.67%, half tablet; and 92.87 +/- 19.5%, 400 mg, fasting).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),%,84.30,195497,DB00277,Theophylline
,7859239,relative extents of absorption,"The mean relative extents of absorption for the four Uni-Dur treatments were not significantly different from Slo-Phyllin treatment or from each other (84.30 +/- 23.6%, 600 mg, fasting; 88.73 +/- 18.63%, 600 mg, fed; 93.65 +/- 19.67%, half tablet; and 92.87 +/- 19.5%, 400 mg, fasting).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),%,88.73,195498,DB00277,Theophylline
,7859239,relative extents of absorption,"The mean relative extents of absorption for the four Uni-Dur treatments were not significantly different from Slo-Phyllin treatment or from each other (84.30 +/- 23.6%, 600 mg, fasting; 88.73 +/- 18.63%, 600 mg, fed; 93.65 +/- 19.67%, half tablet; and 92.87 +/- 19.5%, 400 mg, fasting).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),%,93.65,195499,DB00277,Theophylline
,7859239,relative extents of absorption,"The mean relative extents of absorption for the four Uni-Dur treatments were not significantly different from Slo-Phyllin treatment or from each other (84.30 +/- 23.6%, 600 mg, fasting; 88.73 +/- 18.63%, 600 mg, fed; 93.65 +/- 19.67%, half tablet; and 92.87 +/- 19.5%, 400 mg, fasting).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),%,92.87,195500,DB00277,Theophylline
,7859239,time to peak,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,17.09,195501,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,11.73,195502,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),%,80,195503,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,18.46,195504,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,13.57,195505,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,8.57,195506,DB00277,Theophylline
,7859239,times to 50%,"Differences noted among the four Uni-Dur treatments were as follows: the time to peak theophylline concentration was significantly longer in the fed state (17.09 hours) as were the times to 50% (11.73 hours) and 80% (18.46 hours) absorption compared with fasting (13.57 hours, 8.57 hours, and 14.07 hours, respectively).",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),h,14.07,195507,DB00277,Theophylline
,7859239,maximum theophylline serum concentration,"The Uni-Dur 400-mg treatment resulted in a significantly higher maximum theophylline serum concentration (6.64 mu g/mL) compared with the Uni-Dur 600-mg fasting treatment (5.33 mu g/mL); however, the correlation between in vivo and in vitro data supports the bioequivalence of the two strengths.",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),[g·mu] / [ml],6.64,195508,DB00277,Theophylline
,7859239,maximum theophylline serum concentration,"The Uni-Dur 400-mg treatment resulted in a significantly higher maximum theophylline serum concentration (6.64 mu g/mL) compared with the Uni-Dur 600-mg fasting treatment (5.33 mu g/mL); however, the correlation between in vivo and in vitro data supports the bioequivalence of the two strengths.",Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859239/),[g·mu] / [ml],5.33,195509,DB00277,Theophylline
,7848337,Tmax,Tmax of the test preparation is 6 h; tmax of the reference is 5 h.,[Pharmacokinetics of two theophylline sustained-release preparations in healthy humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848337/),h,6,195542,DB00277,Theophylline
,7848337,tmax,Tmax of the test preparation is 6 h; tmax of the reference is 5 h.,[Pharmacokinetics of two theophylline sustained-release preparations in healthy humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848337/),h,5,195543,DB00277,Theophylline
,7197962,relative bioavailability,The relative bioavailability of the new formulation is about 100%.,[Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197962/),%,100,196205,DB00277,Theophylline
,6500770,maximum concentration,"The maximum concentration was found after 5.2 +/- 0.6 h (mean +/- S.D.) and 5.3 +/- 2.2 h and measured 2.00 +/- 0.28 mg.1-1 and 2.46 +/- 0.60 mg.1-1, respectively.","The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),mg,2.00,196567,DB00277,Theophylline
,6500770,maximum concentration,"The maximum concentration was found after 5.2 +/- 0.6 h (mean +/- S.D.) and 5.3 +/- 2.2 h and measured 2.00 +/- 0.28 mg.1-1 and 2.46 +/- 0.60 mg.1-1, respectively.","The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),mg,2.46,196568,DB00277,Theophylline
,6500770,absolute bioavailability,The absolute bioavailability of the whole tablets was 91.8 +/- 24.7% and that of the broken tablets was 95.8 +/- 9.7%.,"The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),%,91.8,196569,DB00277,Theophylline
,6500770,absolute bioavailability,The absolute bioavailability of the whole tablets was 91.8 +/- 24.7% and that of the broken tablets was 95.8 +/- 9.7%.,"The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500770/),%,95.8,196570,DB00277,Theophylline
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB00277,Theophylline
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB00277,Theophylline
,18611635,serum half-life,Its long serum half-life (8-12 h) allows once-a-day dosing.,Implications of fleroxacin's pharmacokinetic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611635/),h,8-12,196724,DB00277,Theophylline
,3612497,clearances,Caffeine clearances of 1.52-6.71 ml/min/kg were observed and were suggestive of polymorphism with rapid (type I) and slow (type II) metabolizing subpopulations represented.,Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612497/),[ml] / [kg·min],1.52-6.71,196896,DB00277,Theophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],18.8,197526,DB00277,Theophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],53.7,197527,DB00277,Theophylline
,648214,body clearance,"The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively.",Pharmacokinetics of theophylline in hepatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),[ml] / [h·kg],63.0,197528,DB00277,Theophylline
,648214,half-life,The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28.8 +/- 14.3 hours compared to 6.0 +/- 2.1 hours in normal subjects.,Pharmacokinetics of theophylline in hepatic disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),h,28.8,197529,DB00277,Theophylline
,648214,half-life,The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28.8 +/- 14.3 hours compared to 6.0 +/- 2.1 hours in normal subjects.,Pharmacokinetics of theophylline in hepatic disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648214/),h,6.0,197530,DB00277,Theophylline
,7194656,half-life of serum elimination,The half-life of serum elimination was 5.0-7.2 h for theophylline and 5.5-6.9 h for etofylline.,[Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194656/),h,5.0-7.2,198157,DB00277,Theophylline
,7194656,half-life of serum elimination,The half-life of serum elimination was 5.0-7.2 h for theophylline and 5.5-6.9 h for etofylline.,[Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194656/),h,5.5-6.9,198158,DB00277,Theophylline
,7194656,bioavailable,"Etofylline, too, is highly bioavailable: 94% from the dragees, 84% from drops.",[Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194656/),%,94,198159,DB00277,Theophylline
,7194656,bioavailable,"Etofylline, too, is highly bioavailable: 94% from the dragees, 84% from drops.",[Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194656/),%,84,198160,DB00277,Theophylline
,1875916,signal to noise ratio,"The limit of detection, defined as the injected quantity of caffeine giving rise to a signal to noise ratio of 2, is 40 pg, corresponding to a plasma concentration of 1 ng/ml.","Rapid and sensitive gas-chromatographic determination of caffeine in blood plasma, saliva, and xanthine beverages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875916/),,2,198594,DB00277,Theophylline
,6734702,maximal plasma concentration ( Cbmax,"After a single oral dose of 300 mg Theotard , a mean maximal plasma concentration ( Cbmax of 3.49 +/- 1.05 mg/l was obtained after 8 h (tmax).",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734702/),[mg] / [l],3.49,198725,DB00277,Theophylline
,6734702,tmax,"After a single oral dose of 300 mg Theotard , a mean maximal plasma concentration ( Cbmax of 3.49 +/- 1.05 mg/l was obtained after 8 h (tmax).",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734702/),h,8,198726,DB00277,Theophylline
,6734702,peak plasma concentration,"After an identical dose of Theo-Dur, a peak plasma concentration of 4.68 +/- 1.33 mg/l was obtained after 6.33 h.",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734702/),[mg] / [l],4.68,198727,DB00277,Theophylline
,6734702,relative bioavailability,The mean relative bioavailability of theophylline from Theotard was 1.02 +/- 0.16 relative to that of Theo-Dur.,Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734702/),,1.02,198728,DB00277,Theophylline
,6846940,clearance,Erythromycin significantly decreased mean theophylline clearance by 22% from 4.9 L/min to 3.87 L/min (p less than 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[l] / [min],4.9,198915,DB00277,Theophylline
,6846940,clearance,Erythromycin significantly decreased mean theophylline clearance by 22% from 4.9 L/min to 3.87 L/min (p less than 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[l] / [min],3.87,198916,DB00277,Theophylline
,6846940,peak theophylline levels,Mean peak theophylline levels increased 28% from 11.9 micrograms/ml to 15.3 micrograms/ml (p = 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[μg] / [ml],11.9,198917,DB00277,Theophylline
,6846940,peak theophylline levels,Mean peak theophylline levels increased 28% from 11.9 micrograms/ml to 15.3 micrograms/ml (p = 0.05).,The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846940/),[μg] / [ml],15.3,198918,DB00277,Theophylline
,8306413,half-life,"At pH 7.4 and 38 degrees C, the IPM solution showed a half-life of 45 min.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),min,45,198928,DB00277,Theophylline
,8306413,half-lives,"IPM was found to be more stable in these media, with half-lives in the range of 100 min.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),min,100,198929,DB00277,Theophylline
,8306413,terminal half-lives,IPM plasma pharmacokinetics were found to decline monoexponentially with terminal half-lives ranging from 6.8 to 18.7 min and total clearance between 6.0 and 18.3 ml/min.,Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),min,6.8 to 18.7,198930,DB00277,Theophylline
,8306413,total clearance,IPM plasma pharmacokinetics were found to decline monoexponentially with terminal half-lives ranging from 6.8 to 18.7 min and total clearance between 6.0 and 18.3 ml/min.,Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),[ml] / [min],6.0 and 18.3,198931,DB00277,Theophylline
,8306413,Plasma protein binding,"Plasma protein binding of IPM was found to be 55%, and the partition ratio between plasma and red blood cells of 4.9 to 1, respectively.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),%,55,198932,DB00277,Theophylline
,8306413,partition ratio,"Plasma protein binding of IPM was found to be 55%, and the partition ratio between plasma and red blood cells of 4.9 to 1, respectively.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),,4.,198933,DB00277,Theophylline
,8306413,IC50,"Cytotoxicity of IPM to L1210 cells was evaluated, and the results indicated that the IC50 with 1-h and 4-h exposure was 33 and 15 microM, respectively.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),μM,33,198934,DB00277,Theophylline
,8306413,IC50,"Cytotoxicity of IPM to L1210 cells was evaluated, and the results indicated that the IC50 with 1-h and 4-h exposure was 33 and 15 microM, respectively.",Preclinical pharmacokinetics and stability of isophosphoramide mustard. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306413/),μM,15,198935,DB00277,Theophylline
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,5.2,199024,DB00277,Theophylline
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,5.4,199025,DB00277,Theophylline
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,27,199026,DB00277,Theophylline
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,35,199027,DB00277,Theophylline
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],13,199028,DB00277,Theophylline
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],11,199029,DB00277,Theophylline
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],0.032,199030,DB00277,Theophylline
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],0.021,199031,DB00277,Theophylline
,9353563,volume of distribution,"The volume of distribution (33.9 ml) in the peritoneal cavity was similar to the injection volume, indicating that dialysate was not diluted by the fluid in the peritoneal cavity and the effect of drug adsorption on the peritoneal membrane was minimal.",Structure-related pharmacokinetics of xanthines after direct administration into the peritoneal cavity of rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353563/),ml,33.9,199564,DB00277,Theophylline
,9353563,fraction of the administered dose absorbed through,"The fraction of the administered dose absorbed through the peritoneal cavity was 0.71, 0.85, 0.93 for theophylline, enprofylline and MPX, respectively.",Structure-related pharmacokinetics of xanthines after direct administration into the peritoneal cavity of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353563/),,0.71,199565,DB00277,Theophylline
,9353563,fraction of the administered dose absorbed through,"The fraction of the administered dose absorbed through the peritoneal cavity was 0.71, 0.85, 0.93 for theophylline, enprofylline and MPX, respectively.",Structure-related pharmacokinetics of xanthines after direct administration into the peritoneal cavity of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353563/),,0.85,199566,DB00277,Theophylline
,9353563,fraction of the administered dose absorbed through,"The fraction of the administered dose absorbed through the peritoneal cavity was 0.71, 0.85, 0.93 for theophylline, enprofylline and MPX, respectively.",Structure-related pharmacokinetics of xanthines after direct administration into the peritoneal cavity of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353563/),,0.93,199567,DB00277,Theophylline
,25728792,half-life,Foetal non-compartmental pharmacokinetic parameters were as follows: half-life 7.37 ± 1.22 hr; volume of distribution 44.62 ± 11.45 L; area under the curve 14.82 ± 2.71 hr/(μg/mL); and clearance 4.15 ± 0.70 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),h,7.37,199738,DB00277,Theophylline
,25728792,volume of distribution,Foetal non-compartmental pharmacokinetic parameters were as follows: half-life 7.37 ± 1.22 hr; volume of distribution 44.62 ± 11.45 L; area under the curve 14.82 ± 2.71 hr/(μg/mL); and clearance 4.15 ± 0.70 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),l,44.62,199739,DB00277,Theophylline
,25728792,area under the curve,Foetal non-compartmental pharmacokinetic parameters were as follows: half-life 7.37 ± 1.22 hr; volume of distribution 44.62 ± 11.45 L; area under the curve 14.82 ± 2.71 hr/(μg/mL); and clearance 4.15 ± 0.70 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[h] / [ml·μg],14.82,199740,DB00277,Theophylline
,25728792,clearance,Foetal non-compartmental pharmacokinetic parameters were as follows: half-life 7.37 ± 1.22 hr; volume of distribution 44.62 ± 11.45 L; area under the curve 14.82 ± 2.71 hr/(μg/mL); and clearance 4.15 ± 0.70 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[l] / [h],4.15,199741,DB00277,Theophylline
,25728792,half-life,Maternal non-compartmental pharmacokinetic parameters were as follows: half-life 6.54 ± 2.44 hr; volume of distribution 32.48 ± 9.99 L; area under the curve 16.28 ± 4.53 hr/(μg/mL); and clearance 3.69 ± 1.47 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),h,6.54,199742,DB00277,Theophylline
,25728792,volume of distribution,Maternal non-compartmental pharmacokinetic parameters were as follows: half-life 6.54 ± 2.44 hr; volume of distribution 32.48 ± 9.99 L; area under the curve 16.28 ± 4.53 hr/(μg/mL); and clearance 3.69 ± 1.47 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),l,32.48,199743,DB00277,Theophylline
,25728792,area under the curve,Maternal non-compartmental pharmacokinetic parameters were as follows: half-life 6.54 ± 2.44 hr; volume of distribution 32.48 ± 9.99 L; area under the curve 16.28 ± 4.53 hr/(μg/mL); and clearance 3.69 ± 1.47 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[h] / [ml·μg],16.28,199744,DB00277,Theophylline
,25728792,clearance,Maternal non-compartmental pharmacokinetic parameters were as follows: half-life 6.54 ± 2.44 hr; volume of distribution 32.48 ± 9.99 L; area under the curve 16.28 ± 4.53 hr/(μg/mL); and clearance 3.69 ± 1.47 L/hr.,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[l] / [h],3.69,199745,DB00277,Theophylline
,25728792,central volume,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),l,1.38,199746,DB00277,Theophylline
,25728792,2nd peripheral compartment volume,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),l,3.11,199747,DB00277,Theophylline
,25728792,3rd peripheral compartment volume,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),l,60.14,199748,DB00277,Theophylline
,25728792,elimination clearance,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[l] / [h],9.89,199749,DB00277,Theophylline
,25728792,distribution clearance between central and 2nd compartment,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[l] / [h],30.87,199750,DB00277,Theophylline
,25728792,distribution clearance,"Foetal and ewe serum concentration-time profiles were fit together into a 3-compartment population pharmacokinetic model, and parameters were as follows: central volume 1.38 ± 0.11 L; 2nd peripheral compartment volume 3.11 ± 0.29 L; 3rd peripheral compartment volume 60.14 ± 6.02 L; elimination clearance 9.89 ± 0.90 L/hr; distribution clearance between central and 2nd compartment 30.87 ± 2.31 L/hr; and distribution clearance between 2nd and 3rd compartments 13.89 ± 1.11 L/hr.",Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),[l] / [h],13.89,199751,DB00277,Theophylline
,25728792,protein binding,In vitro protein binding of theophylline was 30% lower in foetal serum compared to maternal serum (29.7 ± 4.4 versus 42.0 ± 3.6%-bound).,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),%,29.7,199752,DB00277,Theophylline
,25728792,protein binding,In vitro protein binding of theophylline was 30% lower in foetal serum compared to maternal serum (29.7 ± 4.4 versus 42.0 ± 3.6%-bound).,Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728792/),%,42.0,199753,DB00277,Theophylline
,8593486,first-order absorption rate constant (Ka),"The first-order absorption rate constant (Ka) for a 200-mg tablet in a fasting condition was obtained as 0.0773 (1/h), which was smaller than the elimination rate constant (0.168 1/h), indicating the flip-flop characteristic of this preparation.",Population pharmacokinetics of theophylline. Premarketing study for a once-daily administered preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593486/),[1] / [h],0.0773,200039,DB00277,Theophylline
,8593486,elimination rate constant,"The first-order absorption rate constant (Ka) for a 200-mg tablet in a fasting condition was obtained as 0.0773 (1/h), which was smaller than the elimination rate constant (0.168 1/h), indicating the flip-flop characteristic of this preparation.",Population pharmacokinetics of theophylline. Premarketing study for a once-daily administered preparation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593486/),[1] / [h],0.168,200040,DB00277,Theophylline
,8593486,Ka,"The 400-mg tablet showed a Ka value 19%, smaller than the 200-mg tablet.",Population pharmacokinetics of theophylline. Premarketing study for a once-daily administered preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593486/),%,19,200041,DB00277,Theophylline
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.83,200056,DB00277,Theophylline
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.73,200057,DB00277,Theophylline
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,7.1,200058,DB00277,Theophylline
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,8.1,200059,DB00277,Theophylline
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,1,200189,DB00277,Theophylline
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,4,200190,DB00277,Theophylline
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,1,200191,DB00277,Theophylline
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,52,200192,DB00277,Theophylline
,7194058,maximum concentration,The maximum concentration after approximately 4 h is 22.75 micrograms/ml for clofibric acid and 6.57 micrograms/ml for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),[μg] / [ml],22.75,200193,DB00277,Theophylline
,7194058,maximum concentration,The maximum concentration after approximately 4 h is 22.75 micrograms/ml for clofibric acid and 6.57 micrograms/ml for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),[μg] / [ml],6.57,200194,DB00277,Theophylline
,7194058,elimination half-life,The elimination half-life is 12.12 h for clofibric and 4.33 h for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,12.12,200195,DB00277,Theophylline
,7194058,elimination half-life,The elimination half-life is 12.12 h for clofibric and 4.33 h for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,4.33,200196,DB00277,Theophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.4,200972,DB00277,Theophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200973,DB00277,Theophylline
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200974,DB00277,Theophylline
,1929255,total body clearance,"The total body clearance of theophylline after coadministration of sparfloxacin, 42.81 +/- 6.64 ml/h/kg (mean +/- standard error of the mean), was not significantly different from that after the administration of theophylline alone, 47.11 +/- 7.61 ml/h/kg.","Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929255/),[ml] / [h·kg],42.81,201113,DB00277,Theophylline
,1929255,total body clearance,"The total body clearance of theophylline after coadministration of sparfloxacin, 42.81 +/- 6.64 ml/h/kg (mean +/- standard error of the mean), was not significantly different from that after the administration of theophylline alone, 47.11 +/- 7.61 ml/h/kg.","Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929255/),[ml] / [h·kg],47.11,201114,DB00277,Theophylline
,27071281,recovery,The applied analitycal method showed excellent recovery (94.65%).,Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27071281/),%,94.65,201137,DB00277,Theophylline
,2120178,MICs,"MICs for most pathogens were 1 mg/l or less (including the majority of the pneumococci) but the MICs for Ps. aeruginosa ranged from 0.5 to greater than 16 mg/l, those for 10 of the 22 strains being greater than 2 mg/l.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],1,201322,DB00277,Theophylline
,2120178,MICs,"MICs for most pathogens were 1 mg/l or less (including the majority of the pneumococci) but the MICs for Ps. aeruginosa ranged from 0.5 to greater than 16 mg/l, those for 10 of the 22 strains being greater than 2 mg/l.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],0.5 to greater,201323,DB00277,Theophylline
,2120178,MICs,"MICs for most pathogens were 1 mg/l or less (including the majority of the pneumococci) but the MICs for Ps. aeruginosa ranged from 0.5 to greater than 16 mg/l, those for 10 of the 22 strains being greater than 2 mg/l.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],16,201324,DB00277,Theophylline
greater,2120178,MICs,"MICs for most pathogens were 1 mg/l or less (including the majority of the pneumococci) but the MICs for Ps. aeruginosa ranged from 0.5 to greater than 16 mg/l, those for 10 of the 22 strains being greater than 2 mg/l.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],2,201325,DB00277,Theophylline
,2120178,Cmax,"Pharmacokinetic studies on serum and sputum specimens showed serum Cmax values of 3.5 and 6.0 mg/l, the sputum Cmax being 2.35 and 4.17 mg/l after the different doses.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],3.5,201326,DB00277,Theophylline
,2120178,Cmax,"Pharmacokinetic studies on serum and sputum specimens showed serum Cmax values of 3.5 and 6.0 mg/l, the sputum Cmax being 2.35 and 4.17 mg/l after the different doses.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],6.0,201327,DB00277,Theophylline
,2120178,Cmax,"Pharmacokinetic studies on serum and sputum specimens showed serum Cmax values of 3.5 and 6.0 mg/l, the sputum Cmax being 2.35 and 4.17 mg/l after the different doses.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],2.35,201328,DB00277,Theophylline
,2120178,Cmax,"Pharmacokinetic studies on serum and sputum specimens showed serum Cmax values of 3.5 and 6.0 mg/l, the sputum Cmax being 2.35 and 4.17 mg/l after the different doses.",Temafloxacin in acute purulent exacerbations of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120178/),[mg] / [l],4.17,201329,DB00277,Theophylline
,3717762,clearance,Theophylline clearance during oxygen therapy (0.048 +/- 0.005 L/h/kg) was similar to that during room air breathing (0.050 +/- 0.004 L/h/kg).,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),[l] / [h·kg],0.048,201577,DB00277,Theophylline
,3717762,clearance,Theophylline clearance during oxygen therapy (0.048 +/- 0.005 L/h/kg) was similar to that during room air breathing (0.050 +/- 0.004 L/h/kg).,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),[l] / [h·kg],0.050,201578,DB00277,Theophylline
,3717762,elimination half-life,Values for elimination half-life (7.6 +/- 0.8 versus 6.8 +/- 0.6 h) and volume of distribution at steady state (0.450 +/- 0.021 versus 0.429 +/- 0.024 L/kg) were also unchanged.,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),h,7.6,201579,DB00277,Theophylline
,3717762,elimination half-life,Values for elimination half-life (7.6 +/- 0.8 versus 6.8 +/- 0.6 h) and volume of distribution at steady state (0.450 +/- 0.021 versus 0.429 +/- 0.024 L/kg) were also unchanged.,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),h,6.8,201580,DB00277,Theophylline
,3717762,volume of distribution at steady state,Values for elimination half-life (7.6 +/- 0.8 versus 6.8 +/- 0.6 h) and volume of distribution at steady state (0.450 +/- 0.021 versus 0.429 +/- 0.024 L/kg) were also unchanged.,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),[l] / [kg],0.450,201581,DB00277,Theophylline
,3717762,volume of distribution at steady state,Values for elimination half-life (7.6 +/- 0.8 versus 6.8 +/- 0.6 h) and volume of distribution at steady state (0.450 +/- 0.021 versus 0.429 +/- 0.024 L/kg) were also unchanged.,Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717762/),[l] / [kg],0.429,201582,DB00277,Theophylline
,6845405,hospital stay,"Patients in the pharmacokinetics group had fewer adverse reactions (15.7 vs. 50%), shorter intensive care unit stay (6.6 +/- 5.5 vs. 12.4 +/- 16.3 days), shorter hospital stay (15.4 +/- 10 vs. 22.3 +/- 14.1 days), and a shorter period of time to be placed on oral therapy (5.2 +/- 3.1 vs. 8.6 +/- 7.2 days) than the group with empirically derived regimens.",Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845405/),d,15.4,201923,DB00277,Theophylline
,6845405,hospital stay,"Patients in the pharmacokinetics group had fewer adverse reactions (15.7 vs. 50%), shorter intensive care unit stay (6.6 +/- 5.5 vs. 12.4 +/- 16.3 days), shorter hospital stay (15.4 +/- 10 vs. 22.3 +/- 14.1 days), and a shorter period of time to be placed on oral therapy (5.2 +/- 3.1 vs. 8.6 +/- 7.2 days) than the group with empirically derived regimens.",Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845405/),d,22.3,201924,DB00277,Theophylline
,6845405,period of time to be placed on oral,"Patients in the pharmacokinetics group had fewer adverse reactions (15.7 vs. 50%), shorter intensive care unit stay (6.6 +/- 5.5 vs. 12.4 +/- 16.3 days), shorter hospital stay (15.4 +/- 10 vs. 22.3 +/- 14.1 days), and a shorter period of time to be placed on oral therapy (5.2 +/- 3.1 vs. 8.6 +/- 7.2 days) than the group with empirically derived regimens.",Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845405/),d,5.2,201925,DB00277,Theophylline
,6845405,period of time to be placed on oral,"Patients in the pharmacokinetics group had fewer adverse reactions (15.7 vs. 50%), shorter intensive care unit stay (6.6 +/- 5.5 vs. 12.4 +/- 16.3 days), shorter hospital stay (15.4 +/- 10 vs. 22.3 +/- 14.1 days), and a shorter period of time to be placed on oral therapy (5.2 +/- 3.1 vs. 8.6 +/- 7.2 days) than the group with empirically derived regimens.",Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845405/),d,8.6,201926,DB00277,Theophylline
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],29.1,201975,DB00277,Theophylline
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201976,DB00277,Theophylline
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201977,DB00277,Theophylline
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,7.7,201978,DB00277,Theophylline
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,14.1,201979,DB00277,Theophylline
,6871068,trough concentration,Subsequently oral sustained-release theophylline was administered and the dose adjusted to establish a trough concentration of approximately 10 micrograms/ml.,Prediction of optimum oral theophylline dose in patients with obstructive airways disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6871068/),[μg] / [ml],10,203195,DB00277,Theophylline
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00277,Theophylline
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00277,Theophylline
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00277,Theophylline
,9676347,absolute bioavailability,For the sustained release pellets a liberation/absorption of zero order for 12 h could be noted; the dose-corrected mean absolute bioavailability was 88%.,[Absorption profile and absolute bioavailability of a theophylline sustained-release preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676347/),%,88,204912,DB00277,Theophylline
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],10.9,205057,DB00277,Theophylline
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],15.9,205058,DB00277,Theophylline
,7862714,ED50,"Chronic treatment with AMPH resulted in further increase of ED50 of DZP, which was 20.2 mg/kg, and this elevation was significant not only when compared with saline-treated animals, but also with acute and 3-day administration of the xanthine (p < 0.01, 0.05, and 0.001, respectively).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],20.2,205059,DB00277,Theophylline
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],218,205060,DB00277,Theophylline
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],252,205061,DB00277,Theophylline
,2085904,serum half-life,"Peritoneal dialysis decreased the serum half-life and the area under the serum concentration-time curve (AUC) value of theophylline from 2.1 to 1.5 h and from 38 to 26 micrograms.h/ml, respectively and increased the total body clearance by 47% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),h,2,205329,DB00277,Theophylline
,2085904,area under the serum concentration-time curve (AUC),"Peritoneal dialysis decreased the serum half-life and the area under the serum concentration-time curve (AUC) value of theophylline from 2.1 to 1.5 h and from 38 to 26 micrograms.h/ml, respectively and increased the total body clearance by 47% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),[h·μg] / [ml],38 to 26,205330,DB00277,Theophylline
,2085904,serum half-life,"The dialysis also decreased the serum half-life and the AUC value of phenobarbital from 8.3 to 5.3 h and from 116 to 83 micrograms.h/ml, respectively and increased the total body clearance by 112% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),h,8.3 to 5.3,205331,DB00277,Theophylline
,2085904,AUC,"The dialysis also decreased the serum half-life and the AUC value of phenobarbital from 8.3 to 5.3 h and from 116 to 83 micrograms.h/ml, respectively and increased the total body clearance by 112% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),[h·μg] / [ml],116 to 83,205332,DB00277,Theophylline
,1554321,volume of distribution,The volume of distribution of theophylline was 0.572 +/- 0.076 L/kg during and attack while it was 0.458 +/- 0.116 L/kg during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[l] / [kg],0.572,205366,DB00277,Theophylline
,1554321,volume of distribution,The volume of distribution of theophylline was 0.572 +/- 0.076 L/kg during and attack while it was 0.458 +/- 0.116 L/kg during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[l] / [kg],0.458,205367,DB00277,Theophylline
,1554321,half-life,The half-life of theophylline was 7.741 +/- 3.313 hr. during an attack while its was 4.710 +/- 1.873 hr. during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),h,7.741,205368,DB00277,Theophylline
,1554321,half-life,The half-life of theophylline was 7.741 +/- 3.313 hr. during an attack while its was 4.710 +/- 1.873 hr. during a phase of remission.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),h,4.710,205369,DB00277,Theophylline
,1554321,clearance,The clearance of theophylline was 57.4 +/- 20.9 ml/kg/hr.,[Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554321/),[ml] / [h·kg],57.4,205370,DB00277,Theophylline
,3757567,maximal mean serum concentrations,The maximal mean serum concentrations were 15.5 +/- 1.6 (SEM) micrograms/ml for the od preparation on the 8th hour and 12.7 +/- 2.2 for the bid regimen.,Bioavailability of a once daily-administered theophylline preparation. A comparison study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757567/),[μg] / [ml],15.5,205682,DB00277,Theophylline
,3757567,maximal mean serum concentrations,The maximal mean serum concentrations were 15.5 +/- 1.6 (SEM) micrograms/ml for the od preparation on the 8th hour and 12.7 +/- 2.2 for the bid regimen.,Bioavailability of a once daily-administered theophylline preparation. A comparison study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757567/),,12.7,205683,DB00277,Theophylline
,3757567,trough level,The trough level was 7.4 +/- 1.2 micrograms/ml for the od regimen and 10.6 +/- 1.6 for the bid regimen.,Bioavailability of a once daily-administered theophylline preparation. A comparison study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757567/),[μg] / [ml],7.4,205684,DB00277,Theophylline
,3757567,trough level,The trough level was 7.4 +/- 1.2 micrograms/ml for the od regimen and 10.6 +/- 1.6 for the bid regimen.,Bioavailability of a once daily-administered theophylline preparation. A comparison study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757567/),[μg] / [ml],10.6,205685,DB00277,Theophylline
,22702215,clearance,Theophylline clearance was 0.064 +/- 0.017 liters/kg/hr in the non-pyrexia group and 0.049 +/- 0.010 liters/kg/hr in the pyrexia group.,Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.064,205782,DB00277,Theophylline
,22702215,clearance,Theophylline clearance was 0.064 +/- 0.017 liters/kg/hr in the non-pyrexia group and 0.049 +/- 0.010 liters/kg/hr in the pyrexia group.,Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.049,205783,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.044,205784,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.030,205785,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.071,205786,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.047,205787,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.084,205788,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.055,205789,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.065,205790,DB00277,Theophylline
,22702215,clearance,"Theophylline clearance in the non-pyrexia and pyrexia groups was 0.044 +/- 0.007 liters/kg/hr and 0.030 +/- 0.009 liters/kg/hr (< or = 6 months), 0.071 +/- 0.011 liters/kg/hr and 0.047 +/- 0.008 liters/kg/hr (6 to < or = 12 months), 0.084 +/- 0.012 liters/kg/hr and 0.055 +/- 0.006 liters/ kg/hr (1 to < or = 2 years), and 0.065 +/- 0.007 liters/kg/hr and 0.051 +/- 0.001 liters/kg/hr (2 to < or = 3 years), respectively.",Influences of pyrexia and age on theophylline clearance in young children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22702215/),[l] / [h·kg],0.051,205791,DB00277,Theophylline
,7408406,clearance,"Oral propranolol, 40 mg every 6 hr, induced a fall in theophylline clearance from 0.0464 +/- 0.0294 +/- 0.0129 l/kg/hr (p < 0.001).",Effects of metoprolol and propranolol on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408406/),[l] / [h·kg],0.0464,207056,DB00277,Theophylline
,3989903,biological half-life,"The biological half-life of theophylline was found to be 14.8 h, the volume of distribution 1.02 l/kg and the total plasma clearance 0.86 ml/kg/min.",Pharmacokinetic studies of theophylline in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989903/),h,14.8,207376,DB00277,Theophylline
,3989903,volume of distribution,"The biological half-life of theophylline was found to be 14.8 h, the volume of distribution 1.02 l/kg and the total plasma clearance 0.86 ml/kg/min.",Pharmacokinetic studies of theophylline in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989903/),[l] / [kg],1.02,207377,DB00277,Theophylline
,3989903,total plasma clearance,"The biological half-life of theophylline was found to be 14.8 h, the volume of distribution 1.02 l/kg and the total plasma clearance 0.86 ml/kg/min.",Pharmacokinetic studies of theophylline in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989903/),[ml] / [kg·min],0.86,207378,DB00277,Theophylline
,3989903,bioavailability,The oral absorption of the drug was complete (bioavailability 108%) and rapid (absorption half-life 0.4 h).,Pharmacokinetic studies of theophylline in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989903/),%,108,207379,DB00277,Theophylline
,3989903,absorption half-life,The oral absorption of the drug was complete (bioavailability 108%) and rapid (absorption half-life 0.4 h).,Pharmacokinetic studies of theophylline in horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989903/),h,0.4,207380,DB00277,Theophylline
,9378847,peak plasma concentrations (Cmax),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[μg] / [ml],11.4,207580,DB00277,Theophylline
,9378847,peak plasma concentrations (Cmax),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[μg] / [ml],10.7,207581,DB00277,Theophylline
,9378847,areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[h·μg] / [ml],124,207582,DB00277,Theophylline
,9378847,areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[h·μg] / [ml],126,207583,DB00277,Theophylline
,9378847,volumes of distribution at steady state (Vdss),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),l,31.7,207584,DB00277,Theophylline
,9378847,volumes of distribution at steady state (Vdss),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),l,32.0,207585,DB00277,Theophylline
,9378847,clearances (Cl),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[ml] / [min],48.6,207586,DB00277,Theophylline
,9378847,clearances (Cl),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[ml] / [min],47.4,207587,DB00277,Theophylline
,9378847,half-lives (t1/2),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),h,8.1,207588,DB00277,Theophylline
,9378847,half-lives (t1/2),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),h,8.2,207589,DB00277,Theophylline
,7418716,half-life of absorption,The half-life of absorption was 19 +/- 9 min (mean +/- SD).,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),min,19,207843,DB00277,Theophylline
,7418716,Maximal serum concentrations,Maximal serum concentrations reached after 100 +/- 30 min were found to be in a rather narrow range: 9.8 +/- 2.5 mg x 1(-1).,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),mg,9.8,207844,DB00277,Theophylline
,7418716,absolute bioavailability,The absolute bioavailability of the microcrystalline preparation was high and it showed only small variation: 102.7 +/- 10.2% of the dose.,Disposition and clinical pharmacokinetics of microcrystalline theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418716/),%,102.7,207845,DB00277,Theophylline
,31683708,flow rate,The analytes were separated on an Agilent ZORBAX Eclipse Plus C18 column using a gradient elution of acetonitrile and 0.1% formic acid in water at a flow rate of 0.3 mL/min.,Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683708/),[ml] / [min],0.3,207895,DB00277,Theophylline
,31683708,m/,Gardneramine and I.S. were detected and quantified using positive electrospray ionization in multiple reaction monitoring (MRM) mode with transitions of m/z 413.1→217.9 for gardneramine and m/z 181.2→124.1 for I.S..,Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683708/),,413.1,207896,DB00277,Theophylline
,31683708,m/,Gardneramine and I.S. were detected and quantified using positive electrospray ionization in multiple reaction monitoring (MRM) mode with transitions of m/z 413.1→217.9 for gardneramine and m/z 181.2→124.1 for I.S..,Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683708/),,217.9,207897,DB00277,Theophylline
,31683708,m/z,Gardneramine and I.S. were detected and quantified using positive electrospray ionization in multiple reaction monitoring (MRM) mode with transitions of m/z 413.1→217.9 for gardneramine and m/z 181.2→124.1 for I.S..,Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683708/),,181.2,207898,DB00277,Theophylline
,31683708,m/z,Gardneramine and I.S. were detected and quantified using positive electrospray ionization in multiple reaction monitoring (MRM) mode with transitions of m/z 413.1→217.9 for gardneramine and m/z 181.2→124.1 for I.S..,Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683708/),,124.1,207899,DB00277,Theophylline
,3837249,clearance,The clearance values (mean +/- SD) calculated in the two patient groups were significantly different (asthmatic patients: clearance = 61.2 +/- 15.6 ml/h/kg; CF patients: clearance = 86.3 +/- 22.8 ml/h/kg; P = 0.007).,[Pharmacokinetics of oral theophylline. Comparison between asthmatic and cystic fibrosis patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3837249/),[ml] / [h·kg],61.2,208075,DB00277,Theophylline
,3837249,clearance,The clearance values (mean +/- SD) calculated in the two patient groups were significantly different (asthmatic patients: clearance = 61.2 +/- 15.6 ml/h/kg; CF patients: clearance = 86.3 +/- 22.8 ml/h/kg; P = 0.007).,[Pharmacokinetics of oral theophylline. Comparison between asthmatic and cystic fibrosis patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3837249/),[ml] / [h·kg],86.3,208076,DB00277,Theophylline
,12066575,gamma,"The gamma values were not significantly different (p > 0.05) among the tablets in different dissolution media, with absolute values in DI H2O of 6600 erg/cm3, which is above the minimum threshold value of gamma (approximately 6000 erg/cm3) needed for acceptable in vitro/in vivo correlation.",An adjusted pharmacokinetic equation for predicting drug levels in vivo based on in vitro square root of time release kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12066575/),[erg] / [cm3],6000,208100,DB00277,Theophylline
,972795,total clearance,The average total clearance of theophylline was 87 ml/hr/kg in the children and 57 ml/hr/kg in the adults.,Pharmacokinetics of theophylline in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),[ml] / [h·kg],87,208608,DB00277,Theophylline
,972795,total clearance,The average total clearance of theophylline was 87 ml/hr/kg in the children and 57 ml/hr/kg in the adults.,Pharmacokinetics of theophylline in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),[ml] / [h·kg],57,208609,DB00277,Theophylline
,972795,biologic half-life,"The biologic half-life of theophylline in the children ranged from 1.42 to 7.85 hours, reflecting mainly pronounced interindividual differences in the elimination rate constant of the drug.",Pharmacokinetics of theophylline in children with asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972795/),h,1.42 to 7.85,208610,DB00277,Theophylline
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.35,208657,DB00277,Theophylline
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.07,208658,DB00277,Theophylline
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],30.3,208659,DB00277,Theophylline
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],29.7,208660,DB00277,Theophylline
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208661,DB00277,Theophylline
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208662,DB00277,Theophylline
,21601627,encapsulation rates,"Particle size varied between 1.8 and 2.8mm and encapsulation rates between 27 and 30% for Ca- and Zn-pectinate beads, respectively.",Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),%,27,208950,DB00277,Theophylline
,21601627,encapsulation rates,"Particle size varied between 1.8 and 2.8mm and encapsulation rates between 27 and 30% for Ca- and Zn-pectinate beads, respectively.",Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),%,30,208951,DB00277,Theophylline
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,12.0,208952,DB00277,Theophylline
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,6.0,208953,DB00277,Theophylline
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,2.5,208954,DB00277,Theophylline
,4083583,half-life,"In the 6 horses, total body elimination rate constants were variable, and the half-life of theophylline was 9.7 to 19.3 hours.",Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,9.7 to 19.3,208976,DB00277,Theophylline
,4083583,Clearance,Clearance was 42.3 to 69.2 ml/hr/kg.,Theophylline and dyphylline pharmacokinetics in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[ml] / [h·kg],42.3 to 69.2,208977,DB00277,Theophylline
,4083583,t1/2,The initial distribution phase was rapid (t1/2 approx 3.5 to 4 minutes); a 2nd distribution phase was slower (t1/2 approx 1.5 to 2 hours).,Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),min,3.5 to 4,208978,DB00277,Theophylline
,4083583,t1/2,The initial distribution phase was rapid (t1/2 approx 3.5 to 4 minutes); a 2nd distribution phase was slower (t1/2 approx 1.5 to 2 hours).,Theophylline and dyphylline pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,1.5 to 2,208979,DB00277,Theophylline
,4083583,apparent volume of distribution,The mean apparent volume of distribution was 1.02 L/kg.,Theophylline and dyphylline pharmacokinetics in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[l] / [kg],1.02,208980,DB00277,Theophylline
,4083583,elimination half-life,"In the 6 horses, elimination half-life of dyphylline was 1.9 to 2.9 hours, and clearance was 200 to 320 ml/hr/kg.",Theophylline and dyphylline pharmacokinetics in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),h,1.9 to 2.9,208981,DB00277,Theophylline
,4083583,clearance,"In the 6 horses, elimination half-life of dyphylline was 1.9 to 2.9 hours, and clearance was 200 to 320 ml/hr/kg.",Theophylline and dyphylline pharmacokinetics in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[ml] / [h·kg],200 to 320,208982,DB00277,Theophylline
,4083583,Plasma concentrations,Plasma concentrations (approx 50 micrograms/ml) were observed at 10 minutes after injection without adverse effects.,Theophylline and dyphylline pharmacokinetics in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083583/),[μg] / [ml],50,208983,DB00277,Theophylline
,3395671,plasma level maxima,"After one tablet, plasma level maxima (of plateau-type) were 5-6 ng ml-1 and 2-3 ng ml-1 in two subjects, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],5-6,209285,DB00277,Theophylline
,3395671,plasma level maxima,"After one tablet, plasma level maxima (of plateau-type) were 5-6 ng ml-1 and 2-3 ng ml-1 in two subjects, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],2-3,209286,DB00277,Theophylline
,3395671,plateau level maxima,"After two tablets, plateau level maxima around 18 ng ml-1 and 9 ng ml-1 were found, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],18,209287,DB00277,Theophylline
,3395671,plateau level maxima,"After two tablets, plateau level maxima around 18 ng ml-1 and 9 ng ml-1 were found, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],9,209288,DB00277,Theophylline
,7263108,beta,"The alpha-phase lasted on the average 20 min and beta was 0.175 h(-1), corresponding with a beta-phase half-life of 4.1 h.",Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),1/[h],0.175,209556,DB00277,Theophylline
,7263108,beta-phase half-life,"The alpha-phase lasted on the average 20 min and beta was 0.175 h(-1), corresponding with a beta-phase half-life of 4.1 h.",Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),h,4.1,209557,DB00277,Theophylline
,7263108,volume of distribution,"The mean volume of distribution was 0.60 liter/kg, total body clearance 0.106 l.kg(-1).",Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),[l] / [kg],0.60,209558,DB00277,Theophylline
,7263108,total body clearance,"The mean volume of distribution was 0.60 liter/kg, total body clearance 0.106 l.kg(-1).",Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),[l] / [kg],0.106,209559,DB00277,Theophylline
,7263108,renal clearance,"h(-1), and the renal clearance about 0.017 l.kg(-1).",Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),[l] / [kg],0.017,209560,DB00277,Theophylline
,7263108,bioavailability,Its bioavailability was about 80%.,Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),%,80,209561,DB00277,Theophylline
,7263108,peak levels,Mean peak levels of etofylline were about 3.9 mg/liter after oral administration.,Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),[mg] / [l],3.9,209562,DB00277,Theophylline
,7263108,steady state level,With the Wagner-Nelson equation a mean steady state level for this dose can be calculated at about 0.7-1.4 g/ml.,Pharmacokinetics of etofylline after intravenous and oral administration to humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263108/),[g] / [ml],0.7-1.4,209563,DB00277,Theophylline
,7255850,half life (T 1/2,"After an intra-venous injection of a single dose (4.24 +/- 0.94 mg/kg) of anhydrous theophylline in 20 children aged 4 to 16 years, the pharmacokinetic characteristics (mean and standard deviation) were as follow: half life (T 1/2 6.06 +/- 2.53; apparent distribution volume (Vd) 0.585 +/- 0.148 l/kg and clearance from the body (Cl) at 0.078 +/- 0.35 l/kg/w.",[Theophylline in childhood asthma. Pharmacokinetic and clinical study (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255850/),,6.06,209670,DB00277,Theophylline
,7255850,apparent distribution volume (Vd),"After an intra-venous injection of a single dose (4.24 +/- 0.94 mg/kg) of anhydrous theophylline in 20 children aged 4 to 16 years, the pharmacokinetic characteristics (mean and standard deviation) were as follow: half life (T 1/2 6.06 +/- 2.53; apparent distribution volume (Vd) 0.585 +/- 0.148 l/kg and clearance from the body (Cl) at 0.078 +/- 0.35 l/kg/w.",[Theophylline in childhood asthma. Pharmacokinetic and clinical study (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255850/),[l] / [kg],0.585,209671,DB00277,Theophylline
,7255850,clearance from the body (Cl),"After an intra-venous injection of a single dose (4.24 +/- 0.94 mg/kg) of anhydrous theophylline in 20 children aged 4 to 16 years, the pharmacokinetic characteristics (mean and standard deviation) were as follow: half life (T 1/2 6.06 +/- 2.53; apparent distribution volume (Vd) 0.585 +/- 0.148 l/kg and clearance from the body (Cl) at 0.078 +/- 0.35 l/kg/w.",[Theophylline in childhood asthma. Pharmacokinetic and clinical study (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255850/),[l] / [kg·w],0.078,209672,DB00277,Theophylline
,2754145,bioavailability,"These include (1) a 16-year-old girl with consistent temporal fluctuation in STCs during administration of a sustained-release formulation every 8 hours because of delayed absorption and enhanced elimination of theophylline at night, (2) a 13-year-old girl with markedly delayed absorption of a once-daily preparation administered in the evening, (3) a 5-year-old boy with erratic absorption of a liquid theophylline preparation with significantly increased STCs during the night, and (4) a 49-year-old man with 60% bioavailability of aminophylline tablets.","Are theophylline ""levels"" a reliable indicator of compliance? ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754145/),%,60,210237,DB00277,Theophylline
,1424911,Clearance,"Clearance of theophylline by hemodialysis was 119 ml/min, and the extraction efficiency was 0.56.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),[ml] / [min],119,210722,DB00277,Theophylline
,1424911,extraction efficiency,"Clearance of theophylline by hemodialysis was 119 ml/min, and the extraction efficiency was 0.56.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),,0.56,210723,DB00277,Theophylline
,1424911,elimination half-life,The elimination half-life of theophylline shortened from 5.7 h to 1.6 h during hemodialysis.,Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),h,5.7,210724,DB00277,Theophylline
,1424911,elimination half-life,The elimination half-life of theophylline shortened from 5.7 h to 1.6 h during hemodialysis.,Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),h,1.6,210725,DB00277,Theophylline
,1424911,rate constant (Kd),"The dialysis rate constant (Kd) was 0.32/h, and 79 percent of the total body store of the drug was removed during a 4-h dialysis.",Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424911/),1/[h],0.32,210726,DB00277,Theophylline
,2735986,peak flow rate (PFR),"Baseline peak flow rate (PFR) was significantly (P less than .03) higher in group 1 (170 +/- 85 L/min) than in group 2 (132 +/- 62 L/min), but did not differ significantly at any other times throughout the study.",Computer-assisted optimization of aminophylline therapy in the emergency department. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735986/),[l] / [min],170,210734,DB00277,Theophylline
,2735986,peak flow rate (PFR),"Baseline peak flow rate (PFR) was significantly (P less than .03) higher in group 1 (170 +/- 85 L/min) than in group 2 (132 +/- 62 L/min), but did not differ significantly at any other times throughout the study.",Computer-assisted optimization of aminophylline therapy in the emergency department. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735986/),[l] / [min],132,210735,DB00277,Theophylline
,6686557,bioavailability,"In 4 of the patients, mean bioavailability of the fourth dose was 38.9 +/- 8.4% and that of the sixth dose was 67.9 +/- 25.9% (p less than 0.05) in the other ten patients.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),%,38.9,210931,DB00277,Theophylline
,6686557,bioavailability,"In 4 of the patients, mean bioavailability of the fourth dose was 38.9 +/- 8.4% and that of the sixth dose was 67.9 +/- 25.9% (p less than 0.05) in the other ten patients.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),%,67.9,210932,DB00277,Theophylline
,6686557,steady-state plasma theophylline concentrations,"Morning and night steady-state plasma theophylline concentrations during a continuous intravenous infusion of aminophylline were not different (14.9 +/- 5.3 mg/l vs. 15.6 +/- 5.9 mg/l), demonstrating that there was no diurnal variation in the plasma clearance of theophylline.",Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686557/),[mg] / [l],15.6,210933,DB00277,Theophylline
,6694116,Absolute clearance,"Absolute clearance (uncorrected for body size parameters) was similar in normal (26.8 +/- 5.4 ml/h) and obese (22.5 +/- 3.6 ml/h) male rats, indicating that total metabolic function remained constant in spite of increased body and liver weights.",Theophylline disposition in obese rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694116/),[ml] / [h],26.8,211107,DB00277,Theophylline
,6694116,Absolute clearance,"Absolute clearance (uncorrected for body size parameters) was similar in normal (26.8 +/- 5.4 ml/h) and obese (22.5 +/- 3.6 ml/h) male rats, indicating that total metabolic function remained constant in spite of increased body and liver weights.",Theophylline disposition in obese rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694116/),[ml] / [h],22.5,211108,DB00277,Theophylline
,6694116,partition coefficient,Analysis of drug in fat (partition coefficient = 0.091) indicated limited fat uptake of theophylline.,Theophylline disposition in obese rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694116/),,0.091,211109,DB00277,Theophylline
,1650860,half-life,There was no significant difference in theophylline half-life before treatment (7.25 +/- 2.43 hr) and after treatment (7.82 +/- 3.35 hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),h,7.25,211413,DB00277,Theophylline
,1650860,half-life,There was no significant difference in theophylline half-life before treatment (7.25 +/- 2.43 hr) and after treatment (7.82 +/- 3.35 hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),h,7.82,211414,DB00277,Theophylline
,1650860,clearance,There was no significant difference in theophylline clearance before treatment (0.047 +/- 0.018 L/kg/hr) and after treatment (0.047 +/- 0.020 L/kg/hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),[l] / [h·kg],0.047,211415,DB00277,Theophylline
,1650860,clearance,There was no significant difference in theophylline clearance before treatment (0.047 +/- 0.018 L/kg/hr) and after treatment (0.047 +/- 0.020 L/kg/hr).,"[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650860/),[l] / [h·kg],0.047,211416,DB00277,Theophylline
,17499154,T(max),"However, a delay in T(max) was observed in the exposed group (from 0.16(+/-0.003) to 0.37(+/-0.14)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,0.16,211681,DB00277,Theophylline
,17499154,T(max),"However, a delay in T(max) was observed in the exposed group (from 0.16(+/-0.003) to 0.37(+/-0.14)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,0.37,211682,DB00277,Theophylline
,17499154,t(1/2),"A small, but significant increase in t(1/2) (p<0.05) was detected (1.74(+/-0.25) vs. 1.45(+/-0.12)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,1.74,211683,DB00277,Theophylline
,17499154,t(1/2),"A small, but significant increase in t(1/2) (p<0.05) was detected (1.74(+/-0.25) vs. 1.45(+/-0.12)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,1.45,211684,DB00277,Theophylline
,17499154,CL/F,A significant reduction (p<0.05) of CL/F from 30.54(+/-1.9) to 24.01(+/-3.81)mL/min/kg was seen in the treated group.,The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),[ml] / [kg·min],30.54,211685,DB00277,Theophylline
,17499154,CL/F,A significant reduction (p<0.05) of CL/F from 30.54(+/-1.9) to 24.01(+/-3.81)mL/min/kg was seen in the treated group.,The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),[ml] / [kg·min],24.01,211686,DB00277,Theophylline
,24271523,systemic clearance,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),[l] / [h·kg],0.057,211949,DB00277,Theophylline
,24271523,systemic clearance,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),[l] / [h·kg],0.031,211950,DB00277,Theophylline
,24271523,elimination half-life,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),h,2.03,211951,DB00277,Theophylline
,24271523,elimination half-life,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),h,4.29,211952,DB00277,Theophylline
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],2.3,212122,DB00277,Theophylline
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],0.8,212123,DB00277,Theophylline
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],2.1,212124,DB00277,Theophylline
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.55,212272,DB00277,Theophylline
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.78,212273,DB00277,Theophylline
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212274,DB00277,Theophylline
,3240766,clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212275,DB00277,Theophylline
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,6.11,212276,DB00277,Theophylline
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,5.05,212277,DB00277,Theophylline
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,4.88,212278,DB00277,Theophylline
,3671893,Cmax,"No significant differences were found either in Cmax (a: 7.0 +/- 3.2 micrograms/ml; b: 7.6 +/- 2.6 micrograms/ml), or in Tmax (a: 11.7 +/- 6.1 h; b: 10.2 +/- 3.6 h).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],7.0,212627,DB00277,Theophylline
,3671893,Cmax,"No significant differences were found either in Cmax (a: 7.0 +/- 3.2 micrograms/ml; b: 7.6 +/- 2.6 micrograms/ml), or in Tmax (a: 11.7 +/- 6.1 h; b: 10.2 +/- 3.6 h).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],7.6,212628,DB00277,Theophylline
,3671893,Tmax,"No significant differences were found either in Cmax (a: 7.0 +/- 3.2 micrograms/ml; b: 7.6 +/- 2.6 micrograms/ml), or in Tmax (a: 11.7 +/- 6.1 h; b: 10.2 +/- 3.6 h).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,11.7,212629,DB00277,Theophylline
,3671893,Tmax,"No significant differences were found either in Cmax (a: 7.0 +/- 3.2 micrograms/ml; b: 7.6 +/- 2.6 micrograms/ml), or in Tmax (a: 11.7 +/- 6.1 h; b: 10.2 +/- 3.6 h).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,10.2,212630,DB00277,Theophylline
,3671893,Elimination half-life,Elimination half-life was in a 11.4 +/- 4.4 h and in b 12.9 +/- 4.8 h (p less than 0.05).,Once-daily dosing of a new ultrasustained-release theophylline preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,11.4,212631,DB00277,Theophylline
,3671893,Elimination half-life,Elimination half-life was in a 11.4 +/- 4.4 h and in b 12.9 +/- 4.8 h (p less than 0.05).,Once-daily dosing of a new ultrasustained-release theophylline preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,12.9,212632,DB00277,Theophylline
,3671893,Cmax,"Cmax was 12 +/- 5 and 11 +/- 4 micrograms/ml, respectively (NS).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],12,212633,DB00277,Theophylline
,3671893,Cmax,"Cmax was 12 +/- 5 and 11 +/- 4 micrograms/ml, respectively (NS).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],11,212634,DB00277,Theophylline
,3671893,Tmax,"Tmax was 9 +/- 3 and 11 +/- 3 h, respectively (NS).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,9,212635,DB00277,Theophylline
,3671893,Tmax,"Tmax was 9 +/- 3 and 11 +/- 3 h, respectively (NS).",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),h,11,212636,DB00277,Theophylline
,3671893,trough plasma concentrations,"The trough plasma concentrations were 2.6 +/- 0.9, 6.2 +/- 2.1 and 10.2 +/- 3.1 micrograms/ml, respectively.",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],2.6,212637,DB00277,Theophylline
,3671893,trough plasma concentrations,"The trough plasma concentrations were 2.6 +/- 0.9, 6.2 +/- 2.1 and 10.2 +/- 3.1 micrograms/ml, respectively.",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],6.2,212638,DB00277,Theophylline
,3671893,trough plasma concentrations,"The trough plasma concentrations were 2.6 +/- 0.9, 6.2 +/- 2.1 and 10.2 +/- 3.1 micrograms/ml, respectively.",Once-daily dosing of a new ultrasustained-release theophylline preparation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671893/),[μg] / [ml],10.2,212639,DB00277,Theophylline
,3240714,areas under plasma curves,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),[h·mg] / [l],86.06,213083,DB00277,Theophylline
,3240714,areas under plasma curves,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),[h·mg] / [l],138.32,213084,DB00277,Theophylline
,3240714,peak plasma levels,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),[mg] / [l],6.65,213085,DB00277,Theophylline
,3240714,peak plasma levels,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),[mg] / [l],8.78,213086,DB00277,Theophylline
,3240714,mean residence times,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),h,14.94,213087,DB00277,Theophylline
,3240714,mean residence times,"Comparison of pharmacokinetic parameters showed that the concomitant absorption of capsicum increases areas under plasma curves (from 86.06 +/- 9.78 mg H/liter to 138.32 +/- 17.27 mg H/liter, P less than 0.001), peak plasma levels (from 6.65 +/- 0.76 to 8.78 +/- 0.98 mg/liter, P less than 0.01), and mean residence times (from 14.94 +/- 2.97 to 20.98 +/- 5.75 H, P less than 0.001).",Effects of capsicum fruit on theophylline absorption and bioavailability in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240714/),h,20.98,213088,DB00277,Theophylline
,12760407,Clp,Male Clp values tended to be higher than those of females over this age interval [25.5 ml/hr/kg higher (31%) at 4 years and 12.5 ml/hr/kg higher (22%) at 20 years].,Effect of age and sex on theophylline clearance in young subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760407/),[ml] / [h·kg],25.5,214828,DB00277,Theophylline
,12760407,Clp,Male Clp values tended to be higher than those of females over this age interval [25.5 ml/hr/kg higher (31%) at 4 years and 12.5 ml/hr/kg higher (22%) at 20 years].,Effect of age and sex on theophylline clearance in young subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760407/),[ml] / [h·kg],12.5,214829,DB00277,Theophylline
,7855046,steady state plasma concentrations,"The effects of two fluoroquinolones, enoxacin (ENOX) and ciprofloxacin (CIPRO), have been studied in male Sprague-Dawley rats (n = 33-46) at steady state plasma concentrations of 0-33 mg.l-1, achieved by supplementing an intravenous bolus dose with a constant rate infusion.",Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7855046/),[mg] / [l],0-33,215443,DB00277,Theophylline
,11510627,time (tmax) to peak concentration (Cmax),"In young healthy volunteers, absorption of mizolastine is rapid with time (tmax) to peak concentration (Cmax) of about 1 hour.",Clinical pharmacokinetics of mizolastine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1,215900,DB00277,Theophylline
,11510627,absolute bioavailability,The absolute bioavailability of mizolastine 10mg tablets is about 65%.,Clinical pharmacokinetics of mizolastine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),%,65,215901,DB00277,Theophylline
,11510627,distribution half-life,Distribution is rapid with a mean distribution half-life of 1.5 to 1.9 hours.,Clinical pharmacokinetics of mizolastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1.5 to 1.9,215902,DB00277,Theophylline
,11510627,apparent volume of distribution,Mizolastine is >98% bound to serum albumin and the apparent volume of distribution is between I and 1.4 L/kg.,Clinical pharmacokinetics of mizolastine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [kg],I and 1.4,215903,DB00277,Theophylline
,11510627,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) is 7.3 to 17.1 hours.,Clinical pharmacokinetics of mizolastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,7.3 to 17.1,215904,DB00277,Theophylline
,11510627,apparent oral clearance,"The apparent oral clearance after a repeated oral dose of 10mg is 6.02 L/h, with steady state reached from day 3 and no accumulation between days 1 and 7.",Clinical pharmacokinetics of mizolastine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [h],6.02,215905,DB00277,Theophylline
,7096605,bioavailability,The average bioavailability for the 100- and 300-mg tablets was 98 +/- 0.03% (S.E.M.).,Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7096605/),%,98,215983,DB00277,Theophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB00277,Theophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB00277,Theophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB00277,Theophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB00277,Theophylline
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB00277,Theophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB00277,Theophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB00277,Theophylline
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB00277,Theophylline
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB00277,Theophylline
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB00277,Theophylline
,8368607,t 1/2 beta,"It also was noticed that young dogs have a slower elimination half-life (1 week old, t 1/2 beta = 987 minutes) than do older animals (8 weeks old, t 1/2 beta = 138 minutes).",Effect of age on theophylline pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),min,987,216515,DB00277,Theophylline
,8368607,t 1/2 beta,"It also was noticed that young dogs have a slower elimination half-life (1 week old, t 1/2 beta = 987 minutes) than do older animals (8 weeks old, t 1/2 beta = 138 minutes).",Effect of age on theophylline pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),min,138,216516,DB00277,Theophylline
,8368607,t 1/2 beta,"The values then plateaued until 16 weeks of age, increasing slightly at more advanced age (104 weeks old, t 1/2 beta = 282 minutes).",Effect of age on theophylline pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),min,282,216517,DB00277,Theophylline
,8368607,Cl,"A similar pattern was followed with respect to clearance (1-week-old pups, Cl = 1.17 ml/min/kg of body weight), which increased progressively to reach a value of 7.09 ml/min/kg at 16 weeks of age, then decreased to 3.5 ml/min/kg at 104 weeks of age.",Effect of age on theophylline pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),[ml] / [kg·min],1.17,216518,DB00277,Theophylline
,8368607,Cl,"A similar pattern was followed with respect to clearance (1-week-old pups, Cl = 1.17 ml/min/kg of body weight), which increased progressively to reach a value of 7.09 ml/min/kg at 16 weeks of age, then decreased to 3.5 ml/min/kg at 104 weeks of age.",Effect of age on theophylline pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),[ml] / [kg·min],7.09,216519,DB00277,Theophylline
,8368607,Cl,"A similar pattern was followed with respect to clearance (1-week-old pups, Cl = 1.17 ml/min/kg of body weight), which increased progressively to reach a value of 7.09 ml/min/kg at 16 weeks of age, then decreased to 3.5 ml/min/kg at 104 weeks of age.",Effect of age on theophylline pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),[ml] / [kg·min],3.5,216520,DB00277,Theophylline
,8368607,Volume of distribution beta,"Volume of distribution beta, in relation to body weight, was not significantly different between age groups (between 1.2 and 1.6 L/kg; P < or = 0.03).",Effect of age on theophylline pharmacokinetics in dogs. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368607/),[l] / [kg],1.2 and 1.6,216521,DB00277,Theophylline
,1610026,evening,Patients taking Slo-bid also had significantly better evening peak flow values than patients taking Theo-Dur (424.5 L/min versus 395.4 L/min).,Once-a-day dosing with theophylline: a comparison of four sustained-release products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610026/),[l] / [min],424.5,216950,DB00277,Theophylline
,1610026,peak flow,Patients taking Slo-bid also had significantly better evening peak flow values than patients taking Theo-Dur (424.5 L/min versus 395.4 L/min).,Once-a-day dosing with theophylline: a comparison of four sustained-release products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610026/),[l] / [min],424.5,216951,DB00277,Theophylline
,1610026,peak flow,Patients taking Slo-bid also had significantly better evening peak flow values than patients taking Theo-Dur (424.5 L/min versus 395.4 L/min).,Once-a-day dosing with theophylline: a comparison of four sustained-release products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610026/),[l] / [min],395.4,216952,DB00277,Theophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],233,217325,DB00277,Theophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],191,217326,DB00277,Theophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],242,217327,DB00277,Theophylline
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],212,217328,DB00277,Theophylline
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],0.9,217781,DB00277,Theophylline
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],1.4,217782,DB00277,Theophylline
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.5,217783,DB00277,Theophylline
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.3,217784,DB00277,Theophylline
,10877011,elimination half-life,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217785,DB00277,Theophylline
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217786,DB00277,Theophylline
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],4.1,217787,DB00277,Theophylline
,10877011,saliva:plasma concentrations ratio,Excellent correlations were found between saliva and plasma concentrations of caffeine (r2 = 0.98) with a mean saliva:plasma concentrations ratio of 0.7 +/- 0.1.,The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.7,217788,DB00277,Theophylline
,6683521,Tvss,"The mean time (theophylline) for the body model, Tvss, is 9.9 h; the mean time, which is attributed to the absorption process (Tabs) is 0.7 h; the mean in vivo dissolution time (Tdiss-vivo) for the sustained release formulation is 6.3 h.","[Release, absorption and elimination of theophylline from fast and slowly released oral formulations]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683521/),h,9.9,218518,DB00277,Theophylline
,6683521,mean time,"The mean time (theophylline) for the body model, Tvss, is 9.9 h; the mean time, which is attributed to the absorption process (Tabs) is 0.7 h; the mean in vivo dissolution time (Tdiss-vivo) for the sustained release formulation is 6.3 h.","[Release, absorption and elimination of theophylline from fast and slowly released oral formulations]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683521/),h,0.7,218519,DB00277,Theophylline
,6683521,in vivo dissolution time (Tdiss-vivo),"The mean time (theophylline) for the body model, Tvss, is 9.9 h; the mean time, which is attributed to the absorption process (Tabs) is 0.7 h; the mean in vivo dissolution time (Tdiss-vivo) for the sustained release formulation is 6.3 h.","[Release, absorption and elimination of theophylline from fast and slowly released oral formulations]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683521/),h,6.3,218520,DB00277,Theophylline
,6683521,time after oral administration,The mean time after oral administration of the theophylline solution (Tbiol) is 10.6 h.,"[Release, absorption and elimination of theophylline from fast and slowly released oral formulations]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683521/),h,10.6,218521,DB00277,Theophylline
,8888069,Clearance,"Clearance of theophylline was significantly higher after CSF administration (0.76 vs 0.99 ml/min/kg, p = 0.019).","The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888069/),[ml] / [kg·min],0.76,218776,DB00277,Theophylline
,8888069,Clearance,"Clearance of theophylline was significantly higher after CSF administration (0.76 vs 0.99 ml/min/kg, p = 0.019).","The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888069/),[ml] / [kg·min],0.99,218777,DB00277,Theophylline
,4083298,apparent volume of distribution,"A pharmacokinetic study using theophylline syrup in adult asthmatic patients demonstrated a mean apparent volume of distribution of 0.38 liters/kg, mean elimination rate constant of 0.10 hours-1, and variable rates of clearance of theophylline (total body clearance of 0.38 to 0.96 ml/kg per minute).",Comparison of clinical effects and pharmacokinetics of once-daily Uniphyl and twice-daily Theo-Dur in asthmatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083298/),[l] / [kg],0.38,218827,DB00277,Theophylline
,4083298,elimination rate constant,"A pharmacokinetic study using theophylline syrup in adult asthmatic patients demonstrated a mean apparent volume of distribution of 0.38 liters/kg, mean elimination rate constant of 0.10 hours-1, and variable rates of clearance of theophylline (total body clearance of 0.38 to 0.96 ml/kg per minute).",Comparison of clinical effects and pharmacokinetics of once-daily Uniphyl and twice-daily Theo-Dur in asthmatic patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083298/),1/[h],0.10,218828,DB00277,Theophylline
,4083298,total body clearance,"A pharmacokinetic study using theophylline syrup in adult asthmatic patients demonstrated a mean apparent volume of distribution of 0.38 liters/kg, mean elimination rate constant of 0.10 hours-1, and variable rates of clearance of theophylline (total body clearance of 0.38 to 0.96 ml/kg per minute).",Comparison of clinical effects and pharmacokinetics of once-daily Uniphyl and twice-daily Theo-Dur in asthmatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083298/),[ml] / [kg·min],0.38 to 0.96,218829,DB00277,Theophylline
,2292897,Amplitudes of,"Amplitudes of SCT (AMP) were in the range 0.31 to 2.7 and mean 24-h SCT in the range 19.8 to 119.3 mumol/L. AMP were reproducible only to TT (r = 0.97, p less than 0.001).",[Pharmacokinetics of Teolin 300 tablets and Teotard 350 capsules in asthma patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292897/),,0.31 to 2.7,219287,DB00277,Theophylline
,2292897,SCT,"Amplitudes of SCT (AMP) were in the range 0.31 to 2.7 and mean 24-h SCT in the range 19.8 to 119.3 mumol/L. AMP were reproducible only to TT (r = 0.97, p less than 0.001).",[Pharmacokinetics of Teolin 300 tablets and Teotard 350 capsules in asthma patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292897/),[μM] / [l],19.8 to 119.3,219288,DB00277,Theophylline
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.74,220019,DB00277,Theophylline
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.07,220020,DB00277,Theophylline
,7657856,half-life,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,6.6 to 9.6,220021,DB00277,Theophylline
,7657856,mean residence time,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,10.8 to 15.0,220022,DB00277,Theophylline
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00277,Theophylline
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00277,Theophylline
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00277,Theophylline
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00277,Theophylline
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00277,Theophylline
,8894505,Terminal-phase elimination half-lives,Terminal-phase elimination half-lives were 8.9 hr in sheep and 8.1 hr in cattle.,Systemic clearance and demethylation of caffeine in sheep and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894505/),h,8.9,220569,DB00277,Theophylline
,8894505,Terminal-phase elimination half-lives,Terminal-phase elimination half-lives were 8.9 hr in sheep and 8.1 hr in cattle.,Systemic clearance and demethylation of caffeine in sheep and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894505/),h,8.1,220570,DB00277,Theophylline
,1974189,clearance,"Theophylline clearance (ml/min/kg; mean +/- SD) was 1.7 +/- 0.3, 2.4 +/- 0.5, and 9.5 +/- 1.6 in groups I, II, and III, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],1.7,220673,DB00277,Theophylline
,1974189,clearance,"Theophylline clearance (ml/min/kg; mean +/- SD) was 1.7 +/- 0.3, 2.4 +/- 0.5, and 9.5 +/- 1.6 in groups I, II, and III, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],2.4,220674,DB00277,Theophylline
,1974189,clearance,"Theophylline clearance (ml/min/kg; mean +/- SD) was 1.7 +/- 0.3, 2.4 +/- 0.5, and 9.5 +/- 1.6 in groups I, II, and III, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],9.5,220675,DB00277,Theophylline
,1974189,half-life,"The half-life (harmonic mean) from 0.5 to 12 hr was 7.2, 3.6, and 0.8 hr.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,0.5 to 12,220676,DB00277,Theophylline
,1974189,half-life,"The half-life (harmonic mean) from 0.5 to 12 hr was 7.2, 3.6, and 0.8 hr.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,7.2,220677,DB00277,Theophylline
,1974189,half-life,"The half-life (harmonic mean) from 0.5 to 12 hr was 7.2, 3.6, and 0.8 hr.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,3.6,220678,DB00277,Theophylline
,1974189,half-life,"The half-life (harmonic mean) from 0.5 to 12 hr was 7.2, 3.6, and 0.8 hr.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,0.8,220679,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline (mean +/- SD) from 0 to 24 hr was 60 +/- 10, 41 +/- 6, and 13 +/- 3% of the administered dose.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,60,220680,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline (mean +/- SD) from 0 to 24 hr was 60 +/- 10, 41 +/- 6, and 13 +/- 3% of the administered dose.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,41,220681,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline (mean +/- SD) from 0 to 24 hr was 60 +/- 10, 41 +/- 6, and 13 +/- 3% of the administered dose.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,13,220682,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,10.7,220683,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,17.2,220684,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,12.2,220685,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,20.3,220686,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,19.0,220687,DB00277,Theophylline
,1974189,Mean residence time,"Mean residence time of theophylline increased from 10.7, 17.2, and 12.2 hr in the control period, to 20.3, 19.0, and 18.4 hr after 8-MOP.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),h,18.4,220688,DB00277,Theophylline
,1974189,AUC,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[h·μg] / [ml],204,220689,DB00277,Theophylline
,1974189,AUC,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[h·μg] / [ml],213,220690,DB00277,Theophylline
,1974189,AUC,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[h·μg] / [ml],555,220691,DB00277,Theophylline
,1974189,AUC,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[h·μg] / [ml],364,220692,DB00277,Theophylline
,1974189,AUC,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[h·μg] / [ml],432,220693,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.74,220694,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.57,220695,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.63,220696,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.27,220697,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.33,220698,DB00277,Theophylline
,1974189,clearance,"The AUC (microgram.hr/ml) of theophylline increased from 204, 213, and 204, to 555, 364, and 432, while clearance (ml/min/kg) decreased from 0.74, 0.57 and 0.63, to 0.27, 0.33, and 0.30, respectively.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),[ml] / [kg·min],0.30,220699,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline from 0 to 48 hr increased from 14, 14, and 15, to 24, 21, and 20%.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,14,220700,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline from 0 to 48 hr increased from 14, 14, and 15, to 24, 21, and 20%.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,15,220701,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline from 0 to 48 hr increased from 14, 14, and 15, to 24, 21, and 20%.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,24,220702,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline from 0 to 48 hr increased from 14, 14, and 15, to 24, 21, and 20%.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,21,220703,DB00277,Theophylline
,1974189,Urinary excretion,"Urinary excretion of unchanged theophylline from 0 to 48 hr increased from 14, 14, and 15, to 24, 21, and 20%.",Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974189/),%,20,220704,DB00277,Theophylline
,2064746,maximum serum concentrations,"Mean maximum serum concentrations after the loading dose were 5.8 +/- 2.3 mcg/mL in 25 newborns from group I, and 6.6 +/- 1,3 mcg/mL in 8 newborns from group II (P less than 0.20).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],5.8,221270,DB00277,Theophylline
,2064746,maximum serum concentrations,"Mean maximum serum concentrations after the loading dose were 5.8 +/- 2.3 mcg/mL in 25 newborns from group I, and 6.6 +/- 1,3 mcg/mL in 8 newborns from group II (P less than 0.20).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],6.6,221271,DB00277,Theophylline
,2064746,maximum concentration,"Mean maximum concentration after the fifth maintenance dose was 7.5 +/- 1.7 mcg/mL in 26 newborns from group I, and 5.8 +/- 1.4 mcg/mL in 16 newborns from group II (P = 0.001); mean minimum concentration was 5.3 +/- 1.6 mcg/mL and 4.5 +/- 1.4 mcg/mL, respectively (P greater than 0.10).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],7.5,221272,DB00277,Theophylline
,2064746,maximum concentration,"Mean maximum concentration after the fifth maintenance dose was 7.5 +/- 1.7 mcg/mL in 26 newborns from group I, and 5.8 +/- 1.4 mcg/mL in 16 newborns from group II (P = 0.001); mean minimum concentration was 5.3 +/- 1.6 mcg/mL and 4.5 +/- 1.4 mcg/mL, respectively (P greater than 0.10).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],5.8,221273,DB00277,Theophylline
,2064746,minimum concentration,"Mean maximum concentration after the fifth maintenance dose was 7.5 +/- 1.7 mcg/mL in 26 newborns from group I, and 5.8 +/- 1.4 mcg/mL in 16 newborns from group II (P = 0.001); mean minimum concentration was 5.3 +/- 1.6 mcg/mL and 4.5 +/- 1.4 mcg/mL, respectively (P greater than 0.10).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],5.3,221274,DB00277,Theophylline
,2064746,minimum concentration,"Mean maximum concentration after the fifth maintenance dose was 7.5 +/- 1.7 mcg/mL in 26 newborns from group I, and 5.8 +/- 1.4 mcg/mL in 16 newborns from group II (P = 0.001); mean minimum concentration was 5.3 +/- 1.6 mcg/mL and 4.5 +/- 1.4 mcg/mL, respectively (P greater than 0.10).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[mcg] / [ml],4.5,221275,DB00277,Theophylline
,2064746,clearance,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[ml] / [h·kg],30.21,221276,DB00277,Theophylline
,2064746,clearance,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[ml] / [h·kg],27.1,221277,DB00277,Theophylline
,2064746,apparent distribution volume,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[l] / [kg],0.5,221278,DB00277,Theophylline
,2064746,apparent distribution volume,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),[l] / [kg],0.76,221279,DB00277,Theophylline
,2064746,elimination rate constant,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),1/[h],0.049,221280,DB00277,Theophylline
,2064746,elimination rate constant,"Mean clearance was 30.21 +/- 11.03 and 27.1 +/- 7.7 mL/kg/h; mean apparent distribution volume was 0.5 +/- 0.25 and 0.76 +/- 0.32 L/kg; elimination rate constant was 0.049 +/- 0.04 and 0.040 +/- 0.03/h-1 for both groups respectively, with significant differences between groups only in the apparent distribution volume (P less than 0.001).",[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),1/[h],0.040,221281,DB00277,Theophylline
,2064746,Half-life time (T1/2),Half-life time (T1/2) was from four to 118 hours.,[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),h,four to 118,221282,DB00277,Theophylline
lesser,2064746,half-life time,The study population was divided into three groups according to half-life time: those with a half-life time of lesser than 20 hours (47.6%); an intermediate half-life time of from 20 to 30 hours (23.8%); and a long half-life time of more than 31 hours (28.6%).,[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),h,20,221283,DB00277,Theophylline
,2064746,half-life time,The study population was divided into three groups according to half-life time: those with a half-life time of lesser than 20 hours (47.6%); an intermediate half-life time of from 20 to 30 hours (23.8%); and a long half-life time of more than 31 hours (28.6%).,[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),h,20 to 30,221284,DB00277,Theophylline
more,2064746,half-life time,The study population was divided into three groups according to half-life time: those with a half-life time of lesser than 20 hours (47.6%); an intermediate half-life time of from 20 to 30 hours (23.8%); and a long half-life time of more than 31 hours (28.6%).,[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2064746/),h,31,221285,DB00277,Theophylline
,8620674,peak theophylline levels,"During coadministration with zileuton, mean peak theophylline levels rose from 12.14 to 20.99 mg/L (p < 0.001), while the apparent plasma clearance dropped from 3.74 to 1.91 L/h (p < 0.001).",Effect of zileuton on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620674/),[mg] / [l],12.14 to 20.99,221409,DB00277,Theophylline
,8620674,apparent plasma clearance,"During coadministration with zileuton, mean peak theophylline levels rose from 12.14 to 20.99 mg/L (p < 0.001), while the apparent plasma clearance dropped from 3.74 to 1.91 L/h (p < 0.001).",Effect of zileuton on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620674/),[l] / [h],3,221410,DB00277,Theophylline
,10939036,Cmax,"In Steps I and II, Cmax was 10.8 +/- 1.1 and 10.8 +/- 0.8 micrograms/ml, respectively.",Usefulness and safety of theophylline injection form (Theodrip) for the treatment of acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939036/),[μg] / [ml],10.8,221462,DB00277,Theophylline
,10939036,Cmax,"In Steps I and II, Cmax was 10.8 +/- 1.1 and 10.8 +/- 0.8 micrograms/ml, respectively.",Usefulness and safety of theophylline injection form (Theodrip) for the treatment of acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939036/),[μg] / [ml],10.8,221463,DB00277,Theophylline
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],39.5,221491,DB00277,Theophylline
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],28.1,221492,DB00277,Theophylline
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,7.3,221493,DB00277,Theophylline
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,10.1,221494,DB00277,Theophylline
,6845397,clearance,"Prior to barbiturate treatment, theophylline clearance was 4.78 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.78,221737,DB00277,Theophylline
,6845397,peak value,"After 29 days of barbiturate administration, theophylline clearance attained a peak value of 16.1 ml/kg/min, an increase of 337% from the prebarbiturate rate.",Effect of secobarbital on theophylline clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],16.1,221738,DB00277,Theophylline
,6845397,clearance,"After secobarbital was discontinued, theophylline clearance returned to 4.53 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.53,221739,DB00277,Theophylline
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0. 5,221769,DB00277,Theophylline
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0.3,221770,DB00277,Theophylline
,2791443,Clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],6.01 x 10(-2),222364,DB00277,Theophylline
,2791443,clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],4.09 x 10(-2),222365,DB00277,Theophylline
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,6.93,222366,DB00277,Theophylline
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,8.69,222367,DB00277,Theophylline
,2791443,mean residence time,The mean residence time for passive smokers was 9.89 hours.,Effects of passive smoking on theophylline clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,9.89,222368,DB00277,Theophylline
,2791443,mean residence time,"For nonsmokers, the mean residence time was 13.11 hours (p less than 0.05).",Effects of passive smoking on theophylline clearance. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,13.11,222369,DB00277,Theophylline
,20663043,inhibition constant (K(i)),"Aqueous extract of Danshen (125-2000 microg/ml) competitively inhibited human and rat liver microsomal CYP1A2 activity with inhibition constant (K(i)) values at 190 and 360 microg/ml, respectively.",Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663043/),[μg] / [ml],190,222713,DB00277,Theophylline
,20663043,inhibition constant (K(i)),"Aqueous extract of Danshen (125-2000 microg/ml) competitively inhibited human and rat liver microsomal CYP1A2 activity with inhibition constant (K(i)) values at 190 and 360 microg/ml, respectively.",Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663043/),[μg] / [ml],360,222714,DB00277,Theophylline
,11591894,Total body clearance,"Total body clearance of theophylline was significantly elevated in the children exposed to environmental tobacco smoke (1.36 +/- 0.09 vs. 0.90 +/- 0.04 mL/min per kg, p < 0.0001).",Effect of passive smoking on theophylline clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),[ml] / [kg·min],1.36,222801,DB00277,Theophylline
,11591894,Total body clearance,"Total body clearance of theophylline was significantly elevated in the children exposed to environmental tobacco smoke (1.36 +/- 0.09 vs. 0.90 +/- 0.04 mL/min per kg, p < 0.0001).",Effect of passive smoking on theophylline clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),[ml] / [kg·min],0.90,222802,DB00277,Theophylline
,11591894,Steady-state serum levels,Steady-state serum levels were significantly lower in the passive smoking group (55.3 +/- 2.8 vs. 73.2 +/- 3.3 p < 0.00001) for those receiving nearly identical intravenous doses.,Effect of passive smoking on theophylline clearance in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),,55.3,222803,DB00277,Theophylline
,11591894,Steady-state serum levels,Steady-state serum levels were significantly lower in the passive smoking group (55.3 +/- 2.8 vs. 73.2 +/- 3.3 p < 0.00001) for those receiving nearly identical intravenous doses.,Effect of passive smoking on theophylline clearance in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),,73.2,222804,DB00277,Theophylline
,11591894,length of hospital stay,"The length of hospital stay was longer in the group exposed to passive smoke (4.4 +/- 2.6 vs. 2.9 +/- 1.3 days, p < 0.05).",Effect of passive smoking on theophylline clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),d,4.4,222805,DB00277,Theophylline
,11591894,length of hospital stay,"The length of hospital stay was longer in the group exposed to passive smoke (4.4 +/- 2.6 vs. 2.9 +/- 1.3 days, p < 0.05).",Effect of passive smoking on theophylline clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591894/),d,2.9,222806,DB00277,Theophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,93.6,222883,DB00277,Theophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,105.6,222884,DB00277,Theophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,110.8,222885,DB00277,Theophylline
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,120.1,222886,DB00277,Theophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.89,222887,DB00277,Theophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.59,222888,DB00277,Theophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.35,222889,DB00277,Theophylline
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.20,222890,DB00277,Theophylline
,1983143,renal clearance,Unchanged drug (11.6% +/- 1.75) was excreted in the urine corresponding to a renal clearance of 10.6 +/- 1.6 mL h-1kg-1.,Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [h],10.6,222900,DB00277,Theophylline
,1983143,renal clearance,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[l] / [h·kg],0.58,222901,DB00277,Theophylline
,1983143,renal clearance,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[l] / [h·kg],0.23,222902,DB00277,Theophylline
,1983143,urine flow rate,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [min],1.1,222903,DB00277,Theophylline
,1983143,urine flow rate,"After oral administration, renal clearance of theophylline was higher at steady state than after a single dose (0.58 +/- 0.06 L h-1 kg-1 vs 0.23 +/- 0.03 L h-1 kg-1), while urine flow rate was lower (1.1 +/- 0.5 mL min-1 vs 1.8 +/- 0.9 mL min-1).",Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983143/),[ml] / [min],1.8,222904,DB00277,Theophylline
,3779037,half-life,The mean value of 5.46 h for the theophylline half-life after 48 h pretreatment with erythromycin stearate was not significantly different from the control value of 5.24 h.,Time-dependent inhibition of theophylline elimination by erythromycin stearate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3779037/),h,5.46,223738,DB00277,Theophylline
,3779037,half-life,The mean value of 5.46 h for the theophylline half-life after 48 h pretreatment with erythromycin stearate was not significantly different from the control value of 5.24 h.,Time-dependent inhibition of theophylline elimination by erythromycin stearate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3779037/),h,5.24,223739,DB00277,Theophylline
,3779037,half-life,"The half-life value of 8.48 h after a 1-week course of the antibiotic, however, represented a significant increase (p less than 0.005).",Time-dependent inhibition of theophylline elimination by erythromycin stearate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3779037/),h,8.48,223740,DB00277,Theophylline
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],57.6,224781,DB00277,Theophylline
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],39.5,224782,DB00277,Theophylline
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,8.7,224783,DB00277,Theophylline
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,12,224784,DB00277,Theophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.624,224892,DB00277,Theophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.616,224893,DB00277,Theophylline
,1506654,Volumes of distribution,Volumes of distribution of theophylline in patients with schistosomiasis (mean 0.624 l/kg) did not differ from cirrhotic patients (mean 0.616 l/kg) or normal controls (mean 0.593 l/kg).,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[l] / [kg],0.593,224894,DB00277,Theophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,22.1,224895,DB00277,Theophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,9.9,224896,DB00277,Theophylline
,1506654,half-life,"Cirrhotic patients had a prolonged half-life compared to normal subjects (mean 22.1 vs. 9.9 h), while patients with schistosomiasis did not substantially differ from normal controls (15.8 vs. 9.9 h).",Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),h,15.8,224897,DB00277,Theophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],34.02,224898,DB00277,Theophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],49.20,224899,DB00277,Theophylline
,1506654,Body clearance,Body clearance in patients with schistosomiasis was similar to controls (34.02 vs. 49.20 ml/h per kg) but decreased (29.24 ml/h per kg) in patients with cirrhosis.,Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506654/),[ml] / [h·kg],29.24,224900,DB00277,Theophylline
,7031111,apparent volume of distribution,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[l] / [kg],0.45,225059,DB00277,Theophylline
,7031111,apparent volume of distribution,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[l] / [kg],0.41,225060,DB00277,Theophylline
,7031111,clearance,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[min·ml] / [kg],0.83,225061,DB00277,Theophylline
,7031111,clearance,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),[min·ml] / [kg],0.60,225062,DB00277,Theophylline
,7031111,elimination half-life,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),h,6.65,225063,DB00277,Theophylline
,7031111,elimination half-life,"The mean +/- SD pharmacokinetic parameters for each phase of study were as follows: apparent volume of distribution (L/kg) 0.45 +/- 0.05 (control), 0.41 +/- 0.05 (experimental); clearance (ml . min/kg) 0.83 +/- 0.17 (control), 0.60 +/- 0.11 (experimental); elimination half-life (hr) 6.65 +/- 1.88 (control), 8.10 +/- 1.58 (experimental).",Effect of erythromycin on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031111/),h,8.10,225064,DB00277,Theophylline
,2923963,half-life,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),h,7.32,225219,DB00277,Theophylline
,2923963,clearance,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),[ml] / [kg·min],0.86,225220,DB00277,Theophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],8.15,226329,DB00277,Theophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],12.37,226330,DB00277,Theophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],6.26,226331,DB00277,Theophylline
,8772836,trough plasma theophylline levels,The mean trough plasma theophylline levels ranged from 8.15 +/- 1.59 to 12.37 +/- 1.54 micrograms/ml in SGA babies while in AGA babies they ranged from 6.26 +/- 1.93 to 9.96 +/- 1.96 micrograms/ml in first 8 days of therapy.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],9.96,226332,DB00277,Theophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],11.91,226333,DB00277,Theophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],17.13,226334,DB00277,Theophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],8.17,226335,DB00277,Theophylline
,8772836,peak levels,The mean peak levels in SGA babies ranged from 11.91 +/- 1.84 to 17.13 +/- 1.63 micrograms/ml and in AGA babies ranged from 8.17 +/- 1.84 to 13.02 +/- 1.48 micrograms/ml.,Kinetics of theophylline in apnea of prematurity in small for gestational age babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772836/),[μg] / [ml],13.02,226336,DB00277,Theophylline
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],107,226379,DB00277,Theophylline
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21,226380,DB00277,Theophylline
,8807660,half-life,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),h,5 to 31,226381,DB00277,Theophylline
,8807660,clearance,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],46 to 9,226382,DB00277,Theophylline
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21 to 9,226383,DB00277,Theophylline
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],14 to 6,226384,DB00277,Theophylline
,8138896,oral bioavailability,"The oral bioavailability of theophylline from this formulation in dogs was approximately 80% and was equivalent to that obtained after administration of Theo-Dur, a marketed extended-release theophylline tablet from Key Pharmaceuticals.",Sustained-release oral delivery of theophylline by use of polyvinyl alcohol and polyvinyl alcohol-methyl acrylate polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138896/),%,80,227958,DB00277,Theophylline
,7400475,peak concentration,"In the fasting subjects solutions given orally were absorbed faster (0.95 versus 1.95 hr to peak), reaching a higher peak concentration (7.26 versus 4.87 microgram/ml) than the solutions given rectally.",Bioavailability of theophylline following a rectally administered concentrated aminophylline solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400475/),[μg] / [ml],7.26,229214,DB00277,Theophylline
,7400475,peak concentration,"In the fasting subjects solutions given orally were absorbed faster (0.95 versus 1.95 hr to peak), reaching a higher peak concentration (7.26 versus 4.87 microgram/ml) than the solutions given rectally.",Bioavailability of theophylline following a rectally administered concentrated aminophylline solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400475/),[μg] / [ml],4.87,229215,DB00277,Theophylline
,3190813,Absolute bioavailability,"Absolute bioavailability of theophylline from Euphylong was 88 and 100%, depending on the rate and the total dose of the intravenous reference infusions.",Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190813/),%,88,229275,DB00277,Theophylline
,3190813,Absolute bioavailability,"Absolute bioavailability of theophylline from Euphylong was 88 and 100%, depending on the rate and the total dose of the intravenous reference infusions.",Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190813/),%,100,229276,DB00277,Theophylline
,3190813,Relative bioavailability,"Relative bioavailability ranged between 85 and 112%, depending on the reference formulations.",Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190813/),%,85 and 112,229277,DB00277,Theophylline
,3190813,plateau time,The nocturnal excess is consistently 30-40% and the plateau time is consistently 11-12 h in normal metabolizers.,Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190813/),h,11-12,229278,DB00277,Theophylline
,7177275,Total body,Total body theophylline clearance on the nondialysis day was similar to that reported for patients with normal renal function (57.4 +/- 27.2 ml/kg/h).,Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),[ml] / [h·kg],57.4,229299,DB00277,Theophylline
,7177275,clearance,Total body theophylline clearance on the nondialysis day was similar to that reported for patients with normal renal function (57.4 +/- 27.2 ml/kg/h).,Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),[ml] / [h·kg],57.4,229300,DB00277,Theophylline
,7177275,t 1/2,"Hemodialysis accelerated theophylline elimination and shortened serum theophylline half-life in all patients (nondialysis t 1/2 = 7.3 h +/- 2.3 vs. dialysis t 1/2 = 2.7 +/- 0.9 h, p less than 0.01).",Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),h,7.3,229301,DB00277,Theophylline
,7177275,t 1/2,"Hemodialysis accelerated theophylline elimination and shortened serum theophylline half-life in all patients (nondialysis t 1/2 = 7.3 h +/- 2.3 vs. dialysis t 1/2 = 2.7 +/- 0.9 h, p less than 0.01).",Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),h,2.7,229302,DB00277,Theophylline
,7177275,Di,Dialysis clearance averaged 59.7 +/- 16.4 ml/kg/h with a fraction of drug removed of 0.4 liters in 4 h.,Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),[ml] / [h·kg],59.7,229303,DB00277,Theophylline
,7177275,fraction of drug removed,Dialysis clearance averaged 59.7 +/- 16.4 ml/kg/h with a fraction of drug removed of 0.4 liters in 4 h.,Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7177275/),l,0.4,229304,DB00277,Theophylline
,2315261,clearance,Theophylline clearance was reduced from 45.2 to 36.1 ml/hr/kg (20.1%; P less than 0.005).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),[ml] / [h·kg],45.2,229862,DB00277,Theophylline
,2315261,clearance,Theophylline clearance was reduced from 45.2 to 36.1 ml/hr/kg (20.1%; P less than 0.005).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),[ml] / [h·kg],36,229863,DB00277,Theophylline
,2315261,terminal half-life,The terminal half-life of theophylline was increased from 6.80 to 8.23 hr (21.0%; P less than 0.001).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),h,6.80,229864,DB00277,Theophylline
,2315261,terminal half-life,The terminal half-life of theophylline was increased from 6.80 to 8.23 hr (21.0%; P less than 0.001).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),h,8,229865,DB00277,Theophylline
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],43,229967,DB00277,Theophylline
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],42,229968,DB00277,Theophylline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],0,230473,DB00277,Theophylline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],7.5,230474,DB00277,Theophylline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],15,230475,DB00277,Theophylline
,6840927,bioavailability,"The mean bioavailability of theophylline during a single oral dose was 97%, which did not significantly differ from the i.v. reference.",Pharmacokinetic properties of a new sustained-release theophylline preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840927/),%,97,230534,DB00277,Theophylline
,6840927,bioavailability,"The bioavailability of Teovent-SR measured during a dosing interval at steady state was on the average 110%, significantly (p less than 0.05) higher than the i.v. standard.",Pharmacokinetic properties of a new sustained-release theophylline preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840927/),%,110,230535,DB00277,Theophylline
,8193433,total body clearance,A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 +/- 2.8 to 43.4 +/- 4.7 mL/kg/h [mean +/- SEM]; p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),[ml] / [h·kg],21.7,230969,DB00277,Theophylline
,8193433,total body clearance,A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 +/- 2.8 to 43.4 +/- 4.7 mL/kg/h [mean +/- SEM]; p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),[ml] / [h·kg],43.4,230970,DB00277,Theophylline
,8193433,elimination half-life,The theophylline elimination half-life prior to treatment was 18.2 +/- 2.2 hours and decreased to 9.1 +/- 0.8 hours following treatment (p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),h,18.2,230971,DB00277,Theophylline
,8193433,elimination half-life,The theophylline elimination half-life prior to treatment was 18.2 +/- 2.2 hours and decreased to 9.1 +/- 0.8 hours following treatment (p < 0.01).,Theophylline disposition in Korean patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193433/),h,9.1,230972,DB00277,Theophylline
,2571696,clearance,The maximal value for the intestinal theophylline clearance was estimated to be 0.88 mL min-1 and it equalled the value for the intestinal blood flow at the absorptive site.,"Pharmacokinetic modelling of the effect of activated charcoal on the intestinal secretion of theophylline, using the isolated vascularly perfused rat small intestine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571696/),[ml] / [min],0.88,231570,DB00277,Theophylline
,8703669,peak,"Mean peak and trough plasma concentrations of theophylline ranged from 13.1 to 14.5 micrograms ml-1 and 11.6 to 14.2 micrograms ml-1, respectively, at steady-state when theophylline was administered with or without concurrent dosing of nefazodone.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[μg] / [ml],13.1 to 14.5,231581,DB00277,Theophylline
,8703669,trough plasma concentrations,"Mean peak and trough plasma concentrations of theophylline ranged from 13.1 to 14.5 micrograms ml-1 and 11.6 to 14.2 micrograms ml-1, respectively, at steady-state when theophylline was administered with or without concurrent dosing of nefazodone.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[μg] / [ml],11.6 to 14.2,231582,DB00277,Theophylline
,8703669,area under the curve,"Similarly, the mean area under the curve for theophylline ranged from 93.5 to 103 micrograms ml-1 h.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[h·μg] / [ml],93.5 to 103,231583,DB00277,Theophylline
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,6.72,231707,DB00277,Theophylline
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,7.02,231708,DB00277,Theophylline
,6885207,total body clearance,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),[l] / [h·kg],0.054,232144,DB00277,Theophylline
,6885207,elimination half-life,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),h,6.0,232145,DB00277,Theophylline
,6885207,volume of distribution,"The mean values and SD for total body clearance (0.054 +/- 0.010 l/[h X kg]), elimination half-life (6.0 +/- 1.2 h), and volume of distribution (0.455 +/- 0.046 l/kg) were calculated from the plasma concentration curves after the administration of elixir.",Absorption of sustained-release theophylline tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),[l] / [kg],0.455,232146,DB00277,Theophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,94,232147,DB00277,Theophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,88,232148,DB00277,Theophylline
,6885207,bioavailability,"The mean bioavailability of Theo-Dur was 94%, Phyllocontin continus 88%, and Euphyllin Retard 84%.",Absorption of sustained-release theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885207/),%,84,232149,DB00277,Theophylline
,9029748,total clearance,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],80,232162,DB00277,Theophylline
,9029748,total clearance,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],24,232163,DB00277,Theophylline
,9029748,half-life,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,6.6 to 22,232164,DB00277,Theophylline
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],17 to 1.7,232165,DB00277,Theophylline
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],8.9 to 0.9,232166,DB00277,Theophylline
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],21 to 6.8,232167,DB00277,Theophylline
,9029748,total,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],84,232168,DB00277,Theophylline
,9029748,total,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],22,232169,DB00277,Theophylline
,9029748,partial clearances,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],9.4,232170,DB00277,Theophylline
,9029748,partial clearances,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],25,232171,DB00277,Theophylline
,9029748,half-life,The half-life decreased significantly from 6.6 to 5.7 h.,Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,6.6,232172,DB00277,Theophylline
,9029748,half-life,The half-life decreased significantly from 6.6 to 5.7 h.,Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,5.7,232173,DB00277,Theophylline
,24076258,C(max),"C(max) decreased from (12.4 ± 1.6) to (8.7 ± 0.9) and (8.6 ± 2.0) mg/L, T(1/2) increased by 116 and 96%, V(d) increased by 51 and 49% for total theophylline in rats treated with dosage regimen A and B of baicalin, respectively.",Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076258/),[mg] / [l],12.4,232357,DB00277,Theophylline
,24076258,C(max),"C(max) decreased from (12.4 ± 1.6) to (8.7 ± 0.9) and (8.6 ± 2.0) mg/L, T(1/2) increased by 116 and 96%, V(d) increased by 51 and 49% for total theophylline in rats treated with dosage regimen A and B of baicalin, respectively.",Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076258/),[mg] / [l],8.7,232358,DB00277,Theophylline
,24076258,C(max),"C(max) decreased from (12.4 ± 1.6) to (8.7 ± 0.9) and (8.6 ± 2.0) mg/L, T(1/2) increased by 116 and 96%, V(d) increased by 51 and 49% for total theophylline in rats treated with dosage regimen A and B of baicalin, respectively.",Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076258/),[mg] / [l],8.6,232359,DB00277,Theophylline
,24076258,K(i),"Baicalin decreased metabolism of phenacetin and exhibited a mixed-type inhibition in rat liver microsomes, with a K(i) value of 88.1 μM in vitro.",Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076258/),μM,88.1,232360,DB00277,Theophylline
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[mg] / [h·kg],22.6,232722,DB00277,Theophylline
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[ml] / [h·kg],36.1,232723,DB00277,Theophylline
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[ml] / [h·kg],60.9,232724,DB00277,Theophylline
,33951339,tmax,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,1.5,232747,DB00277,Theophylline
,33951339,tmax,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,3.0,232748,DB00277,Theophylline
,33951339,t1/2,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,5.,232749,DB00277,Theophylline
,33951339,t1/2,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,10,232750,DB00277,Theophylline
,33951339,tmax,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,8,232751,DB00277,Theophylline
,33951339,t1/2,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,7.2,232752,DB00277,Theophylline
,33951339,t1/2,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,13,232753,DB00277,Theophylline
,25323694,peak concentrations (C max),"Following intravenous and oral administration, the peak concentrations (C max) were found to be (16.5 ± 3.0) µg/mL at (0.08 ± 0) h and (7.4 ± 1.5) µg/mL at (1.83 ± 1.11) h, respectively.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[μg] / [ml],16.5,233299,DB00277,Theophylline
,25323694,peak concentrations (C max),"Following intravenous and oral administration, the peak concentrations (C max) were found to be (16.5 ± 3.0) µg/mL at (0.08 ± 0) h and (7.4 ± 1.5) µg/mL at (1.83 ± 1.11) h, respectively.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[μg] / [ml],7.4,233300,DB00277,Theophylline
,25323694,elimination half-time (t 1/2),"The elimination half-time (t 1/2) after intravenous and oral administration were, respectively, (13.1 ± 4.17) h and (11.65 ± 1.14) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,13.1,233301,DB00277,Theophylline
,25323694,elimination half-time (t 1/2),"The elimination half-time (t 1/2) after intravenous and oral administration were, respectively, (13.1 ± 4.17) h and (11.65 ± 1.14) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,11.65,233302,DB00277,Theophylline
,25323694,Areas under the plasma concentration-time curve (AUC),"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],209.6,233303,DB00277,Theophylline
,25323694,AUC0-t,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],209.6,233304,DB00277,Theophylline
,25323694,AUC0→∞,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],219.5,233305,DB00277,Theophylline
,25323694,AUC0-t,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],165.1,233306,DB00277,Theophylline
,25323694,AUC0→∞,"Areas under the plasma concentration-time curve (AUC) were (209.6 ± 22.8) µg h mL(-1)(AUC0-t ) and (219.5 ± 28.3) µg h mL(-1) (AUC0→∞ ) after intravenous, and (165.1 ± 37.0) µg h mL(-1)(AUC0-t ) and (179.3 ± 35.6) µg h mL(-1) (AUC0→∞ ) after oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[h·μg] / [ml],179.3,233307,DB00277,Theophylline
,25323694,retention time (MRT),"Mean retention time (MRT) after intravenous and oral administration were, respectively, (14.06 ± 0.86) and (15.27 ± 0.62) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,14.06,233308,DB00277,Theophylline
,25323694,retention time (MRT),"Mean retention time (MRT) after intravenous and oral administration were, respectively, (14.06 ± 0.86) and (15.27 ± 0.62) h.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),h,15.27,233309,DB00277,Theophylline
,25323694,total clearance rates (CLtol),The total clearance rates (CLtol) were (0.77 ± 0.10) mL min(-1) kg(-1) of intravenous and (0.97 ± 0.20) mL min(-1) kg(-1) of oral administration.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[ml] / [kg·min],0.77,233310,DB00277,Theophylline
,25323694,total clearance rates (CLtol),The total clearance rates (CLtol) were (0.77 ± 0.10) mL min(-1) kg(-1) of intravenous and (0.97 ± 0.20) mL min(-1) kg(-1) of oral administration.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[ml] / [kg·min],0.97,233311,DB00277,Theophylline
,25323694,apparent distribution volume (V d),"The apparent distribution volume (V d) was (0.87 ± 0.27) and (0.97 ± 0.20) L kg(-1), respectively, for intravenous and oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[l] / [kg],0.87,233312,DB00277,Theophylline
,25323694,apparent distribution volume (V d),"The apparent distribution volume (V d) was (0.87 ± 0.27) and (0.97 ± 0.20) L kg(-1), respectively, for intravenous and oral administration.",Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),[l] / [kg],0.97,233313,DB00277,Theophylline
,25323694,absolute bioavailability (F),The absolute bioavailability (F) after oral administration was (83.1 ± 11.7) %.,Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323694/),%,83.1,233314,DB00277,Theophylline
,7648380,clearance,"Twenty-four adult male volunteers with average theophylline clearance (3.0 and 5.5 L.h-1) received three treatments on separate occasions: Uni-Dur 800 mg once-daily, Uni-Dur 400 mg twice-daily, and Uniphyl 800 mg once-daily.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),[l] / [h],3.0,233321,DB00277,Theophylline
,7648380,clearance,"Twenty-four adult male volunteers with average theophylline clearance (3.0 and 5.5 L.h-1) received three treatments on separate occasions: Uni-Dur 800 mg once-daily, Uni-Dur 400 mg twice-daily, and Uniphyl 800 mg once-daily.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),[l] / [h],5.5,233322,DB00277,Theophylline
,7648380,area under the plasma concentration-time curve (AUC,"The area under the plasma concentration-time curve (AUC; microgram.mL-1.h) for theophylline over 24 hours on day 5 was 187 for Uni-Dur 800 mg once-daily, 187 for Uni-Dur 400 mg twice-daily, and 172 for Uniphyl 800 mg once-daily; the peak plasma concentrations were 10.4, 9.4, and 11.0 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),[h·μg] / [ml],187,233323,DB00277,Theophylline
,7648380,area under the plasma concentration-time curve (AUC,"The area under the plasma concentration-time curve (AUC; microgram.mL-1.h) for theophylline over 24 hours on day 5 was 187 for Uni-Dur 800 mg once-daily, 187 for Uni-Dur 400 mg twice-daily, and 172 for Uniphyl 800 mg once-daily; the peak plasma concentrations were 10.4, 9.4, and 11.0 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,172,233324,DB00277,Theophylline
,7648380,peak plasma concentrations,"The area under the plasma concentration-time curve (AUC; microgram.mL-1.h) for theophylline over 24 hours on day 5 was 187 for Uni-Dur 800 mg once-daily, 187 for Uni-Dur 400 mg twice-daily, and 172 for Uniphyl 800 mg once-daily; the peak plasma concentrations were 10.4, 9.4, and 11.0 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,10.4,233325,DB00277,Theophylline
,7648380,peak plasma concentrations,"The area under the plasma concentration-time curve (AUC; microgram.mL-1.h) for theophylline over 24 hours on day 5 was 187 for Uni-Dur 800 mg once-daily, 187 for Uni-Dur 400 mg twice-daily, and 172 for Uniphyl 800 mg once-daily; the peak plasma concentrations were 10.4, 9.4, and 11.0 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,9.4,233326,DB00277,Theophylline
,7648380,peak plasma concentrations,"The area under the plasma concentration-time curve (AUC; microgram.mL-1.h) for theophylline over 24 hours on day 5 was 187 for Uni-Dur 800 mg once-daily, 187 for Uni-Dur 400 mg twice-daily, and 172 for Uniphyl 800 mg once-daily; the peak plasma concentrations were 10.4, 9.4, and 11.0 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,11.0,233327,DB00277,Theophylline
,7648380,trough concentrations,"mL-1 and the trough concentrations were 5.5, 7.2, and 3.5 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,5.5,233328,DB00277,Theophylline
,7648380,trough concentrations,"mL-1 and the trough concentrations were 5.5, 7.2, and 3.5 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,7.2,233329,DB00277,Theophylline
,7648380,trough concentrations,"mL-1 and the trough concentrations were 5.5, 7.2, and 3.5 micrograms.",Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648380/),μg,3.5,233330,DB00277,Theophylline
,6507464,bioavailability,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),%,74 to 81,233352,DB00277,Theophylline
,6507464,plasma clearance,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),[l] / [h],22 to 24,233353,DB00277,Theophylline
,6628514,half-life,The dyphylline half-life for the solution was 2.16 +/- 0.18 h and for the tablet 2.59 +/- 0.56 h.,Pharmacokinetics and bioavailability of three dyphylline preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),h,2.16,233435,DB00277,Theophylline
,6628514,half-life,The dyphylline half-life for the solution was 2.16 +/- 0.18 h and for the tablet 2.59 +/- 0.56 h.,Pharmacokinetics and bioavailability of three dyphylline preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),h,2.59,233436,DB00277,Theophylline
,6628514,clearance rate,The mean clearance rate for S was 13.6 +/- 1.7 h-1 and volume of distribution 43.0 +/- 3.91.,Pharmacokinetics and bioavailability of three dyphylline preparations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),1/[h],13.6,233437,DB00277,Theophylline
,6628514,volume of distribution,The mean clearance rate for S was 13.6 +/- 1.7 h-1 and volume of distribution 43.0 +/- 3.91.,Pharmacokinetics and bioavailability of three dyphylline preparations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,43.0,233438,DB00277,Theophylline
,6628514,Cmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),[μg] / [ml],33.7,233439,DB00277,Theophylline
,6628514,Cmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),[μg] / [ml],27.7,233440,DB00277,Theophylline
,6628514,Cmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,10.4,233441,DB00277,Theophylline
,6628514,Tmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,0.33,233442,DB00277,Theophylline
,6628514,Tmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,0.66,233443,DB00277,Theophylline
,6628514,Tmax,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,2.13,233444,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,2.13,233445,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,108.4,233446,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,113.9,233447,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,104.0,233448,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,105.00,233449,DB00277,Theophylline
,6628514,AUC,"Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00",Pharmacokinetics and bioavailability of three dyphylline preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628514/),,100.00,233450,DB00277,Theophylline
,6473926,t1/2,"Significant prolongations of the half-life (t1/2) of the drug and reductions in its body clearance were observed during exercise to 30% of VO2, max both at 22 and 40 degrees C, as well as during exercise to 50% of VO2, max at 22 degrees C. t1/2 was (mean +/- SEM) 8.5 +/- 0.8, 8.0 +/- 1.0 and 7.2 +/- 1.0 h at the three exercise sessions, respectively, compared with 6.4 +/- 0.9 h at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),h,8.5,233807,DB00277,Theophylline
,6473926,t1/2,"Significant prolongations of the half-life (t1/2) of the drug and reductions in its body clearance were observed during exercise to 30% of VO2, max both at 22 and 40 degrees C, as well as during exercise to 50% of VO2, max at 22 degrees C. t1/2 was (mean +/- SEM) 8.5 +/- 0.8, 8.0 +/- 1.0 and 7.2 +/- 1.0 h at the three exercise sessions, respectively, compared with 6.4 +/- 0.9 h at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),h,8.0,233808,DB00277,Theophylline
,6473926,t1/2,"Significant prolongations of the half-life (t1/2) of the drug and reductions in its body clearance were observed during exercise to 30% of VO2, max both at 22 and 40 degrees C, as well as during exercise to 50% of VO2, max at 22 degrees C. t1/2 was (mean +/- SEM) 8.5 +/- 0.8, 8.0 +/- 1.0 and 7.2 +/- 1.0 h at the three exercise sessions, respectively, compared with 6.4 +/- 0.9 h at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),h,7.2,233809,DB00277,Theophylline
,6473926,t1/2,"Significant prolongations of the half-life (t1/2) of the drug and reductions in its body clearance were observed during exercise to 30% of VO2, max both at 22 and 40 degrees C, as well as during exercise to 50% of VO2, max at 22 degrees C. t1/2 was (mean +/- SEM) 8.5 +/- 0.8, 8.0 +/- 1.0 and 7.2 +/- 1.0 h at the three exercise sessions, respectively, compared with 6.4 +/- 0.9 h at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),h,6.4,233810,DB00277,Theophylline
,6473926,Plasma clearances,"Plasma clearances at the three exercise sessions were 0.70 +/- 0.09, 0.62 +/- 0.1 and 0.75 +/- 0.09 ml/min/kg, respectively, compared with 0.99 +/- 0.13 ml/min/kg at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),[ml] / [kg·min],0.70,233811,DB00277,Theophylline
,6473926,Plasma clearances,"Plasma clearances at the three exercise sessions were 0.70 +/- 0.09, 0.62 +/- 0.1 and 0.75 +/- 0.09 ml/min/kg, respectively, compared with 0.99 +/- 0.13 ml/min/kg at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),[ml] / [kg·min],0.62,233812,DB00277,Theophylline
,6473926,Plasma clearances,"Plasma clearances at the three exercise sessions were 0.70 +/- 0.09, 0.62 +/- 0.1 and 0.75 +/- 0.09 ml/min/kg, respectively, compared with 0.99 +/- 0.13 ml/min/kg at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),[ml] / [kg·min],0.75,233813,DB00277,Theophylline
,6473926,Plasma clearances,"Plasma clearances at the three exercise sessions were 0.70 +/- 0.09, 0.62 +/- 0.1 and 0.75 +/- 0.09 ml/min/kg, respectively, compared with 0.99 +/- 0.13 ml/min/kg at rest.",Effect of exercise and environmental heat on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473926/),[ml] / [kg·min],0.99,233814,DB00277,Theophylline
,3975263,Clearance,"Clearance decreased as the dose of theophylline increased going from 0.064 +/- 0.016 to 0.052 +/- 0.011 1.h-1.kg-1 at the 2 and 6 mg/kg doses, respectively (p less than 0.02).",Theophylline kinetics: dose dependency and single sample prediction of clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975263/),[1] / [h·kg],0.064,233988,DB00277,Theophylline
,3975263,Clearance,"Clearance decreased as the dose of theophylline increased going from 0.064 +/- 0.016 to 0.052 +/- 0.011 1.h-1.kg-1 at the 2 and 6 mg/kg doses, respectively (p less than 0.02).",Theophylline kinetics: dose dependency and single sample prediction of clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975263/),[1] / [h·kg],0.052,233989,DB00277,Theophylline
,1862252,clearance,"With respect to 10 controls, theophylline clearance was found to be significantly reduced (30 +/- 2 vs. 75 +/- 11 ml/kg/h, mean +/- SD, p less than 0.01).",Theophylline pharmacokinetics and liver function indexes in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862252/),[ml] / [h·kg],30,234158,DB00277,Theophylline
,1862252,clearance,"With respect to 10 controls, theophylline clearance was found to be significantly reduced (30 +/- 2 vs. 75 +/- 11 ml/kg/h, mean +/- SD, p less than 0.01).",Theophylline pharmacokinetics and liver function indexes in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862252/),[ml] / [h·kg],75,234159,DB00277,Theophylline
less,1993318,clearance rates,"For clearance rates less than or equal to 0.6 mL/(kg.min), the TE (CV) must not exceed 3% if the predicted infusion rate is to produce, with 95% confidence, a concentration within the therapeutic range.",Analytical goals for determinations of theophylline concentration in serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1993318/),[ml] / [kg·min],0.6,234308,DB00277,Theophylline
,3207556,"oral clearance of theophylline at steady state, (CL/F)ss","The oral clearance of theophylline at steady state, (CL/F)ss, decreased from a mean (+/- s.d.) value of 0.035 (+/- 0.008) 1 h-1 kg-1 to 0.024 (+/- 0.004) 1 h-1 kg-1 during ciprofloxacin treatment.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.035,234462,DB00277,Theophylline
,3207556,"oral clearance of theophylline at steady state, (CL/F)ss","The oral clearance of theophylline at steady state, (CL/F)ss, decreased from a mean (+/- s.d.) value of 0.035 (+/- 0.008) 1 h-1 kg-1 to 0.024 (+/- 0.004) 1 h-1 kg-1 during ciprofloxacin treatment.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.024,234463,DB00277,Theophylline
,3207556,"clearance, CL/F","Single sample estimates of theophylline clearance, CL/F, similarly decreased from 0.040 (+/- 0.014) 1 h-1 kg-1 to 0.018 (+/- 0.008) 1 h-1 kg-1.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.040,234464,DB00277,Theophylline
,3207556,"clearance, CL/F","Single sample estimates of theophylline clearance, CL/F, similarly decreased from 0.040 (+/- 0.014) 1 h-1 kg-1 to 0.018 (+/- 0.008) 1 h-1 kg-1.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.018,234465,DB00277,Theophylline
,9840213,%AUCF,The average %AUCF for the core-in-cup tablet was 9.26+/-3.15 while that for the core only tablet was 16.19+/-2.37 (p = 0.0545).,Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840213/),,9.26,234961,DB00277,Theophylline
,9840213,%AUCF,The average %AUCF for the core-in-cup tablet was 9.26+/-3.15 while that for the core only tablet was 16.19+/-2.37 (p = 0.0545).,Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840213/),,16.19,234962,DB00277,Theophylline
,26194842,flow rate,"Separation was performed on Waters(®) C18 column (µBondapak™ 5 µm, 150 × 3.9 mm) using a mobile phase consisting of water-acetonitrile (96:4 v/v) at a flow rate of 1 mL/min.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),[ml] / [min],1,235179,DB00277,Theophylline
,26194842,extraction recoveries,"The extraction recoveries of theophylline at the three levels of quality control samples were 63.1, 69.4 and 69.7%.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),%,63.1,235180,DB00277,Theophylline
,26194842,extraction recoveries,"The extraction recoveries of theophylline at the three levels of quality control samples were 63.1, 69.4 and 69.7%.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),%,69.4,235181,DB00277,Theophylline
,26194842,extraction recoveries,"The extraction recoveries of theophylline at the three levels of quality control samples were 63.1, 69.4 and 69.7%.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),%,69.7,235182,DB00277,Theophylline
,26194842,retention time,"The method was rapid with retention time of theophylline and the internal standard observed at ∼5.2 and 6.5 min, respectively.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),min,∼5.2,235183,DB00277,Theophylline
,26194842,retention time,"The method was rapid with retention time of theophylline and the internal standard observed at ∼5.2 and 6.5 min, respectively.",A simple HPLC-UV method for the quantification of theophylline in rabbit plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194842/),min,6.5,235184,DB00277,Theophylline
,23871018,total run time,Each sample was run at 0.5 mL/min for a total run time of 7 min/sample.,Simultaneous quantification of caffeine and its three primary metabolites in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23871018/),[min] / [sample],7,235555,DB00277,Theophylline
,8403737,urinary recovery,"However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%).",The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403737/),%,37,235590,DB00277,Theophylline
,8403737,urinary recovery,"However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%).",The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403737/),%,74,235591,DB00277,Theophylline
,8062311,steady state serum theophylline concentrations (STCs),Ten patients with acute exacerbation of asthma receiving IV theophylline for > or = 48 hours and with steady state serum theophylline concentrations (STCs) between 4.5 and 15.5 mg/L (25 and 86 mumol/L) were enrolled into the study.,Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[mg] / [l],4.5 and 15.5,235624,DB00277,Theophylline
,8062311,steady state serum theophylline concentrations (STCs),Ten patients with acute exacerbation of asthma receiving IV theophylline for > or = 48 hours and with steady state serum theophylline concentrations (STCs) between 4.5 and 15.5 mg/L (25 and 86 mumol/L) were enrolled into the study.,Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[μM] / [l],25 and 86,235625,DB00277,Theophylline
,8062311,area under the curve,"The differences in the area under the curve values between Uniphyl dosing and IV theophylline were 11% in the NTL group (1214.6 +/- 247.9 mumol/h.L-1 vs 1370.4 +/- 148.1 mumol/h.L-1, 95% confidence interval, 74% to 103%; P = 0.068) and 10% in the TL group (1959.4 +/- 165.1 mumol/h.L-1 vs 1784.6 +/- 119.4 mumol/h.L-1, 95% confidence interval, 103% to 117%; P = 0.013).",Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[μM] / [h·l],1214.6,235626,DB00277,Theophylline
,8062311,area under the curve,"The differences in the area under the curve values between Uniphyl dosing and IV theophylline were 11% in the NTL group (1214.6 +/- 247.9 mumol/h.L-1 vs 1370.4 +/- 148.1 mumol/h.L-1, 95% confidence interval, 74% to 103%; P = 0.068) and 10% in the TL group (1959.4 +/- 165.1 mumol/h.L-1 vs 1784.6 +/- 119.4 mumol/h.L-1, 95% confidence interval, 103% to 117%; P = 0.013).",Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[μM] / [h·l],1370.4,235627,DB00277,Theophylline
,8062311,area under the curve,"The differences in the area under the curve values between Uniphyl dosing and IV theophylline were 11% in the NTL group (1214.6 +/- 247.9 mumol/h.L-1 vs 1370.4 +/- 148.1 mumol/h.L-1, 95% confidence interval, 74% to 103%; P = 0.068) and 10% in the TL group (1959.4 +/- 165.1 mumol/h.L-1 vs 1784.6 +/- 119.4 mumol/h.L-1, 95% confidence interval, 103% to 117%; P = 0.013).",Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[μM] / [h·l],1959.4,235628,DB00277,Theophylline
,8062311,area under the curve,"The differences in the area under the curve values between Uniphyl dosing and IV theophylline were 11% in the NTL group (1214.6 +/- 247.9 mumol/h.L-1 vs 1370.4 +/- 148.1 mumol/h.L-1, 95% confidence interval, 74% to 103%; P = 0.068) and 10% in the TL group (1959.4 +/- 165.1 mumol/h.L-1 vs 1784.6 +/- 119.4 mumol/h.L-1, 95% confidence interval, 103% to 117%; P = 0.013).",Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062311/),[μM] / [h·l],1784.6,235629,DB00277,Theophylline
,10366903,RSD%,RSD% of 0.5% have become standard for quality control assays.,Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),%,0.5,236201,DB00277,Theophylline
,10366903,total analysis time,"A number of pharmaceuticals (e.g. acetaminophen, salicylic acid, sulfamethoxazole, theophylline, tolbutamide, and trimethoprim) have been determined in human plasma on underivatized fused silica capillaries by MEKC without sample pretreatment, the total analysis time being only 10 min.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),min,10,236202,DB00277,Theophylline
,10366903,detection limit,"The separation system is tested in a concentration range between 10 ng/mL and 100 micrograms/mL, the detection limit being about 5 ng/mL.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),[ng] / [ml],5,236203,DB00277,Theophylline
,18379181,oral clearance,"The mean oral clearance was 0.0249 (l/h), and the inter- and intraindividual variation was 30.3% and 28.3%, respectively, in the basic model.",[Population pharmacokinetic analysis of two theophylline formulations in premature neonates and infants with apnea]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18379181/),[l] / [h],0.0249,237171,DB00277,Theophylline
,2121750,clearance,Group I patients had a lower mean theophylline clearance of 0.42 +/- 0.23 ml/kg/min compared to Group II 0.64 +/- 0.24 ml/kg/min (P = 0.003).,Theophylline plasma clearance in critically ill geriatric patients receiving total parenteral nutrition and in control patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121750/),[ml] / [kg·min],0.42,237212,DB00277,Theophylline
,2121750,clearance,Group I patients had a lower mean theophylline clearance of 0.42 +/- 0.23 ml/kg/min compared to Group II 0.64 +/- 0.24 ml/kg/min (P = 0.003).,Theophylline plasma clearance in critically ill geriatric patients receiving total parenteral nutrition and in control patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121750/),[ml] / [kg·min],0.64,237213,DB00277,Theophylline
,7164821,half-time,"The absorption of theophylline both from the tablets and from the solution was rapid (mean half-time 14.3 and 16.1 min., respectively) and almost complete.",Pharmacokinetics and dose regimen of oral theophylline in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7164821/),min,14.3,237558,DB00277,Theophylline
,7164821,half-time,"The absorption of theophylline both from the tablets and from the solution was rapid (mean half-time 14.3 and 16.1 min., respectively) and almost complete.",Pharmacokinetics and dose regimen of oral theophylline in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7164821/),min,16.1,237559,DB00277,Theophylline
,2792166,half-life,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.7,237637,DB00277,Theophylline
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.514,237638,DB00277,Theophylline
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.5,237639,DB00277,Theophylline
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.519,237640,DB00277,Theophylline
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.63,237641,DB00277,Theophylline
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.65,237642,DB00277,Theophylline
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.6,237643,DB00277,Theophylline
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,5.5,237644,DB00277,Theophylline
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.64,237645,DB00277,Theophylline
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.22,237646,DB00277,Theophylline
,2792166,half-life,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,6.2,237647,DB00277,Theophylline
,2792166,clearance,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.03,237648,DB00277,Theophylline
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00277,Theophylline
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00277,Theophylline
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00277,Theophylline
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00277,Theophylline
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00277,Theophylline
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00277,Theophylline
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00277,Theophylline
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00277,Theophylline
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00277,Theophylline
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00277,Theophylline
,909026,clearance,"The resulting steady-state serum concentrations increased to a greater degree than would have been predicted if increases in serum concentration were proportional to changes in dose, and the subsequent calculation of clearance revealed values of 1.37 +/- 0.09 ml/kg/minute (mean +/- SE of the mean) at the lower infusion rate and of 1.21 +/- 0.06 ml/kg/minute at the higher infusion rate (p less than 0.02).",Dose-dependent kinetics of theophylline disposition in asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/909026/),[ml] / [kg·min],1.37,238346,DB00277,Theophylline
,909026,clearance,"The resulting steady-state serum concentrations increased to a greater degree than would have been predicted if increases in serum concentration were proportional to changes in dose, and the subsequent calculation of clearance revealed values of 1.37 +/- 0.09 ml/kg/minute (mean +/- SE of the mean) at the lower infusion rate and of 1.21 +/- 0.06 ml/kg/minute at the higher infusion rate (p less than 0.02).",Dose-dependent kinetics of theophylline disposition in asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/909026/),[ml] / [kg·min],1.21,238347,DB00277,Theophylline
,3694539,total volume of,"The total volume of theophylline distribution averaged 0.72 +/- 0.09 liters/kg (+/- S.D.), indicating net tissue binding as reflected in a tissue/intracellular water partition coefficient of 1.17 +/- 0.10.",Theophylline distribution kinetics analyzed by reference to simultaneously injected urea and inulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694539/),[l] / [kg],0.72,238486,DB00277,Theophylline
,3694539,tissue/intracellular water partition coefficient,"The total volume of theophylline distribution averaged 0.72 +/- 0.09 liters/kg (+/- S.D.), indicating net tissue binding as reflected in a tissue/intracellular water partition coefficient of 1.17 +/- 0.10.",Theophylline distribution kinetics analyzed by reference to simultaneously injected urea and inulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694539/),,1.17,238487,DB00277,Theophylline
,3694539,intercompartmental clearances,Cardiac output measurements averaged 4.78 +/- 0.95 liters/min and were similar to the sum of compartmental blood flows estimated from the intercompartmental clearances of urea and inulin (4.62 +/- 1.10 liters/min) and to the sum of theophylline intercompartmental clearances (5.10 +/- 1.29 liters/min).,Theophylline distribution kinetics analyzed by reference to simultaneously injected urea and inulin. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694539/),[l] / [min],4.62,238488,DB00277,Theophylline
,3694539,intercompartmental clearances,Cardiac output measurements averaged 4.78 +/- 0.95 liters/min and were similar to the sum of compartmental blood flows estimated from the intercompartmental clearances of urea and inulin (4.62 +/- 1.10 liters/min) and to the sum of theophylline intercompartmental clearances (5.10 +/- 1.29 liters/min).,Theophylline distribution kinetics analyzed by reference to simultaneously injected urea and inulin. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694539/),[l] / [min],5.10,238489,DB00277,Theophylline
,6629546,t1/2abs,"Theophylline was rapidly absorbed from the Theodel tablet, with a t1/2abs of 0.44 +/- 0.37 h; maximum plasma concentrations of 8.0 +/- 2.3 mg/l were reached after 1.8 +/- 0.8 h.","Bioavailability of Theodel, a new theophylline tablet, in humans. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629546/),h,0.44,238928,DB00277,Theophylline
,6629546,maximum plasma concentrations,"Theophylline was rapidly absorbed from the Theodel tablet, with a t1/2abs of 0.44 +/- 0.37 h; maximum plasma concentrations of 8.0 +/- 2.3 mg/l were reached after 1.8 +/- 0.8 h.","Bioavailability of Theodel, a new theophylline tablet, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629546/),[mg] / [l],8.0,238929,DB00277,Theophylline
,6629546,plasma elimination half-life,The plasma elimination half-life ranged from 5.9 to 10.4 h.,"Bioavailability of Theodel, a new theophylline tablet, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629546/),h,5.9 to 10.4,238930,DB00277,Theophylline
,6629546,plasma clearance,"Based on the assumption that absorption is complete, the plasma clearance ranged from 0.028 to 0.048 1 X h-1 X kg-1, and the apparent volume of distribution from 0.38 to 0.57 1/kg.","Bioavailability of Theodel, a new theophylline tablet, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629546/),[1] / [h·kg],0.028 to 0.048,238931,DB00277,Theophylline
,6629546,apparent volume of distribution,"Based on the assumption that absorption is complete, the plasma clearance ranged from 0.028 to 0.048 1 X h-1 X kg-1, and the apparent volume of distribution from 0.38 to 0.57 1/kg.","Bioavailability of Theodel, a new theophylline tablet, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629546/),[1] / [kg],0.38 to 0.57,238932,DB00277,Theophylline
,3663446,root mean squared prediction errors,"The corresponding root mean squared prediction errors (precision) were 2.59 and 1.17 mg l-1, respectively.",The accuracy of a pharmacokinetic theophylline predictor using once daily dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663446/),[mg] / [l],2.59,239971,DB00277,Theophylline
,3663446,root mean squared prediction errors,"The corresponding root mean squared prediction errors (precision) were 2.59 and 1.17 mg l-1, respectively.",The accuracy of a pharmacokinetic theophylline predictor using once daily dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663446/),[mg] / [l],1.17,239972,DB00277,Theophylline
,1762184,plasma clearance,"Decreased plasma clearance of theophylline was noted in patients with liver cirrhosis and the clearance was significantly lower in Child C group than in Child A, B groups (17.5 +/- 3.4 ml/Kg/hr vs 27.6 +/- 8.7, p less than 0.05).",[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762184/),[ml] / [h·kg],17.5,240237,DB00277,Theophylline
,1762184,plasma clearance,"Decreased plasma clearance of theophylline was noted in patients with liver cirrhosis and the clearance was significantly lower in Child C group than in Child A, B groups (17.5 +/- 3.4 ml/Kg/hr vs 27.6 +/- 8.7, p less than 0.05).",[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762184/),,27.6,240238,DB00277,Theophylline
,1762184,clearance,"Decreased plasma clearance of theophylline was noted in patients with liver cirrhosis and the clearance was significantly lower in Child C group than in Child A, B groups (17.5 +/- 3.4 ml/Kg/hr vs 27.6 +/- 8.7, p less than 0.05).",[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762184/),[ml] / [h·kg],17.5,240239,DB00277,Theophylline
,1762184,clearance,"Decreased plasma clearance of theophylline was noted in patients with liver cirrhosis and the clearance was significantly lower in Child C group than in Child A, B groups (17.5 +/- 3.4 ml/Kg/hr vs 27.6 +/- 8.7, p less than 0.05).",[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762184/),,27.6,240240,DB00277,Theophylline
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,5.2,240577,DB00277,Theophylline
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,8.2,240578,DB00277,Theophylline
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],16.3,240579,DB00277,Theophylline
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],25.9,240580,DB00277,Theophylline
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],106,240581,DB00277,Theophylline
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],58.2,240582,DB00277,Theophylline
,10893702,plasma concentrations,"2) After the intravenous bolus injection (30 sec) and the 15-min constant rate infusion of theophylline to dogs, the plasma concentrations of theophylline were 27.37 +/- 3.67 micrograms/ml and 18.34 +/- 2.32 micrograms/ml immediately after the completion of administration, respectively.",Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893702/),[μg] / [ml],27.37,241263,DB00277,Theophylline
,10893702,plasma concentrations,"2) After the intravenous bolus injection (30 sec) and the 15-min constant rate infusion of theophylline to dogs, the plasma concentrations of theophylline were 27.37 +/- 3.67 micrograms/ml and 18.34 +/- 2.32 micrograms/ml immediately after the completion of administration, respectively.",Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893702/),[μg] / [ml],18.34,241264,DB00277,Theophylline
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,10.8,242191,DB00277,Theophylline
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,9.9,242192,DB00277,Theophylline
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242193,DB00277,Theophylline
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242194,DB00277,Theophylline
,20669017,apparent volume of distribution [Vd(ss)],"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[l] / [kg],0.45,242773,DB00277,Theophylline
,20669017,terminal elimination half-life (t(1/2) (β)),"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),h,4.08,242774,DB00277,Theophylline
,20669017,systemic clearance (Cl),"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[ml] / [kg·min],0.75,242775,DB00277,Theophylline
,20669017,V(max),"PX was rapidly formed in liver, showing saturable-kinetic properties in this organ, with V(max) 8.11 μg/g h and K(m) 12.58 μg/g.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[μg] / [g·h],8.11,242776,DB00277,Theophylline
,20669017,K(m),"PX was rapidly formed in liver, showing saturable-kinetic properties in this organ, with V(max) 8.11 μg/g h and K(m) 12.58 μg/g.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[μg] / [g],12.58,242777,DB00277,Theophylline
,20669017,half-life (t(1/2 el)),"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),h,2.12,242778,DB00277,Theophylline
,20669017,Vd(ss),"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[l] / [kg],0.35,242779,DB00277,Theophylline
,20669017,Cl,"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[ml] / [kg·min],1.24,242780,DB00277,Theophylline
,20159037,C(max),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),[μg] / [ml],6.05,243322,DB00277,Theophylline
,20159037,C(max),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),[μg] / [ml],2.55,243323,DB00277,Theophylline
,20159037,AUC(0-infinity),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),[h·μg] / [ml],70.24,243324,DB00277,Theophylline
,20159037,AUC(0-infinity),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),[h·μg] / [ml],33.00,243325,DB00277,Theophylline
,20159037,T(max),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),h,6.00,243326,DB00277,Theophylline
,20159037,T(max),"Significant differences (p<0.05) in the plasma concentration-time curves between the two formulations were found, with higher C(max) (6.05+/-2.00 vs. 2.55+/-0.82 microg/mL), higher AUC(0-infinity) (70.24+/-16.10 vs. 33.00+/-8.96 h microg/mL) and delayed T(max) (6.00+/-2.12 vs. 3.17+/-0.98 h) for the formulation containing PEG 6000.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),h,3.17,243327,DB00277,Theophylline
,20159037,Absolute bioavailability,"Absolute bioavailability of theophylline was 96% and 46% for the formulations containing PEG 6000 and glycerol monostearate, respectively.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),%,96,243328,DB00277,Theophylline
,20159037,Absolute bioavailability,"Absolute bioavailability of theophylline was 96% and 46% for the formulations containing PEG 6000 and glycerol monostearate, respectively.",In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159037/),%,46,243329,DB00277,Theophylline
,3550629,elimination half-life,"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),h,8.70,243342,DB00277,Theophylline
,3550629,elimination half-life,"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),h,4.61,243343,DB00277,Theophylline
,3550629,elimination half-life,"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),h,5.01,243344,DB00277,Theophylline
,3550629,area under concentration versus time curve (AUC),"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),[h·μg] / [ml],214.61,243345,DB00277,Theophylline
,3550629,area under concentration versus time curve (AUC),"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),[h·μg] / [ml],128.64,243346,DB00277,Theophylline
,3550629,area under concentration versus time curve (AUC),"Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D).",[Changes in the pharmacokinetics of theophylline during estrus in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550629/),[h·μg] / [ml],165.57,243347,DB00277,Theophylline
,3757782,Css,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[μg] / [ml],9.3,243391,DB00277,Theophylline
,3757782,Css,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[μg] / [ml],10.6,243392,DB00277,Theophylline
,3757782,Cl,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[ml] / [h]·kg],49.0,243393,DB00277,Theophylline
,3757782,Cl,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[ml] / [h]·kg],43.6,243394,DB00277,Theophylline
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],189.9,244120,DB00277,Theophylline
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],274.9,244121,DB00277,Theophylline
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],28.4,244122,DB00277,Theophylline
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],19.8,244123,DB00277,Theophylline
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.04,244288,DB00277,Theophylline
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.64,244289,DB00277,Theophylline
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.02,244290,DB00277,Theophylline
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],44.40,244291,DB00277,Theophylline
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],45.66,244292,DB00277,Theophylline
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],46.87,244293,DB00277,Theophylline
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.601,244294,DB00277,Theophylline
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.591,244295,DB00277,Theophylline
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.602,244296,DB00277,Theophylline
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.32,244297,DB00277,Theophylline
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.50,244298,DB00277,Theophylline
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],42.10,244299,DB00277,Theophylline
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],43.77,244300,DB00277,Theophylline
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.451,244301,DB00277,Theophylline
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.483,244302,DB00277,Theophylline
,1753813,plasmatic concentration,The mean plasmatic concentration (SD) was 11.3 (7) micrograms/ml.,[The use of the determination of plasma theophylline concentrations in the hospital]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1753813/),[μg] / [ml],11.3,244303,DB00277,Theophylline
,10924397,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),h,31.4,244859,DB00277,Theophylline
,10924397,steady state volume of distribution (V(SS)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[l] / [kg],0.62,244860,DB00277,Theophylline
,10924397,total body clearance (Cl(T)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],14.7,244861,DB00277,Theophylline
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.62,244862,DB00277,Theophylline
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.34,244863,DB00277,Theophylline
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,36.0,244864,DB00277,Theophylline
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,39.2,244865,DB00277,Theophylline
,10924397,terminal elimination half-life,"The terminal elimination half-life of the former, estimated in two camels, was 70.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),,70,244866,DB00277,Theophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],0.69,244982,DB00277,Theophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],1.37,244983,DB00277,Theophylline
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],2.62,244984,DB00277,Theophylline
,25150710,k(e0),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),1/[min],0.805,244985,DB00277,Theophylline
,25150710,E0,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.76,244986,DB00277,Theophylline
,25150710,Emax,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.398,244987,DB00277,Theophylline
,25150710,Ce(50 na),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],2.38,244988,DB00277,Theophylline
,25150710,C(e50 wa),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],4.49,244989,DB00277,Theophylline
,25150710,γ,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,2.21,244990,DB00277,Theophylline
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,7.7,245443,DB00277,Theophylline
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,9.8,245444,DB00277,Theophylline
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.8,245445,DB00277,Theophylline
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.60,245446,DB00277,Theophylline
,10850374,volume of distribution,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[l] / [kg],0.937,245772,DB00277,Theophylline
,10850374,elimination rate constant,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0249,245773,DB00277,Theophylline
,10850374,elimination half-life,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,32.1,245774,DB00277,Theophylline
,10850374,total body clearance,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[ml] / [h·kg],21.7,245775,DB00277,Theophylline
,10850374,elimination half-life,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,95.1,245776,DB00277,Theophylline
,10850374,elimination rate constant,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0079,245777,DB00277,Theophylline
,10850374,serum concentrations,"The mean (+/- S.E.M.) serum concentrations of theophylline and caffeine on the sixth day after aminophylline infusion were 10.4 +/- 2.28 microg/ml (range, 6.38-13.4 microg/ml) and 2.94 +/- 0.98 microg/ml (range, 1.80-4.44 microg/ml), respectively.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[μg] / [ml],2.94,245778,DB00277,Theophylline
,10850374,concentration ratio,"The mean (+/- S.E.M.) caffeine to theophylline concentration ratio on the day after discontinuation of aminophylline infusion was 0.71 +/- 0.23 (range, 0.39-1.03).",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),,0.71,245779,DB00277,Theophylline
,2917585,clearance,For the combined group (corrected for the patient effect) the oldest third (mean age 70 years) had a mean clearance of 0.53 versus 0.72 for the middle third (mean age 47 years) and 0.73 ml/min/kg CBW for the youngest third (mean age 26 years).,The relationship between theophylline clearance and age in adult life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917585/),[ml] / [cbw·kg·min],0.53,245833,DB00277,Theophylline
,2917585,clearance,For the combined group (corrected for the patient effect) the oldest third (mean age 70 years) had a mean clearance of 0.53 versus 0.72 for the middle third (mean age 47 years) and 0.73 ml/min/kg CBW for the youngest third (mean age 26 years).,The relationship between theophylline clearance and age in adult life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917585/),[ml] / [cbw·kg·min],0.72,245834,DB00277,Theophylline
,2917585,clearance,For the combined group (corrected for the patient effect) the oldest third (mean age 70 years) had a mean clearance of 0.53 versus 0.72 for the middle third (mean age 47 years) and 0.73 ml/min/kg CBW for the youngest third (mean age 26 years).,The relationship between theophylline clearance and age in adult life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917585/),[ml] / [cbw·kg·min],0.73,245835,DB00277,Theophylline
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],2.47,246341,DB00277,Theophylline
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],1.85,246342,DB00277,Theophylline
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],233.48,246343,DB00277,Theophylline
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],307.43,246344,DB00277,Theophylline
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],13.2,246345,DB00277,Theophylline
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],16.7,246346,DB00277,Theophylline
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],6.4,246347,DB00277,Theophylline
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],9.0,246348,DB00277,Theophylline
,3709629,elimination half-life,"The pharmacokinetic parameters of enprofylline were (mean): elimination half-life 1.9 h, total body clearance 191.1 ml X kg-1.",Enprofylline: pharmacokinetics and comparison with theophylline of acute effects on bronchial reactivity in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709629/),h,1.9,246654,DB00277,Theophylline
,3709629,total body clearance,"The pharmacokinetic parameters of enprofylline were (mean): elimination half-life 1.9 h, total body clearance 191.1 ml X kg-1.",Enprofylline: pharmacokinetics and comparison with theophylline of acute effects on bronchial reactivity in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709629/),[ml] / [kg],191.1,246655,DB00277,Theophylline
,3709629,volume of distribution,"h-1, volume of distribution 0.481 X kg-1, and protein binding 49%.",Enprofylline: pharmacokinetics and comparison with theophylline of acute effects on bronchial reactivity in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709629/),1/[kg],0.481,246656,DB00277,Theophylline
,3709629,protein binding,"h-1, volume of distribution 0.481 X kg-1, and protein binding 49%.",Enprofylline: pharmacokinetics and comparison with theophylline of acute effects on bronchial reactivity in normal subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709629/),%,49,246657,DB00277,Theophylline
,9919837,clearance,Undernourished asthma patients had a mean theophylline clearance of 85.6 (SE = 6.2) ml/hr/kg while it was 125.6 (SE = 3.8) ml/hr/kg in well-nourished asthma patients.,Theophylline clearance in undernourished asthma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9919837/),[ml] / [h·kg],85.6,246999,DB00277,Theophylline
,9919837,clearance,Undernourished asthma patients had a mean theophylline clearance of 85.6 (SE = 6.2) ml/hr/kg while it was 125.6 (SE = 3.8) ml/hr/kg in well-nourished asthma patients.,Theophylline clearance in undernourished asthma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9919837/),[ml] / [h·kg],125.6,247000,DB00277,Theophylline
,6645309,body clearance,"Patients with congestion of the liver showed a significant reduction of the theophylline body clearance to 25.7 ml/kg/h +/- 12.1 vs 68.3 ml/kg/h +/- 14.8 in the control group, and a corresponding prolongation of the half-life to 5.7 h +/- 2.5 vs 3.1 h +/- 1.4 in the control group.",Theophylline elimination in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645309/),[ml] / [h·kg],25.7,247783,DB00277,Theophylline
,6645309,body clearance,"Patients with congestion of the liver showed a significant reduction of the theophylline body clearance to 25.7 ml/kg/h +/- 12.1 vs 68.3 ml/kg/h +/- 14.8 in the control group, and a corresponding prolongation of the half-life to 5.7 h +/- 2.5 vs 3.1 h +/- 1.4 in the control group.",Theophylline elimination in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645309/),[ml] / [h·kg],68.3,247784,DB00277,Theophylline
,6645309,half-life,"Patients with congestion of the liver showed a significant reduction of the theophylline body clearance to 25.7 ml/kg/h +/- 12.1 vs 68.3 ml/kg/h +/- 14.8 in the control group, and a corresponding prolongation of the half-life to 5.7 h +/- 2.5 vs 3.1 h +/- 1.4 in the control group.",Theophylline elimination in congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645309/),h,5.7,247785,DB00277,Theophylline
,6645309,half-life,"Patients with congestion of the liver showed a significant reduction of the theophylline body clearance to 25.7 ml/kg/h +/- 12.1 vs 68.3 ml/kg/h +/- 14.8 in the control group, and a corresponding prolongation of the half-life to 5.7 h +/- 2.5 vs 3.1 h +/- 1.4 in the control group.",Theophylline elimination in congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645309/),h,3.1,247786,DB00277,Theophylline
,8469622,apparent theophylline clearance,"Using a two-way analysis of variance, no significant changes in apparent theophylline clearance were observed between placebo, and isradipine 2.5 and 5 mg (0.815 +/- 0.164, 0.870 +/- 0.212, and 0.827 +/- 0.164 ml/min/kg, respectively; p = 0.136).",The effect of isradipine on theophylline pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8469622/),[ml] / [kg·min],0.815,248374,DB00277,Theophylline
,8469622,apparent theophylline clearance,"Using a two-way analysis of variance, no significant changes in apparent theophylline clearance were observed between placebo, and isradipine 2.5 and 5 mg (0.815 +/- 0.164, 0.870 +/- 0.212, and 0.827 +/- 0.164 ml/min/kg, respectively; p = 0.136).",The effect of isradipine on theophylline pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8469622/),[ml] / [kg·min],0.870,248375,DB00277,Theophylline
,8469622,apparent theophylline clearance,"Using a two-way analysis of variance, no significant changes in apparent theophylline clearance were observed between placebo, and isradipine 2.5 and 5 mg (0.815 +/- 0.164, 0.870 +/- 0.212, and 0.827 +/- 0.164 ml/min/kg, respectively; p = 0.136).",The effect of isradipine on theophylline pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8469622/),[ml] / [kg·min],0.827,248376,DB00277,Theophylline
,6638669,half-life,"The theophylline half-life was reduced with charcoal from 10.2 to 4.6 h (p less than 0.001), and clearance increased from 35.6 to 72.6 ml/kg/h (p less than 0.001).",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,10.2 to 4.6,248440,DB00277,Theophylline
,6638669,clearance,"The theophylline half-life was reduced with charcoal from 10.2 to 4.6 h (p less than 0.001), and clearance increased from 35.6 to 72.6 ml/kg/h (p less than 0.001).",Increased serum theophylline clearance with orally administered activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),[ml] / [h·kg],35.6 to 72.6,248441,DB00277,Theophylline
,6638669,half-life,"In a patient with an initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity (arrhythmias and seizures), the administration of charcoal (4 doses of 30 g every 2 h) reduced the half-life from 34.4 to 5.7 h concomitant with rapid resolution of signs of toxicity.",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,34.4,248442,DB00277,Theophylline
,6638669,half-life,"In a patient with an initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity (arrhythmias and seizures), the administration of charcoal (4 doses of 30 g every 2 h) reduced the half-life from 34.4 to 5.7 h concomitant with rapid resolution of signs of toxicity.",Increased serum theophylline clearance with orally administered activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638669/),h,5,248443,DB00277,Theophylline
,8897286,half-life,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),h,4.16,248777,DB00277,Theophylline
,8897286,half-life,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),h,7.08,248778,DB00277,Theophylline
,8897286,Vc,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),l,0.18,248779,DB00277,Theophylline
,8897286,Vc,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),l,0.24,248780,DB00277,Theophylline
,8897286,Vp,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),l,0.08,248781,DB00277,Theophylline
,8897286,Vp,"At the same time, plasma concentrations of theophylline decreased significantly and half-life increased from 4.16 +/- 0.57 h (CG) to 7.08 +/- 0.69 h (HG), as did the distribution volumes values of central (Vc) and peripheral (Vp) compartments (Vc: CG, 0.18 +/- 0.03 L; HG, 0.24 +/- 0.03 L) (Vp: CG, 0.08 +/- 0.05 L; HG, 0.13 +/- 0.05 L).",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),l,0.13,248782,DB00277,Theophylline
,8897286,intrinsic clearance (CLint),"The theophylline intrinsic clearance (CLint) dropped from 1.35 +/- 0.43 mL/min (CG) to 0.93 +/- 0.10 mL/min (HG)1, which can be attributed to a significant fall in the quantity of hepatic microsomal enzymes.",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),[ml] / [min],1.35,248783,DB00277,Theophylline
,8897286,intrinsic clearance (CLint),"The theophylline intrinsic clearance (CLint) dropped from 1.35 +/- 0.43 mL/min (CG) to 0.93 +/- 0.10 mL/min (HG)1, which can be attributed to a significant fall in the quantity of hepatic microsomal enzymes.",Influence of partial hepatectomy on theophylline pharmacokinetics in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897286/),[ml] / [min],0.93,248784,DB00277,Theophylline
greater,2980291,plasma trough concentrations,Doses were individualised with the intention of achieving plasma trough concentrations greater than 8 micrograms/ml with CR-capsules.,"Comparison between steady state pharmacokinetics and effects of two once-daily, slow-release theophylline formulations in nocturnal asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2980291/),[μg] / [ml],8,251498,DB00277,Theophylline
,18254143,total chromatographic run time,"The total chromatographic run time was 3.0 min and the elution of DFL and IS occurred at approximately 1.46 and 2.15 min, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),min,3.0,251739,DB00277,Theophylline
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,267.5,251740,DB00277,Theophylline
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,181.1,251741,DB00277,Theophylline
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,281.1,251742,DB00277,Theophylline
,3429057,time required to reach maximum plasma concentration,The in vivo studies demonstrated that the time required to reach maximum plasma concentration of theophylline was about 8 h.,"Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,8,251881,DB00277,Theophylline
,3429057,mean residence time,"The mean residence time in vivo, MRT, was 18.6 h.","Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,18.6,251882,DB00277,Theophylline
,3429057,MRT,"The mean residence time in vivo, MRT, was 18.6 h.","Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429057/),h,18.6,251883,DB00277,Theophylline
,3671881,PaO2,"To this purpose 6 beagle dogs received 8 mg/kg i.v. of theophylline while breathing air, after acute hypoxia (PaO2 of 48.5 +/- 0.3 mmHg) and after 96 hours of hypoxia.",Theophylline disposition during acute and chronic hypoxia in the conscious dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671881/),mmh,48.5,252209,DB00277,Theophylline
,3671881,volume of distribution,"Theophylline volume of distribution, while breathing air, was 0.51 +/- 0.03 L/kg and was not affected by hypoxia.",Theophylline disposition during acute and chronic hypoxia in the conscious dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671881/),[l] / [kg],0.51,252210,DB00277,Theophylline
,3671881,metabolic,Theophylline metabolic and renal clearances were 1.53 +/- 0.24 and 0.18 +/- 0.04 mL/min/kg and remained constant when the dogs were hypoxic.,Theophylline disposition during acute and chronic hypoxia in the conscious dog. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671881/),[ml] / [kg·min],1.53,252211,DB00277,Theophylline
,3671881,renal clearances,Theophylline metabolic and renal clearances were 1.53 +/- 0.24 and 0.18 +/- 0.04 mL/min/kg and remained constant when the dogs were hypoxic.,Theophylline disposition during acute and chronic hypoxia in the conscious dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671881/),[ml] / [kg·min],0.18,252212,DB00277,Theophylline
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.155,253177,DB00277,Theophylline
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.060,253178,DB00277,Theophylline
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.107,253179,DB00277,Theophylline
,8483845,half-life,The half-life for acetaminophen was determined to be 20.9 +/- 1.0 min (n = 6) for a 2 mg/kg dosing.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),min,20.9,253490,DB00277,Theophylline
,8483845,half-life of elimination,The half-life of elimination for theophylline was determined to be 3.0 +/- 0.1 hr (n = 4) for a 4 mg/kg dose.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),h,3.0,253491,DB00277,Theophylline
,8483845,constant flow rate,The capillary ultrafiltration probes exhibited a constant flow rate of 2.4 +/- 0.1 microL/min and removed 50 nL/min/mm of fluid from the extracellular space.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),[μl] / [min],2.4,253492,DB00277,Theophylline
,3672570,clearance,Mean (+/- SD) theophylline clearance during acute illness was 0.044 +/- 0.011 L X h-1 X kg-1 compared to 0.043 +/- 0.012 L X h-1 X kg-1 1 month later.,Theophylline clearance during and after mild upper respiratory infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672570/),[l] / [h·kg],0.044,253606,DB00277,Theophylline
,3672570,clearance,Mean (+/- SD) theophylline clearance during acute illness was 0.044 +/- 0.011 L X h-1 X kg-1 compared to 0.043 +/- 0.012 L X h-1 X kg-1 1 month later.,Theophylline clearance during and after mild upper respiratory infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672570/),[l] / [h·kg],0.043,253607,DB00277,Theophylline
,3678595,maximum plasma concentration,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),[μg] / [ml],3.19,254053,DB00277,Theophylline
,3678595,maximum plasma concentration,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),[μg] / [ml],4.51,254054,DB00277,Theophylline
,3678595,time needed to reach this,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),h,8.71,254055,DB00277,Theophylline
,3678595,time needed to reach this,"After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),h,1.96,254056,DB00277,Theophylline
,3678595,absolute,"Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (+/- SD) 92.7 +/- 23.2% and 83.14 +/- 14.69%, respectively.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),%,92.7,254057,DB00277,Theophylline
,3678595,relative percentage bioavailabilities,"Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (+/- SD) 92.7 +/- 23.2% and 83.14 +/- 14.69%, respectively.",Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3678595/),%,83.14,254058,DB00277,Theophylline
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],4.22,254110,DB00277,Theophylline
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],8.02,254111,DB00277,Theophylline
,7223441,kel,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00457,254447,DB00277,Theophylline
,7223441,beta,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00296,254448,DB00277,Theophylline
,7223441,clearance,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[-1·min·ml] / [kg],2.04,254449,DB00277,Theophylline
,7223441,Vd beta,"The mean values in the group of pretreated animals were: kel 0.00457 min.-1, beta 0.00296 min.-1, clearance 2.04 ml kg-1 min.-1, Vd beta 693 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[ml] / [kg],693,254450,DB00277,Theophylline
,7223441,kel,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00293,254451,DB00277,Theophylline
,7223441,kel,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),-1·min,0.00198,254452,DB00277,Theophylline
,7223441,clearance,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[-1·min·ml] / [kg],1.50,254453,DB00277,Theophylline
,7223441,Vd beta,"By way of comparison, the values obtained in non-pretreated guinea pigs were: kel 0.00293 min.-1 beta 0.00198 min.-1, clearance 1.50 ml kg-1 min.-1, Vd beta 757 ml kg-1.",Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[ml] / [kg],757,254454,DB00277,Theophylline
,7223441,general plasma concentration level,The general plasma concentration level was 0-1.8 . 10(-8) mol ml-1 (0-3 microgram ml-1).,Pharmacokinetics of theophylline and 3-methylxanthine in guinea pigs. Multiple dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223441/),[mol] / [ml],0-1.8 .,254455,DB00277,Theophylline
,25243874,Tmax,"Garden cress caused a decrease in Cmax to a lesser extent and delayed Tmax of theophylline (2.10 ± 0.24 h versus 3.40 ± 0.74 h), while AUC0-∞ increased by 37.44%.","Effects of fenugreek, garden cress, and black seed on theophylline pharmacokinetics in beagle dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243874/),h,2.10,254760,DB00277,Theophylline
,25243874,Tmax,"Garden cress caused a decrease in Cmax to a lesser extent and delayed Tmax of theophylline (2.10 ± 0.24 h versus 3.40 ± 0.74 h), while AUC0-∞ increased by 37.44%.","Effects of fenugreek, garden cress, and black seed on theophylline pharmacokinetics in beagle dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243874/),h,3.40,254761,DB00277,Theophylline
,2859173,fraction bound,The fraction bound (15%) remained constant in the concentration range of 1-100 micrograms/ml.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),%,15,254861,DB00277,Theophylline
,2859173,half-life,"The mean half-life and elimination rate constant were 1 hr and 0.70 hr-1, respectively.","Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),h,1,254862,DB00277,Theophylline
,2859173,elimination rate constant,"The mean half-life and elimination rate constant were 1 hr and 0.70 hr-1, respectively.","Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),1/[h],0.70,254863,DB00277,Theophylline
,2859173,apparent volume of distribution,The average apparent volume of distribution was 1.50 liters/kg and total clearance was 0.90 liter/hr/kg.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[l] / [kg],1.50,254864,DB00277,Theophylline
,2859173,total clearance,The average apparent volume of distribution was 1.50 liters/kg and total clearance was 0.90 liter/hr/kg.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[l] / [h·kg],0.90,254865,DB00277,Theophylline
,2859173,apparent Km,These findings indicate that in the rat paraxanthine is eliminated by a saturable process with an apparent Km of about 31 micrograms/ml and an apparent Vmax of about 0.40 micrograms/ml/min.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[μg] / [ml],31,254866,DB00277,Theophylline
,2859173,apparent Vmax,These findings indicate that in the rat paraxanthine is eliminated by a saturable process with an apparent Km of about 31 micrograms/ml and an apparent Vmax of about 0.40 micrograms/ml/min.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[μg] / [min·ml],0.40,254867,DB00277,Theophylline
,9484872,half-life,"It reaches peak plasma levels around 2 h after administration, then declines bi-exponentially, with an extended half-life of around 12 h.",Pharmacokinetics of grepafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9484872/),h,12,255441,DB00277,Theophylline
,16850398,relative bioavailabilities,"In dogs and minipigs, their relative bioavailabilities of EC-coated beads were 33.1% and 47.0%, respectively, and in vivo TP release from EC-coated beads in the gastrointestinal tract of dogs and minipigs were not reflected in vitro data.","Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850398/),%,33.1,255689,DB00277,Theophylline
,16850398,relative bioavailabilities,"In dogs and minipigs, their relative bioavailabilities of EC-coated beads were 33.1% and 47.0%, respectively, and in vivo TP release from EC-coated beads in the gastrointestinal tract of dogs and minipigs were not reflected in vitro data.","Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850398/),%,47.0,255690,DB00277,Theophylline
,16850398,relative bioavailability,"In monkeys, relative bioavailability of EC-coated beads was 80.0% and the highest among the three species, and release amount of TP from EC-coated beads at 24 h after oral administration was 82.8% and 92.4%, which was almost correlated to in vitro data.","Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850398/),%,80.0,255691,DB00277,Theophylline
,16850398,release amount,"In monkeys, relative bioavailability of EC-coated beads was 80.0% and the highest among the three species, and release amount of TP from EC-coated beads at 24 h after oral administration was 82.8% and 92.4%, which was almost correlated to in vitro data.","Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850398/),%,82.8,255692,DB00277,Theophylline
,16850398,release amount,"In monkeys, relative bioavailability of EC-coated beads was 80.0% and the highest among the three species, and release amount of TP from EC-coated beads at 24 h after oral administration was 82.8% and 92.4%, which was almost correlated to in vitro data.","Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850398/),%,92.4,255693,DB00277,Theophylline
,2706320,t75%,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),h,11.6,256052,DB00277,Theophylline
,2706320,t75%,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),h,9.2,256053,DB00277,Theophylline
,2706320,t75%,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),h,13.1,256054,DB00277,Theophylline
,2706320,t75%,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),h,8.8,256055,DB00277,Theophylline
,2706320,peak-trough fluctuation in the steady state,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,80,256056,DB00277,Theophylline
,2706320,peak-trough fluctuation in the steady state,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,103,256057,DB00277,Theophylline
,2706320,peak-trough fluctuation in the steady state,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,66,256058,DB00277,Theophylline
,2706320,peak-trough fluctuation in the steady state,"Significantly better sustained release characteristics, resulting in longer plateau time (t75%, 11.6 vs 9.2 h on day 6 and 13.1 vs 8.8 h on day 7) and smaller per cent peak-trough fluctuation in the steady state (per cent PTF, 80 vs 103 per cent on day 6 and 66 vs 100 per cent on day 7), were found for B in comparison with T.",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,100,256059,DB00277,Theophylline
,2706320,relative bioavailability,"The extent of absorption on both days, however, was smaller for B compared with T (relative bioavailability 84 per cent and 81 per cent, respectively).",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,84,256060,DB00277,Theophylline
,2706320,relative bioavailability,"The extent of absorption on both days, however, was smaller for B compared with T (relative bioavailability 84 per cent and 81 per cent, respectively).",Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706320/),%,81,256061,DB00277,Theophylline
,8364261,Peak plasma theophylline concentrations,"Peak plasma theophylline concentrations were significantly lower prior to feeding (5.3 mumol/L, 95 percent confidence interval [CI] 0.78-10.0 mumol/L, p = 0.028).",Theophylline disposition following parenteral feeding of malnourished patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364261/),[μM] / [l],5.3,256236,DB00277,Theophylline
,8364261,Volume of distribution,"Volume of distribution decreased after parenteral feeding (0.08 L/kg, 95 percent CI 0.006-0.15 L/kg, p = 0.037).",Theophylline disposition following parenteral feeding of malnourished patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364261/),[l] / [kg],0.08,256237,DB00277,Theophylline
,8364261,elimination rate,"The elimination rate of theophylline increased after parenteral feeding reflected by an increase in the elimination rate constant (0.06 h-1, 95 percent CI 0.01-0.10 h-1, p = 0.023).",Theophylline disposition following parenteral feeding of malnourished patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364261/),1/[h],0.06,256238,DB00277,Theophylline
,8364261,elimination rate constant,"The elimination rate of theophylline increased after parenteral feeding reflected by an increase in the elimination rate constant (0.06 h-1, 95 percent CI 0.01-0.10 h-1, p = 0.023).",Theophylline disposition following parenteral feeding of malnourished patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364261/),1/[h],0.06,256239,DB00277,Theophylline
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,9.2,256242,DB00277,Theophylline
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,13.1,256243,DB00277,Theophylline
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,3.7,256244,DB00277,Theophylline
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [kg·min],4.4,256245,DB00277,Theophylline
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [kg·min],2.0,256246,DB00277,Theophylline
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [·kg·min],1.6,256247,DB00277,Theophylline
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],1.3,256248,DB00277,Theophylline
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],0.8,256249,DB00277,Theophylline
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],0.3,256250,DB00277,Theophylline
,7438966,clearance,"Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22.9 +/- 3.9 ml/h/kg) and apparent volume of distribution (0.630 +/- 0.150 1/kg) were somewhat greater than previously reported for newborn infants at 4--15 days.",Factors affecting theophylline pharmacokinetics in premature infants with apnea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438966/),[ml] / [h·kg],22.9,256290,DB00277,Theophylline
,7438966,apparent volume of distribution,"Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22.9 +/- 3.9 ml/h/kg) and apparent volume of distribution (0.630 +/- 0.150 1/kg) were somewhat greater than previously reported for newborn infants at 4--15 days.",Factors affecting theophylline pharmacokinetics in premature infants with apnea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438966/),[1] / [kg],0.630,256291,DB00277,Theophylline
,9736563,maximum,"These were as follows: maximum concentration at steady state, 1.01 (0.96 to 1.07); area under the concentration-time curve from 0 to 12 h, 0.98 (0.94 to 1.02); half-life, 0.99 (0.95 to 1.03); total clearance at steady state, 1. 02 (0.99 to 1.06); and volume of distribution in the elimination phase, 1.01 (0.97 to 1.05).",Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736563/),,1,256531,DB00277,Theophylline
,9736563,half-life,"These were as follows: maximum concentration at steady state, 1.01 (0.96 to 1.07); area under the concentration-time curve from 0 to 12 h, 0.98 (0.94 to 1.02); half-life, 0.99 (0.95 to 1.03); total clearance at steady state, 1. 02 (0.99 to 1.06); and volume of distribution in the elimination phase, 1.01 (0.97 to 1.05).",Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736563/),,0,256532,DB00277,Theophylline
,9736563,total clearance at steady state,"These were as follows: maximum concentration at steady state, 1.01 (0.96 to 1.07); area under the concentration-time curve from 0 to 12 h, 0.98 (0.94 to 1.02); half-life, 0.99 (0.95 to 1.03); total clearance at steady state, 1. 02 (0.99 to 1.06); and volume of distribution in the elimination phase, 1.01 (0.97 to 1.05).",Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736563/),,1. 02,256533,DB00277,Theophylline
,9736563,volume of distribution in the elimination phase,"These were as follows: maximum concentration at steady state, 1.01 (0.96 to 1.07); area under the concentration-time curve from 0 to 12 h, 0.98 (0.94 to 1.02); half-life, 0.99 (0.95 to 1.03); total clearance at steady state, 1. 02 (0.99 to 1.06); and volume of distribution in the elimination phase, 1.01 (0.97 to 1.05).",Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736563/),,1,256534,DB00277,Theophylline
,6538428,plasma t1/2,"The mean plasma t1/2 after i.v. dosing was 6.5 h (3.5-9 h), and the mean plasma t1/2 after oral doses was 5.7 h (3-12 h).",A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538428/),h,6.5,257231,DB00277,Theophylline
,6538428,plasma t1/2,"The mean plasma t1/2 after i.v. dosing was 6.5 h (3.5-9 h), and the mean plasma t1/2 after oral doses was 5.7 h (3-12 h).",A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538428/),h,5.7,257232,DB00277,Theophylline
,6538428,total excretion,"The calculated total of 23% (11-70%) of the intravenous dose was excreted in urine, and the mean total excretion after the oral dose was 12% (7-19%).",A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538428/),%,12,257233,DB00277,Theophylline
,6538428,absolute bioavailability,The absolute bioavailability of oral theophylline was 94 +/- 20%,A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538428/),%,94,257234,DB00277,Theophylline
,1940278,bioavailability,Ofloxacin has favorable pharmacokinetics with almost 100% bioavailability; peak serum concentrations obtained one to two hours following oral dosing are higher than those achieved with ciprofloxacin.,Ofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940278/),,100,258002,DB00277,Theophylline
,3604256,renal excretion,The only changes in erythromycin pharmacokinetics were an increase in the renal excretion (0-12 h) from 5.5 +/- 4.0 mg to 11.2 +/- 6.0 mg (P less than 0.03) and an increase in renal clearance (0-2 h) from 9.0 +/- 6.0 ml/min to 21.6 +/- 15 ml/min (P less than 0.05) in the presence of theophylline.,The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604256/),mg,5.5,258097,DB00277,Theophylline
,3604256,renal excretion,The only changes in erythromycin pharmacokinetics were an increase in the renal excretion (0-12 h) from 5.5 +/- 4.0 mg to 11.2 +/- 6.0 mg (P less than 0.03) and an increase in renal clearance (0-2 h) from 9.0 +/- 6.0 ml/min to 21.6 +/- 15 ml/min (P less than 0.05) in the presence of theophylline.,The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604256/),mg,11.2,258098,DB00277,Theophylline
,3604256,renal clearance (0-2 h),The only changes in erythromycin pharmacokinetics were an increase in the renal excretion (0-12 h) from 5.5 +/- 4.0 mg to 11.2 +/- 6.0 mg (P less than 0.03) and an increase in renal clearance (0-2 h) from 9.0 +/- 6.0 ml/min to 21.6 +/- 15 ml/min (P less than 0.05) in the presence of theophylline.,The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604256/),[ml] / [min],9.0,258099,DB00277,Theophylline
,3604256,renal clearance (0-2 h),The only changes in erythromycin pharmacokinetics were an increase in the renal excretion (0-12 h) from 5.5 +/- 4.0 mg to 11.2 +/- 6.0 mg (P less than 0.03) and an increase in renal clearance (0-2 h) from 9.0 +/- 6.0 ml/min to 21.6 +/- 15 ml/min (P less than 0.05) in the presence of theophylline.,The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604256/),[ml] / [min],21.6,258100,DB00277,Theophylline
,6345176,steady state plasma level,"In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined.",Intravenous administration of enprofylline to asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6345176/),[mg] / [l],5,258334,DB00277,Theophylline
,6345176,steady state level,The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l.,Intravenous administration of enprofylline to asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6345176/),[mg] / [l],15,258335,DB00277,Theophylline
,7222176,clearance,The hemodialysis clearance of 39.4 ml/kg/hr was comparable to two other reports and indicated that theophylline was significantly hemodialyzed.,Theophylline hemodialysis clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222176/),[ml] / [h·kg],39.4,261028,DB00277,Theophylline
,7222176,total body clearance,The total body clearance of 52.4 ml/kg/hr was similar to that observed in non-renal-failure smoking patients and suggested that renal failure did not appreciably affect the total body clearance in the patient.,Theophylline hemodialysis clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222176/),[ml] / [h·kg],52.4,261029,DB00277,Theophylline
,7222176,plasma protein binding,The plasma protein binding was 40% before dialysis and 33% after dialysis.,Theophylline hemodialysis clearance. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222176/),%,40,261030,DB00277,Theophylline
,7222176,plasma protein binding,The plasma protein binding was 40% before dialysis and 33% after dialysis.,Theophylline hemodialysis clearance. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222176/),%,33,261031,DB00277,Theophylline
,2614856,elimination rate constant (lambda z),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),1/[h],0.07,261352,DB00277,Theophylline
,2614856,apparent volume of distribution (Vz),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[l] / [kg],0.80,261353,DB00277,Theophylline
,2614856,clearance (Cl),"The elimination rate constant (lambda z), apparent volume of distribution (Vz), and clearance (Cl) determined by compartmental analysis of the intravenous data were 0.07 +/- 0.01 h-1, 0.80 +/- 0.06 l/kg, and 0.06 +/- 0.01 l/kg/h (mean +/- SD), respectively.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[l] / [h·kg],0.06,261354,DB00277,Theophylline
,2614856,Mean residence time,Mean residence time determined by statistical moment theory of the oral data was different (P less than 0.05) for the immediate-release aminophylline (13.8 +/- 2.8 h) and sustained-release theophylline (18.2 +/- 2.3 h) formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),h,13.8,261355,DB00277,Theophylline
,2614856,Mean residence time,Mean residence time determined by statistical moment theory of the oral data was different (P less than 0.05) for the immediate-release aminophylline (13.8 +/- 2.8 h) and sustained-release theophylline (18.2 +/- 2.3 h) formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),h,18.2,261356,DB00277,Theophylline
,2614856,peak theophylline plasma concentration,Immediate-release aminophylline tablets quickly achieved peak theophylline plasma concentration of 11.51 +/- 1.4 micrograms/ml at 1.6 +/- 0.6 h while the sustained-release theophylline tablets were more slowly absorbed and achieved peak theophylline concentrations of 17.20 +/- 1.3 micrograms/ml at 7.3 +/- 1.0 h.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],11.51,261357,DB00277,Theophylline
,2614856,peak theophylline concentrations,Immediate-release aminophylline tablets quickly achieved peak theophylline plasma concentration of 11.51 +/- 1.4 micrograms/ml at 1.6 +/- 0.6 h while the sustained-release theophylline tablets were more slowly absorbed and achieved peak theophylline concentrations of 17.20 +/- 1.3 micrograms/ml at 7.3 +/- 1.0 h.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],17.20,261358,DB00277,Theophylline
,2614856,Absolute bioavailability,Absolute bioavailability was 87% for the immediate-release and 97% for the sustained-release formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),%,87,261359,DB00277,Theophylline
,2614856,Absolute bioavailability,Absolute bioavailability was 87% for the immediate-release and 97% for the sustained-release formulation.,Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),%,97,261360,DB00277,Theophylline
,2614856,trough-peak,"Using the principle of superposition, a loading dose of 20 mg/kg of the sustained-release formulation followed by maintenance doses of 15 mg/kg every 24 h was predicted to achieve trough-peak theophylline plasma concentrations between 6 and 17 micrograms/ml.",Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614856/),[μg] / [ml],6 and 17,261361,DB00277,Theophylline
,6839957,Cltot,"Cltot of theophylline, based on total body weight (TBW), averaged 0.60 +/- 0.20 ml/min/kg in obese nonsmokers and did not differ from the nonobese, nonsmoking group.",Theophylline clearance in obese patients in relation to smoking and congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839957/),[ml] / [kg·min],0.60,262029,DB00277,Theophylline
,6839957,Cltot,"In obese nonsmoking patients with CHF, Cltot based on TBW was 0.40 +/- 0.14 ml/min/kg, which was similar to Cltot values in nonsmoking CHF patients who were not obese.",Theophylline clearance in obese patients in relation to smoking and congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839957/),[ml] / [kg·min],0.40,262030,DB00277,Theophylline
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,7.59,262576,DB00277,Theophylline
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,9.05,262577,DB00277,Theophylline
,1559313,peak theophylline concentration (Cmax),The mean peak theophylline concentration (Cmax) of 8.33 +/- 2.16 mg/L occurred 1.02 +/- 0.26 h after ingestion.,Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),[mg] / [l],8.33,263217,DB00277,Theophylline
,1559313,Cmax,"The delay between the Cmax and the subsequent eosinopenic or hypokalaemic nadirs was 4.52 +/- 1.73 and 3.65 +/- 1.32 h, respectively.",Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),,4,263218,DB00277,Theophylline
,1559313,Cmax,"The delay between the Cmax and the subsequent eosinopenic or hypokalaemic nadirs was 4.52 +/- 1.73 and 3.65 +/- 1.32 h, respectively.",Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),,3,263219,DB00277,Theophylline
,1559313,maximal eosinopenic,"The maximal eosinopenic and hypokalaemic effects (Emax) of the drug were 83 +/- 25.8% and 16 +/- 9.7% of the possible, respectively.",Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),%,83,263220,DB00277,Theophylline
,1559313,concentrations,"The theophylline concentrations causing 50% of the Emax (EC50) were 5.06 +/- 1.84 and 5.04 +/- 2.09 mg/L, respectively.",Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),[mg] / [l],5.06,263221,DB00277,Theophylline
,1559313,concentrations,"The theophylline concentrations causing 50% of the Emax (EC50) were 5.06 +/- 1.84 and 5.04 +/- 2.09 mg/L, respectively.",Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559313/),[mg] / [l],5.04,263222,DB00277,Theophylline
,7229966,half-life,"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),h,2.8,263321,DB00277,Theophylline
,7229966,volume of distribution,"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),h,4.4,263322,DB00277,Theophylline
,7229966,Vd(beta),"However, the data obtained following rapid intravenous aminophylline administration in the rabbit fit either the one-compartment model (half-life = 2.8 hr and the volume of distribution = 4.4 hr and Vd(beta) = 0.708 liter/kg).","Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229966/),[l] / [kg],0.708,263323,DB00277,Theophylline
,8106577,flow-rate,"The mobile phase consisted of a mixture of 10 mM acetate buffer (pH 4.0)-methanol-acetonitrile (56:40:4, v/v/v) with a flow-rate of 0.50 ml/min.",High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ml] / [min],0.50,263838,DB00277,Theophylline
,8106577,total run time,The total run time was ca. 19 min.,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),min,19,263839,DB00277,Theophylline
,8106577,limits of detection,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ng] / [ml],3.3,263840,DB00277,Theophylline
,8106577,limits of detection,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ng] / [ml],6.2,263841,DB00277,Theophylline
,8106577,signal-to-noise ratio,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),,3,263842,DB00277,Theophylline
,8106577,half-life,CPA was found to be degraded in rat blood in vitro with a half-life of 24 min at 37 degrees C.,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),min,24,263843,DB00277,Theophylline
less,7420268,bioavailability,"Nevertheless, for only two tablets could it be claimed with 95% confidence level that the bioavailability was less than 95%.",Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420268/),%,95,264526,DB00277,Theophylline
less,7420268,bioavailability,For none can it be stated at this confidence level that the bioavailability is less than 90%.,Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420268/),%,90,264527,DB00277,Theophylline
,18626752,bioavailability,"The bioavailability of etoposide was 12.9 and 13.9% in monkeys and rats, respectively.",Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626752/),%,12.9,264608,DB00277,Theophylline
,18626752,bioavailability,"The bioavailability of etoposide was 12.9 and 13.9% in monkeys and rats, respectively.",Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626752/),%,13.9,264609,DB00277,Theophylline
,17512147,half-life,"The mean plasma level of theophylline gradually increased to a maximum (6.09microg/mL) 12h after administration of Tablet A, but then decreased, with a half-life of 9.10h.",In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17512147/),h,9.10,265390,DB00277,Theophylline
,17512147,maximum,"After administration of Tablet B, a similar finding was noted, with a maximum of 7.87microg/mL and a half-life of 7.76h.",In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17512147/),[μg] / [ml],7.87,265391,DB00277,Theophylline
,17512147,half-life,"After administration of Tablet B, a similar finding was noted, with a maximum of 7.87microg/mL and a half-life of 7.76h.",In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17512147/),h,7.76,265392,DB00277,Theophylline
,17512147,T(max),"The T(max) of Tablet A was 10-12h after administration, relatively constant.",In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17512147/),h,10-12,265393,DB00277,Theophylline
,7956718,peak concentrations,"Theophylline was absorbed rapidly in all subjects and within 2 h reached comparable peak concentrations in both groups (cancer patients: 57.8 +/- 14.4 mumol/l; controls; 65.0 +/- 10.6 mumol/l; N.S., means +/- s.d.).",The disposition of theophylline in patients with lung and breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[μM] / [l],57.8,265887,DB00277,Theophylline
,7956718,peak concentrations,"Theophylline was absorbed rapidly in all subjects and within 2 h reached comparable peak concentrations in both groups (cancer patients: 57.8 +/- 14.4 mumol/l; controls; 65.0 +/- 10.6 mumol/l; N.S., means +/- s.d.).",The disposition of theophylline in patients with lung and breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[μM] / [l],65.0,265888,DB00277,Theophylline
,7956718,apparent volume of distribution,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[l] / [kg],0.44,265889,DB00277,Theophylline
,7956718,apparent volume of distribution,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[l] / [kg],0.40,265890,DB00277,Theophylline
,7956718,total body clearance,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[ml] / [h·kg],40.8,265891,DB00277,Theophylline
,7956718,total body clearance,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),[ml] / [h·kg],34.8,265892,DB00277,Theophylline
,7956718,elimination half-life,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),h,8.0,265893,DB00277,Theophylline
,7956718,elimination half-life,"No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h).",The disposition of theophylline in patients with lung and breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956718/),h,8.5,265894,DB00277,Theophylline
,9676351,plateau times,"With long plateau times (T: 17.3 h) and small peak-trough fluctuations (T: 49.0%), established quality criteria for high quality theophylline preparations were fulfilled by the test formulation.",[Pharmacokinetics of theophylline in sustained-release formulation in young asthmatics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9676351/),h,17.3,266232,DB00277,Theophylline
,4002738,elimination half-lives,"However, after four to eight hours the slope of the curves declined, resulting in elimination half-lives of about 70 min.",Dose-dependent elimination of theophylline in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002738/),min,70,267087,DB00277,Theophylline
,4002738,half-lives,Similar half-lives of 70 min were also found after doses of 6 or 11 mg/kg.,Dose-dependent elimination of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002738/),min,70,267088,DB00277,Theophylline
,552145,half-time,"The half-time of Bamifylline plasma concentrations ranges from 1.5 hours to 2.0 hours, which is appreciably shorter than that of Theophylline which exceeds four hours.",Metabolic and pharmacokinetic studies on Bamifylline. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552145/),h,1.5,268237,DB00277,Theophylline
,552145,half-time,"The half-time of Bamifylline plasma concentrations ranges from 1.5 hours to 2.0 hours, which is appreciably shorter than that of Theophylline which exceeds four hours.",Metabolic and pharmacokinetic studies on Bamifylline. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552145/),h,2.0,268238,DB00277,Theophylline
exceeds,552145,half-time,"The half-time of Bamifylline plasma concentrations ranges from 1.5 hours to 2.0 hours, which is appreciably shorter than that of Theophylline which exceeds four hours.",Metabolic and pharmacokinetic studies on Bamifylline. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552145/),h,four,268239,DB00277,Theophylline
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,17.8,268318,DB00277,Theophylline
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,27.7,268319,DB00277,Theophylline
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,30.8,268320,DB00277,Theophylline
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,38.8,268321,DB00277,Theophylline
>,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,100,268322,DB00277,Theophylline
>,25264242,[I]/Ki ratio,"The results of a static model indicated an [I]/Ki ratio >0.1 for CYP1A2, 2C8, 2C9 and 2C19.",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,0.1,268323,DB00277,Theophylline
<,25264242,AUC ratios,Simulation of the area under the plasma concentration-time curve (AUC) of these four CYP substrates in the presence and absence of orteronel revealed geometric mean AUC ratios <1.25.,Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,1.25,268324,DB00277,Theophylline
,11874526,terminal elimination half-life (t(1/2 beta),"The data obtained median and (range) were as follows: the terminal elimination half-life (t(1/2 beta), h) was 3.04 (2.03-3.62); apparent total body clearance (Cl/F, L/h/kg) was 1.27 (0.74-2.99); the apparent volume of distribution at steady state (V(ss)/F, L/kg) was 4.94 (3.57-12.54); and renal clearance (Cl(r), L/h/kg) determined in two camels was 0.005 and 0.004, respectively.","The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),h,3.04,268467,DB00277,Theophylline
,11874526,apparent total body clearance (Cl/F,"The data obtained median and (range) were as follows: the terminal elimination half-life (t(1/2 beta), h) was 3.04 (2.03-3.62); apparent total body clearance (Cl/F, L/h/kg) was 1.27 (0.74-2.99); the apparent volume of distribution at steady state (V(ss)/F, L/kg) was 4.94 (3.57-12.54); and renal clearance (Cl(r), L/h/kg) determined in two camels was 0.005 and 0.004, respectively.","The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),[l] / [h·kg],1.27,268468,DB00277,Theophylline
,11874526,apparent volume of distribution at steady state (V(ss)/F,"The data obtained median and (range) were as follows: the terminal elimination half-life (t(1/2 beta), h) was 3.04 (2.03-3.62); apparent total body clearance (Cl/F, L/h/kg) was 1.27 (0.74-2.99); the apparent volume of distribution at steady state (V(ss)/F, L/kg) was 4.94 (3.57-12.54); and renal clearance (Cl(r), L/h/kg) determined in two camels was 0.005 and 0.004, respectively.","The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),[l] / [kg],4.94,268469,DB00277,Theophylline
,11874526,renal clearance (Cl(r),"The data obtained median and (range) were as follows: the terminal elimination half-life (t(1/2 beta), h) was 3.04 (2.03-3.62); apparent total body clearance (Cl/F, L/h/kg) was 1.27 (0.74-2.99); the apparent volume of distribution at steady state (V(ss)/F, L/kg) was 4.94 (3.57-12.54); and renal clearance (Cl(r), L/h/kg) determined in two camels was 0.005 and 0.004, respectively.","The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),[l] / [h·kg],0.005,268470,DB00277,Theophylline
,11874526,renal clearance (Cl(r),"The data obtained median and (range) were as follows: the terminal elimination half-life (t(1/2 beta), h) was 3.04 (2.03-3.62); apparent total body clearance (Cl/F, L/h/kg) was 1.27 (0.74-2.99); the apparent volume of distribution at steady state (V(ss)/F, L/kg) was 4.94 (3.57-12.54); and renal clearance (Cl(r), L/h/kg) determined in two camels was 0.005 and 0.004, respectively.","The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),[l] / [h·kg],0.004,268471,DB00277,Theophylline
,11874526,detection time,The detection time of etamiphylline in urine after an i.m. dose of 3.5 mg/kg body weight ranged between 12 and 13 days.,"The pharmacokinetics, metabolism and urinary detection time of etamiphylline in camels after intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874526/),d,12 and 13,268472,DB00277,Theophylline
,8129214,clearances,"Sixteen subjects with theophylline clearances ranging from 0.39 to 0.95 mL/min/kg (average, 0.60 mL/min/kg) and theophylline elimination half-lives ranging from 5.1 to 10.5 hours (average 7.9 hours) completed the study.",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),[ml] / [kg·min],0.39 to 0.95,269117,DB00277,Theophylline
,8129214,clearances,"Sixteen subjects with theophylline clearances ranging from 0.39 to 0.95 mL/min/kg (average, 0.60 mL/min/kg) and theophylline elimination half-lives ranging from 5.1 to 10.5 hours (average 7.9 hours) completed the study.",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),[ml] / [kg·min],0.60,269118,DB00277,Theophylline
,8129214,elimination half-lives,"Sixteen subjects with theophylline clearances ranging from 0.39 to 0.95 mL/min/kg (average, 0.60 mL/min/kg) and theophylline elimination half-lives ranging from 5.1 to 10.5 hours (average 7.9 hours) completed the study.",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),h,5.1 to 10.5,269119,DB00277,Theophylline
,8129214,elimination half-lives,"Sixteen subjects with theophylline clearances ranging from 0.39 to 0.95 mL/min/kg (average, 0.60 mL/min/kg) and theophylline elimination half-lives ranging from 5.1 to 10.5 hours (average 7.9 hours) completed the study.",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),h,7.9,269120,DB00277,Theophylline
,8129214,times to maximum theophylline concentration,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),h,11.3,269121,DB00277,Theophylline
,8129214,times to maximum theophylline concentration,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),h,11.5,269122,DB00277,Theophylline
,8129214,peak to trough concentration ratios,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),%,74,269123,DB00277,Theophylline
,8129214,peak to trough concentration ratios,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),%,62,269124,DB00277,Theophylline
,8129214,peak to trough concentration ratios,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),h,21.4,269125,DB00277,Theophylline
,8129214,peak to trough concentration ratios,"Both formulations demonstrated similar times to maximum theophylline concentration (11.3 hours for Theo-24 and 11.5 hours for Theo-Dur), similar peak to trough concentration ratios relative to the trough concentration (74% for Theo-24, 62% for Theo-Dur) and similar periods of time within 5 to 15 mg/L (25.2 to 75.7 mumol/L; 21.4 hours for Theo-24, 19.4 hours for Theo-Dur).",Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129214/),,19.4,269126,DB00277,Theophylline
,7361576,biological half-lives,"A rather wide range of biological half-lives from about 3-16 hours and plasma clearance values of about 1.5-115 ml kg-1 hr-1 were found in the investigated patients, who were from 31 to 73 years of age.",Bioavailability and pharmacokinetics in man of orally administered theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),h,3-16,269364,DB00277,Theophylline
,7361576,plasma clearance,"A rather wide range of biological half-lives from about 3-16 hours and plasma clearance values of about 1.5-115 ml kg-1 hr-1 were found in the investigated patients, who were from 31 to 73 years of age.",Bioavailability and pharmacokinetics in man of orally administered theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),[ml] / [h·kg],1.5-115,269365,DB00277,Theophylline
,7361576,apparent volumes of distribution during the eliminatory beta-phase (Vdbeta),"The apparent volumes of distribution during the eliminatory beta-phase (Vdbeta) were within the range 0.394-0.6161 kg-1 with a mean value of 0.484 1 kg-1 +/- 0.082 S.D., as determined from the intravenous data, and in excellent agreement with the value obtained from the peroral data.",Bioavailability and pharmacokinetics in man of orally administered theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),1/[kg],0.394-0.6161,269366,DB00277,Theophylline
,7361576,apparent volumes of distribution during the eliminatory beta-phase (Vdbeta),"The apparent volumes of distribution during the eliminatory beta-phase (Vdbeta) were within the range 0.394-0.6161 kg-1 with a mean value of 0.484 1 kg-1 +/- 0.082 S.D., as determined from the intravenous data, and in excellent agreement with the value obtained from the peroral data.",Bioavailability and pharmacokinetics in man of orally administered theophylline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),[1] / [kg],0.484,269367,DB00277,Theophylline
,7361576,absorption rate constants,"In the oral experiments absorption rate constants of from about 0.57 to 2.17 hr-1 were found for the administered microparticulate theophylline tablet preparation, Nuelin from Riker Laboratories.",Bioavailability and pharmacokinetics in man of orally administered theophylline. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),1/[h],0.57 to 2.17,269368,DB00277,Theophylline
,7361576,lag-times,A wide range of lag-times from 0 to 1.32 hours were also demonstrated in the experiments.,Bioavailability and pharmacokinetics in man of orally administered theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),h,0 to 1.32,269369,DB00277,Theophylline
,7361576,systemic availability,The systemic availability of theophylline in this preparation varied from 82.8 to 103% as determined on basis of the ratios of areas under the oral and intravenous serum concentration curves.,Bioavailability and pharmacokinetics in man of orally administered theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361576/),%,82.8 to 103,269370,DB00277,Theophylline
,1437699,Total systemic clearance,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[ml] / [min],122.6,269567,DB00277,Theophylline
,1437699,volume of distribution at steady state,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[l] / [kg],0.49,269568,DB00277,Theophylline
,1437699,half-life,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),h,3.1,269569,DB00277,Theophylline
,1437699,mean residence time,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),h,5.0,269570,DB00277,Theophylline
,1437699,renal clearance,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[ml] / [min],89.1,269571,DB00277,Theophylline
>,7612107,peak STCs,Five patients had peak STCs in the toxic range (> 20 micrograms/ml).,Theophylline pharmacokinetics in Thai children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[μg] / [ml],20,269778,DB00277,Theophylline
,7612107,plasma half life (t1/2),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),h,3.08,269779,DB00277,Theophylline
,7612107,elimination rate constant (Kel),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),1/[h],0.26,269780,DB00277,Theophylline
,7612107,absorption rate constant (Ka),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),1/[h],2.21,269781,DB00277,Theophylline
,7612107,volume of distribution (Vd),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[l] / [kg],0.23,269782,DB00277,Theophylline
,7612107,plasma clearance (CI),"Using the PC Nonlin computer interpolation program by a modification with a baseline decay method and the Lagrange polynominal interpolation technique, approximate pharmacokinetic parameters were calculated and the results were as follows: plasma half life (t1/2) = 3.08 hours, elimination rate constant (Kel) = 0.26 hour-1, absorption rate constant (Ka) = 2.21 hour-1, volume of distribution (Vd) = 0.23 l/kg and plasma clearance (CI) = 56 ml/kg/hour.",Theophylline pharmacokinetics in Thai children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612107/),[ml] / [h·kg],56,269783,DB00277,Theophylline
,4096745,relative bioavailability,During the observation period 0-24 h the relative bioavailability of GTR-80 (calculated on the basis of equivalent doses) was 135% versus control preparation and 80% versus solution.,[Pharmacokinetics and biologic availability of a new theophylline sustained-release preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096745/),%,135,269797,DB00277,Theophylline
,4096745,relative bioavailability,During the observation period 0-24 h the relative bioavailability of GTR-80 (calculated on the basis of equivalent doses) was 135% versus control preparation and 80% versus solution.,[Pharmacokinetics and biologic availability of a new theophylline sustained-release preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096745/),%,80,269798,DB00277,Theophylline
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,70,269860,DB00277,Theophylline
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,50,269861,DB00277,Theophylline
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,1.7-2.1,269862,DB00277,Theophylline
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,2.1-3.1,269863,DB00277,Theophylline
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,50,269864,DB00277,Theophylline
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,75,269865,DB00277,Theophylline
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,29,269967,DB00277,Theophylline
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,22,269968,DB00277,Theophylline
,2227075,half-life,"Doxofylline possessed a very short distribution phase following intravenous administration, with a sustained elimination phase (half-life 1.83 +/- 0.37 h).",Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2227075/),h,1.83,270188,DB00277,Theophylline
,2227075,peak serum doxofylline concentration,"After oral administration, the peak serum doxofylline concentration was 15.21 +/- 1.73 micrograms/ml and the mean elimination half-life was 7.01 +/- 0.80 h; there was a large inter-subject variability.",Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2227075/),[μg] / [ml],15.21,270189,DB00277,Theophylline
,2227075,elimination half-life,"After oral administration, the peak serum doxofylline concentration was 15.21 +/- 1.73 micrograms/ml and the mean elimination half-life was 7.01 +/- 0.80 h; there was a large inter-subject variability.",Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2227075/),h,7.01,270190,DB00277,Theophylline
,2737801,terminal elimination rate constant,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),1/[h],0.119 to 0.101,271508,DB00277,Theophylline
,2737801,total body clearance,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],31.2 to 26.5,271509,DB00277,Theophylline
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,16.3,271510,DB00277,Theophylline
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,15.5,271511,DB00277,Theophylline
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],4.5,271512,DB00277,Theophylline
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],3.9,271513,DB00277,Theophylline
,11262908,CL,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),[l] / [h],2.39,272375,DB00277,Theophylline
,11262908,t1/2,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),h,90.18,272376,DB00277,Theophylline
,11262908,CL,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),[l] / [h],8.10,272377,DB00277,Theophylline
,11262908,t1/2,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),h,8.60,272378,DB00277,Theophylline
,7438680,Total body clearances,Total body clearances of theophylline were 29.5 +/- 7.8 ml/hr/kg TBW and 58.8 +/- 15.9 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],29.5,272726,DB00277,Theophylline
,7438680,Total body clearances,Total body clearances of theophylline were 29.5 +/- 7.8 ml/hr/kg TBW and 58.8 +/- 15.9 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],58.8,272727,DB00277,Theophylline
,7438680,ClT,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],19.7,272728,DB00277,Theophylline
,7438680,ClT,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],47.7,272729,DB00277,Theophylline
,7438680,clearance,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],34.5,272730,DB00277,Theophylline
,7438680,clearance,In patients with congestive heart failure (CHF) (N = 4) theophylline ClT was 19.7 +/- 1.9 ml/hr/kg TBW or 47.7 +/- 8.3 ml/hr/kg IBW while in those with no CHF (N = 8) clearance was 34.5 +/- 3.5 ml/hr/kg TBW or 64.3 +/- 16.2 ml/hr/kg IBW.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],64.3,272731,DB00277,Theophylline
,7438680,ClT,Our data suggest that maintenance doses of theophylline in markedly obese patients with CHF should be based on a theophylline ClT of 19.7 ml/hr/kg TBW and of 34.5 ml/hr/kg TBW in those with no CHF.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],19.7,272732,DB00277,Theophylline
,7438680,ClT,Our data suggest that maintenance doses of theophylline in markedly obese patients with CHF should be based on a theophylline ClT of 19.7 ml/hr/kg TBW and of 34.5 ml/hr/kg TBW in those with no CHF.,Theophylline clearance: effect of marked obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438680/),[ml] / [h·kg],34.5,272733,DB00277,Theophylline
,3528119,peak concentrations,"Pharmacokinetic analysis showed that Choledyl SA peaked earlier (4.7 +/- 1.0 hr) than did Theo-Dur (9.6 +/- 8.2 hr), with higher peak concentrations, 6.4 +/- 0.7 micrograms/ml versus 4.1 +/- 0.5 micrograms/ml for Theo-Dur, and greater are under the curve, 102.4 +/- 15.7 micrograms/ml X hr versus 75.3 +/- 9.1 micrograms/ml X hr for Theo-Dur. 88% absorption was achieved in 6 hr with Choledyl SA versus 10 hr with Theo-Dur.",Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528119/),[μg] / [ml],6.4,272836,DB00277,Theophylline
,3528119,peak concentrations,"Pharmacokinetic analysis showed that Choledyl SA peaked earlier (4.7 +/- 1.0 hr) than did Theo-Dur (9.6 +/- 8.2 hr), with higher peak concentrations, 6.4 +/- 0.7 micrograms/ml versus 4.1 +/- 0.5 micrograms/ml for Theo-Dur, and greater are under the curve, 102.4 +/- 15.7 micrograms/ml X hr versus 75.3 +/- 9.1 micrograms/ml X hr for Theo-Dur. 88% absorption was achieved in 6 hr with Choledyl SA versus 10 hr with Theo-Dur.",Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528119/),[μg] / [ml],4.1,272837,DB00277,Theophylline
,3528119,are under the curve,"Pharmacokinetic analysis showed that Choledyl SA peaked earlier (4.7 +/- 1.0 hr) than did Theo-Dur (9.6 +/- 8.2 hr), with higher peak concentrations, 6.4 +/- 0.7 micrograms/ml versus 4.1 +/- 0.5 micrograms/ml for Theo-Dur, and greater are under the curve, 102.4 +/- 15.7 micrograms/ml X hr versus 75.3 +/- 9.1 micrograms/ml X hr for Theo-Dur. 88% absorption was achieved in 6 hr with Choledyl SA versus 10 hr with Theo-Dur.",Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528119/),[μg] / [h·ml],102.4,272838,DB00277,Theophylline
,3528119,are under the curve,"Pharmacokinetic analysis showed that Choledyl SA peaked earlier (4.7 +/- 1.0 hr) than did Theo-Dur (9.6 +/- 8.2 hr), with higher peak concentrations, 6.4 +/- 0.7 micrograms/ml versus 4.1 +/- 0.5 micrograms/ml for Theo-Dur, and greater are under the curve, 102.4 +/- 15.7 micrograms/ml X hr versus 75.3 +/- 9.1 micrograms/ml X hr for Theo-Dur. 88% absorption was achieved in 6 hr with Choledyl SA versus 10 hr with Theo-Dur.",Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528119/),[μg] / [h·ml],75.3,272839,DB00277,Theophylline
,23285701,method,The method recovery of TMZ from human plasma was consistent and ranged 37.1-41.1%.,Validated HPLC method for determination of temozolomide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23285701/),%,37.1-41.1,272947,DB00277,Theophylline
,23285701,recovery,The method recovery of TMZ from human plasma was consistent and ranged 37.1-41.1%.,Validated HPLC method for determination of temozolomide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23285701/),%,37.1-41.1,272948,DB00277,Theophylline
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00277,Theophylline
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00277,Theophylline
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00277,Theophylline
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00277,Theophylline
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00277,Theophylline
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00277,Theophylline
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00277,Theophylline
,512873,half-life,"The mean dyphylline half-life was 1.8 +/- 0.2 hr; the mean total body clearance rate and mean renal clearance rate were 333 +/- 62 and 276 +/- 52 ml/min, respectively; and the mean volume of distribution was 0.8 +/- 0.2 liter/kg.",Urinary excretion of dyphylline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),h,1.8,273500,DB00277,Theophylline
,512873,total body clearance rate,"The mean dyphylline half-life was 1.8 +/- 0.2 hr; the mean total body clearance rate and mean renal clearance rate were 333 +/- 62 and 276 +/- 52 ml/min, respectively; and the mean volume of distribution was 0.8 +/- 0.2 liter/kg.",Urinary excretion of dyphylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),[ml] / [min],333,273501,DB00277,Theophylline
,512873,renal clearance rate,"The mean dyphylline half-life was 1.8 +/- 0.2 hr; the mean total body clearance rate and mean renal clearance rate were 333 +/- 62 and 276 +/- 52 ml/min, respectively; and the mean volume of distribution was 0.8 +/- 0.2 liter/kg.",Urinary excretion of dyphylline in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),[ml] / [min],276,273502,DB00277,Theophylline
,512873,volume of distribution,"The mean dyphylline half-life was 1.8 +/- 0.2 hr; the mean total body clearance rate and mean renal clearance rate were 333 +/- 62 and 276 +/- 52 ml/min, respectively; and the mean volume of distribution was 0.8 +/- 0.2 liter/kg.",Urinary excretion of dyphylline in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),[l] / [kg],0.8,273503,DB00277,Theophylline
,512873,peak serum dyphylline concentrations,"Dyphylline doses of 19--27 mg/kg, resulting in peak serum dyphylline concentrations of 19.3--23.5 micrograms/ml, were tolerated well by four subjects.",Urinary excretion of dyphylline in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),[μg] / [ml],19.3--23.5,273504,DB00277,Theophylline
,512873,peak serum dyphylline concentration,"One subject had a severe headache following a 28-mg/kg dose, associated with a peak serum dyphylline concentration of 36.4 micrograms/ml.",Urinary excretion of dyphylline in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512873/),[μg] / [ml],36.4,273505,DB00277,Theophylline
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],52,273907,DB00277,Theophylline
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],64,273908,DB00277,Theophylline
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],79,273909,DB00277,Theophylline
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],90,273910,DB00277,Theophylline
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],94,273911,DB00277,Theophylline
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],141,273912,DB00277,Theophylline
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],100,273913,DB00277,Theophylline
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],131,273914,DB00277,Theophylline
,14558437,relative bioavailability,The relative bioavailability of formulation A as compared to the solution was 72%.,Relative bioavailability and bioequivalence study of theophylline sustained release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558437/),%,72,274184,DB00277,Theophylline
